

530, 393

Rec'd PCT 04 APR 2005

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



10/530393


(43) International Publication Date
22 April 2004 (22.04.2004)

PCT

(10) International Publication Number
WO 2004/033657 A2

- (51) International Patent Classification⁷: C12N
- (21) International Application Number: PCT/US2003/032167
- (22) International Filing Date: 7 October 2003 (07.10.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/416,821 7 October 2002 (07.10.2002) US
- (71) Applicants (for all designated States except US): ANTI-GENICS, INC. [US/US]; 630 Fifth Avenue, Suite 2100, New York, NY 10011 (US). UNIVERSITY OF CONNECTICUT HEALTH CENTER [US/US]; 263 Farmington Avenue, Farmington, CT 06030-5355 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): LECLAIR, Ken [US/US]; 46 Morton Street, Needham, MA 02494 (US). SRIVASTAVA, Pramod, K. [IN/US]; 70 Pheasant Run, Avon, CT 06001 (US).
- (74) Agents: ANTILER, Adriane, M. et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HEAT SHOCK PROTEIN BINDING FRAGMENTS OF CD91, AND USES THEREOF



(57) Abstract: The present invention relates to compositions and methods for the use of natural and recombinant p95 forms and fragments as heat shock protein binding proteins. The invention is based, in part, on the Applicant's discovery that a p95 can be recombinantly expressed. The present invention also relates to CD91 polypeptide fragments that comprise at least p95 and additional contiguous sequence from domain II, III, and IV of CD91. The present invention provides nucleic acid molecules encoding a CD91 polypeptide fragment or an analog, derivative or mimetic thereof, CD91 polypeptide fragments, or analogs, derivatives or mimetics thereof, vectors comprising a nucleic acid molecule encoding a CD91 polypeptide fragment, expression vectors comprising a nucleic acid molecule encoding a CD91 polypeptide fragment, eukaryotic and prokaryotic cells recombinantly expressing a CD91 polypeptide fragment, methods of identifying compounds that interact with a CD91 polypeptide fragment or the interaction of a CD91 polypeptide fragment and CD91 ligands, methods for modulating an immune response with the compositions and methods of the invention, and methods for treatment using the compositions and methods disclosed herein.

BEST AVAILABLE COPY

WO 2004/033657 A2

HEAT SHOCK PROTEIN BINDING FRAGMENTS OF CD91, AND USES THEREOF

1. INTRODUCTION

5 The present invention relates to compositions and methods for use of a CD91 polypeptide fragments that bind to heat shock proteins. Specifically, the present invention relates to compositions and methods for use of CD91 heat shock protein-binding fragments that comprise amino acid residues of specific domains of CD91. The invention encompasses nucleic acid molecules, CD91 polypeptide fragments, cells that express CD91
10 fragments, and antibodies and other molecules that bind such CD91 polypeptide fragments and CD91 polypeptide fragment-HSP complexes. The invention also relates to screening assays to identify compounds that modulate the interaction of an HSP with the CD91 polypeptide fragment, and methods for using such compounds, and methods for using compositions comprising the CD91 polypeptide fragments for the diagnosis and treatment
15 of immune disorders, proliferative disorders, and infectious diseases.

2. BACKGROUND OF THE INVENTION

2.1 HEAT SHOCK PROTEINS

Heat shock proteins (HSPs), also referred to as stress proteins, were first identified
20 as proteins synthesized by cells in response to heat shock. HSPs have been classified into five families, based on molecular weight, HSP100, HSP90, HSP70, HSP60, and sHSP. Many members of these families were found subsequently to be induced in response to other stressful stimuli including nutrient deprivation, metabolic disruption, oxygen radicals, and infection with intracellular pathogens (see Welch, 1993, *Sci. Am.* 268:56-64; Young,
25 1990, *Annu. Rev. Immunol.* 8:401-420; Craig, 1993, *Science* 260:1902-1903; Gething *et al.*, 1992, *Nature* 355:33-45; and Lindquist *et al.*, 1988, *Annu. Rev. Genetics* 22:631-677).

Heat shock proteins are among the most highly conserved proteins in existence. For example, DnaK, the HSP70 from *E. coli* has about 50% amino acid sequence identity with HSP70 proteins from excoiates (Bardwell *et al.*, 1984, *Proc. Natl. Acad. Sci.* 81:848-852).
30 The HSP60 and HSP90 families also show similarly high levels of intra-family conservation (Hickey *et al.*, 1989, *Mol. Cell Biol.* 9:2615-2626; Jindal, 1989, *Mol. Cell Biol.* 9:2279-

2283). In addition, it has been discovered that the HSP60, HSP70 and HSP90 families also comprise proteins that are related to the stress proteins in sequence, for example, having greater than 35% amino acid identity, but whose expression levels are not altered by stress.

Studies on the cellular response to heat shock and other physiological stresses revealed that the HSPs are involved not only in cellular protection against these adverse conditions, but also in essential biochemical and immunological processes in unstressed cells. HSPs accomplish different kinds of chaperoning functions. For example, members of the HSP70 family, located in the cell cytoplasm, nucleus, mitochondria, or endoplasmic reticulum (Lindquist *et al.*, 1988, Ann. Rev. Genetics 22:631-677), are involved in the presentation of antigens to the cells of the immune system, and are also involved in the transfer, folding and assembly of proteins in normal cells. HSPs are capable of binding proteins or peptides, and releasing the bound proteins or peptides in the presence of adenosine triphosphate (ATP) or low pH.

2.2 IMMUNOGENICITY OF HSP-PEPTIDE COMPLEXES

Srivastava *et al.* demonstrated immune response to methylcholanthrene-induced sarcomas of inbred mice (1988, Immunol. Today 9:78-83). In these studies, it was found that the molecules responsible for the individually distinct immunogenicity of these tumors were glycoproteins of 96kDa (gp96) and intracellular proteins of 84 to 86kDa (p84/p86) (Srivastava *et al.*, 1986, Proc. Natl. Acad. Sci. USA 83:3407-3411; Ullrich *et al.*, 1986, Proc. Natl. Acad. Sci. USA 83:3121-3125). Immunization of mice with gp96 or p84/86 isolated from a particular tumor rendered the mice immune to that particular tumor, but not to antigenically distinct tumors. Isolation and characterization of genes encoding gp96 and p84/86 revealed significant homology between them, and showed that gp96 and p84/86 were, respectively, the endoplasmic reticular and cytosolic counterparts of the same heat shock proteins (Srivastava *et al.*, 1988, Immunogenetics 28:205-207; Srivastava *et al.*, 1991, Curr. Top. Microbiol. Immunol. 167:109-123). Further, HSP70 was shown to elicit immunity to the tumor from which it was isolated but not to antigenically distinct tumors. However, HSP70 depleted of peptides was found to lose its immunogenic activity (Udono and Srivastava, 1993, J. Exp. Med. 178:1391-1396). These observations suggested that the heat shock proteins are not immunogenic per se, but form noncovalent complexes with antigenic peptides, and the complexes can elicit specific immunity to the antigenic peptides

(Srivastava, 1993, Adv. Cancer Res. 62:153-177; Udonon *et al.*, 1994, J. Immunol., 152:5398-5403; Suto *et al.*, 1995, Science, 269:1585-1588).

Noncovalent complexes of HSPs and peptide, purified from cancer cells, can be used for the treatment and prevention of cancer and have been described in PCT

5 publications WO 96/10411, dated April 11, 1996, and WO 97/10001, dated March 20, 1997 (see also U.S. Patent No. 5,985,270 issued November 16, 1999).

2.3 CD91

CD91, also known as the alpha (2) macroglobulin ("α2M") receptor, was initially
10 identified as a protein related to the Low Density Lipoprotein (LDL) receptor and is also referred to as LDL Receptor Related Protein (LRP) (Strickland *et al.*, 1990, J. Biol. Chem. 265:17401-17404; Kristensen *et al.*, 1990, FEBS Lett. 276:151-155). The protein consists of an 420 kDa α subunit, an 85 kDa β subunit and a 39 kDa tightly associated molecule (RAP). The α and β subunits are encoded by a single transcript of approximately 15 Kb in
15 size (Van Leuven *et al.*, 1993, Biochim. Biophys. Acta. 1173:71-74). The receptor has been shown to be present in cells of the monocytic lineage and in hepatocytes, fibroblasts and keratinocytes. CD91 has been shown previously to bind the activated form of the plasma glycoprotein α2M, which binds to and inhibits a wide variety of endoproteases. CD91 also binds to other ligands such as transforming growth factor β (O'Connor-McCourt *et al.*,
20 1987, J. Biol. Chem. 262:14090-14099), platelet-derived growth factor (Huang *et al.*, 1984, Proc. Natl. Acad. Sci. U.S.A. 81:342-346), and fibroblast growth factor (Dennis *et al.*, 1989, J. Biol. Chem. 264:7210-7216). The α2M receptor plays a role in endocytosis of a diversity of ligands. In addition to α2M, other ligands of CD91 include lipoprotein complexes, lactoferrin, tissue-type plasminogen activator (tPA), Apolipoprotein E (ApoE), urokinase-type plasminogen activator (uPA), and exotoxins. Thus, CD91 plays roles in a variety of
25 cellular processes, including endocytosis, antigen presentation, cholesterol regulation, ApoE-containing lipoprotein clearance, and chylomicron remnant removal. α2M is thus believed to regulate, and specifically decrease, the activities of its various ligands. Complexed with these various ligands, α2M binds CD91 on the cell surface and is
30 internalized through receptor-mediated endocytosis. Uptake of α2M-complexed ligands has been assumed thus far to be the primary function of CD91, although a role for it in lipid metabolism is also assumed. CD91 ligands other than α2M, such as tissue-specific

plasminogen activator-inhibitor complex (Orth *et al.*, 1992, Proc. Natl. Acad. Sci. U.S.A. 89:7422-7426) and urokinase-PAI1 complex (Nykjaer *et al.*, 1992, J. Biol. Chem. 267:14543-14546), have been identified. These ligands attest to a role for CD91 in clearing a range of extracellular, plasma products. Ligands such as lipoprotein complexes, lactoferrin, tissue-type plasminogen activator (tPA), urokinase-type plasminogen activator (uPA), and exotoxins are typically endocytosed by cell upon binding to CD91.

CD91 (herein referred to interchangeably as the alpha (2) macroglobulin receptor, "α2MR", "the α2M receptor", or LDL (low-density lipoprotein) receptor-Related Protein ("LRP")), is primarily expressed in liver, brain and placenta. The extracellular domain of the human receptor comprises six 50-amino acid EGF repeats and 31 complement repeats of approximately 40-42 amino acids. The complement repeats are organized, from the amino to the carboxy-terminus, into clusters of 2, 8, 10 and 11 repeats, called Cluster I, II, III and IV (Herz *et al.*, 1988, EMBO J. 7:4119-4127). Cluster I comprises the nucleotide sequence of the p80 fragment, shown to bind heat shock proteins (Binder *et al.*, 2000, Nature Immunology, 1:151-155). Another study points to Cluster II (CI-II), which contains complement repeats 3-10 (CR3-10), as the major ligand binding portion of the receptor (Horn *et al.*, 1997, J. Biol. Chem. 272:13608-13613).

The numerous ligands of CD91 bind to and or interact with the known domains and regions of the receptor molecule as shown in Figure 4. These ligands include HSPs, which bind to cluster domain region I, ApoE, α2M, tPA, Prourokinase, tPA:PAI-1, uPA:PAI-1, TFPI, Lactopherrin, LPL, and Factor VIII which bind or interact with cluster domain II region. ApoE also binds or interacts with cluster domain III region. ApoE, α2M, tPA, Prourokinase, tPA:PAI-1, uPA:PAI-1, Tissue factor pathway inhibitor (TFPI), Lactopherrin, LPL, Factor VIII, and Pseudomonas Exotoxin A all bind or interact with region IV.

Additional ligands that are known to bind or interact with CD91 include hepatic lipase, factor Ixa, factor VIIa, MMP-13, MMP-9, shingolipid activator protein (SAP), pregnancy zone protein, complement C3, C1 inhibitor, antithrombin III, heparin cofactor II, alpha1-antitrypsin, thrombospondin-1, thrombospondin-2, rhinovirus, and HIV-Tat.

Human α2M is synthesized as a 1474 amino acid precursor, the first 23 of which function as a signal sequence that is cleaved to yield a 1451 amino acid mature protein (Kan *et al.*, 1985, Proc. Natl. Acad. Sci. U.S.A. 82:2282-2286). In experiments with recombinant protein, the carboxy-terminal 138 amino acids of α2M (representing amino acids 1314-1451 of the mature protein) was found to bind the receptor. This domain has been called the

RBD (receptor-binding domain; Salvesent *et al.*, 1992, FEBS Lett. 313:198-202; Holtet *et al.*, 1994, FEBS Lett. 344:242-246). An RBD variant (RBDv), a proteolytic fragment of $\alpha 2M$ comprising an additional 15 amino terminal residues (representing amino acids 1314-1451 of the mature protein) binds to the receptor with almost the same affinity as $\alpha 2M$ -proteinase (Holtet *et al.*, 1994, FEBS Lett. 344:242-246).

Alignment of $\alpha 2MR$ ligands identifies a conserved domain present in the RBDs of α macroglobulins. The conserved sequence spans amino acids 1366-1392 of human $\alpha 2M$. Conserved residues within this domain are Phe₁₃₆₆, Leu₁₃₆₉, Lys₁₃₇₀, Val₁₃₇₃, Lys₁₃₇₄, Glu₁₃₇₇, Val₁₃₈₂, Arg₁₃₈₄ (Nielsen *et al.*, 1996, J. Biol. Chem. 271:12909-12912). Of these, Lys₁₃₇₀ and Lys₁₃₇₄ were shown to be critical for receptor binding (Nielsen *et al.*, 1996, J. Biol. Chem. 271:12909-12912).

Binding of ligands, including the binding to $\alpha 2M$, to CD91 is inhibited by CD91-associated protein (RAP). RAP is a 39 kDa folding chaperone that resides in the endoplasmic reticulum and is required for the normal processing of CD91. RAP has the ability to competitively inhibit the binding of CD91 to all CD91 ligands tested. One study shows RAP to bind to complement repeats C5-C7 in cluster II (Cl-II) of CD91 (Horn *et al.*, 1997, J. Biol. Chem. 272:13608-13613); another shows RAP to bind to all two-repeat modules in Cl-II except the C9-C10 module (Andersen *et al.*, J. Biol. Chem., Mar. 24, 2000, PMID: 10747921; published electronically ahead of print). Three structural domains, 1, 2 and 3, have been identified in RAP, consisting of amino acid residues 18-112, 113-218 and 219-323, respectively. Ligand competition titration of recombinant RAP domains indicates that determinants for the inhibition of test ligands reside in the C-terminal regions of domains 1 and 3 (Ellgaard *et al.*, 1997, Eur. J. Biochem. 244:544-51).

2.4 ANTIGEN PRESENTATION

Major histocompatibility complex (MHC) molecules present antigens on the cell surface of antigen-presenting cells. Cytotoxic T lymphocytes (CTLs) then recognize MHC molecules and their associated peptides and kill the target cell. Antigens are processed by two distinct antigen processing routes depending upon whether their origin is intracellular or extracellular. Intracellular or endogenous protein antigens, *i.e.*, antigens synthesized within the antigen-presenting cell, are presented by MHC class I (MHC I) molecules to CD8+ cytotoxic T lymphocytes. On the other hand, extracellular or exogenously synthesized antigenic determinants are presented on the cell surface of "specialized" or

“professional” antigen presenting cells (APCs) (macrophages, for example) by MHC class II molecules to CD4+ T cells (see, generally, Fundamental Immunology, W.E. Paul (ed.), New York: Raven Press, 1984). This compartmental segregation of antigen processing routes is important to prevent tissue destruction that could otherwise occur during an immune response as a result of shedding of neighboring cell MHC I antigens.

The heat shock protein gp96 chaperones a wide array of peptides, depending upon the source from which gp96 is isolated (for review, see Srivastava *et al.*, 1998, Immunity 8: 657-665; Srivastava, 2002, Nat Rev Immunol. 2(3):185-94.). Tumor-derived gp96 carries tumor-antigenic peptides (Ishii *et al.*, 1999, J. Immunology 162:1303-1309); gp96 preparations from virus-infected cells carry viral epitopes (Suto and Srivastava, 1995, Science 269:1585-1588; Nieland *et al.*, 1998, Proc. Natl. Acad. Sci. USA 95:1800-1805), and gp96 preparations from cells transfected with model antigens such as ovalbumin or β -galactosidase are associated with the corresponding epitopes (Arnold *et al.*, 1995, J. Exp. Med. 182:885-889; Breloer *et al.*, 1998, Eur. J. Immunol. 28:1016-1021). The association of gp96 with peptides occurs *in vivo* (Menoret and Srivastava, 1999, Biochem. Biophys. Research Commun. 262:813-818). Gp96-peptide complexes, whether isolated from cells (Tamura *et al.*, 1997, Science 278:117-120), or reconstituted *in vitro* (Blachere *et al.*, 1997, J. Exp. Med. 186:1183-1406) are excellent immunogens and have been used extensively to elicit CD8+ T cell responses specific for the gp96-chaperoned antigenic peptides.

The capacity of gp96-peptide complexes to elicit an immune response is dependent upon the transfer of the peptide to MHC class I molecules of antigen-presenting cells (Suto and Srivastava, 1995, *supra*). Endogenously synthesized antigens chaperoned by gp96 in the endoplasmic reticulum [ER] can prime antigen-specific CD8+ T cells (or MHC I-restricted CTLs) *in vivo*; this priming of CD8+ T cells requires macrophages. However, the process whereby exogenously introduced gp96-peptide complexes elicit the antigen-specific CD8+ T cell response is not completely understood since there is no established pathway for the translocation of extracellular antigens into the class I presentation machinery. Yet antigenic peptides of extracellular origin associated with HSPs are somehow salvaged by macrophages, channeled into the endogenous pathway, and presented by MHC I molecules to be recognized by CD8+ lymphocytes (Suto and Srivastava, 1995, *supra*; Blachere *et al.*, 1997, J. Exp. Med. 186:1315-22).

2.5 HSP-CD91 INTERACTIONS

The studies reported by Basu *et al.* indicate that the heat shock proteins gp96, hsp90, hsp70, and calreticulin are additional ligands for the CD91 (Basu *et al.*, 2001, Immunity 14(3):303-13). Gp96 engages a region of CD91, located in an amino terminal fragment termed the p80 fragment (Binder *et al.*, 2000, Nature immunology, 1:151-155; WO 01/92474). The human gp96-coding gene has been mapped previously by us at chromosome 12 (q24.2 q24.3) (Maki *et al.*, 1993, Somatic Cell Mol. Gen. 19:73-81). It is of interest in this regard that the CD91 gene has been mapped to the same chromosome and at a not too distant location (q13 q14) (Hilliker *et al.* Genomics 13:472-474). Gp96 appears to bind CD91 directly and not through other ligands such as α 2M. Homogenous preparations of gp96, in solution, or cross-linked to a solid matrix, bind to CD91. Indeed, the major ligand for the CD91, α 2M, actually inhibits interaction of gp96 with CD91, instead of promoting it, providing evidence that gp96 is a direct ligand for CD91. The 80 kDa protein, p80, shown to bind gp96 is clearly an amino terminal degradation product of the α subunit of CD91 (Binder *et al.*, 2000, Nature Immunology, 1:151-155). Degradation products of CD91 in this size range have also been observed in previous studies (Jensen *et al.*, 1989, Biochem. Arch. 5:171-176), and may indicate the existence of a discrete ectodomain in CD91 which may be particularly sensitive to proteolytic cleavage.

The observations of Basu *et al.* that α 2 macroglobulin and anti-CD91 antibodies inhibit re-presentation by each of the four HSPs completely, indicate that CD91 is the only principle receptor involved in uptake of the four HSPs (Basu *et al.*, 2001, *supra*). Considering the increasingly obvious role which the HSPs play in innate (Basu *et al.*, 2000, Int. Immunol. 12(11):1539-1546) and adaptive immune response, this observation is somewhat counter-intuitive. However, the data on complete inhibition by two independent means are quite compelling (PCT publication WO 01/92474, dated December 6, 2001). Binder reported significant differences between hsp70 and hsp90/gp96 in their ability to compete for binding to gp96 receptors (Binder *et al.*, 2000, J. Immunol. 165:2582-2587). Another group has also observed similar differences between gp96 and hsp70 (Arnold-Schild *et al.*, 1999, J. Immunol. 162:3757-3760). These differences are not inconsistent with Basu's report pointing to a single receptor for the four HSPs. They simply suggest that the various HSPs interact with a single receptor with widely differing affinities

As shown in Binder *et al.*, the heat shock protein-CD91 interaction provides a new type of function for CD91, or a fragment thereof, a function of a sensor, not only of the extracellular environment with its previously known plasma-based ligands, but also a sensor of the intracellular milieu as well. HSPs such as gp96 are obligate intracellular molecules and are released into the extracellular milieu only under conditions of necrotic (but not apoptotic) cell death (PCT publication WO 01/92474, dated December 6, 2001). Thus, the CD91 may act as a sensor for necrotic cell death, just as the scavenger receptor CD36 and the recently identified phosphatidyl serine-binding protein act as sensors of apoptotic cell death and receptors for apoptotic cells (Savill *et al.*, 1992, J. Clin. Invest.90:1513-1522; Fadok *et al.*, 2000, Nature 405:85-90). Interaction of the macrophages with the apoptotic cells leads to a down-regulation of the inflammatory cytokines such as TNF (Fadok *et al.*, 2000, *supra*), while gp96-APC interaction leads to re-presentation of gp96-chaperoned peptides by MHC I molecules of the APC, followed by stimulation of antigen-specific T cells (Suto and Srivastava, 1995, *supra*) and, in addition, secretion of pro-inflammatory cytokines such as TNF, GM-CSF and IL-12. Interestingly, $\alpha 2M$, an independent ligand for the CD91, inhibits representation of gp96-chaperoned peptides by macrophages. This observation of Binder suggests that re-presentation of gp96-chaperoned peptides can not occur physiologically in blood, but only within tissues as a result of localized necrotic cell death. This is consistent with the complete absence of gp96 or other HSPs in blood under all conditions tested. Together, Binder's observations point towards a possible mechanism whereby the release of HSPs in the blood as a result of severe tissue injury and lysis will not lead to a systemic and lethal pro-inflammatory cytokine cascade.

It is possible, therefore, that CD91 renders it possible for the APCs to sample (i) the extracellular milieu of the blood through $\alpha 2M$ and other plasma ligands and (ii) the intracellular milieu of the tissues through HSPs, particularly of the gp96 family. The former permits APCs to implement their primordial phagocytic function, while the latter allows them to execute its innate and adaptive immunological functions. Viewed in another perspective, recognition of apoptotic cells by APCs through CD36 or phosphatidyl serine, leads to anti-inflammatory signals, while interaction of the APC with necrotic cells through CD91 leads to pro-inflammatory innate and adaptive immune responses (see Srivastava *et al.*, 1998, Immunity 8: 657-665).

Citation or discussion of a reference herein shall not be construed as an admission that such is prior art to the present invention.

3. SUMMARY OF THE INVENTION

The present invention relates natural and recombinant fragments of CD91 which bind HSPs, compositions and methods for the use of such CD91 fragments, and their use as heat shock protein-binding proteins. The invention is based, in part, on the Applicant's discovery of fragments of CD91 that bind HSPs and can be recombinantly expressed and secreted from a cell. In particular, the Applicant has shown that an epitope-tagged p95 and p110 fragments of CD91, as well as other CD91 polypeptides, can be expressed recombinantly in eukaryotic and prokaryotic cells. The present invention also relates to compositions and methods for the use of a CD91 polypeptide fragment that comprises domain I of CD91 and additional contiguous sequence of domain II, natural and recombinant polypeptide forms and fragments, and their use as heat shock protein-binding proteins.

The present invention encompasses CD91 fragment proteins and derivatives thereof that are capable of binding HSPs, herein termed "a CD91 polypeptide fragment of the invention." The present invention also provides nucleic acid molecules encoding a CD91 polypeptide fragment of the invention or derivative thereof. The invention also encompasses a vector comprising a nucleic acid molecule encoding a CD91 polypeptide fragment, expression vectors, and eukaryotic and prokaryotic cells recombinantly expressing a CD91 polypeptide fragment of the invention. The present invention also provides a method for making a CD91 polypeptide fragment.

In one embodiment, the invention provides a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, wherein the nucleotide sequence is not flanked by sequences adjacent to SEQ ID NO:1 in the native CD91 nucleotide sequence.

In another embodiment, the invention provides a nucleic acid molecule comprising a nucleotide sequence which encodes a polypeptide consisting of the amino acid sequence of SEQ ID NO:2, 3, 6, 7, 8, 9, 10, 11, or 12.

The invention further provides a nucleic acid molecule comprising a nucleotide sequence which 1) hybridizes over its full length to the nucleotide sequence of SEQ ID NO:1 under conditions of stringent washing and 2) encodes a polypeptide that is capable of (i) being recombinantly produced and secreted into culture medium and (ii) binding to a heat shock protein.

The invention still further provides a nucleic acid molecule comprising a nucleotide sequence which 1) hybridizes over its full length to the nucleic acid sequence of SEQ ID NO:1, 14, 15, 16, or 17 under conditions of stringent washing; and 2) encodes a polypeptide that is capable of (i) being recombinantly produced and secreted into culture medium and
5 (ii) binding to a heat shock protein.

The invention still further provides a nucleic acid molecule comprising a nucleotide sequence which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2, 3, 6, 7, 8, 9, 10, 11, or 12, wherein said polypeptide interacts with a heat shock protein. In one embodiment, the isolated nucleic acid molecule of the invention, further
10 comprises a heterologous nucleotide sequence.

The invention still further provides a vector comprising the nucleic acid molecule of the invention, as described herein above.

In one aspect, the invention provides an expression vector comprising the nucleic acid molecule of the invention, wherein the nucleotide sequence is operatively associated
15 with a nucleotide regulatory sequence that controls expression of the nucleotide sequence in a host cell.

The invention further provides a genetically engineered host cell comprising the nucleic acid molecule of the invention, wherein the nucleotide sequence is operatively associated with a nucleotide regulatory sequence that controls expression of the nucleotide
20 sequence in the host cell. The invention still further provides an host cell comprising the expression vector of the invention as described herein above.

In another embodiment, the invention provides a polypeptide comprising the amino acid sequence of SEQ ID NO:2, 3, 6, 7, 8, 9, 10, 11, or 12, wherein the amino acid sequence is not flanked by sequences which are adjacent to SEQ ID NO:2, 3, 6, 7, 8, 9, 10, 11, or 12,
25 respectively, in the native CD91 polypeptide sequence.

The invention also provides an isolated polypeptide comprising a contiguous amino acid sequence, wherein said amino acid sequence consists of amino acid residues 1-851 of SEQ ID NO:11, fused to one or more contiguous amino acids of amino acid residues 852-4420 of SEQ ID NO:11.

The invention further provides an isolated polypeptide encoded by a nucleic acid molecule that hybridizes under stringent conditions to a complement of SEQ ID NO: 1, 14, 15, 16, or 17, wherein said polypeptide binds to a heat shock protein.
30

The invention still further provides an isolated polypeptide encoded by a nucleic acid molecule which hybridizes under stringent conditions to a complement of a nucleic acid molecule consisting of a nucleotide sequence that encodes a polypeptide consisting of the amino acid sequence of SEQ ID NO:2, 6, 8, 10, 11, or 12, wherein said polypeptide
5 binds to a heat shock protein. In certain embodiments, the heat shock protein is selected from the group consisting of a gp96, hsp 90, hsp 70, and calreticulin. In one embodiment, the heat shock protein is gp96.

The invention also provides a fusion polypeptide comprising the amino acid sequence of SEQ ID NO:2, 3, 6, 7, 8, 9, 10, 11, or 12 and a heterologous amino acid
10 sequence.

The invention also provides a kit comprising the CD91 polypeptide fragment of the invention in one or more containers. In one embodiment, a kit is provided, packaged in one or more containers, comprising a CD91 polypeptide fragment of the invention, nucleic acid encoding an CD91 polypeptide fragment of the invention, or a cell expressing a CD91
15 polypeptide fragment of the invention. In one embodiment, the kit the CD91 polypeptide fragment of the invention, nucleic acid encoding an CD91 polypeptide fragment of the invention, or cell expressing a CD91 polypeptide fragment of the invention is purified. In another embodiment, the kit further comprises instructions for use in treating an autoimmune disorder, an infectious disease, or a proliferative disorder.

20 According to another aspect of the invention, the invention provides a method for making the polypeptide of the invention, comprising the steps of (a) culturing a cell comprising a recombinant nucleotide sequence encoding the polypeptide of the invention, under conditions such that the polypeptide is expressed by said cell, and (b) recovering the expressed polypeptide from the cell culture.

25 The invention further provides an antibody or fragment thereof that immunospecifically binds to a CD91 polypeptide fragment that binds an HSP, wherein the CD91 polypeptide fragment comprises the amino acid sequence of SEQ ID NO.:2, 3, 6, 7, 8, 9, 10, 11, or 12. In various embodiments, the antibody is a polyclonal antibody, a monoclonal antibody, a humanized antibody, a single chain antibody, or a chimeric
30 antibody. In another embodiment, the antibody or fragment thereof is a Fab fragment. The invention provides an anti-idiotypic antibody which binds to the antibody or fragment of the invention described herein above.

The invention provides a kit comprising in one or more containers the antibody of the invention described herein above, and optionally instructions for its use to detect a CD91 polypeptide fragment.

The invention also provides a method for treating a CD91-related disease or disorder comprising administering the polypeptide as described herein above to a mammal in need thereof in an amount effective to treat the disease or disorder. In certain embodiments, the disease or disorder is an autoimmune disorder, a disease or disorder involving disruption of antigen presentation or endocytosis, a disease or disorder involving cytokine clearance or inflammation, a proliferative disorder, a viral disorder or other infectious disease, hypercholesterolemia, Alzheimer's disease, diabetes, or osteoporosis.

The invention also provides a method for modulating an immune response comprising administering a CD91 polypeptide fragment of the invention, a compound identified by the methods of the invention, or a complex of an HSP and a CD91 polypeptide fragment of the invention to a mammal in need thereof in an amount effective to modulate an immune response. In certain embodiments, an immune response is stimulated. In certain other embodiments, an immune response is inhibited or blocked.

The invention also provides a method for modulating an immune response comprising administering to a mammal a purified compound identified by the methods of the invention that modulates the interaction of a CD91 ligand (*e.g.*, a heat shock protein) with CD91. In one embodiment, the compound is an agonist which enhances the interaction of a CD91 ligand (*e.g.*, a heat shock protein) with CD91. In another embodiment of this method the compound is an antagonist that interferes with the interaction between a CD91 ligand (*e.g.*, a heat shock protein) with CD91.

In another embodiment, the invention provides a method for identifying a compound that modulates an HSP-CD91-mediated process, comprising (a) contacting a test compound with a heat shock protein and a CD91 polypeptide fragment that binds a CD91 ligand, and (b) measuring the level of the CD91 polypeptide fragment activity or expression, such that if the level of activity or expression measured in (b) differs from the level of the CD91 polypeptide fragment activity or expression measured in the presence the heat shock protein but in the absence of the test compound, then a compound that modulates an HSP-CD91-mediated process is identified. In a specific embodiment, the compound identified is an antagonist which interferes with the interaction of the heat shock protein with the CD91 polypeptide fragment. In certain embodiments, the test compound is a small molecule or a

peptide. In certain embodiments, the peptide comprises at least 5 consecutive amino acids of the CD91 polypeptide fragment. In certain embodiments, the HSP-CD91-mediated process affects an autoimmune disorder, a disease or disorder involving disruption of antigen presentation or endocytosis, a disease or disorder involving cytokine clearance or inflammation, a proliferative disorder, a viral disorder or other infectious disease, hypercholesterolemia, Alzheimer's disease, diabetes, or osteoporosis.

The invention further provides a method for identifying a compound that modulates the binding of a heat shock protein to CD91, comprising (a) contacting a heat shock protein with a CD91 polypeptide fragment, or derivative thereof, which CD91 polypeptide fragment that binds a CD91 ligand, in the presence of a test compound under conditions conducive to binding, and (b) measuring the level of heat shock protein bound to the CD91 polypeptide fragment or derivative thereof, such that if the level of bound heat shock protein measured in (b) differs from the level of heat shock protein measured bound to the CD91 polypeptide fragment or derivative thereof measured under said conditions in the absence of the test compound, then a compound that modulates the binding of an HSP to the CD91 polypeptide fragment is identified. In one specific embodiment, the CD91 polypeptide fragment, or derivative thereof, is immobilized to a solid support. In another specific embodiment, the solid support is a microtiter dish. In another specific embodiment, the level of bound heat shock protein is measured using a heat shock protein-specific antibody. In another specific embodiment, the heat shock protein is labeled and the level of bound heat shock protein is measured by detecting the label. In another specific embodiment, the heat shock protein is labeled with a fluorescent label.

The CD91 polypeptide fragment of the invention is a polypeptide fragment of CD91 that comprises at least domain I (p95) of CD91 (but not full length CD91). In certain embodiments the CD91 polypeptide fragment comprises additional contiguous amino acids extending into domains II, II, or IV or CD91.

In various embodiments, the CD91 polypeptide fragment ligand is gp96 or another heat shock protein.

The term "HSP-CD91 interaction" as used herein refers to a process dependent and/or responsive, either directly or indirectly, to the interaction of HSP with a CD91 protein. Such processes include processes that result from an aberrant level of expression, synthesis and/or activity of a CD91 protein, such as endocytic activities relating to the binding of the various CD91 ligands, including but not limited to HSPs. Such processes can

include, but are not limited to, endocytosis, antigen presentation, cholesterol regulation, apoE-containing lipoprotein clearance, and chylomicron remnant removal.

The terms "HSP-CD91 disorder" and "HSP-CD91-related condition", as used herein, refers to a disorder and a condition, respectively, involving a HSP-CD91 protein interaction. Such disorders and conditions may result, for example, from an aberrant ability of a CD91 protein to interact with HSP, perhaps due to aberrant levels of HSP and/or CD91 protein expression, synthesis and/or activity relative to levels found in normal, unaffected, unimpaired individuals, levels found in clinically normal individuals, and/or levels found in a population whose levels represent a baseline, average HSP and/or CD91 protein levels. Such disorders may include, but are not limited to, autoimmune disorders, diseases and disorders involving disruption of antigen presentation and/or endocytosis, diseases and disorders involving cytokine clearance and/or inflammation, proliferative disorders, viral disorders and other infectious diseases, hypercholesterolemia, Alzheimer's disease, diabetes, and osteoporosis.

The term "CD91 ligand" as used herein, refers to a molecule capable of binding to a CD91 protein or a CD91 polypeptide fragment. Such CD91 ligands include but are not limited to, CD91 protein complexes (complexes of CD91 and another molecule), heat shock proteins, and heat shock protein complexes (complexes of a heat shock protein and another molecule). In addition, CD91 ligands also include molecules which can readily be identified as CD91 ligands using standard binding assays well known in the art. Such CD91 ligands are typically endocytosed by cells upon binding to a CD91 protein.

4. BRIEF DESCRIPTION OF THE FIGURES

FIG. 1. Pictorial representation of CD91, a multiligand receptor.

FIG. 2A-C. Expression and purification of recombinant human CD91-p95 Fragment with anti-HA Mab affinity purification. (1A) The p95 epitope-tagged protein eluted from the HA affinity was visualized by staining with Coomassie Brilliant Blue. (1C) anti-CD91 antibody (8G1) Western blot indicating presence of epitope -tagged protein in elution. (1B) The eluate was applied to anti-HA affinity resins for single step purification of recombinant human CD91 protein fragment.

FIG. 3. Mouse CD91-p80 protein structural motifs (SEQ ID NO:4). Residues 25-66 correspond to CR1, residues 70-110 correspond to CR2, residues 111-149 correspond to

EGF-like #1 domain, residues 150-189 correspond to EGF-like #2 domain, residues 190-473 correspond to YWTD β -propeller #1 region, residues 474-520 correspond to EGF-like #3 domain, residues 521-799 correspond to YWTD β -propeller #2, and residues 800-843 correspond to EGF-like #4.

- 5 **FIG. 4.** Structural motifs of human CD91 protein (SEQ ID NO:5) GenBank accession no. S02392. Amino acid residues of domains I-IV are indicated with repeats and beta propeller regions identified by residue numbers. A transmembrane domain is identified at amino acid residues 4421-4444 and an intracellular domain at residues 4445-4544. The remaining coding sequence without the transmembrane domains is residues 1-4420 (SEQ ID NO:11).
- 10 **FIG. 5.** Shows a photograph of an acrylamide gel of Ni NTA-purified recombinant CD91 fragments of p95 (first lane) and p110 (second lane).

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to compositions and methods for the use of CD91 polypeptide fragments. In particular, the present invention provides a composition comprising CD91 polypeptide fragments comprising the ligand-binding domain, an isolated nucleic acid molecule encoding a CD91 polypeptide fragment, isolated and/or recombinant cells expressing the nucleic acid and protein molecules of the invention, antibodies to CD91 polypeptide fragments, molecules and compounds that modulate the interaction of a CD91 polypeptide fragment with a CD91 ligand, such as an HSP. The invention further encompasses methods for the use of a ligand-binding CD91 polypeptide fragment as a dominant negative inhibitor of the heat shock protein receptor CD91. The invention further encompasses screening assays to identify compounds that modulate the interaction of a CD91 polypeptide fragment with an HSP, or another CD91 ligand, and methods for the use of these molecules and complexes for the diagnosis and treatment of immune disorders, proliferative disorders, and infectious diseases.

The CD91 polypeptide fragment of the invention is a ligand-binding fragment of CD91. The term "CD91 ligand" as used herein, refers to a molecule capable of binding to CD91. Such CD91 ligands include but are not limited to heat shock proteins and heat shock protein complexes. In addition, ligands also include molecules which can readily be identified as CD91 ligands using standard binding assays well known in the art. Such CD91 ligands are typically endocytosed by cell upon binding to CD91.

An HSP useful in the practice of the invention may be selected from among any cellular protein that satisfies the following criteria: the intracellular concentration of an HSP increases when a cell is exposed to a stressful stimulus; an HSP can bind other proteins or peptides, and can release the bound proteins or peptides in the presence of adenosine triphosphate (ATP) or low pH; or an HSP possesses at least 35% homology with any cellular protein having any of the above properties. Preferably, the HSP used in the compositions and methods of the present invention includes, but are not limited to, HSP90, gp96, BiP, HSP70, HSP 110, grp170, DnaK, Hsc70, calreticulin, or a smallHSP (sHSP), alone or in combination. In a preferred embodiment, an HSP is a mammalian (e.g., mouse, rat, primate, domestic animal such as dog, cat, cow, horse) HSP, and is most preferably, human.

HSPs useful in the practice of the invention include, but are not limited to, members of the HSP60 family, HSP70 family, HSP90 family, HSP100 family, sHSP family, calreticulin, and other proteins in the endoplasmic reticulum that contain thioredoxin-like domain(s), such as, but not limited to, ERp72 and ERp61.

HSP analogs, muteins, derivatives, and fragments can also be used in place of HSPs according to the invention. An HSP peptide-binding "fragment" for use in the invention refers to a polypeptide, comprising a HSP peptide-binding domain that is capable of becoming non-covalently associated with a peptide to form a complex that is capable of modulating a CD91-mediated immune response. In one embodiment, an HSP peptide-binding fragment is a polypeptide comprising an HSP peptide-binding domain of approximately 100 to 200 amino acids.

Databases can also be searched to identify sequences with various degrees of similarities to a query sequence using programs, such as FASTA and BLAST, which rank the similar sequences by alignment scores and statistics. Such nucleotide sequences of non-limiting examples of HSPs that can be used for preparation of the HSPs used in the methods of the invention are as follows: human HSP70, Genbank Accession No. NM_005345, Sargent *et al.*, 1989, Proc. Natl. Acad. Sci. U.S.A., 86:1968-1972; human HSP90, Genbank Accession No. X15183, Yamazaki *et al.*, Nucl. Acids Res. 17:7108; human gp96: Genbank Accession No. X15187, Maki *et al.*, 1990, Proc. Natl. Acad. Sci., 87: 5658-5562; human BiP: Genbank Accession No. M19645; Ting *et al.*, 1988, DNA 7: 275-286; human HSP27, Genbank Accession No. M24743; Hickey *et al.*, 1986, Nucleic Acids Res. 14:4127-45; mouse HSP70: Genbank Accession No. M35021, Hunt *et al.*, 1990, Gene, 87:199-204;

mouse gp96: Genbank Accession No. M16370, Srivastava *et al.*, 1987, Proc. Natl. Acad. Sci., 85:3807-3811; and mouse BiP: Genbank Accession No. U16277, Haas *et al.*, 1988, Proc. Natl. Acad. Sci. U.S.A., 85: 2250-2254. Due to the degeneracy of the genetic code, the term "HSP sequence", as used herein, refers not only to the naturally occurring amino acid and nucleotide sequence but also encompasses all the other degenerate sequences that encode the HSP.

The aforementioned HSP families also contain proteins that are related to HSPs in sequence, for example, having greater than 35% amino acid identity, but whose expression levels are not altered by stress. Therefore, it is contemplated that the definition of heat shock or stress protein, as used herein, embraces other proteins, mutants, analogs, and variants thereof having at least 35% to 55%, preferably 55% to 75%, and most preferably 75%, 85%, 90%, 95%, or 98% amino acid identity with members of these families whose expression levels in a cell are enhanced in response to a stressful stimulus. The determination of percent identity between two sequences can also be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA 87:2264-2268, modified as in Karlin and Altschul, 1993, Proc. Natl. Acad. Sci. USA 90:5873-5877. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul, *et al.*, 1990, J. Mol. Biol. 215:403-410. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to a nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to a protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.*, 1997, Nucleic Acids Res.25:3389-3402. Alternatively, PSI-Blast can be used to perform an iterated search which detects distant relationships between molecules (Altschul *et al.*, 1997, *supra*). When utilizing BLAST, Gapped BLAST, and PSI-Blast programs, the default parameters of the respective programs (*e.g.*, XBLAST and NBLAST) can be used (see <http://www.ncbi.nlm.nih.gov>). Another preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, 1988, CABIOS 4:11-17. Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing

amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.

The isolated CD91 polypeptide fragments of the invention may include any CD91 fragment containing a ligand binding domain. Such CD91 polypeptide fragments may be capable of modulating, *i.e.*, suppressing or enhancing, an immune response in a mammal.

The CD91 polypeptide fragments for use in the invention can be purified from natural sources, chemically synthesized, or recombinantly produced. The HSPs and/or antigenic molecules for use in the invention can be purified from natural sources, chemically synthesized, or recombinantly produced. Although the HSPs may be allogeneic to the patient, in a preferred embodiment, the HSPs are autologous to the patient to whom they are administered.

5.1 COMPOSITIONS OF THE INVENTION

The present invention provides compositions for use of CD91 polypeptide fragments in modulating the interaction between CD91 and a CD91 ligand, such as, for example, an HSP. Such compositions can be used in methods to modulate an immune response. Such compositions include CD91 polypeptide fragments, nucleic acids that encode CD91 polypeptide fragments, antibodies that specifically recognize HSP-CD91 polypeptide fragment complexes or recognize HSP binding domain of CD91, isolated recombinant or genetically engineered cells that express CD91 polypeptide fragments, HSP-CD91 polypeptide fragment complexes, and isolated and recombinant cells that contain recombinant CD91 polypeptide fragments and/or HSP sequences. In addition, in various methods of the invention, sequences encoding a CD91 polypeptide fragment and an HSP are used for immunotherapy. In other embodiments, CD91 polypeptide fragments of the invention and CD91-HSP complexes are used for immunotherapy. Such compositions can be used, for example, in immunotherapy against proliferative disorders, infectious diseases, and other HSP-CD91-related disorders. Methods for the synthesis and production of such compositions are described herein.

5.1.1 NUCLEIC ACIDS OF THE INVENTION

A nucleic acid molecule encoding a CD91 polypeptide fragment of the invention includes:

(a) a nucleic acid molecule consisting of the DNA sequence of p95 (SEQ ID NO:1, the human CD91-p95 DNA sequence);

(b) a nucleic acid molecule that encodes a p95 protein product (SEQ ID NOS: 2 and 3);

(c) a nucleic acid molecule that encodes a CD91 fragment protein product that comprises at least amino acid residues 1-851 of SEQ ID NO:5, and can comprise additional contiguous sequence of SEQ ID NO:5 but does not encompass the entire receptor protein;

(d) nucleic acid molecules that encode fusion proteins comprising a CD91 polypeptide fragment of the invention fused to a heterologous polypeptide;

(e) nucleic acid molecules that 1) hybridize over their full length to a second nucleic acid molecule which encodes a polypeptide consisting of the amino acid sequence of SEQ ID NO:1 under conditions of stringent washing; and 2) encode a polypeptide that is capable of being recombinantly produced and released into the culture media and binds to heat shock proteins;

(f) nucleic acid molecules that 1) hybridize over their full length to a second nucleic acid molecule consisting of the nucleotide sequence of SEQ ID NO:2, 6, 8, or 10 under conditions of stringent washing; and 2) encode a polypeptide that is capable of being recombinantly produced and secreted into culture media and binds to heat shock proteins; and

(g) nucleic acid molecules greater than 20, 30, 40, 50, 60, 70, 80, 90, 100, or more base pairs long that have at least 80%, 85%, 90%, 95%, 98%, or more nucleotide sequence identity to the nucleotide sequences of (a)-(f) above, wherein such nucleic acid molecule which encodes a gene product having the capacity to (a) bind a heat shock protein and (b) be recombinantly expressed and released from a cell.

As used herein, a nucleic acid molecule that "hybridizes over its full length" refers to a nucleic acid molecule that hybridizes to a specified nucleic acid molecule which is substantially the same length of the specified nucleic acid molecule, such that the duplexes formed after hybridization do not contain intervening sequences of single stranded regions of DNA, such as introns.

As used herein, a nucleic acid molecule that is "heterologous" to a specified nucleic acid molecule refers to a nucleic acid molecule that is derived from a different organism than the organism from which the specified nucleic acid molecule is derived.

Examples of nucleic acid molecules encoding CD91 polypeptide fragments include, but are not limited to, human CD91-p95 DNA sequence (SEQ ID NO:1); human CD91-p110 DNA sequence (SEQ ID NO:14); human CD91-p282 DNA sequence (SEQ ID

NO:15); human CD91-p373 DNA sequence (SEQ ID NO:16); human CD91-p494 DNA sequence (SEQ ID NO:17); and human CD91 fragment that does not include the transmembrane domain (SEQ ID NO:18).

In certain embodiments, the nucleic acid molecules of the invention described above can be isolated.

The nucleic acid molecules of the invention further include nucleotide sequences that encode polypeptides having at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or higher amino acid sequence identity to the polypeptides encoded by the p95 and CD91 polypeptide fragment nucleotide sequences of (a)-(d) above having the capacity to (a) bind a heat shock protein and (b) be recombinantly expressed and released from a cell.

To determine the percent identity of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (*i.e.*, % identity = # of identical overlapping positions/total # of overlapping positions x 100%). In one embodiment, the two sequences are the same length.

The determination of percent identity between two sequences can also be accomplished using a mathematical algorithm as described in Section 5 above.

The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, typically only exact matches are counted.

The nucleic acid molecules of the invention further include: (a) any nucleotide sequence that hybridizes to a CD91 fragment nucleic acid molecule of the invention described in (a)-(e) above, under stringent conditions, *e.g.*, hybridization to filter-bound DNA in 6x sodium chloride/sodium citrate (SSC) at about 45°C followed by one or more washes in 0.2xSSC/0.1% SDS at about 50-65°C, or (b) under highly stringent conditions, *e.g.*, hybridization to filter-bound nucleic acid in 6xSSC at about 45°C followed by one or

more washes in 0.1x SSC/0.2% SDS at about 68°C, or under other hybridization conditions which are apparent to those of skill in the art (see, for example, Ausubel F.M. *et al.*, eds., 1989, Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc., and John Wiley & sons, Inc., New York, at pp. 6.3.1-6.3.6 and 2.10.3). Preferably the

5 CD91 fragment nucleic acid molecule that hybridizes under conditions described under (a) and (b), above, is one that comprises the complement of a nucleic acid molecule that encodes a CD91 fragment protein product. In a preferred embodiment, nucleic acid molecules that hybridize under conditions (a) and (b), above, encode protein products, *e.g.*, protein products functionally equivalent to a CD91 fragment protein product. Preferably,
10 the nucleic acids of the invention encode human CD91 protein fragments.

Functionally equivalent CD91 fragment protein products include naturally occurring CD91 polypeptide fragments of CD91 present in the same or different species and variants thereof. Functionally equivalent CD91 fragment protein products also include protein
15 products that retain at least one of the biological activities of a CD91 fragment protein product, and/or which are recognized by and bind to antibodies (polyclonal or monoclonal) directed against a CD91 fragment protein product.

Among the nucleic acid molecules of the invention are deoxyoligonucleotides (“oligos”) which hybridize under highly stringent or stringent conditions to the nucleic acid molecules described above that encode CD91 polypeptide fragments. In general, for probes
20 between 14 and 70 nucleotides in length the melting temperature (T_m) is calculated using the formula: $T_m(^{\circ}\text{C}) = 81.5 + 16.6 (\log [\text{monovalent cations (molar)}]) + 0.41 (\% \text{ G+C}) - (500/N)$ where N is the length of the probe. If the hybridization is carried out in a solution containing formamide, the melting temperature is calculated using the equation $T_m(^{\circ}\text{C}) =$
25 $81.5 + 16.6 (\log [\text{monovalent cations (molar)}]) + 0.41 (\% \text{ G+C}) - (0.61\% \text{ formamide}) - (500/N)$ where N is the length of the probe. In general, hybridization is carried out at about 20-25 degrees below T_m (for DNA-DNA hybrids) or 10-15 degrees below T_m (for RNA-DNA hybrids).

Exemplary highly stringent conditions may refer, *e.g.*, to washing in 6xSSC/0.05% sodium pyrophosphate at 37°C (for about 14-base oligos), 48°C (for about 17-base oligos),
30 55°C (for about 20-base oligos), and 60°C (for about 23-base oligos).

The nucleic acid molecules of the invention further comprise the complements of the nucleic acids described above. Such molecules can, for example, act as antisense

molecules, useful, for example, in CD91 nucleic acid regulation, and/or as antisense primers in amplification reactions of CD91 nucleic acid sequences.

5 Nucleic acid sequences of the invention encoding a CD91 fragment protein product or complements thereof, may be used as part of ribozyme and/or triple helix sequences, also useful for CD91 nucleic acid regulation.

10 Still further, the nucleic acid molecules of the invention may be used as components of diagnostic methods whereby, for example, the presence of a particular CD91 fragment nucleotide sequence involved in a CD91-related disorder or a HSP-CD91-related disorder, such as a proliferative cell disorder, an autoimmune disorder, or an infectious disease is detected.

15 p95 fragment nucleic acid molecules refer to p95 nucleic acid sequences that can be at least 10, 12, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1050, or more contiguous nucleotides in length. Alternatively, the fragments can comprise sequences that encode at least 10, 20, 30, 40, 50, 60, 70, 80 or more contiguous amino acid residues of the p95 fragment protein products. In one embodiment, the p95 fragment nucleic acid molecule encodes a gene product exhibiting at least one biological activity of a corresponding CD91 protein product. Fragments can also refer to portions of p95 polypeptide fragment coding regions that encode domains of, or mature p95 fragment protein products.

20 With respect to CD91 fragment nucleic acid sequence variants or polymorphisms, any and all nucleotide variations and resulting amino acid polymorphisms or variations that are the result of natural allelic variation of the CD91 fragment are intended to be within the scope of the present invention. Allelic variants or polymorphism include, but are not limited to, ones that alter the functional activity of the CD91 fragment protein product.

25 With respect to the cloning of additional allelic variants of the human CD91 fragment nucleic acid fragment of CD91 and homologous and orthologs from other species, the isolated CD91 fragment nucleic acid sequences disclosed herein may be labeled and used to screen a cDNA library constructed from mRNA obtained from appropriate cells or tissues derived from the organism of interest. The hybridization conditions used should
30 generally be of a lower stringency when the cDNA library is derived from an organism different from the type of organism from which the labeled sequence was derived, and can routinely be determined based on, *e.g.*, relative relatedness of the target and reference organisms.

Alternatively, the labeled fragment may be used to screen a genomic library derived from the organism of interest, again, using appropriately stringent conditions. Appropriate stringency conditions are well known to those of skill in the art as discussed above, and will vary predictably depending on the specific organisms from which the library and the labeled sequences are derived. For guidance regarding such conditions see, for example, Sambrook, *et al.*, 1989, Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Press, N.Y.; and Ausubel, *et al.*, 1989-1999, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y., both of which are incorporated herein by reference in their entirety.

Further, a CD91 fragment nucleic acid molecule of a CD91 allelic gene variant may be isolated from, for example, human nucleic acid, by performing PCR using two degenerate oligonucleotide primer pools designed on the basis of amino acid sequences within the CD91 fragment protein product disclosed herein. The template for the reaction may be cDNA obtained by reverse transcription of mRNA prepared from, for example, human or non-human cell lines or tissue known or suspected to express a wild type or mutant CD91 fragment nucleic acid of a CD91 allele. In one embodiment, the allelic variant is isolated from an individual who has a CD91-mediated disorder or a HSP-CD91 related disorder.

The PCR product may be subcloned and sequenced to ensure that the amplified sequences represent the sequences of a CD91 fragment nucleic acid sequence. The PCR fragment may then be used to isolate a full length cDNA clone by a variety of methods. For example, the amplified fragment may be labeled and used to screen a bacteriophage cDNA library. Alternatively, the labeled fragment may be used to isolate genomic clones via the screening of a genomic library.

A cDNA of an allelic, *e.g.*, mutant, variant of the CD91 fragment nucleic acid may be isolated, for example, by using PCR, a technique that is well known to those of skill in the art. In this case, the first cDNA strand may be synthesized by hybridizing an oligo-dT oligonucleotide to mRNA isolated from tissue known or suspected to be expressed in an individual putatively carrying a mutant CD91 fragment sequence, and by extending the new strand with reverse transcriptase. The second strand of the cDNA is then synthesized using an oligonucleotide that hybridizes specifically to the 5' end of the normal gene. Using these two primers, the product is then amplified via PCR, cloned into a suitable vector, and subjected to DNA sequence analysis through methods well known to those of skill in the

art. By comparing the DNA sequence of the mutant CD91 fragment sequence to that of the normal CD91 fragment sequence, the mutation(s) responsible for the loss or alteration of function of the mutant CD91 fragment protein product can be ascertained.

Alternatively, a genomic library can be constructed using DNA obtained from an individual suspected of or known to carry a mutant CD91 fragment sequence, or a cDNA library can be constructed using RNA from a tissue known, or suspected, to express a mutant CD91 fragment sequence. An unimpaired CD91 fragment nucleic acid or any suitable fragment thereof may then be labeled and used as a probe to identify the corresponding mutant CD91 fragment sequence in such libraries. Clones containing the mutant CD91 fragment nucleic acid sequences may then be purified and subjected to sequence analysis according to methods well known to those of skill in the art.

Additionally, an expression library can be constructed utilizing cDNA synthesized from, for example, RNA isolated from a tissue known, or suspected, to express a mutant CD91 allele in an individual suspected of or known to carry such a mutant allele. In this manner, gene products made by the putatively mutant tissue may be expressed and screened using standard antibody screening techniques in conjunction with antibodies raised against the normal CD91 gene product (For screening techniques, see, for example, Harlow and Lane, eds., 1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Press, Cold Spring Harbor.)

In cases where a mutation in a CD91 fragment sequence results in an expressed protein product with altered function (*e.g.*, as a result of a missense or a frameshift mutation), a polyclonal set of anti-CD91 fragment protein product antibodies are likely to cross-react with the mutant CD91 fragment protein product. Library clones detected via their reaction with such labeled antibodies can be purified and subjected to sequence analysis according to methods well known to those of skill in the art.

CD91 fragment mutations or polymorphisms can further be detected using PCR amplification techniques. Primers can routinely be designed to amplify overlapping regions of a whole CD91 fragment sequence.

The invention also includes nucleic acid molecules, preferably DNA molecules, that are the complements of the nucleotide sequences of the preceding paragraphs.

In certain embodiments, the nucleic acid molecules of the invention are present as part of nucleic acid molecules comprising nucleic acid sequences that contain or encode heterologous (*e.g.*, vector, expression vector, or fusion protein) sequences.

5.1.2 AMINO ACIDS AND POLYPEPTIDES OF THE INVENTION

The present invention encompasses CD91 polypeptide fragments and analogs, derivatives and mimetics thereof that are capable of binding HSPs. Examples of CD91 polypeptide fragments include, but are not limited to, human CD91-p95 amino acid sequence (SEQ ID NO:2); soluble recombinant epitope-tagged human CD91-p95 amino acid sequence (SEQ ID NO:3); human CD91-p95 amino acid sequence (SEQ ID NO:13) with residues 1-851 corresponding to domain I and a 5.2 kD tag following amino acid residue 851; human CD91-p282 protein amino acid sequence (SEQ ID NO:6) with amino acid residues 1-851 corresponding to domain I and residues 852-2517 correspond to domain II, and a 5.2 kD tag following amino acid residue 2517; human CD91-p373 protein amino acid sequence (SEQ ID NO:8) with residues 1-851 corresponding to domain I, residues 852-2517 corresponding to domain II, and residues 2518-3330 corresponding to domain III and a 5.2 kD tag following amino acid residue 3330; and human CD91-p494 protein amino acid sequence (SEQ ID NO:10) with residues 1-851 corresponding to domain I, residues 852-2517 correspond to domain II, residues 2518-3330 corresponding to domain III, and residues 3330-4420 corresponding to domain IV and a 5.2 kD tag is shown following amino acid residue 4420. Other examples of CD91 polypeptide fragments include, but are not limited to recombinant CD91-“LRP25”. In one embodiment, the CD91 polypeptide fragment of the invention is not LRP25. Examples of CD91 polypeptide fragments of the invention include, but are not limited to, fragments of the mouse CD91 amino acid sequence (GenBank No. 109553), the human CD91 amino acid sequence (GenBank No. 88083), or the chicken CD91 amino acid sequence (GenBank No. 1079416). Such fragments comprise one or more of the domains or fragments thereof corresponding the CD91 domains shown in Figure 4. In one embodiment, the CD91 polypeptide fragment of the invention is not a full length CD91. In one embodiment, the CD91 polypeptide fragment of the invention does not comprise the CD91 transmembrane domain, such as, but not limited to the transmembrane domain shown in Figure 4.

CD91 polypeptide fragments, can be prepared for a variety of uses. For example, such gene products, can be used for the generation of antibodies, in diagnostic assays, or for mapping and the identification of other cellular or extracellular gene products involved in the regulation of a HSP-CD91 related disorders, such as cancer, infectious disease or autoimmune disorders.

A "CD91 polypeptide fragment" of the invention, includes those polypeptides encoded by a CD91 fragment nucleic acid sequences described in Section 5.1, above. In addition, CD91 polypeptide fragments of the invention may include proteins that represent functionally equivalent (see Section 5.1 for a definition) gene products. Such an equivalent CD91 polypeptide fragments may contain deletions, including internal deletions, additions, including additions yielding fusion proteins, or substitutions of amino acid residues within and/or adjacent to the amino acid sequence encoded by the gene sequences encoding CD91 polypeptide fragments described, above, in Section 5.1, but that result in a "silent" change, in that the change produces a functionally equivalent product encoded by the fragment of the CD91 gene. Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

Alternatively, where alteration of function is desired, deletion or non-conservative alterations can be engineered to produce altered CD91 polypeptide fragments. Such alterations can, for example, alter one or more of the biological functions of the CD91 polypeptide fragments. Further, such alterations can be selected so as to generate CD91 polypeptide fragments that are better suited for expression, scale up, etc. in the host cells chosen. For example, cysteine residues can be deleted or substituted with another amino acid residue in order to eliminate disulfide bridges.

Peptides and/or proteins corresponding to one or more domains of a CD91 polypeptide fragment as well as fusion proteins in which CD91 polypeptide fragments or portions of a CD91 polypeptide fragments such as a truncated CD91 polypeptide fragments or a peptide or a domain, is fused to an unrelated protein are also within the scope of this invention. Related proteins can also be fused with, for example domains from CD91 polypeptides derived from different organisms or non-contiguous domains of CD91. Such proteins and peptides can be designed on the basis of the CD91 fragment nucleotide sequences disclosed in Section 5.1, above, and/or on the basis of the CD91 polypeptide fragment amino acid sequence disclosed herein. Fusion proteins include, but are not limited to, IgFc fusions which stabilize the CD91 polypeptide fragments and prolong half life *in*

vivo; or fusions to any amino acid sequence that allows the fusion protein to be anchored to the cell membrane; or fusions of CD91 polypeptide fragment domains to an enzyme, fluorescent protein, luminescent protein, or a flag epitope protein or peptide which provides a marker function.

5 p95 polypeptides of the invention comprise residues 1-851 of SEQ ID NO:5. p95 polypeptide sequences can also include domains encoded by at least one exon of the cDNA sequence, or fragments thereof. Such domains include, but are not limited, for example, the HSP binding domain, the β -propeller #1 domain, the β -propeller #2 domain, the CR1 domain, the CR2 domain, the EGF-like domain #1, the EGF-like domain #2, the EGF-like domain #3, and the EGF-like domain #4 (as shown in the mouse amino acid sequence of p80 in Figure 3).

10 In certain embodiments of the invention, the CD91 polypeptide fragment of the invention comprises amino acid residues corresponding to Domain I and at least a portion of Domain II of a CD91 protein. In certain embodiments of the invention, the CD91 polypeptide fragment of the invention comprises at least amino acid residues 1-852 of the human CD91 protein. In other embodiments, the CD91 polypeptide fragment of the invention comprises amino acids from 1 through 853, 890, 894, 931, 935, 971, 975, 1011, 1014, 1051, 1061, 1097, 1103, 1140, 1143, 1182, 1184, 1221, 1226, 1261, 1268, 1531, 1539, 1578, 1582, 1846, 1849, 1886, 1932, 2151, 2154, 2194, 2198, 2473, 2481, or 2517 of the human CD91 protein.

20 In certain embodiments of the invention, the CD91 polypeptide fragment of the invention comprises amino acid residues corresponding to domain I, domain II, and at least a portion of domain III of a CD91 protein. In certain embodiments of the invention, the CD91 polypeptide fragment of the invention comprises at least amino acid residues 1-2518 of the human CD91 protein. In other embodiments, the CD91 polypeptide fragment of the invention comprises amino acids from 1 through 2523, 2561, 2565, 2600, 2604, 2639, 2651, 2688, 2695, 2730, 2733, 2769, 2773, 2812, 2817, 2853, 2857, 2897, 2903, 2939, 2943, 2980, 2985, 3021, 3028, 3284, 3293, or 3330 of the human CD91 protein.

25 In certain embodiments of the invention, the CD91 polypeptide fragment of the invention comprises amino acid residues corresponding to domain I, domain II, domain III and at least a portion of domain IV of a CD91 protein. In certain embodiments of the invention, the CD91 polypeptide fragment of the invention comprises at least amino acid residues 1-3331 of the human CD91 protein. In other embodiments, the CD91 polypeptide

30

fragment of the invention comprises amino acids from 1 through 3333, 3369, 3373, 3408, 3412, 3448, 3452, 3489, 3493, 3531, 3535, 3570, 3574, 3609, 3612, 3647, 3653, 3690, 3694, 3731, 3740, 3776, 3784, 3822, 3827, 3843, 3860, 3867, 4075, 1425, 4142, 4150, 4182, 4199, 4231, 4235, 4267, 4271, 4278, 4303, 4307, 4339, 4343, 4374, 4376, 4408, or 4420 of the human CD91 protein.

In preferred embodiments, the CD91 polypeptide fragment comprises amino acid residues 1-986 (p110) or amino acid residues 1-2517 (p282) of SEQ ID NO:5. In other preferred embodiments, the CD91 polypeptide fragment comprises amino acid residues that comprise domain I and II of the receptor, wherein the receptor is a CD91 (alpha (2) macroglobulin receptor). In certain preferred embodiments, the receptor is from a mammal. In yet other preferred embodiments, the CD91 polypeptide fragment comprises amino acid residues that comprise domain I and contiguous complement repeats of the CD91, wherein the receptor is from a non-human origin. Such complement repeats or other regions may extend the sequence beyond domain I through complement repeats that correspond to CR3 of human CD91 (amino acid residues 854-890), CR4 of human CD91 (amino acid residues 895-931), CR5 of human CD91 (amino acid residues 936-971), or CR6 of human CD91 (amino acid residues 976-1011). In other embodiments, the CD91 polypeptide fragment comprises an amino acid sequence corresponding to domain I of a CD91 and the following 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, or 150 contiguous amino acids of domain II of a CD91.

In certain embodiments of the invention, the CD91 polypeptide fragment of the invention comprises amino acid residues 1-851 of the human CD91 protein and at least one of the defined regions selected from the group consisting of amino acid residues 854-890, 895-931, 936-971, 976-1011, 1015-1051, 1062-1097, 1104-1140, 1145-1182, 1185-1221, 1227-1261, 1269-1531, 1540-1578, 1583-1846, 1850-1886, 1934-2151, 2159-2194, 2199-2473, 2482-2517, 2524-2561, 2566-2600, 2605-2639, 2652-2688, 2696-2730, 2734-2769, 2774-2812, 2818-2853, 2858-2897, 2904-2939, 2944-2980, 2986-3021, 3029-3284, 3294-3330, 3334-3369, 3374-3408, 3413-3448, 3453-3489, 3494-3531, 3536-3570, 3575-3609, 3613-3647, 3654-3690, 3695-3731, 3741-3776, 3785-3822, 3828-3860, 3868-4142, 4151-4182, 4200-4231, 4236-4267, 4272-4303, 4308-4339, 4344-4374, 4377-4408, 4421-4444, and 4445-4544 of the human CD91 protein.

In other embodiments, CD91 polypeptide fragments refer to CD91 polypeptide sequences that comprise amino acid residue 1 through at least amino acid residue 851, 855,

860, 865, 870, 875, 880, 885, 890, 895, 900, 905, 910, 915, 920, 925, 930, 935, 940, 945,
950, 955, 960, 965, 970, 975, 980, 985, 990, 995, 1000, 1005, 1010, 1015, 1020, 1025,
1030, 1035, 1040, 1045, 1050, 1055, 1060, 1065, 1070, 1075, 1080, 1085, 1090, 1095,
1100, 1105, 1110, 1115, 1120, 1125, 1130, 1135, 1140, 1145, 1150, 1155, 1160, 1165,
5 1170, 1175, 1180, 1185, 1190, 1195, 1200, 1205, 1210, 1215, 1220, 1225, 1230, 1235,
1240, 1245, 1250, 1255, 1260, 1265, 1270, 1275, 1280, 1285, 1290, 1295, 1300, 1305,
1310, 1315, 1320, 1325, 1330, 1335, 1340, 1345, 1350, 1355, 1360, 1365, 1370, 1375,
1380, 1385, 1390, 1395, 1400, 1405, 1410, 1415, 1420, 1425, 1430, 1435, 1440, 1445,
1450, 1455, 1460, 1465, 1470, 1475, 1480, 1485, 1490, 1495, 1500, 1505, 1510, 1515,
10 1520, 1525, 1530, 1535, 1540, 1545, 1550, 1555, 1560, 1565, 1570, 1575, 1580, 1585,
1590, 1595, 1600, 1605, 1610, 1615, 1620, 1625, 1630, 1635, 1640, 1645, 1650, 1655,
1660, 1665, 1670, 1675, 1680, 1685, 1690, 1695, 1700, 1705, 1710, 1715, 1720, 1725,
1730, 1735, 1740, 1745, 1750, 1755, 1760, 1765, 1770, 1775, 1780, 1785, 1790, 1795,
1800, 1805, 1810, 1815, 1820, 1825, 1830, 1835, 1840, 1845, 1850, 1855, 1860, 1865,
15 1870, 1875, 1880, 1885, 1890, 1895, 1900, 1905, 1910, 1915, 1920, 1925, 1930, 1935,
1940, 1945, 1950, 1955, 1960, 1965, 1970, 1975, 1980, 1985, 1990, 1995, 2000, 2005,
2010, 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050, 2055, 2060, 2065, 2070, 2075,
2080, 2085, 2090, 2095, 2100, 2105, 2110, 2115, 2120, 2125, 2130, 2135, 2140, 2145,
2150, 2155, 2160, 2165, 2170, 2175, 2180, 2185, 2190, 2195, 2200, 2205, 2210, 2215,
20 2220, 2225, 2230, 2235, 2240, 2245, 2250, 2255, 2260, 2265, 2270, 2275, 2280, 2285,
2290, 2295, 2300, 2305, 2310, 2315, 2320, 2325, 2330, 2335, 2340, 2345, 2350, 2355,
2360, 2365, 2370, 2375, 2380, 2385, 2390, 2395, 2400, 2405, 2410, 2415, 2420, 2425,
2430, 2435, 2440, 2445, 2450, 2455, 2460, 2465, 2470, 2475, 2480, 2485, 2490, 2495,
2500, 2505, 2510, 2515, 2520, 2525, 2530, 2535, 2540, 2545, 2550, 2555, 2560, 2565,
25 2570, 2575, 2580, 2585, 2590, 2595, 2600, 2605, 2610, 2615, 2620, 2625, 2630, 2635,
2640, 2645, 2650, 2655, 2660, 2665, 2670, 2675, 2680, 2685, 2690, 2695, 2700, 2705,
2710, 2715, 2720, 2725, 2730, 2735, 2740, 2745, 2750, 2755, 2760, 2765, 2770, 2775,
2780, 2785, 2790, 2795, 2800, 2805, 2810, 2815, 2820, 2825, 2830, 2835, 2840, 2845,
2850, 2855, 2860, 2865, 2870, 2875, 2880, 2885, 2890, 2895, 2900, 2905, 2910, 2915,
30 2920, 2925, 2930, 2935, 2940, 2945, 2950, 2955, 2960, 2965, 2970, 2975, 2980, 2985,
2990, 2995, 3000, 3005, 3010, 3015, 3020, 3025, 3030, 3035, 3040, 3045, 3050, 3055,
3060, 3065, 3070, 3075, 3080, 3085, 3090, 3095, 3100, 3105, 3110, 3115, 3120, 3125,
3130, 3135, 3140, 3145, 3150, 3155, 3160, 3165, 3170, 3175, 3180, 3185, 3190, 3195,

3200, 3205, 3210, 3215, 3220, 3225, 3230, 3235, 3240, 3245, 3250, 3255, 3260, 3265,
3270, 3275, 3280, 3285, 3290, 3295, 3300, 3305, 3310, 3315, 3320, 3325, 3330, 3335,
3340, 3345, 3350, 3355, 3360, 3365, 3370, 3375, 3380, 3385, 3390, 3395, 3400, 3405,
3410, 3415, 3420, 3425, 3430, 3435, 3440, 3445, 3450, 3455, 3460, 3465, 3470, 3475,
5 3480, 3485, 3490, 3495, 3500, 3505, 3510, 3515, 3520, 3525, 3530, 3535, 3540, 3545,
3550, 3555, 3560, 3565, 3570, 3575, 3580, 3585, 3590, 3595, 3600, 3605, 3610, 3615,
3620, 3625, 3630, 3635, 3640, 3645, 3650, 3655, 3660, 3665, 3670, 3675, 3680, 3685,
3690, 3695, 3700, 3705, 3710, 3715, 3720, 3725, 3730, 3735, 3740, 3745, 3750, 3755,
3760, 3765, 3770, 3775, 3780, 3785, 3790, 3795, 3800, 3805, 3810, 3815, 3820, 3825,
10 3830, 3835, 3840, 3845, 3850, 3855, 3860, 3865, 3870, 3875, 3880, 3885, 3890, 3895,
3900, 3905, 3910, 3915, 3920, 3925, 3930, 3935, 3940, 3945, 3950, 3955, 3960, 3965,
3970, 3975, 3980, 3985, 3990, 3995, 4000, 4005, 4010, 4015, 4020, 4025, 4030, 4035,
4040, 4045, 4050, 4055, 4060, 4065, 4070, 4075, 4080, 4085, 4090, 4095, 4100, 4105,
4110, 4115, 4120, 4125, 4130, 4135, 4140, 4145, 4150, 4155, 4160, 4165, 4170, 4175,
15 4180, 4185, 4190, 4195, 4200, 4205, 4210, 4215, 4220, 4225, 4230, 4235, 4240, 4245,
4250, 4255, 4260, 4265, 4270, 4275, 4280, 4285, 4290, 4295, 4300, 4305, 4310, 4315,
4320, 4325, 4330, 4335, 4340, 4345, 4350, 4355, 4360, 4365, 4370, 4375, 4380, 4385,
4390, 4395, 4400, 4405, 4410, 4415, 4420, 4425, 4430, 4435, 4440, 4445, 4450, 4455,
4460, 4465, 4470, 4475, 4480, 4485, 4490, 4495, 4500, 4505, 4510, 4515, 4520, 4525,
20 4530, 4535, or 4540.

The CD91 polypeptide fragment of the invention can further comprise posttranslational modifications, including, but not limited to glycosylations, acetylations, myristylations, and phosphorylations. If the native CD91 polypeptide fragment does not have recognition motifs that allow such modifications, it would be routine for one skilled in the art to introduce into a gene nucleotide sequences that encode motifs such as enzyme recognition signals so as to produce a modified CD91 fragment gene product.

The CD91 polypeptide fragments and fusion proteins thereof, may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing the CD91 fragment polypeptides, peptides, fusion peptide and fusion polypeptides of the invention by expressing nucleic acid containing CD91 gene sequences are described herein. Methods that are well known to those skilled in the art can be used to construct expression vectors containing CD91 gene-polypeptide fragment product coding sequences and appropriate transcriptional and translational control signals. These methods include, for

example, *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination. See, for example, the techniques described in Sambrook, *et al.*, 1989, *supra*, and Ausubel, *et al.*, 1989, *supra*. Alternatively, RNA capable of encoding CD91 fragment gene product sequences may be chemically synthesized using, for example, synthesizers.

5 See, for example, the techniques described in "Oligonucleotide Synthesis", 1984, Gait, ed., IRL Press, Oxford.

5.1.2.1

VARIANTS, DERIVATIVES, AND ANALOGS OF CD91 POLYPEPTIDE FRAGMENTS

CD91 polypeptide fragment derivatives can be made by altering CD91 polypeptide
10 fragment coding sequences by substitutions, additions or deletions that provide for functionally equivalent molecules. Due to the degeneracy of nucleotide coding sequences, other DNA sequences which encode substantially the same amino acid sequence as a CD91 polypeptide fragment encoding nucleic acid may be used in the practice of the present invention. These include but are not limited to nucleotide sequences comprising all or
15 CD91 polypeptide fragment-binding portions of a CD91 polypeptide fragment encoding nucleic acid which are altered by the substitution of different codons that encode a functionally equivalent amino acid residue within the sequence, thus producing a silent change. Likewise, the CD91 polypeptide fragment derivatives of the invention include, but are not limited to, those containing, as a primary amino acid sequence, all or a CD91
20 polypeptide fragment-binding portion of the amino acid sequence of a CD91 polypeptide fragment, including altered sequences in which functionally equivalent amino acid residues are substituted for residues within the sequence resulting in a silent change. In certain embodiments of the invention the CD91 polypeptide fragment derivative comprises about 1,
2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100,
25 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, or 400 amino acid substitutions.

For example, one or more amino acid residues within the C-terminal of a peptide or a N-terminus protecting group can be substituted. An amino acid residue can be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected
30 from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged

(basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Additionally, D-amino acids may be used. The term "D-amino acid" as used herein, refers to an amino acid having a D-configuration. A D-amino acid may be a naturally occurring amino acid or an unnatural amino acid. Thus, polypeptides of the invention may comprise D-amino acids, a combination of D- and L-amino acids, and various "designer" amino acids (*e.g.*, β -methyl amino acids, C α -methyl amino acids, and N α -methyl amino acids, etc.) to convey special properties. Synthetic amino acids include ornithine for lysine, fluorophenylalanine for phenylalanine, and norleucine for leucine or isoleucine. Substitutions can also be made using phosphorous analogs of amino acids, such as α -amino phosphonic acids and α -amino phosphinic acids, or amino acids having non-peptide linkages, nucleic acids, nucleic acid analogs such as phosphorothioates or peptide nucleic acids ("PNAs"), hormones, antigens, synthetic or naturally occurring drugs, opiates, dopamine, serotonin, catecholamines, thrombin, acetylcholine, prostaglandins, organic molecules, pheromones, adenosine, sucrose, glucose, lactose and galactose.

The CD91 polypeptide fragment derivatives and analogs of the invention can be produced by various methods known in the art. The manipulations which result in their production can occur at the nucleic acid or protein level. For example, the cloned CD91 fragment nucleic acid sequence can be modified by any of numerous strategies known in the art (Maniatis, T., 1990, Molecular Cloning, A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York). The sequence can be cleaved at appropriate sites with restriction endonuclease(s), followed by further enzymatic modification if desired, isolated, and ligated *in vitro*. In the production of the nucleic acid encoding a derivative or analog of CD91 polypeptide fragment, care should be taken to ensure that the modified gene remains within the same translational reading frame as a CD91 fragment, uninterrupted by translational stop signals, in the region of the nucleic acid where the desired CD91 polypeptide fragment activity is encoded.

Manipulations of the CD91 polypeptide fragment sequence may also be made at the protein level. Included within the scope of the invention are CD91 polypeptide fragments or other derivatives or analogs which are differentially modified during or after translation, *e.g.*, by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known

techniques, including but not limited to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH_4 ; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.

5.1.3 RECOMBINANT EXPRESSION

5 In various embodiments of the invention, sequences encoding a CD91 polypeptide fragment, an HSP, or a CD91 ligand are inserted into an expression vector for propagation and expression in recombinant cells. Thus, in one embodiment, a CD91 polypeptide fragment, HSP, or a CD91 ligand coding region is linked to a non-native promoter for expression in recombinant cells.

10 The amino acid sequence of soluble recombinant human CD91 corresponds to SEQ ID NO:3. Based on this invention and the knowledge that HSPs play a role in immune responses, compositions comprising agonists and antagonists of CD91 polypeptide fragment and HSPs interactions can be used to modulate the immune response. Thus, recombinant CD91 polypeptide fragments, complexes of CD91 polypeptide fragments and an HSP or
15 HSP-antigenic peptide complexes, and recombinant cells expressing a CD91 polypeptide fragments or complexes comprising a CD91 polypeptide fragments and peptides can be used in methods for immunotherapy and diagnostic methods described herein.

In various embodiments of the invention, sequences encoding a CD91 polypeptide fragment, and/or a heat shock protein, or fragments thereof, are inserted into an expression
20 vector for propagation and expression in recombinant cells. An expression construct, as used herein, refers to a nucleotide sequence encoding a particular gene product, such as a CD91 polypeptide fragment or HSP, operably associated with one or more regulatory regions which allows expression of the encoded gene product in an appropriate host cell. "Operably-associated" refers to an association in which the regulatory regions and the
25 nucleotide sequence encoding the gene product to be expressed are joined and positioned in such a way as to permit transcription, and ultimately, translation. In any of the embodiments disclosed herein, cells recombinantly expressing a CD91 polypeptide fragment may also be engineered to suppress or inhibit expression of endogenous CD91.

Alternatively, cell lines lacking CD91 or having mutant or non-functional CD91 can
30 be employed. A nucleic acid encoding a CD91 polypeptide fragment may be used to alter the activity or expression of CD91. An antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including but not limited to

5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including but not limited to arabinose, 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group consisting of a phosphorothioate (S-ODNs), a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an α -anomeric oligonucleotide. An α -anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other (Gautier *et al.*, 1987, Nucl. Acids Res. 15, 6625-6641). The oligonucleotide is a 2'-O-methylribonucleotide (Inoue *et al.*, 1987, Nucl. Acids Res. 15, 6131-6148), or a chimeric RNA-DNA analogue (Inoue *et al.*, 1987, FEBS Lett. 215, 327-330).

Oligonucleotides of the invention may be synthesized by standard methods known in the art, *e.g.* by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein *et al.* (1988, Nucl. Acids Res. 16, 3209), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin *et al.*, 1988, Proc. Natl. Acad. Sci. U.S.A. 85, 7448-7451), etc.

While antisense nucleotides complementary to the target gene coding region sequence could be used, those complementary to the transcribed, untranslated region are most preferred.

The DNA may be obtained from known sequences derived from sequence databases by standard procedures known in the art by DNA amplification or molecular cloning directly from a tissue, cell culture, or cloned DNA (e.g., a DNA "library"). Any eukaryotic cell may serve as the nucleic acid source for obtaining the coding region of an HSP encoding gene. Nucleic acid sequences encoding HSPs can be isolated from vertebrate, mammalian, as well as primate sources, including humans. Clones derived from genomic DNA may contain regulatory and intron DNA regions in addition to coding regions; clones derived from cDNA will contain only exon sequences. Whatever the source, the HSP gene should be cloned into a suitable vector for propagation of the gene.

Vectors based on *E. coli* are the most popular and versatile systems for high level expression of foreign proteins (Makrides, 1996, Microbiol Rev, 60:512-538). Non-limiting examples of regulatory regions that can be used for expression in *E. coli* may include but not limited to *lac*, *trp*, *lpp*, *phoA*, *recA*, *tac*, λP_L , and phage T3 and T7 promoters (Makrides, 1996, Microbiol Rev, 60:512-538). Non-limiting examples of prokaryotic expression vectors may include the λ gt vector series such as λ gt11 (Huynh *et al.*, 1984 in "DNA Cloning Techniques", Vol. I: A Practical Approach (D. Glover, ed.), pp. 49-78, IRL Press, Oxford), and the pET vector series (Studier *et al.*, 1990, Methods Enzymol., 185:60-89). However, a potential drawback of a prokaryotic host-vector system is the inability to perform many of the post-translational processing events of mammalian cells. Thus, an eukaryotic host-vector system is preferred, a mammalian host-vector system is more preferred, and a human host-vector system is the most preferred.

The regulatory regions necessary for transcription of a CD91 fragment sequence, for example, can be provided by the expression vector. A translation initiation codon (ATG) may also be provided to express a nucleotide sequence encoding a CD91 polypeptide fragment that lacks an initiation codon. In a compatible host-construct system, cellular proteins required for transcription, such as RNA polymerase and transcription factors, will bind to the regulatory regions on the expression construct to effect transcription of a CD91 fragment sequence in the host organism. The precise nature of the regulatory regions needed for gene expression may vary from host cell to host cell. Generally, a promoter is required which is capable of binding RNA polymerase to initiate the transcription of an

operably-associated nucleic acid sequence. Such regulatory regions may include those 5'-non-coding sequences involved with initiation of transcription and translation, such as the TATA box, the cap site, a CAAT box, and the like. The non-coding region 3' to the coding sequence may contain transcriptional termination regulatory sequences, such as terminators and polyadenylation sites.

Both constitutive and inducible regulatory regions may be used for expression of a CD91 polypeptide fragment, HSP, or a CD91 ligand. It may be desirable to use inducible promoters when the conditions optimal for growth of the recombinant cells and the conditions for high level expression of the gene product are different. Examples of useful regulatory regions are provided in the next section below.

For expression of a CD91 polypeptide fragment, HSP, or a CD91 ligand gene product in mammalian host cells, a variety of regulatory regions can be used, for example, the SV40 early and late promoters, the cytomegalovirus (CMV) immediate early promoter, and the Rous sarcoma virus long terminal repeat (RSV-LTR) promoter. Inducible promoters that may be useful in mammalian cells include but are not limited to those associated with the metallothionein II gene, mouse mammary tumor virus glucocorticoid responsive long terminal repeats (MMTV-LTR), the β -interferon gene, and the HSP70 gene (Williams *et al.*, 1989, Cancer Res. 49:2735-42; Taylor *et al.*, 1990, Mol. Cell Biol., 10:165-75). It may be advantageous to use heat shock promoters or stress promoters to drive expression of a CD91 fragment in recombinant host cells.

The following animal regulatory regions, which exhibit tissue specificity and have been utilized in transgenic animals, can also be used in tumor cells of a particular tissue type: elastase I gene control region which is active in pancreatic acinar cells (Swift *et al.*, 1984, Cell 38:639-646; Ornitz *et al.*, 1986, Cold Spring Harbor Symp. Quant. Biol. 50:399-409; MacDonald, 1987, Hepatology 7:425-515); insulin gene control region which is active in pancreatic beta cells (Hanahan, 1985, Nature 315:115-122), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl *et al.*, 1984, Cell 38:647-658; Adames *et al.*, 1985, Nature 318:533-538; Alexander *et al.*, 1987, Mol. Cell. Biol. 7:1436-1444), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder *et al.*, 1986, Cell 45:485-495), albumin gene control region which is active in liver (Pinkert *et al.*, 1987, Genes and Devel. 1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf *et al.*, 1985, Mol. Cell. Biol. 5:1639-1648; Hammer *et al.*, 1987, Science 235:53-58; alpha 1-antitrypsin gene control region

which is active in the liver (Kelsey *et al.*, 1987, Genes and Devel. 1:161-171), beta-globin gene control region which is active in myeloid cells (Mogam *et al.*, 1985, Nature 315:338-340; Kollias *et al.*, 1986, Cell 46:89-94; myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead *et al.*, 1987, Cell 48:703-712);
5 myosin light chain-2 gene control region which is active in skeletal muscle (Sani, 1985, Nature 314:283-286), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason *et al.*, 1986, Science 234:1372-1378).

The efficiency of expression of a CD91 fragment in a host cell may be enhanced by the inclusion of appropriate transcription enhancer elements in the expression vector, such
10 as those found in SV40 virus, Hepatitis B virus, cytomegalovirus, immunoglobulin genes, metallothionein, β -actin (see Bittner *et al.*, 1987, Methods in Enzymol. 153:516-544; Gorman, 1990, Curr. Op. in Biotechnol. 1:36-47).

The expression vector may also contain sequences that permit maintenance and replication of the vector in more than one type of host cell, or integration of the vector into
15 the host chromosome. Such sequences may include but are not limited to replication origins, autonomously replicating sequences (ARS), centromere DNA, and telomere DNA. It may also be advantageous to use shuttle vectors that can be replicated and maintained in at least two types of host cells.

In addition, the expression vector may contain selectable or screenable marker genes
20 for initially isolating or identifying host cells that contain DNA encoding a CD91 polypeptide fragment. For long term, high yield production of a CD91 polypeptide fragment, stable expression in mammalian cells is preferred. A number of selection systems may be used for mammalian cells, including, but not limited, to the Herpes simplex virus thymidine kinase (Wigler *et al.*, 1977, Cell 11:223), hypoxanthine-guanine
25 phosphoribosyltransferase (Szybalski and Szybalski, 1962, Proc. Natl. Acad. Sci. USA 48:2026), and adenine phosphoribosyltransferase (Lowy *et al.*, 1980, Cell 22:817) genes can be employed in *tk⁻*, *hgprt⁻* or *aprt⁻* cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for dihydrofolate reductase (*dhfr*), which confers resistance to methotrexate (Wigler *et al.*, 1980, Natl. Acad. Sci. USA 77:3567; O'Hare *et al.*, 1981, Proc.
30 Natl. Acad. Sci. USA 78:1527); *gpt*, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA 78:2072); neomycin phosphotransferase (neo), which confers resistance to the aminoglycoside G-418 (Colberre-Garapin *et al.*, 1981, J. Mol. Biol. 150:1); and hygromycin phosphotransferase (*hyg*), which

confers resistance to hygromycin (Santerre *et al.*, 1984, Gene 30:147). Other selectable markers, such as but not limited to histidinol and Zeocin™ can also be used.

In order to insert the DNA sequence encoding a CD91 polypeptide fragment, HSP, or a CD91 ligand into the cloning site of a vector, DNA sequences with regulatory functions, such as promoters, must be attached to DNA sequences encoding a CD91 polypeptide fragment, HSP, or a CD91 ligand, respectively. To do this, linkers or adapters providing the appropriate compatible restriction sites may be ligated to the ends of cDNA or synthetic DNA encoding a CD91 polypeptide fragment, by techniques well known in the art (Wu *et al.*, 1987, Methods in Enzymol 152:343-349). Cleavage with a restriction enzyme can be followed by modification to create blunt ends by digesting back or filling in single-stranded DNA termini before ligation. Alternatively, a desired restriction enzyme site can be introduced into a fragment of DNA by amplification of the DNA by use of PCR with primers containing the desired restriction enzyme site.

In one embodiment, an expression construct comprising a CD91 polypeptide fragment sequence operably associated with regulatory regions can be directly introduced into appropriate host cells for expression and production of a CD91 polypeptide fragment without further cloning (see, for example, U.S. Patent No. 5,580,859). The expression constructs may also contain DNA sequences that facilitate integration of a CD91 fragment sequence into the genome of the host cell, *e.g.*, via homologous recombination. In this instance, it is not necessary to employ an expression vector comprising a replication origin suitable for appropriate host cells in order to propagate and express a CD91 polypeptide fragment in the host cells.

Expression constructs containing cloned nucleotide sequence encoding a CD91 polypeptide fragment, an HSP, or other CD91 ligand, can be introduced into the host cell by a variety of techniques known in the art, including but not limited to, for prokaryotic cells, bacterial transformation (Hanahan, 1985, in DNA Cloning, A Practical Approach, 1:109-136), and for eukaryotic cells, calcium phosphate mediated transfection (Wigler *et al.*, 1977, Cell 11:223-232), liposome-mediated transfection (Schaefer-Ridder *et al.*, 1982, Science 215:166-168), electroporation (Wolff *et al.*, 1987, Proc Natl Acad Sci 84:3344), and microinjection (Cappechi, 1980, Cell 22:479-488).

For long term, high yield production of a properly processed CD91 polypeptide fragment, HSP, or a CD91 ligand, stable expression in mammalian cells is preferred. Cell lines that stably express a CD91 polypeptide fragment, HSP, or a CD91 ligand or a CD91

polypeptide fragment-peptide complex may be engineered by using a vector that contains a selectable marker. By way of example but not limitation, following the introduction of the expression constructs, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the expression construct confers resistance to the selection and optimally allows cells to stably integrate the expression construct into their chromosomes and to grow in culture and to be expanded into cell lines. Such cells can be cultured for a long period of time while the desired gene product is expressed continuously.

The recombinant cells may be cultured under standard conditions of temperature, incubation time, optical density, and media composition. Alternatively, recombinant antigenic cells may be cultured under conditions emulating the nutritional and physiological requirements of the cancer cell or infected cell. However, conditions for growth of recombinant cells may be different from those for expression of a CD91 polypeptide fragment, HSPs, or a CD91 ligand, or antigenic peptide.

5.1.4 PEPTIDE SYNTHESIS

An alternative to producing peptides and polypeptides comprising HSP, a CD91 polypeptide fragment or CD91 ligand sequences by recombinant techniques is peptide synthesis. For example, a peptide corresponding to a portion of an HSP or a CD91 polypeptide fragment comprising the receptor-binding domain, which can be used as an antagonist in the therapeutic methods described herein, can be synthesized by use of a peptide synthesizer. Peptides corresponding to CD91 polypeptide fragment sequences useful for therapeutic methods described herein can also be produced synthetically. Conventional peptide synthesis may be used or other synthetic protocols well known in the art.

For example, peptides having the amino acid sequence of a CD91 polypeptide fragment, an HSP, or a CD91 ligand, or an analog, mutein, fragment, or derivative thereof, may be synthesized by solid-phase peptide synthesis using procedures similar to those described by Merrifield, 1963, J. Am. Chem. Soc., 85:2149. During synthesis, N- α -protected amino acids having protected side chains are added stepwise to a growing polypeptide chain linked by its C-terminal and to an insoluble polymeric support, *i.e.*, polystyrene beads. The peptides are synthesized by linking an amino group of an N- α -deprotected amino acid to an α -carboxyl group of an N- α -protected amino acid that has

been activated by reacting it with a reagent such as dicyclohexylcarbodiimide. The attachment of a free amino group to the activated carboxyl leads to peptide bond formation. The most commonly used N- α -protecting groups include Boc which is acid labile and Fmoc which is base labile. Details of appropriate chemistries, resins, protecting groups, protected amino acids and reagents are well known in the art and so are not discussed in detail herein (See, Atherton, *et al.*, 1989, Solid Phase Peptide Synthesis: A Practical Approach, IRL Press, and Bodanszky, 1993, Peptide Chemistry, A Practical Textbook, 2nd Ed., Springer-Verlag).

Purification of the resulting CD91 polypeptide fragment, HSP, or CD91 ligand peptide is accomplished using conventional procedures, such as preparative HPLC using gel permeation, partition and/or ion exchange chromatography. The choice of appropriate matrices and buffers are well known in the art and so are not described in detail herein.

In addition, analogs and derivatives of a CD91 polypeptide fragment, HSP, or a CD91 ligand protein can be chemically synthesized. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into a CD91 polypeptide fragment, HSP, or a CD91 ligand sequence. Non-classical amino acids include but are not limited to the D-isomers of the common amino acids, α -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, γ -Abu, ϵ -Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, β -alanine, fluoro-amino acids, designer amino acids such as β -methyl amino acids, C α -methyl amino acids, N α -methyl amino acids, and amino acid analogs in general.

5.1.5 ANTIBODIES SPECIFIC FOR CD91 POLYPEPTIDE FRAGMENTS AND CD91 POLYPEPTIDE FRAGMENT-HSP COMPLEXES

Described herein are methods for the production of antibodies capable of specifically recognizing CD91 polypeptide fragment epitopes, HSP-CD91 polypeptide fragment complex epitopes or epitopes of conserved variants or peptide fragments of the receptor or receptor complexes. Such antibodies are useful for recognizing the HSP-binding domain of CD91 for use in therapeutic and diagnostic methods of the invention.

Such antibodies may include, but are not limited to, polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')₂ fragments, fragments produced by a Fab expression library, anti-

idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. Such antibodies may be used, for example, in the detection of a CD91 polypeptide fragment or HSP-CD91 polypeptide fragment complex in an biological sample. Such antibodies may also be utilized in conjunction with, for example, compound screening schemes, as described below, in Section 5.2, for the evaluation of the effect of test compounds on the interaction between HSPs and the CD91 fragment protein. The interaction between HSPs and the CD91 fragment protein can be an immunospecific binding of the two.

Anti-CD91 fragment protein complex antibodies may additionally be used as a method for the inhibition of abnormal CD91 product activity. Thus, such antibodies may, be utilized as part of treatment methods for HSP-CD91 related disorders, *e.g.*, autoimmune disorders.

For the production of antibodies against CD91 fragment protein or peptide complexes thereof, various host animals may be immunized by injection with a CD91 fragment protein or HSP-CD91 fragment protein complex, or a portion thereof. An antigenic portion of CD91 fragment protein or HSP-CD91 fragment protein complex can be readily predicted by algorithms known in the art. In certain embodiments, anti-CD91 polypeptide fragment antibodies may be generated to certain CD91 polypeptide fragments such as, but not limited to, p95, p110, p282, p373, or p494. Such antibodies may be utilized as part of the treatment methods of the invention for HSP-CD91 related disorders.

Host animals may include, but are not limited to rabbits, mice, and rats, to name but a few. Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*.

Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of animals immunized with an antigen, such as a CD91 polypeptide fragment protein or HSP-CD91 polypeptide fragment protein complex, or an antigenic functional derivative thereof. For the production of polyclonal antibodies, host animals such as those described above, may be immunized by injection with CD91 polypeptide fragment protein or HSP-CD91 polypeptide fragment protein complex, or portion thereof, supplemented with adjuvants as also described above.

Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, may be obtained by any technique that provides the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique of Kohler and Milstein, (1975, Nature 256, 495-497; and U.S. Patent No. 4,376,110), the human B-cell hybridoma technique (Kosbor *et al.*, 1983, Immunology Today 4: 72; Cole *et al.*, 1983, Proc. Natl. Acad. Sci. USA 80, 2026-2030), and the EBV-hybridoma technique (Cole *et al.*, 1985, Monoclonal Antibodies And Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the mAb of this invention may be cultivated *in vitro* or *in vivo*. Production of high titers of mAbs *in vivo* makes this the presently preferred method of production.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison, *et al.*, 1984, Proc. Natl. Acad. Sci., 81: 6851-6855; Neuberger, *et al.*, 1984, Nature 312: 604-608; Takeda, *et al.*, 1985, Nature, 314: 452-454) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region (see, *e.g.*, Cabilly *et al.*, U.S. Patent No. 4,816,567; and Boss *et al.*, U.S. Patent No. 4,816,397, which are incorporated herein by reference in their entirety).

In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals (see PCT International Publication No. WO 89/12690, published December 12, 1989). According to the invention, human antibodies may be used and can be obtained by using human hybridomas (Cote *et al.*, 1983, Proc. Natl. Acad. Sci. U.S.A. 80:2026-2030) or by transforming human B cells with EBV virus *in vitro* (Cole *et al.*, 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, pp. 77-96). Techniques developed for the production of "chimeric antibodies" (Morrison *et al.*, 1984, Proc. Natl. Acad. Sci. U.S.A. 81:6851-6855; Neuberger *et al.*, 1984, Nature 312:604-608; Takeda *et al.*, 1985, Nature 314:452-454) by splicing the genes from a mouse antibody molecule specific for an CD91 polypeptide fragment protein -HSP complex together with genes from a human antibody molecule of appropriate biological activity can also be used; such antibodies are within the scope of this invention.

Humanized antibodies are also provided (see U.S. Patent No. 5,225,539 by Winter). An immunoglobulin light or heavy chain variable region consists of a "framework" region interrupted by three hypervariable regions, referred to as complementarity determining regions (CDRs). The extent of the framework region and CDRs have been precisely
5 defined (see, "Sequences of Proteins of Immunological Interest", Kabat, E. *et al.*, U.S. Department of Health and Human Services (1983). Briefly, humanized antibodies are antibody molecules from non-human species having one or more CDRs from the non-human species and a framework region from a human immunoglobulin molecule. Such CDRS-grafted antibodies have been successfully constructed against various antigens, for
10 example, antibodies against IL-2 receptor as described in Queen *et al.*, 1989, Proc. Natl. Acad. Sci. USA 86:10029; antibodies against the cell surface receptor CAMPATH as described in Riechmann *et al.*, 1988, Nature 332:323; antibodies against hepatitis B in Co *et al.*, 1991, Proc. Natl. Acad. Sci. USA 88:2869; as well as against viral antigens of the respiratory syncytial virus in Tempest *et al.*, 1991, Bio-Technology 9:267. Humanized
15 antibodies are most preferred for therapeutic use in humans.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent 4,946,778; Bird, 1988, Science 242: 423-426; Huston *et al.*, 1988, Proc. Natl. Acad. Sci. USA 85: 5879-5883; and Ward *et al.*, 1989, Nature 334: 544-546) can be
20 adapted to produce single chain antibodies against CD91 polypeptide fragment protein or HSP-CD91 polypeptide fragment protein complexes, or portions thereof. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.

Antibody fragments that recognize specific epitopes may be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')₂
25 fragments, which can be produced by pepsin digestion of the antibody molecule and the Fab fragments, which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed (Huse *et al.*, 1989, Science, 246: 1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

30 Antibodies to the CD91 polypeptide fragment can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" the CD91 polypeptide fragment, using techniques well known to those skilled in the art (see, *e.g.*, Greenspan & Bona, 1993, FASEB J 7(5):437-444; and Nissinoff, 1991, J. Immunol. 147(8):2429-2438). For example antibodies which

bind to the CD91 polypeptide fragment and competitively inhibit the binding of HSPs to the CD91 polypeptide fragment can be used to generate anti-idiotypes that "mimic" the ECD and, therefore, bind and neutralize HSPs. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens to neutralize the native ligand and treat HSP-CD91-related disorders, such as immunological disorders, proliferative disorders, and infectious diseases.

Alternatively, antibodies to a CD91 polypeptide fragment that can act as agonists of a CD91 polypeptide fragment activity or CD91 activity can be generated. Such antibodies will bind to a CD91 polypeptide fragment and CD91 and can potentially activate the signal transducing activity of the CD91 the activation of a CD91 would be particularly useful for treating proliferative disorders, such as cancer, and infectious diseases. In addition, antibodies that act as antagonist of a CD91 polypeptide fragment activity, *i.e.*, potential inhibitors of the activation of a CD91, would be particularly useful for treating autoimmune disorders. Methods for assaying for such agonists and antagonists are described in detail in Section 5.2, below.

5.2 ASSAYS FOR THE IDENTIFICATION OF COMPOUNDS THAT INTERACT WITH THE CD91 POLYPEPTIDE FRAGMENT

Methods for identifying compounds that interact with the CD91 polypeptide fragment, or enhance or block the function of the CD91 polypeptide fragment, are included in the invention. The present invention provides *in vitro* and *in vivo* assay systems, described in the subsections below, which can be used to identify compounds or compositions that interact with the CD91 polypeptide fragment, or modulate the activity of the CD91 polypeptide fragment and its interaction with HSPs or HSP-peptide complexes.

The invention provides screening methodologies useful in the identification of small molecules, proteins and other compounds which interact with the CD91 polypeptide fragment, or modulate the interaction of HSPs with the CD91 polypeptide fragment. Such compounds may bind the CD91 polypeptide fragment genes or gene products with differing affinities, and may serve as regulators of receptor activity *in vivo* with useful therapeutic applications in modulating the immune response. For example, certain compounds that inhibit receptor function may be used in patients to downregulate destructive immune responses which are caused by cellular release of HSPs. In one embodiment, the compound is an agonist which enhances the interaction of the heat shock protein and a CD91

polypeptide fragment. In another embodiment of this method the compound in an antagonist that interferes with the interaction between the heat shock protein and a CD91 polypeptide fragment.

Methods to screen potential agents for their ability to interact with the CD91 polypeptide fragment, or modulate CD91 polypeptide fragment expression and activity can be designed based on the Applicant's discovery of the receptor and its role in HSP or HSP-peptide complex binding and recognition. CD91 polypeptide fragments, nucleic acids, and derivatives can be used in screening assays to detect molecules that specifically bind to CD91 or HSP proteins, derivatives, or nucleic acids, and thus have potential use to modulate the CD91 HSP interactions and thereby modulate an immune response. In a preferred embodiment, such assays are performed to screen for molecules with potential utility as anti-autoimmune disease, anti-cancer, anti-infective drugs, and immunomodulatory drugs (such as anti-viral drugs and antibiotic drugs), or lead compounds for drug development. For example, recombinant cells expressing CD91 fragment nucleic acids can be used to recombinantly produce CD91 polypeptide fragment protein for use in these assays, to screen for molecules that interfere with the binding of HSPs to the CD91 polypeptide fragment. Similar methods can be used to screen for molecules that bind to the CD91 polypeptide fragment derivatives or encoding nucleic acids. Methods that can be used to carry out the foregoing are commonly known in the art.

Compounds capable of specifically binding the CD91 polypeptide fragment protein can be useful for immunotherapy. In one embodiment, an assay is disclosed for identifying compounds that specifically bind the CD91 polypeptide fragment protein comprising: (a) contacting a CD91 polypeptide fragment protein with one or more test compounds under conditions conducive to binding; and (b) identifying one or more test compounds which specifically bind to the CD91 polypeptide fragment protein, such that a compound capable of specifically binding the CD91 polypeptide fragment protein is identified as a compound useful for immunotherapy.

Another method encompassed by the invention for identifying a compound useful for immunotherapy involves identifying a compound which modulates the binding of an CD91 polypeptide fragment ligand to the CD91 polypeptide fragment. The term "CD91 polypeptide fragment ligand" as used herein, refers to an molecule capable of binding to the CD91 polypeptide fragment. Such CD91 polypeptide fragment ligands include, but are not limited to, heat shock proteins and heat shock protein complexes.

The method comprises the steps of: (a) contacting a CD91 polypeptide fragment with a CD91 polypeptide fragment ligand, or analog, derivative or mimetic thereof, in the presence of one or more test compound; and (b) measuring the amount of CD91 polypeptide fragment ligand, or analog, derivative or mimetic thereof, bound to the CD91 polypeptide fragment, such that if the amount of bound CD91 polypeptide fragment ligand measured in (b) differs from the amount of bound CD91 polypeptide fragment measured in the absence of the test compound, then a compound can be useful for immunotherapy that modulates the binding of a CD91 polypeptide fragment ligand to the CD91 polypeptide fragment is identified.

In another embodiment, a method for identifying a compound useful for immunotherapy which modulates the interaction between the CD91 polypeptide fragment and an CD91 polypeptide fragment ligand is provided by the invention. This method comprises the steps of: (a) contacting an CD91 polypeptide fragment with one or more test compounds; and (b) measuring the level of CD91 polypeptide fragment activity or expression, such that if the level of activity or expression measured in (b) differs from the level of CD91 polypeptide fragment activity in the absence of one or more test compounds, then a compound that modulates the interaction between the CD91 polypeptide fragment and an CD91 polypeptide fragment ligand is identified.

In another embodiment, an assay for identifying a compound that modulates an HSP-CD91 polypeptide fragment-mediated process is disclosed. This assay comprises: (a) contacting a test compound with an HSP and a CD91 polypeptide fragment; and (b) measuring the level of CD91 polypeptide fragment activity or expression, such that if the level of activity or expression measured in (b) differs from the level of CD91 polypeptide fragment activity in the absence of the test compound, then a compound that modulates an HSP-CD91 polypeptide fragment-mediated process is identified. In another embodiment, in which the compound identified is an antagonist which interferes with the interaction of the HSP with the CD91 polypeptide fragment, the method further comprises the step of determining whether the level interferes with the interaction of the HSP and the CD91 polypeptide fragment.

In another embodiment, a cell-based method for identifying a compound that modulates an HSP-CD91 polypeptide fragment-mediated process is described. This method comprises the following steps: (a) contacting a test compound with a heat shock protein and an CD91 polypeptide fragment-expressing cell; and (b) measuring the level of CD91

polypeptide fragment activity or expression in the cell, such that if the level of activity or expression measured in (b) differs from the level of CD91 polypeptide fragment activity in the absence of the test compound, then a compound that modulates an HSP-CD91 polypeptide fragment protein-mediated process is identified.

5 In another embodiment, a receptor-ligand binding assay for identifying a compound that interacts with CD91 polypeptide fragment, or modulates the binding of an HSP to CD91 polypeptide fragment. One such method comprises: (a) contacting an HSP with an CD91 polypeptide fragment, or analog, derivative or mimetic thereof, in the presence of a test compound; and (b) measuring the amount of heat shock protein bound to the CD91
10 polypeptide fragment, or analog, derivative or mimetic thereof, such that if the amount of bound heat shock protein measured in (b) differs from the amount of bound heat shock protein measured in the absence of the test compound, then a compound that modulates the binding of an HSP to the CD91 polypeptide fragment is identified.

The assays of the present invention may be first optimized on a small scale (*i.e.*, in
15 test tubes), and then scaled up for high-throughput assays. In various embodiments, the *in vitro* screening assays of the present invention may be performed using purified components or cell lysates. In other embodiments, the screening assays may be carried out in intact cells in culture and in animal models. In accordance with the present invention, test compounds which are shown to modulate the activity of the CD91 polypeptide fragment as described
20 herein *in vitro*, will further be assayed *in vivo*, including cultured cells and animal models to determine if the test compound has the similar effects *in vivo*, via interactions with endogenous CD91, and to determine the effects of the test compound on antigen presentation, cytokine release, intracellular Ca^{++} release, T-cell cytotoxicity, tumor progression, the accumulation or degradation of positive and negative regulators, cellular
25 proliferation, *etc.*

Proteins that are identified as interacting with a CD91 polypeptide fragment can be further identified and sequenced for use in the methods of the invention. Further identification can be by affinity chromatography, analyzed on SDS-PAGE, stained with coomassie blue or transferred onto PVDF membrane and stained with coomassie blue, all of it
30 under keratin-free conditions. Protein bands can then be excised with a razor from the gel or membrane. Tryptic peptides from an 80kDa faint coomassie band can be extracted by 50% acetonitrile, 5% formic acid, dried, and loaded onto a 75 m 10 cm, reverse-phase C18, microcapillary column (3 μl vol) and tryptic peptides can be separated by on-line

microcapillary liquid chromatography-tandem mass spectrometry followed by database searching using the SEQUEST program as previously described. (Gatlin *et al.*, 2000, Anal. Chem. 72:757-63; Link *et al.*, 1999, Nat. Biotechnol. 17:676-82). The analysis can be carried out in a data-dependent auto-MS/MS fashion using a Finnigan LCQ iontrap Mass Spectrometer.

5.2.1 CD91 POLYPEPTIDE FRAGMENT - LIGAND BINDING ASSAYS

The screening assays, described herein, can be used to identify compounds and compositions, including peptides and organic, non-protein molecules that interact with a CD91 polypeptide fragment, or that modulate the interaction between HSPs and a CD91 polypeptide fragment. Recombinant, synthetic, and otherwise exogenous compounds may have binding capacity and, therefore, may be candidates for pharmaceutical agents. Alternatively, the proteins and compounds include endogenous cellular components which interact with the identified genes and proteins *in vivo*. Such endogenous components may provide new targets for pharmaceutical and therapeutic interventions.

Thus, in a preferred embodiment, both naturally occurring and/or synthetic compounds (*e.g.*, libraries of small molecules or peptides), may be screened for interacting with a CD91 polypeptide fragment and/or modulating CD91 polypeptide fragment activity. In another series of embodiments, cell lysates or tissue homogenates may be screened for proteins or other compounds which bind to one of the normal or mutant CD91 fragment nucleic acids and CD91 polypeptide fragment.

The screening assays described herein may be used to identify small molecules, peptides or proteins, or derivatives, analogs and fragments thereof, that interact with and/or modulate the interaction of HSPs with a CD91 polypeptide fragment. Such compounds may be used as agonists or antagonists of the uptake of CD91 ligands, such as HSPs and HSP complexes, by the cell surface receptor. For example, compounds that modulate a CD91 polypeptide fragment-ligand interaction include, but are not limited to, compounds that bind to a CD91 polypeptide fragment, thereby either inhibiting (antagonists) or enhancing (agonists) the binding of ligands, such as HSPs and HSP complexes, to the receptor, as well as compounds that bind to the ligand, such as for example, HSPs, thereby preventing or enhancing binding of ligand to the receptor. Compounds that affect CD91 fragment DNA activity (by affecting CD91 fragment DNA expression, including molecules, *e.g.*, proteins or small organic molecules, that affect transcription or interfere with splicing

events so that expression of CD91 fragment can be modulated) can also be identified in the screens of the invention.

The screening assays described herein are designed to detect compounds that modulate, *i.e.*, interfere with or enhance, ligand-CD91 polypeptide fragment interactions, including HSP-CD91 polypeptide fragment interactions. As described in detail below, such assays are functional assays, such as binding assays, that can be adapted to a high-throughput screening methodologies.

Binding assays can be used to identify compounds that modulate the interaction between ligands, for example, HSPs, and a CD91 polypeptide fragment. In one aspect of the invention the screens may be designed to identify compounds that disrupt the interaction between a CD91 polypeptide fragment and a ligand, such as, for example, HSPs or peptides derived from an HSP, or another CD91 ligand. Such compounds will be useful as lead compounds for antagonists of HSP-CD91-related disorders and conditions, such as immune disorders, proliferative disorders, and infectious diseases.

Binding assays may be performed either as direct binding assays or as competition binding assays. In a direct binding assay, a test compound is tested for binding either to a CD91 polypeptide fragment or to a CD91 ligand, such as an HSP. Then, in a second step, the test compound is tested for its ability to modulate the ligand-CD91 polypeptide fragment interaction. Competition binding assays, on the other hand, assess the ability of a test compound to compete with a ligand, *i.e.*, an HSP, for binding to CD91 polypeptide fragment.

In a direct binding assay, either the ligand and/or CD91 polypeptide fragment is contacted with a test compound under conditions that allow binding of the test compound to the ligand or the receptor. The binding may take place in solution or on a solid surface.

Preferably, the test compound is previously labeled for detection. Any detectable compound may be used for labeling, such as but not limited to, a luminescent, fluorescent, or radioactive isotope or group containing same, or a nonisotopic label, such as an enzyme or dye. After a period of incubation sufficient for binding to take place, the reaction is exposed to conditions and manipulations that remove excess or non-specifically bound test compound. Typically, it involves washing with an appropriate buffer. Finally, the presence of a ligand-test compound (*e.g.*, HSP-test compound) or a CD91 polypeptide fragment -test compound complex is detected.

In a competition binding assay, test compounds are assayed for their ability to disrupt or enhance the binding of the ligand (*e.g.*, HSP) to a CD91 polypeptide fragment. Labeled ligand (*e.g.*, HSP) may be mixed with a CD91 polypeptide fragment or derivative thereof, and placed under conditions in which the interaction between them would normally occur, with and without the addition of the test compound. The amount of labeled ligand (*e.g.*, HSP) that binds a CD91 polypeptide fragment may be compared to the amount bound in the presence or absence of test compound.

In a preferred embodiment, to facilitate complex formation and detection, the binding assay is carried out with one or more components immobilized on a solid surface. In various embodiments, the solid support could be, but is not restricted to, polycarbonate, polystyrene, polypropylene, polyethylene, glass, nitrocellulose, dextran, nylon, polyacrylamide and agarose. The support configuration can include beads, membranes, microparticles, the interior surface of a reaction vessel such as a microtiter plate, test tube or other reaction vessel. The immobilization of a CD91 polypeptide fragment, or other component, can be achieved through covalent or non-covalent attachments. In one embodiment, the attachment may be indirect, *i.e.*, through an attached antibody. In another embodiment, a CD91 polypeptide fragment and negative controls are tagged with an epitope, such as glutathione S-transferase (GST) so that the attachment to the solid surface can be mediated by a commercially available antibody such as anti-GST (Santa Cruz Biotechnology).

For example, such an affinity binding assay may be performed using a CD91 polypeptide fragment which is immobilized to a solid support. Typically, the non-mobilized component of the binding reaction, in this case either ligand (*e.g.*, HSP) or the test compound, is labeled to enable detection. A variety of labeling methods are available and may be used, such as luminescent, chromophore, fluorescent, or radioactive isotope or group containing same, and nonisotopic labels, such as enzymes or dyes. In a preferred embodiment, the test compound is labeled with a fluorophore such as fluorescein isothiocyanate (FITC, available from Sigma Chemicals, St. Louis).

The labeled test compounds, or ligand (*e.g.*, HSP) plus test compounds, are then allowed to contact with the solid support, under conditions that allow specific binding to occur. After the binding reaction has taken place, unbound and non-specifically bound test compounds are separated by means of washing the surface. Attachment of the binding partner to the solid phase can be accomplished in various ways known to those skilled in the

art, including but not limited to chemical cross-linking, non-specific adhesion to a plastic surface, interaction with an antibody attached to the solid phase, interaction between a ligand attached to the binding partner (such as biotin) and a ligand-binding protein (such as avidin or streptavidin) attached to the solid phase, and so on.

5 Finally, the label remaining on the solid surface may be detected by any detection method known in the art. For example, if the test compound is labeled with a fluorophore, a fluorimeter may be used to detect complexes.

Preferably, the CD91 polypeptide fragment is added to binding assays in the form of intact cells that express the CD91 polypeptide fragment, or isolated membranes containing
10 the CD91 polypeptide fragment. Thus, direct binding to the CD91 polypeptide fragment or the ability of a test compound to modulate a ligand-CD91 polypeptide fragment complex (e.g., HSP-CD91 polypeptide fragment complex) may be assayed in intact cells in culture or in animal models in the presence and absence of the test compound. A labeled ligand (e.g., HSP) may be mixed with cells that express the CD91 polypeptide fragment, or to crude
15 extracts obtained from such cells, and the test compound may be added. Isolated membranes may be used to identify compounds that interact with the CD91 polypeptide fragment. For example, in a typical experiment using isolated membranes, cells may be genetically engineered to express the CD91 polypeptide fragment. Membranes can be harvested by standard techniques and used in an *in vitro* binding assay. Labeled ligand
20 (e.g., ¹²⁵I-labeled HSP) is bound to the membranes and assayed for specific activity; specific binding is determined by comparison with binding assays performed in the presence of excess unlabeled (cold) ligand.

Alternatively, soluble CD91 polypeptide fragment may be recombinantly expressed and utilized in non-cell based assays to identify compounds that bind to the CD91
25 polypeptide fragment. The recombinantly expressed CD91 polypeptide fragment polypeptides or fusion proteins containing the extracellular domain (ECD) of the CD91 polypeptide fragment, or derivatives thereof, can be used in the non-cell based screening assays. In non-cell based assays the recombinantly expressed the CD91 polypeptide fragment is attached to a solid substrate such as a test tube, microtiter well or a column, by
30 means well known to those in the art (see Ausubel *et al.*, *supra*). The test compounds are then assayed for their ability to bind to the CD91 polypeptide fragment.

Alternatively, the binding reaction may be carried out in solution. In this assay, the labeled component is allowed to interact with its binding partner(s) in solution. If the size

differences between the labeled component and its binding partner(s) permit such a separation, the separation can be achieved by passing the products of the binding reaction through an ultrafilter whose pores allow passage of unbound labeled component but not of its binding partner(s) or of labeled component bound to its partner(s). Separation can also
5 be achieved using any reagent capable of capturing a binding partner of the labeled component from solution, such as an antibody against the binding partner, a ligand-binding protein which can interact with a ligand previously attached to the binding partner, and so on.

In a one embodiment, for example, a phage library can be screened by passing phage
10 from a continuous phage display library through a column containing purified CD91 fragment, or derivative, analog, fragment, or domain, thereof, linked to a solid phase, such as plastic beads. By altering the stringency of the washing buffer, it is possible to enrich for phage that express peptides with high affinity for the CD91 polypeptide fragment. Phage isolated from the column can be cloned and the affinities of the short peptides can be
15 measured directly. Sequences for more than one oligonucleotide can be combined to test for even higher affinity binding to the CD91 polypeptide fragment. Knowing which amino acid sequences confer the strongest binding to the CD91 polypeptide fragment, computer models can be used to identify the molecular contacts between the CD91 polypeptide fragment and the test compound. This will allow the design of non-protein compounds
20 which mimic those contacts. Such a compound may have the same activity of the peptide and can be used therapeutically, having the advantage of being efficient and less costly to produce.

In another specific embodiment of this aspect of the invention, the solid support is membranes containing the CD91 polypeptide fragment attached to a microtiter dish. Test
25 compounds, for example, cells that express library members are cultivated under conditions that allow expression of the library members in the microtiter dish. Library members that bind to the protein (or nucleic acid or derivative) are harvested. Such methods, are described by way of example in Parmley and Smith, 1988, Gene 73:305-318; Fowlkes *et al.*, 1992, BioTechniques 13:422-427; PCT Publication No. WO 94/18318; and in
30 references cited hereinabove.

In another embodiment of the present invention, interactions between the CD91 polypeptide fragment or ligand (*e.g.*, HSP) and a test compound may be assayed *in vitro*. Known or unknown molecules are assayed for specific binding to the CD91 fragment

nucleic acids, proteins, or derivatives under conditions conducive to binding, and then molecules that specifically bind to the CD91 polypeptide fragment are identified. The two components can be measured in a variety of ways. One approach is to label one of the components with an easily detectable label, place it together with a test component(s) under conditions that allow binding to occur, perform a separation step which separates bound labeled component from unbound labeled component, and then measure the amount of bound component. In one embodiment, the CD91 polypeptide fragment can be labeled and added to a test agent, using conditions that allow binding to occur. Binding of the test agent can be determined using polyacrylamide gel analysis to compare complexes formed in the presence and absence of the test agent.

In other embodiments, antigen-specific response assays may be used to detect the effect of a candidate compound on presentation of antigenic molecule by an CD91 ligand, for example an HSP or HSP complex. Such assays may be *in vitro* or *in vivo*, and may encompass, for example, but not limited to, antigen representation assays, or tumor challenge or rejection assays to detect modulation of CD91 or HSP activity by the compounds identified by the methods of the invention. For example, an antigen presentation assay may be performed to determine the activity of a CD91 polypeptide fragment or the effect of a compound *in vivo* on the uptake of complexes capable of interacting with a CD91 polypeptide fragment, *e.g.*, HSP-antigenic molecule complexes, by cells expressing the a CD91 polypeptide fragment. Such re-presentation assays are known in the art, and have been described previously (Suto and Srivastava, 1995, Science 269:1585-1588). For example, in one embodiment, antigen presenting cells, such as a macrophage cell line (*e.g.*, RAW264.7), are mixed with antigen-specific T cells in media, using approximately 10,000 cells of each type at approximately a 1:1 ratio. Complexes of HSP (10 μ g/ml) and a peptide antigen, as well as test compound, is added to the cells and the culture is incubated for approximately 20 hours. Stimulation of T cells may then be measured in the presence and absence of test compound.

In another embodiment, antigen-specific T cell stimulation may be assayed. In one embodiment an IFN- γ release assay may be used. After washing, cells are fixed, permeabilized, and reacted with dye-labeled antibodies reactive with human IFN- γ (PE-anti-IFN- γ). Samples are analyzed by flow cytometry using standard techniques. Alternatively, a filter immunoassay, ELISA (enzyme linked immunosorbent assay), or enzyme-linked immunospot assay (ELISPOT) assay, may be used to detect specific

cytokines produced by an activated T cell. In one embodiment, for example, a nitrocellulose-backed microtiter plate is coated with a purified cytokine-specific primary antibody, *i.e.*, anti-IFN- γ , and the plate is blocked to avoid background due to nonspecific binding of other proteins. A sample of APC cells stimulated with antigen is diluted onto the wells of the microtiter plate. A labeled, *e.g.*, biotin-labeled, secondary anti-cytokine antibody is added. The antibody cytokine complex can then be detected, *i.e.*, by enzyme-conjugated streptavidin—cytokine-secreting cells will appear as “spots” by visual, microscopic, or electronic detection methods. In another embodiment, “tetramer staining” assay (Altman et al., 1996, Science 274: 94-96) may be used to identify antigen-specific T-cells. For example, an MHC molecule containing a specific peptide antigen, such as a tumor-specific antigen, is multimerized to make soluble peptide tetramers and labeled, for example, by complexing to streptavidin. The MHC-peptide antigen complex is then mixed with a population of stimulated T cells. Biotin is then used to stain T cells which recognize and bind to the MHC-antigen complex.

5.2.2 COMPOUNDS THAT CAN BE SCREENED IN ACCORDANCE WITH THE INVENTION

The screening assays described herein may be used to identify small molecules, peptides or proteins, or derivatives, analogs and fragments thereof, that interact with, or modulate the interaction of a ligand (*e.g.*, HSP) with a CD91 polypeptide fragment. The compounds which may be screened in accordance with the invention include, but are not limited to small molecules, peptides, antibodies and fragments thereof, and other organic compounds (*e.g.*, peptidomimetics) that bind to a CD91 polypeptide fragment and either inhibit the activity triggered by the natural ligand (*i.e.*, antagonists) or mimic the activity triggered by the natural ligand (*i.e.*, agonists), as well as small molecules, peptides, antibodies or fragments thereof, and other organic compounds. In another embodiment, such compounds include ligand sequences, such as HSP sequences, which can bind to the active site of a CD91 polypeptide fragment, and block its activity.

Compounds that may be used for screening include, but are not limited to, peptides such as, for example, soluble peptides, including but not limited to members of random peptide libraries; (see, *e.g.*, Lam *et al.*, 1991, Nature 354:82-84; Houghten *et al.*, 1991, Nature 354:84-86), and combinatorial chemistry-derived molecular library made of D- and/or L- configuration amino acids, phosphopeptides (including, but not limited to,

members of random or partially degenerate, directed phosphopeptide libraries; see, *e.g.*, Songyang *et al.*, 1993, Cell 72:767-778), antibodies (including, but not limited to, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and FAb, F(ab')₂ and FAb expression library fragments, and epitope-binding fragments thereof),
5 and small organic or inorganic molecules.

In one embodiment of the present invention, peptide libraries may be used as a source of test compounds that can be used to screen for modulators of CD91 polypeptide fragment interactions, such as HSP-CD91 polypeptide fragment interactions. Diversity libraries, such as random or combinatorial peptide or nonpeptide libraries can be screened
10 for molecules that specifically bind to the CD91 polypeptide fragment. Many libraries are known in the art that can be used, *e.g.*, chemically synthesized libraries, recombinant (*e.g.*, phage display libraries), and *in vitro* translation-based libraries.

Examples of chemically synthesized libraries are described in Fodor *et al.*, 1991, Science 251:767-773; Houghten *et al.*, 1991, Nature 354:84-86; Lam *et al.*, 1991,
15 Nature 354:82-84; Medynski, 1994, Bio/Technology 12:709-710; Gallop *et al.*, 1994, J. Medicinal Chemistry 37(9):1233-1251; Ohlmeyer *et al.*, 1993, Proc. Natl. Acad. Sci. USA 90:10922-10926; Erb *et al.*, 1994, Proc. Natl. Acad. Sci. USA 91:11422-11426; Houghten *et al.*, 1992, Biotechniques 13:412; Jayawickreme *et al.*, 1994, Proc. Natl. Acad. Sci. USA 91:1614-1618; Salmon *et al.*, 1993, Proc. Natl. Acad. Sci. USA 90:11708-11712; PCT
20 Publication No. WO 93/20242; and Brenner and Lerner, 1992, Proc. Natl. Acad. Sci. USA 89:5381-5383.

Examples of phage display libraries are described in Scott & Smith, 1990, Science 249:386-390; Devlin *et al.*, 1990, Science, 249:404-406; Christian *et al.*, 1992, J. Mol. Biol. 227:711-718; Lenstra, 1992, J. Immunol. Meth. 152:149-157; Kay *et al.*, 1993,
25 Gene 128:59-65; and PCT Publication No. WO 94/18318 dated August 18, 1994.

By way of examples of nonpeptide libraries, a benzodiazepine library (*see e.g.*, Bunin *et al.*, 1994, Proc. Natl. Acad. Sci. USA 91:4708-4712) can be adapted for use. Peptoid libraries (Simon *et al.*, 1992, Proc. Natl. Acad. Sci. USA 89:9367-9371) can also be used. Another example of a library that can be used, in which the amide functionalities in
30 peptides have been permethylated to generate a chemically transformed combinatorial library, is described by Ostresh *et al.* (1994, Proc. Natl. Acad. Sci. USA 91:11138-11142).

Screening the libraries can be accomplished by any of a variety of commonly known methods. See, *e.g.*, the following references, which disclose screening of peptide libraries:

Parmley & Smith, 1989, Adv. Exp. Med. Biol. 251:215-218; Scott & Smith, 1990, Science 249:386-390; Fowlkes *et al.*, 1992; BioTechniques 13:422-427; Oldenburg *et al.*, 1992, Proc. Natl. Acad. Sci. USA 89:5393-5397; Yu *et al.*, 1994, Cell 76:933-945; Staudt *et al.*, 1988, Science 241:577-580; Bock *et al.*, 1992, Nature 355:564-566; Tuerk *et al.*, 1992, Proc. Natl. Acad. Sci. USA 89:6988-6992; Ellington *et al.*, 1992, Nature 355:850-852; U.S. Patent No. 5,096,815, U.S. Patent No. 5,223,409, and U.S. Patent No. 5,198,346, all to Ladner *et al.*; Rebar & Pabo, 1993, Science 263:671-673; and PCT Publication No. WO 94/18318.

In another embodiment of the present invention, the screening may be performed by adding the labeled ligand (*e.g.*, HSP) to *in vitro* translation systems such as a rabbit reticulocyte lysate (RRL) system and then proceeding with *in vitro* priming reaction. *In vitro* translation-based libraries include but are not limited to those described in PCT Publication No. WO 91/05058 dated April 18, 1991; and Mattheakis *et al.*, 1994, Proc. Natl. Acad. Sci. USA 91:9022-9026.

Compounds that can be tested and identified methods described herein can include, but are not limited to, compounds obtained from any commercial source, including Aldrich (Milwaukee, WI 53233), Sigma Chemical (St. Louis, MO), Fluka Chemie AG (Buchs, Switzerland) Fluka Chemical Corp. (Ronkonkoma, NY;), Eastman Chemical Company, Fine Chemicals (Kingsport, TN), Boehringer Mannheim GmbH (Mannheim, Germany), Takasago (Rockleigh, NJ), SST Corporation (Clifton, NJ), Ferro (Zachary, LA 70791), Riedel-deHaen Aktiengesellschaft (Seelze, Germany), PPG Industries Inc., Fine Chemicals (Pittsburgh, PA 15272). Further any kind of natural products may be screened using the methods of the invention, including microbial, fungal, plant or animal extracts.

Furthermore, diversity libraries of test compounds, including small molecule test compounds, may be utilized. Typically small molecules range in molecular weight from about 400 to 10,000 Daltons. For example, libraries may be commercially obtained from Specs and BioSpecs B.V. (Rijswijk, The Netherlands), Chembridge Corporation (San Diego, CA), Contract Service Company (Dolgoprudny, Moscow Region, Russia), Comgenex USA Inc. (Princeton, NJ), Maybridge Chemicals Ltd. (Cornwall PL34 OHW, United Kingdom), and Asinex (Moscow, Russia).

Still further, combinatorial library methods known in the art, can be utilize, including, but not limited to: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the

“one-bead one-compound” library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, 1997, *Anticancer Drug Des.* 12:145). Combinatorial
5 libraries of test compounds, including small molecule test compounds, can be utilized, and may, for example, be generated as disclosed in Eichler & Houghten, 1995, *Mol. Med.* Today 1:174-180; Dolle, 1997, *Mol. Divers.* 2:223-236; and Lam, 1997, *Anticancer Drug Des.* 12:145-167.

Examples of methods for the synthesis of molecular libraries can be found in the art,
10 for example in: DeWitt *et al.*, 1993, *Proc. Natl. Acad. Sci. USA* 90:6909; Erb *et al.*, 1994, *Proc. Natl. Acad. Sci. USA* 91:11422; Zuckermann *et al.*, 1994, *J. Med. Chem.* 37:2678; Cho *et al.*, 1993, *Science* 261:1303; Carrell *et al.*, 1994, *Angew. Chem. Int. Ed. Engl.* 33:2059; Carell *et al.*, 1994, *Angew. Chem. Int. Ed. Engl.* 33:2061; and Gallop *et al.*, 1994, *J. Med. Chem.* 37:1233.

15 Libraries of compounds may be presented in solution (*e.g.*, Houghten, 1992, *BioTechniques* 13:412-421), or on beads (Lam, 1991, *Nature* 354:82-84), chips (Fodor, 1993, *Nature* 364:555-556), bacteria (U.S. Patent No. 5,223,409), spores (Patent Nos. 5,571,698; 5,403,484; and 5,223,409), plasmids (Cull *et al.*, 1992, *Proc. Natl. Acad. Sci. USA* 89:1865-1869) or phage (Scott and Smith, 1990, *Science* 249:386-390; Devlin, 1990,
20 *Science* 249:404-406; Cwirla *et al.*, 1990, *Proc. Natl. Acad. Sci. USA* 87:6378-6382; and Felici, 1991, *J. Mol. Biol.* 222:301-310).

Screening the libraries can be accomplished by any of a variety of commonly known methods. See, *e.g.*, the following references, which disclose screening of peptide libraries: Parmley & Smith, 1989, *Adv. Exp. Med. Biol.* 251:215-218; Scott & Smith, 1990,
25 *Science* 249:386-390; Fowlkes *et al.*, 1992; *BioTechniques* 13:422-427; Oldenburg *et al.*, 1992, *Proc. Natl. Acad. Sci. USA* 89:5393-5397; Yu *et al.*, 1994, *Cell* 76:933-945; Staudt *et al.*, 1988, *Science* 241:577-580; Bock *et al.*, 1992, *Nature* 355:564-566; Tuerk *et al.*, 1992, *Proc. Natl. Acad. Sci. USA* 89:6988-6992; Ellington *et al.*, 1992, *Nature* 355:850-852; U.S. Patent No. 5,096,815, U.S. Patent No. 5,223,409, and U.S. Patent No. 5,198,346, all to
30 Ladner *et al.*; Rebar & Pabo, 1993, *Science* 263:671-673; and PCT Publication No. WO 94/18318.

5.3 THERAPEUTIC USES

The invention further encompasses methods for modulating the immune response. CD91 recognizes and transports antigenic peptide complexes (*e.g.*, HSP-antigenic peptide complexes) for the purpose of presenting such antigenic molecules to cells of the immune system and eliciting an immune response. Thus, the CD91 polypeptide fragment compositions and methods of the invention may be used for therapeutic treatment of HSP-CD91-related disorders and conditions, such as autoimmune diseases, cancer and infectious diseases. In particular, as described in detail herein below, recombinant cells comprising CD91 polypeptide fragment, antibodies, and other compounds that interact with CD91, or modulate the interaction between CD91 and its ligands, *e.g.*, HSP, as well as other compounds that modulate HSP-CD91-mediated processes may be used to elicit, or block, an immune response to treat such HSP-CD91-related disorders and conditions. Recombinant cells comprising CD91 polypeptide fragment, antibodies, and other compounds that interact with CD91, or modulate the interaction between CD91 and its ligands, *e.g.*, HSP, as well as other compounds that modulate HSP-CD91-mediated processes may also be used to effect binding of other CD91 ligands and thereby impact lipid metabolism.

Compounds, such as those identified by screening methods provided herein, that modulate a CD91 ligand-CD91 polypeptide fragment interaction can be useful as therapeutics. Such compounds, include, but are not limited to, agonists, antagonists, such as antibodies, antisense RNAs and ribozymes. Compounds which interfere with ligand (*e.g.*, HSP) - CD91 polypeptide fragment interaction can be used to modulate, *i.e.*, increase or decrease an immune response, and can be used to treat autoimmune responses and conditions. Other antibodies, agonists, antagonists, antisense RNAs and ribozymes may upregulate ligand (*e.g.*, HSP)-CD91 polypeptide fragment interaction, activity, or expression, and would inhibit or enhance the uptake of antigen complexes (*e.g.*, HSP-antigen complexes) by CD91, and therefore be useful in stimulating the host's immune system prior to, or concurrent with, the administration of a vaccine. Described below are methods and compositions for the use of such compounds in the treatment of HSP-CD91-related disorders, such as immune disorders, proliferative disorders, and infectious diseases.

In one embodiment an antagonist of CD91 polypeptide fragment-ligand interaction is used to block the immune response. Such antagonists include compounds that interfere

with binding of a ligand (*e.g.*, an HSP) to a CD91 polypeptide fragment portion of a CD91 by competing for binding to CD91, the ligand, or a ligand-peptide complex.

In one embodiment, the antagonist is an antibody specific for the CD91 polypeptide fragment, or a fragment thereof which contains the HSP ligand binding site. In another
5 embodiment the antagonist is an antibody specific for an HSP, which interferes with binding of the HSP to the receptor.

In another embodiment, the antagonist is a peptide which comprises at least contiguous 10 amino acids of an HSP sequence. Such a peptide can bind to the ligand binding site of the CD91 polypeptide fragment or CD91 endogenous and block the
10 interaction of an HSP or HSP complex.

Such peptides may be produced synthetically or by using standard molecular biology techniques. Amino acid sequences and nucleotide sequences of naturally occurring CD91 ligands, such as HSPs, are generally available in sequence databases, such as GenBank. Computer programs, such as Entrez, can be used to browse the database, and retrieve any
15 amino acid sequence and genetic sequence data of interest by accession number.

Additionally, compounds, such as those identified via techniques such as those described herein above, in Section 5.2, that are capable of modulating a CD91 polypeptide fragment-ligand interaction can be administered using standard techniques that are well known to those of skill in the art.

20 5.3.1 TARGET AUTOIMMUNE DISEASES

Autoimmune diseases that can be treated by the methods, CD91 polypeptide fragments, or compounds identified by the methods of the present invention include, but are not limited to, insulin dependent diabetes mellitus (*i.e.*, IDDM, or autoimmune diabetes), multiple sclerosis, systemic lupus erythematosus, Sjogren's syndrome, scleroderma,
25 polymyositis, chronic active hepatitis, mixed connective tissue disease, primary biliary cirrhosis, pernicious anemia, autoimmune thyroiditis, idiopathic Addison's disease, vitiligo, gluten-sensitive enteropathy, Graves' disease, myasthenia gravis, autoimmune neutropenia, idiopathic thrombocytopenia purpura, rheumatoid arthritis, cirrhosis, pemphigus vulgaris, autoimmune infertility, Goodpasture's disease, bullous pemphigoid, discoid lupus,
30 ulcerative colitis, and dense deposit disease. The diseases set forth above, as referred to herein, include those exhibited by animal models for such diseases, such as, for example

non-obese diabetic (NOD) mice for IDDM and experimental autoimmune encephalomyelitis (EAE) mice for multiple sclerosis.

The methods and compounds identified by the methods of the present invention can be used to treat such autoimmune diseases by reducing or eliminating the immune response to the patient's own (self) tissue, or, alternatively, by reducing or eliminating a pre-existing autoimmune response directed at tissues or organs transplanted to replace self tissues or organs damaged by the autoimmune response.

5.3.2 TARGET INFECTIOUS DISEASES

The infectious diseases that can be treated or prevented using the methods, CD91 polypeptide fragments, and compounds identified by the methods of the present invention include those caused by intracellular pathogens such as viruses, bacteria, protozoans, and intracellular parasites. Viruses include, but are not limited to viral diseases such as those caused by hepatitis type B virus, parvoviruses, such as adeno-associated virus and cytomegalovirus, papovaviruses such as papilloma virus, polyoma viruses, and SV40, adenoviruses, herpes viruses such as herpes simplex type I (HSV-I), herpes simplex type II (HSV-II), and Epstein-Barr virus, poxviruses, such as variola (smallpox) and vaccinia virus, RNA viruses, including but not limited to human immunodeficiency virus type I (HIV-I), human immunodeficiency virus type II (HIV-II), human T-cell lymphotropic virus type I (HTLV-I), and human T-cell lymphotropic virus type II (HTLV-II); influenza virus, measles virus, rabies virus, Sendai virus, picornaviruses such as poliomyelitis virus, coxsackieviruses, rhinoviruses, reoviruses, togaviruses such as rubella virus (German measles) and Semliki forest virus, arboviruses, and hepatitis type A virus.

In another embodiment, bacterial infections can be treated or prevented such as, but not limited to disorders caused by pathogenic bacteria including, but not limited to, *Streptococcus pyogenes*, *Streptococcus pneumoniae*, *Neisseria gonorrhoea*, *Neisseria meningitidis*, *Corynebacterium diphtheriae*, *Clostridium botulinum*, *Clostridium perfringens*, *Clostridium tetani*, *Haemophilus influenzae*, *Klebsiella pneumoniae*, *Klebsiella ozaenae*, *Klebsiella rhinoscleromatis*, *Staphylococcus aureus*, *Vibrio cholerae*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Campylobacter (Vibrio) fetus*, *Campylobacter jejuni*, *Aeromonas hydrophila*, *Bacillus cereus*, *Edwardsiella tarda*, *Yersinia enterocolitica*, *Yersinia pestis*, *Yersinia pseudotuberculosis*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Salmonella typhimurium*, *Salmonella typhi*, *Treponema pallidum*,

Treponema pertenue, *Treponema carateneum*, *Borrelia vincentii*, *Borrelia burgdorferi*,
Leptospira icterohemorrhagiae, *Mycobacterium tuberculosis*, *Toxoplasma gondii*,
Pneumocystis carinii, *Francisella tularensis*, *Brucella abortus*, *Brucella suis*, *Brucella*
melitensis, *Mycoplasma spp.*, *Rickettsia prowazeki*, *Rickettsia tsutsugumushi*, *Chlamydia*
 5 *spp.*, and *Helicobacter pylori*.

In another preferred embodiment, the methods can be used to treat or prevent
 infections caused by pathogenic protozoans such as, but not limited to, *Entamoeba*
histolytica, *Trichomonas tenax*, *Trichomonas hominis*, *Trichomonas vaginalis*,
Trypanosoma gambiense, *Trypanosoma rhodesiense*, *Trypanosoma cruzi*, *Leishmania*
 10 *donovani*, *Leishmania tropica*, *Leishmania braziliensis*, *Pneumocystis pneumonia*,
Plasmodium vivax, *Plasmodium falciparum*, and *Plasmodium malaria*.

5.3.3 TARGET PROLIFERATIVE CELL DISORDERS

With respect to specific proliferative and oncogenic disease associated with HSP-
 $\alpha 2\text{M}$ receptor activity, the diseases that can be treated or prevented by the methods CD91
 15 polypeptide fragments, or compounds identified by the methods of the present invention
 include, but are not limited to: human sarcomas and carcinomas, *e.g.*, fibrosarcoma,
 myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma,
 angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma,
 synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon
 20 carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell
 carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland
 carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma,
 medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct
 carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical
 25 cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma,
 epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma,
 ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma,
 meningioma, melanoma, neuroblastoma, retinoblastoma; leukemias, *e.g.*, acute lymphocytic
 leukemia and acute myelocytic leukemia (myeloblastic, promyelocytic, myelomonocytic,
 30 monocytic and erythroleukemia); chronic leukemia (chronic myelocytic (granulocytic)
 leukemia and chronic lymphocytic leukemia); and polycythemia vera, lymphoma

(Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenström's macroglobulinemia, and heavy chain disease.

Diseases and disorders involving a deficiency in cell proliferation or in which cell proliferation is desired for treatment or prevention, and that can be treated or prevented by inhibiting the $\alpha 2M$ receptor function, include but are not limited to degenerative disorders, growth deficiencies, hypoproliferative disorders, physical trauma, lesions, and wounds; for example, to promote wound healing, or to promote regeneration in degenerated, lesioned or injured tissues, etc.

5.3.4 USE OF CD91 POLYPEPTIDE FRAGMENT AS DOMINANT NEGATIVE MUTANTS

In another embodiment of the invention, dominant negative mutants ("dominant negatives") may be used therapeutically to block the immune response to an HSP-antigen complex, *e.g.*, to treat an auto-immune disorder. In general, such dominant-negatives are mutants which, when expressed, interact with ligand (*i.e.*, HSP-antigenic molecule complex), but lack one or more functions, *i.e.* endocytotic functions and/or signaling functions, of normal CD91. Such mutants interfere with the function of normal CD91 in the same cell or in a different cell, *e.g.* by titration of HSP-peptide complexes from the wild type receptor. Such a mutation, for example, can be one or more point mutation(s), a deletion, insertion, or other mutation in either the extracellular of the 515 kDa subunit, or the extracellular, transmembrane or intracellular domains of the 85 kDa subunit of the $\alpha(2)$ macroglobulin receptor (*see* Krieger and Herz, 1994, *Annu. Rev. Biochem* 63:601-637 for CD91 subunit configuration). However, in construction of dominant negative mutations in the either subunit, care should be taken to ensure that the cleavage domain (signaling cleavage between amino acids 3525 and 3526 of the precursor of CD91) remains intact so that the 515 kDa subunit is processed and presented on the cell surface. Additionally, care should be taken to ensure that the domains by which the two subunits associate should also remain functional. For example, in a specific embodiment, the C-terminal intracellular domain of the 85 kDa subunit is truncated. In another embodiment, a point mutation on the N-terminal 515 kDa subunit blocks endocytosis but not ligand binding. In another embodiment, the N-terminal 515 kDa subunit is expressed as a fusion protein, wherein the C-terminus of said fusion protein is the transmembrane domain and optionally the intracellular domain, of another Type I single transmembrane receptor.

Expression of a such a dominant negative mutation in cell can block uptake of ligand by normal functional receptors in the same or neighboring cells by titrating out the amount of available ligand. Thus, a recombinant antigen presenting cell expressing such a dominant negative can be used to titrate out HSP-antigenic molecule complexes when administered to a patient in need of treatment for an autoimmune disorder.

CD91 polypeptide fragments

In one embodiment of the present invention, an HSP-CD91 competitive antagonist is a CD91 polypeptide fragment, preferably a soluble peptide, that can bind to HSPs and therefore competitively inhibit or decrease HSP binding to the native (*e.g.* full length CD91) receptor.

Functional expression of HSP-binding portions of CD91 polypeptide fragment is preferably carried out as described for the CR8 domain by Huang *et al.*, 1999, J. Biol. Chem 274:14130-14136. Briefly, to maintain proper folding, the protein is expressed as a GST fusion, expressed recombinantly, the GST portion cleaved, uncleaved protein removed on GSH-Sepharose, and cleaved protein refolded. Since the complement repeats bind to calcium, proper folding is assayed by measuring the binding of the refolded protein to calcium.

In a specific mode of the embodiment, an HSP-binding portion of a CD91 polypeptide fragment consists of or comprises at least one complement repeat, most preferably selected from CR3-CR10. In another specific mode of the embodiment, an HSP-binding portion of a CD91 polypeptide fragment comprises a cluster of complement repeats, most preferably C1-II. In other modes of the embodiment, the HSP-binding portion consists of at least 10, more preferably at least 20, yet more preferably at least 30, yet more preferably at least 40, and most preferably at least 80 (continuous) amino acids. In specific modes of the embodiment, such fragments are not larger than 40-45 amino acids. In other specific modes of the embodiment, such fragments are not larger than 80-90 amino acids. Exemplary preferred peptides include but are not limited to those consisting of amino acids of SEQ ID NOs:2 or 3 of human p95.

Derivatives or analogs of HSP-binding portions of a CD91 polypeptide fragment are also contemplated as competitive antagonists of HSP-CD91 polypeptide fragment complexes. Such derivative or analogs include but are not limited to those molecules comprising regions that are substantially homologous to the extracellular domain of a CD91

polypeptide fragment or fragments thereof (e.g., in various embodiments, at least 60% or 70% or 80% or 90% or 95% identity over an amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art) or whose encoding nucleic acid is capable of hybridizing to a sequence encoding a CD91 polypeptide fragment that binds HSP, such hybridizing occurring under stringent, moderately stringent, or nonstringent conditions. In certain specific embodiments, a CD91 polypeptide fragment derivative is a chimeric or fusion protein comprising an HSP-binding portion of a CD91 polypeptide fragment, preferably consisting of at least one complement repeat of C1-II) joined at its amino- or carboxy-terminus via a peptide bond to an amino acid sequence of a different protein. Such a chimeric protein can be produced recombinantly as described above, by omitting the cleavage repurification steps.

Other HSP-binding CD91 polypeptide fragment derivatives can be made by altering CD91 polypeptide fragment coding sequences by substitutions, additions or deletions that provide for functionally equivalent molecules. Due to the degeneracy of nucleotide coding sequences, other DNA sequences which encode substantially the same amino acid sequence as an HSP-binding CD91 polypeptide fragment coding sequence or fragment thereof may be used in the practice of the present invention. Selection of suitable alterations and production of HSP-binding CD91 polypeptide fragment derivatives can be made applying the same principles described above for CD91 polypeptide fragment derivatives and using the general methods described in Sections 5.1.2 and 5.1.3.

HSP peptides

In another mode of the embodiment, the antagonist is a peptide which comprises at least contiguous 10 amino acids of an HSP sequence. Such a peptide can bind to the ligand binding site of a CD91 polypeptide fragment and block the interaction of an HSP or HSP complex. Such peptides may be produced synthetically or by using standard molecular biology techniques. Amino acid sequences and nucleotide sequences of naturally occurring HSPs are generally available in sequence databases, such as GenBank. Computer programs, such as Entrez, can be used to browse the database, and retrieve any amino acid sequence and genetic sequence data of interest by accession number. Methods for recombinant and synthetic production of such peptides are described in Sections 5.1.2 and 5.1.3. Additionally, compounds, such as those identified via techniques such as those described herein above, in Section 5.2, that are capable of modulating a CD91 polypeptide fragment

activity can be administered using standard techniques that are well known to those of skill in the art.

RAP

In one embodiment of the present invention, an HSP-CD91 polypeptide fragment competitive antagonist is α 2MR-associated protein (RAP) (Genbank accession no. A39875) or a CD91 polypeptide fragment-binding portion thereof. In a specific mode of the embodiment, an CD91 polypeptide fragment-binding portion of RAP consists of or comprises a fragment of the RAP RBD consisting of at least 10 (continuous) amino acids. In other modes of the embodiment, the fragment consists of at least 20, 30, 40, 50, 75 or 100 amino acids of the RBD. In specific modes of the embodiment, such fragments are not larger than 28, 50 or 100 amino acids. In other specific modes of the embodiment, a p95 protein-binding portion of RAP comprises a CD91 polypeptide fragment-binding portion of domain 1 or 3, *e.g.* as depicted in Nielsen *et al.*, *supra*, Fig. 3, Group D or E. Expression of recombinant RAP or a CD91 polypeptide fragment-binding portion thereof, is preferably achieved as described by Anderson, U.S. Patent No. 5,399,349.

6. EXAMPLE: CLONING, EXPRESSION, AND PURIFICATION OF p95 AND p110

6.1 INTRODUCTION

The Example presented herein describes the successful identification of an interaction between gp96, HSP90, HSP70, and calreticulin with CD91 present in macrophages and dendritic cells. The experiments presented herein form the basis for the purification of a p95 or p110 polypeptide or a fragment or an analog, derivative or mimetic thereof and for the screening and therapeutic methods of the present invention.

6.2 MATERIALS AND METHODS

Purification of HSPs. HSPs were purified as described (Srivastava, P.K., 1997, Methods: A companion to Methods in Enzymology 12:165-171; Basu and Srivastava, 1999, J. Exp. Med. 189(5):797-802). All buffers used for purifications were prepared with endotoxin free water (Nanopure Infinity UV/UF, Barnstead/Thermolyne, Dubuque, IA) and all glasswares used for purification were cleaned with endotoxin free water and baked in a

400iF oven (Gruenberg, Williamsport, PA). The HSP-containing fractions were identified by immunoblots.

Conjugation of proteins to FITC and staining of cells. Purified proteins were conjugated to FITC using the FluoroTag FITC conjugation kits (SIGMA) as per the manufacturers protocol. Conjugation was confirmed by a 2kDa increase in molecular weight by SDS-PAGE and by immunoblotting with an anti-FITC monoclonal antibody. Incubations of indicated amounts of FITC-tagged proteins and cells were done in the presence of 1% nonfat dry milk (Carnation®) in PBS for 20min at 4°C. After repeated washing, cells were analyzed by flow cytometry (Becton Dickenson, La Jolla, California).

Cells were also labeled with propidium iodide just before FACScan analysis. Cells staining positive for propidium iodide were gated out of the events. No differences were observed in the binding of HSPs to Mac-1+ cells from pristaned or non-pristaned mice. Fixed or unfixed cells were labeled with FITC-tagged HSP as above. Labeled cells were visualized using a Zeiss LSM confocal microscope.

Affinity chromatography. Proteins (1mg) in 2ml volume were incubated with 2ml of equilibrated AminoLink beads in PBS with a reductant (NaCNBH_3) for 1 hour. Uncoupled protein was removed by extensive washing of the column and unreactive groups quenched. Immobilization yields were typically >92% of the starting amount of protein. Columns were stored at 4°C until used. Such columns were made with antibodies described herein (purified as described in Srivastava *et al.*, 1986, Proc. Natl. Acad. Sci., U.S.A. 83:3407-3411) and albumin.

Purification of Recombinant Human CD91-p95 or p110 fragment A construct was engineered to express and export soluble, epitope-tagged CD91-p95 or p110 protein. The construct comprised the p95 or p110 cDNA fragment of human CD91 (SEQ ID NO:1 or 12 respectively) operably linked to synthetic oligonucleotides encoding a thrombin protease recognition and cleavage site, thrombin, monoclonal antibody epitope, an HA(haemagglutinin)(12CA5) epitope, biotin-ligase recognition sequence (AviTag Biotin Ligase) and 6X-His hexa-histidine purification sequence just prior to an engineered stop codon. Expression plasmid DNA was transfected into HEK-293. After drug resistance selection, supernatants from cell clones secreting high levels of recombinant epitope-tagged human CD91-p95 or p110 protein were applied to anti-HA affinity resins for single step purification of recombinant human CD91-p95 or p110 protein. ELISA assays were performed with HRP conjugated Anti-penta-His antibodies and anti-HA antibodies that bind

to epitopes on tagged protein fragments to confirm presence of protein fragment. ELISA assays were performed with HRP conjugated anti-HA antibodies and anti-CD91 (8G1) antibodies that bind to epitopes on tagged protein fragment to confirm presence of protein fragment. After drug resistance selection, supernatants from cell clones secreting high levels of recombinant epitope-tagged human CD91-p95 or p110 protein can also be applied to Ni-NTA affinity resins for single step purification of recombinant human CD91-p95 or p110 protein.

6.3 RESULTS

Expression of p80

Random decamers were used in an RT-PCR reaction to synthesize cDNA from total human liver RNA (April 2001). Synthetic oligonucleotide primers specific to a defined fragment of the CD91 gene (Human mRNA for LDL receptor related protein; GenBank Accession #X13916) amplified the expected 2.35kB product from this cDNA. The amplicon was cloned and sequenced. Primers were chosen to amplify a region of this sequence encoding for the first 728 amino acids of CD91. The molecular weight of the translated protein from this 728 amino acid N-terminal portion of CD91 is approximately 80kD.

A construct was engineered to express and export a soluble, epitope-tagged CD91-p80 protein. A "tag" sequence was added, in-frame, to the end of the CD91-p80 PCR product that encoded for thrombin, an HA(haemagglutinin)(12CA5) epitope, biotin-ligase recognition sequence (AviTag Biotin Ligase) and 6X-His hexa-histidine purification sequence just prior to an engineered stop codon. This construct was cloned into mammalian expression vector pCDNA3 (Invitrogen) and transfected into a variety of mammalian cell lines. After failing to detect any secreted recombinant CD91-p80 in transfection supernatants, an IFA was performed on transfected cells using anti-HA-FITC. The IFA clearly showed individual cells to brightly stain anti-HA-FITC. These cells non-productively express HA peptide linked to a CD91 fragment. However, this recombinant CD91-p80, presumably mis-folded and sequestered in the endoplasmic reticulum.

Thus, the p80 construct engineered to express and export soluble, epitope-tagged CD91-p80 expressed protein, only produced a protein which was retained in intracellular compartments.

Expression of p95 and p110

Applicants recognized the importance of the CD91 tertiary structure (most notably the six YWTD beta-propeller motifs) and its effect on expression of secreted, functional recombinant protein. The CD91-p80 construct terminates in a position which disrupts a beta-propeller motif. An extension to the CD91-p80 clone was designed to alleviate this problem. The extension was designed to encode an additional 123 amino acids of CD91 resulting in the cDNA encoding p95, ending in a region that preserves the well-defined tertiary structure. With the added extension, the molecular weight of the translated recombinant protein is approximately 95kD (851 amino acids from the N-terminus of CD91). The resulting CD91 fragment was named p95 (SEQ ID NO:2).

For p110, an additional 135 amino acids of CD91 were added. With the added extension, the molecular weight of the translated recombinant protein is approximately 110kD (986 amino acids from the N-terminus of CD91), and the resulting CD91 fragment was named p110 (SEQ ID NO:12 and 13).

The p95 extension was generated by PCR using a 3.3kB cloned region of the 5'-end of human CD91 RNA as a template. The extension was cloned, in-frame, into the existing CD91-p80 clone and maintains all the C-terminal "tag" sequences.

A soluble, epitope-tagged CD91-p95 protein was successfully expressed and exported using the construct. The expressed protein consisted of the p95 fragment, Thrombin, HA epitope (12CA5), AviTag Biotin Ligase, and 6X-His, (SEQ ID NO:3). Cells transfected with this construct cloned into pcDNA3 (Invitrogen) and pcDNA5/FRT/TO (Invitrogen) expression vectors have been shown by ELISA to secrete a protein in the 100kD range that is recognized by anti-HA and anti-CD91 (8G1). The p95 epitope-tagged protein eluted from the HA affinity column was visualized by staining with Coomassie Brilliant Blue (Figure 2). The expressed protein was not restricted to intracellular compartments as was the case with the p80 fragment of CD91.

Similarly, the p110 expression construct was constructed and the expressed protein purified by affinity chromatography using Ni-nitroloetic (NTA) (Figure 5).

These methods are also used to recombinantly express CD91 polypeptide fragments of the invention that comprise CD91 polypeptides comprising amino acid sequence extending into domain II region of CD91. In other embodiments, the CD91 fragment comprises p95 plus additional amino acid sequences extending into domain III region of CD91. In yet other embodiments, the CD91 fragment comprises additional amino acid

sequences extending into domain IV region of CD91. In yet other embodiments, the CD91 fragment comprises fragments of specific amino acid residues as described in Section 5.2 above.

5 *Expression of p282*

The p282 CD91 fragment of cDNA encodes four additional YWTD beta propeller structural motifs, which extends to amino acid residue 2517 of the CD91 sequence SEQ ID NO:2 (see Figure 4 (SEQ ID NO:7)). In particular, the p282 fragment comprises amino acid residues that encode four additional propeller regions than p110 corresponding to
10 amino acid residues 1269-1531, 1583-1846, 1934-2151, and 2199-2473, respectively, of SEQ ID NO: 2. Extensions to additional amino acids preserves the well-defined tertiary structure necessary for recombinant expression. With the added extension, the molecular weight of the translated recombinant protein is approximately 282kD (2517 amino acids from the N-terminus of CD91). The resulting CD91 fragment is named p282 (SEQ ID
15 NO:7).

The p282 extension is generated by PCR using a cloned region of the human CD91 RNA as a template. The extension is cloned, in-frame, into the existing CD91-p80 clone and maintains all the C-terminal "tag" sequences.

A soluble, epitope-tagged CD91-p282 protein is successfully expressed and
20 exported using the construct. The expressed protein consists of the p282 fragment, Thrombin, HA epitope (12CA5), AviTag Biotin Ligase, and 6X-His, (SEQ ID NO:6). Cells transfected with this construct cloned into pcDNA3 (Invitrogen) and pcDNA5/FRT/TO (Invitrogen) expression vectors are confirmed by ELISA to secrete a protein in the 290kD range that is recognized by anti-HA and anti-CD91. The p282 epitope-tagged protein eluted
25 from the HA affinity column is visualized by staining with Coomassie Brilliant Blue. The expressed protein is not restricted to intracellular compartments as is the case with the p80 fragment of CD91. The expressed p282 protein is purified by affinity chromatography using Ni-nitroloetic (NTA).

30 *Expression of p373*

The p373 CD91 fragment of cDNA encodes a complete additional YWTD beta propeller structural motif, which extends to amino acid residue 3330 of the CD91 sequence

SEQ ID NO:2 (see Figure 4 (SEQ ID NO:9)). In particular, the p373 fragment comprises amino acid residues that encode one additional propeller region than p282, corresponding to amino acid residues 3019-3284 of SEQ ID NO:2. Extensions to additional amino acids preserves the well-defined tertiary structure necessary for recombinant expression. With the added extension, the molecular weight of the translated recombinant protein is approximately 373kD (3330 amino acids from the N-terminus of CD91). The resulting CD91 fragment is named p373 (SEQ ID NO:9).

The p373 extension is generated by PCR using a 3.3kB extension is generated by PCR using a cloned region of the human CD91 RNA as a template. The extension is cloned, in-frame, into the existing CD91-p80 clone and maintains all the C-terminal "tag" sequences.

A soluble, epitope-tagged CD91-p373 protein is successfully expressed and exported using the construct. The expressed protein consists of the p373 fragment, Thrombin, HA epitope (12CA5), AviTag Biotin Ligase, and 6X-His, (SEQ ID NO:8). Cells transfected with this construct cloned into pcDNA3 (Invitrogen) and pcDNA5/FRT/TO (Invitrogen) expression vectors are confirmed by ELISA to secrete a protein in the 380kD range that is recognized by anti-HA and anti-CD91. The p373 epitope-tagged protein eluted from the HA affinity column is visualized by staining with Coomassie Brilliant Blue. The expressed protein is not restricted to intracellular compartments as is the case with the p80 fragment of CD91. The expressed p373 protein is purified by affinity chromatography using Ni-nitroloetic (NTA).

Expression of p494

The p494 CD91 fragment of cDNA encodes an additional YWTD beta propeller structural motifs, which extends to amino acid residue 4420 of the CD91 sequence SEQ ID NO:2 (see Figure 4 (SEQ ID NO:11)). In particular, the p494 fragment comprises amino acid residues that encode one additional propeller region than p373, corresponding to amino acid residues 3828-4142 of SEQ ID NO:2. The p494 fragment also comprises amino acid residues that encode a furin cleavage site at residue 3943 of SEQ ID NO:2 and CHO side groups at residues 4075 and 4125 of SEQ ID NO:2. Applicants recognized the importance of the CD91 tertiary structure encoded by p95 (most notably the six YWTD beta-propeller motifs) and its effect on expression of secreted, functional recombinant protein. Extensions

to additional amino acids preserves the well-defined tertiary structure necessary for recombinant expression. With the added extension, the molecular weight of the translated recombinant protein is approximately 494kD (4420 amino acids from the N-terminus of CD91). The resulting CD91 fragment is named p494 (SEQ ID NO:11).

5 The p494 extension is generated by PCR using a 3.3kB extension is generated by PCR using a cloned region of the human CD91 RNA as a template. The extension is cloned, in-frame, into the existing CD91-p80 clone and maintains all the C-terminal "tag" sequences.

10 A soluble, epitope-tagged CD91-p494 protein is successfully expressed and exported using the construct. The expressed protein consists of the p494 fragment, Thrombin, HA epitope (12CA5), AviTag Biotin Ligase, and 6X-His, (SEQ ID NO:10). Cells transfected with this construct cloned into pcDNA3 (Invitrogen) and pcDNA5/FRT/TO (Invitrogen) expression vectors are confirmed by ELISA to secrete a protein in the 500kD range that is recognized by anti-HA and anti-CD91. The p494
15 epitope-tagged protein eluted from the HA affinity column is visualized by staining with Coomassie Brilliant Blue. The expressed protein is not restricted to intracellular compartments as is the case with the p80 fragment of CD91. The expressed p494 protein is purified by affinity chromatography using Ni-nitroloiticetic (NTA).

20 The invention is not to be limited in scope by the specific embodiments described which are intended as single illustrations of individual aspects of the invention, and functionally equivalent methods and components are within the scope of the invention. Indeed various modifications of the invention, in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the
25 appended claims.

 All references cited herein, including patent applications, patents, and other publications, are incorporated by reference herein in their entireties for all purposes.

WHAT IS CLAIMED:

1. A nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, wherein the nucleotide sequence is not flanked by sequences adjacent to SEQ ID NO:1 in the native CD91 nucleotide sequence.
- 5 2. A nucleic acid molecule comprising a nucleotide sequence which encodes a polypeptide consisting of the amino acid sequence of SEQ ID NO:2, 3, 6, 7, 8, 9, 10, 11, or 12.
3. A nucleic acid molecule comprising a nucleotide sequence which 1) hybridizes over its full length to the nucleotide sequence of SEQ ID NO:1 under conditions of stringent
10 washing and 2) encodes a polypeptide that is capable of (i) being recombinantly produced and secreted into culture medium and (ii) binding to a heat shock protein.
4. A nucleic acid molecule comprising a nucleotide sequence which 1) hybridizes over its full length to the nucleic acid sequence of SEQ ID NO: 1, 14, 15, 16, or 17 under
15 conditions of stringent washing; and 2) encodes a polypeptide that is capable of (i) being recombinantly produced and secreted into culture medium and (ii) binding to a heat shock protein.
5. A nucleic acid molecule comprising a nucleotide sequence which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, 3, 6, 7, 8, 9, 10, 11, or 12, wherein said polypeptide interacts with a heat shock protein.
- 20 6. The isolated nucleic acid molecule of any one of claims 1-5, further comprising a heterologous nucleotide sequence.
7. A vector comprising the nucleic acid molecule of any one of claims 1-5.
8. An expression vector comprising the nucleic acid molecule of any one of claims 1-5, wherein the nucleotide sequence is operatively associated with a nucleotide regulatory
25 sequence that controls expression of the nucleotide sequence in a host cell.

9. A genetically engineered host cell comprising the nucleic acid molecule of any one of claims 1-5, wherein the nucleotide sequence is operatively associated with a nucleotide regulatory sequence that controls expression of the nucleotide sequence in the host cell.

10. A host cell comprising the expression vector of claim 8.

5 11. A polypeptide comprising the amino acid sequence of SEQ ID NO:2, 3, 6, 7, 8, 9, 10, 11, or 12, wherein the amino acid sequence is not flanked by sequences adjacent to SEQ ID NO:2, 3, 6, 7, 8, 9, 10, 11, or 12, respectively, in the native CD91 polypeptide sequence.

10 12. An isolated polypeptide comprising a contiguous amino acid sequence, wherein said amino acid sequence consists of amino acid residues 1-851 of SEQ ID NO:11, fused to one or more contiguous amino acids of amino acid residues 852-4420 of SEQ ID NO:11.

13. An isolated polypeptide encoded by a nucleic acid molecule that hybridizes under stringent conditions to a complement of SEQ ID NO: 1, 14, 15, 16, or 17, wherein said polypeptide binds to a heat shock protein.

15 14. An isolated polypeptide encoded by a nucleic acid molecule which hybridizes under stringent conditions to a complement of a nucleic acid molecule consisting of a nucleotide sequence that encodes a polypeptide consisting of the amino acid sequence of SEQ ID NO:2, 6, 8, 10, 11, or 12, wherein said polypeptide binds to a heat shock protein.

20 15. The polypeptide of claim 13 or 14, wherein the heat shock protein is selected from the group consisting of a gp96, hsp 90, hsp 70, and calreticulin.

16. The polypeptide of claim 15, wherein the heat shock protein is gp96.

17. A fusion polypeptide comprising the amino acid sequence of SEQ ID NO:2, 3, 6, 7, 8, 9, 10, 11, or 12 and a heterologous amino acid sequence.

25 18. A method for making the polypeptide of any one of claims 12-17, comprising the steps of:

- (a) culturing a cell comprising a recombinant nucleotide sequence encoding the polypeptide of any one of claims 11-17, under conditions such that the polypeptide is expressed by said cell; and
- (b) recovering the expressed polypeptide from the cell culture.

- 5 19. An antibody or fragment thereof that immunospecifically binds to a CD91 polypeptide fragment, wherein the CD91 polypeptide fragment comprises the amino acid sequence of SEQ ID NO.:2, 3, 6, 7, 8, 9, 10, 11, or 12.
- 10 20. The antibody or fragment of claim 19, wherein the antibody is a polyclonal antibody, a monoclonal antibody, a humanized antibody, a single chain antibody, or a chimeric antibody.
21. The antibody or fragment of claim 20, wherein the antibody or fragment thereof is a Fab fragment.
22. An anti-idiotypic antibody which binds to the antibody or fragment of claim 19.
- 15 23. A kit comprising the antibody of claim 19 and instructions for use of the antibody to detect a CD91 polypeptide fragment.
24. A method for treating a CD91-related disease or disorder comprising administering the polypeptide of any one of claims 11-17 to a mammal in need thereof in an amount effective to treat the disease or disorder.
- 20 25. The method of claim 24, wherein the disease or disorder is an autoimmune disorder, a disease or disorder involving disruption of antigen presentation or endocytosis, a disease or disorder involving cytokine clearance or inflammation, a proliferative disorder, a viral disorder or other infectious disease, hypercholesterolemia, Alzheimer's disease, diabetes, or osteoporosis.
- 25 26. A method for identifying a compound that modulates an HSP-CD91-mediated process, comprising:

- (a) contacting a test compound with a heat shock protein and a CD91 polypeptide fragment that binds a CD91 ligand; and
- (b) measuring the level of the CD91 polypeptide fragment activity or expression,

5 such that if the level of activity or expression measured in (b) differs from the level of the CD91 polypeptide fragment activity or expression measured in the presence the heat shock protein but in the absence of the test compound, then a compound that modulates an HSP-CD91-mediated process is identified.

10 27. The method of Claim 26, wherein the compound identified is an antagonist which interferes with the interaction of the heat shock protein with the CD91 polypeptide fragment.

28. The method of Claim 26 in which the test compound is a small molecule or a peptide.

15 29. The method of Claim 28 in which the peptide comprises at least 5 consecutive amino acids of the CD91 polypeptide fragment.

30. The method of Claim 26 in which the HSP-CD91-mediated process affects an autoimmune disorder, a disease or disorder involving disruption of antigen presentation or endocytosis, a disease or disorder involving cytokine clearance or inflammation, a proliferative disorder, a viral disorder or other infectious disease, hypercholesterolemia, 20 Alzheimer's disease, diabetes, or osteoporosis.

31. A method for identifying a compound that modulates the binding of a heat shock protein to CD91, comprising:

- (a) contacting a heat shock protein with a CD91 polypeptide fragment, or derivative thereof, which CD91 polypeptide fragment binds a CD91 25 ligand, in the presence of a test compound under conditions conducive to binding; and

- (b) . measuring the level of heat shock protein bound to the CD91 polypeptide fragment, analog, derivative or mimetic thereof,

such that if the level of bound heat shock protein measured in (b) differs from the level of heat shock protein measured bound to the CD91 polypeptide fragment or analog, derivative,
5 or mimetic thereof measured under said conditions in the absence of the test compound, then a compound that modulates the binding of an HSP to the CD91 polypeptide fragment is identified.

32. The method of Claim 31 wherein the CD91 polypeptide fragment, or derivative thereof, is immobilized to a solid support.

10 33. The method of Claim 32 wherein the solid support is a microtiter dish.

34. The method of Claim 31 wherein the level of bound heat shock protein is measured using a heat shock protein-specific antibody.

35. The method of Claim 31 wherein the heat shock protein is labeled and the level of bound heat shock protein is measured by detecting the label.

15 36. The method of Claim 35 wherein the heat shock protein is labeled with a fluorescent label.




FIG. 1




FIG. 2

SHEET 3 OF 5

20

MLTPPLLLLVPLLSALVSG-ATMDA

PKTCSPKQFACRDQITCISKGWRCDGERDCPDGSDEAPEICPQSKAQRCPPNEHSCLGTELCVPMSRLCNGIQDCMDGSDEGAHCRELRANCSRMGCQHHCCVPTPSGPTCYCNSSFOLEADGKTCKDFDCSVYGTCSQLCTNTDGSSFTCGCEGYLLQPDNRSCKAKN

EPVDRPPVLLIANSQNILATYLSGAQVSTITPTSTRQTTAMDPSYANETVCWVHVGDSSAAQTQLKCARMP
 GLKGFVDEHTINISLSLHHVEQMAIDWLTGNFYFVDDIDDRIFFVCHNRNGDTCTVLLDLELYNPKGIALDP
 AMGVFFTDYGGQPKVERCDMDGQNRKLVDSKIVFPHGITLDELVSRLVYADAYLDYIEVVDYEGKGRQ
 TIIQGIIEHLYGLTVFENLYATNSDNANTQQKTSVIRVNRFNSTFYQVTRVDKGGALHIYHRRQPRV

RSHACENDQYGKPGGCSDICLLANSHKARTCRCRSGFSLGSDGKSK

KPEHEFLVYGKORPGIIRGMDMGAKVPDEHMIPTENLMNPRALDPHASTGFIYFADTTISYLIGRQKIDG
 TERETILKDGTHNVGVAVDWMGDNLVNTDDGPKKTSVARLEKAAQTRKTLLEGKMTHPRAIVVDPLNG
 WMYWTDWEEDPKDSRRGRLERAWMDGSHRDIFVTSKTVLWPNGLSLDIPAGRLXWDAFYDRIETILLNG
 TDRKIVYEGPELNHAFGLCHHGNLFWTEYRSGSVYRLERGVAGAPPTVILLRSERPPIFEIRMYDAHE

QQVGTNKCRVNNGGCSSLCLATPGSRQCACAEDQVLDTDGVTCL...CR1
25-66CR2
70-110EGF-like #1
111-149EGF-like #2
150-189YWTD
β-Propeller
#1EGF-like #3
474-520YWTD
β-Propeller
#2EGF-like #4
800-843

FIG. 3




FIG. 4




FIG. 5

SEQUENCE LISTING

<110> Antigenics, Inc.

<120> Heat Shock Protein Binding Fragments of CD91, and Uses Thereof

<130> 8449-304

<150> 60/416,821

<151> 2002-10-07

<160> 17

<170> PatentIn version 3.2

<210> 1

<211> 2553

<212> DNA

<213> H. sapiens

<400> 1

```

atgctgaccc cgccgttget cctgctgctg ccctgctct cagctctggt cgcggcggct      60
cgacgccc ctaagacttg cagccccaag cagtttgctt gcagagatca aataacctgt      120
atctcaaagg gctggcgggt cgacgggtgag agggactgcc cagacggatc tgacgaggcc      180
cctgagattt gtccacagag taaggccag cgatgccagc caaacgagca taactgcctg      240
ggctactgagc tgtgtgttcc catgtccgc ctctgcaatg gggccagga ctgcatggac      300
ggctcagatg aggggcccc ctgccgagag ctccaaggca actgctctcg cctgggctgc      360
cagcaccatt gtgtccccac actcgatggg ccacctgct actgcaacag cagctttcag      420
cttcaggcag atggcaagac ctgcaaagat tttgatgagt gctcagtgtg cggcacctgc      480
agccagctat gcaccaacac agacgggtcc ttcatatgtg gctgtgttga aggatacctc      540
ctgcagccgg ataaccgctc ctgcaaggcc aagaacgagc cagtagaccg gccccctgtg      600
ttgatag ccaactccca gaacatcttg gccacgtacc tgagtggggc ccagggtgtct      660
accatcacac ctacgagcac gcggcagacc acagccatgg acttcagcta tgccaacgag      720
accgtatgct ggggtgcatgt tggggacagt gctgctcaga cgcagctcaa gtgtgcccgc      780
atgcctggcc taaagggtt cgtggatgag cacaccatca acatctccct cagtctgcac      840
cacgtggaac agatggccat cgactggctg acaggcaact tctactttgt ggatgacatc      900
gatgatagga tctttgtctg caacagaaat ggggacacat gtgtcacatt gctagacctg      960
gaactctaca accccaaggg cattgccctg gaccctgcca tggggaagggt gtttttctact     1020
gactatgggc agatcccaaa ggtggaacgc tgtgacatgg atgggcagaa ccgcaccaag     1080
ctcgtcgaca gcaagattgt gtttcctcat ggcatcacgc tggacctggt cagccgcctt     1140
gtctactggg cagatgccta tctggactat attgaagtgg tggactatga gggcaagggc     1200

```

cgccagacca tcattccagg catcctgatt gagcacctgt acggcctgac tgtgtttgag 1260
 aattatctct atgccaccaa ctccgacaat gccaatgccc agcagaagac gagtgtgatc 1320
 cgtgtgaacc gctttaacag caccgagtag cagggtgtca cccgggtgga caagggtggt 1380
 gccctccaca tctaccacca gaggcgtcag ccccgagtga ggagccatgc ctgtgaaaac 1440
 gaccagtatg ggaagccggg tggctgctct gacatctgcc tgctggccaa cagccacaag 1500
 gcgcggacct gccgctgccg ttccggcttc agcctgggca gtgacgggaa gtcattgcaag 1560
 aagccggagc atgagctgtt cctcgtgtat ggcaagggcc ggccaggcat catccggggc 1620
 atggatatgg gggccaaggc cccgatgag cacatgatcc ccattgaaaa cctcatgaac 1680
 ccccgagccc tggacttcca cgctgagacc ggcttcatct actttgccga caccaccagc 1740
 tacctcattg gccgccagaa gattgatggc actgagcggg agaccatcct gaaggacggc 1800
 atccacaatg tggaggggtg ggccgtggac tggatgggag acaatctgta ctggacggac 1860
 ctggggccca aaaagacaat cagcgtggcc aggctggaga aagctgctca gacccgcaag 1920
 actttaatcg agggcaaaat gacacacccc agggctattg tggatggatcc actcaatggg 1980
 tggatgtact ggacagactg ggaggaggac cccaaggaca gtcggcgtgg gcggtggag 2040
 agggcgtgga tggatggctc acaccgagac atctttgtca cctccaagac agtgctttgg 2100
 cccaatgggc taagcctgga catcccggct gggcgccctc actgggtgga tgccttctac 2160
 gaccgcatcg agacgatact gctcaatggc acagaccgga agattgtgta tgaaggctct 2220
 gagctgaacc acgcctttgg cctgtgtcac catggcaact acctcttctg gactgagtat 2280
 cggagtggca gtgtctaccg cttggaacgg ggtgtaggag gcgcaccccc cactgtgacc 2340
 cttctgcgca gtgagcggcc ccccatcttt gagatccgaa tgtatgatgc ccagcagcag 2400
 caagttggca ccaacaaatg ccgggtgaac aatggcggct gcagcagcct gtgcttggcc 2460
 acccctggga gccgccagtg cgctgtgtct gaggaccagg tgttggacgc agacggcgctc 2520
 acttgcttgg cgaaccatc ctacgtgcct cca 2553

<210> 2
 <211> 851
 <212> PRT
 <213> H. sapiens

<400> 2

Met Leu Thr Pro Pro Leu Leu Leu Leu Leu Pro Leu Leu Ser Ala Leu
 1 5 10 15

Ala Ala Ala Ala Ile Asp Ala Pro Lys Thr Cys Ser Pro Lys Gln Phe
 20 25 30

Ala Cys Arg Asp Gln Ile Thr Cys Ile Ser Lys Gly Trp Arg Cys Asp
 35 40 45

Gly Glu Arg Asp Cys Pro Asp Gly Ser Asp Glu Ala Pro Glu Ile Cys
 50 55 60

Pro Gln Ser Lys Ala Gln Arg Cys Gln Pro Asn Glu His Asn Cys Leu
 65 70 75 80

Gly Thr Glu Leu Cys Val Pro Met Ser Arg Leu Cys Asn Gly Val Gln
 85 90 95

Asp Cys Met Asp Gly Ser Asp Glu Gly Pro His Cys Arg Glu Leu Gln
 100 105 110

Gly Asn Cys Ser Arg Leu Gly Cys Gln His His Cys Val Pro Thr Leu
 115 120 125

Asp Gly Pro Thr Cys Tyr Cys Asn Ser Ser Phe Gln Leu Gln Ala Asp
 130 135 140

Gly Lys Thr Cys Lys Asp Phe Asp Glu Cys Ser Val Tyr Gly Thr Cys
 145 150 155 160

Ser Gln Leu Cys Thr Asn Thr Asp Gly Ser Phe Ile Cys Gly Cys Val
 165 170 175

Glu Gly Tyr Leu Leu Gln Pro Asp Asn Arg Ser Cys Lys Ala Lys Asn
 180 185 190

Glu Pro Val Asp Arg Pro Pro Val Leu Leu Ile Ala Asn Ser Gln Asn
 195 200 205

Ile Leu Ala Thr Tyr Leu Ser Gly Ala Gln Val Ser Thr Ile Thr Pro
 210 215 220

Thr Ser Thr Arg Gln Thr Thr Ala Met Asp Phe Ser Tyr Ala Asn Glu
 225 230 235 240

Thr Val Cys Trp Val His Val Gly Asp Ser Ala Ala Gln Thr Gln Leu
 245 250 255

Lys Cys Ala Arg Met Pro Gly Leu Lys Gly Phe Val Asp Glu His Thr
 260 265 270

Ile Asn Ile Ser Leu Ser Leu His His Val Glu Gln Met Ala Ile Asp
 275 280 285

Trp Leu Thr Gly Asn Phe Tyr Phe Val Asp Asp Ile Asp Asp Arg Ile
 290 295 300

Phe Val Cys Asn Arg Asn Gly Asp Thr Cys Val Thr Leu Leu Asp Leu
 305 310 315 320

Glu Leu Tyr Asn Pro Lys Gly Ile Ala Leu Asp Pro Ala Met Gly Lys
 325 330 335

Val Phe Phe Thr Asp Tyr Gly Gln Ile Pro Lys Val Glu Arg Cys Asp
 340 345 350

Met Asp Gly Gln Asn Arg Thr Lys Leu Val Asp Ser Lys Ile Val Phe
 355 360 365

Pro His Gly Ile Thr Leu Asp Leu Val Ser Arg Leu Val Tyr Trp Ala
 370 375 380

Asp Ala Tyr Leu Asp Tyr Ile Glu Val Val Asp Tyr Glu Gly Lys Gly
 385 390 395 400

Arg Gln Thr Ile Ile Gln Gly Ile Leu Ile Glu His Leu Tyr Gly Leu
 405 410 415

Thr Val Phe Glu Asn Tyr Leu Tyr Ala Thr Asn Ser Asp Asn Ala Asn
 420 425 430

Ala Gln Gln Lys Thr Ser Val Ile Arg Val Asn Arg Phe Asn Ser Thr
 435 440 445

Glu Tyr Gln Val Val Thr Arg Val Asp Lys Gly Gly Ala Leu His Ile
 450 455 460

Tyr His Gln Arg Arg Gln Pro Arg Val Arg Ser His Ala Cys Glu Asn
 465 470 475 480

Asp Gln Tyr Gly Lys Pro Gly Gly Cys Ser Asp Ile Cys Leu Leu Ala
 485 490 495

Asn Ser His Lys Ala Arg Thr Cys Arg Cys Arg Ser Gly Phe Ser Leu
 500 505 510

Gly Ser Asp Gly Lys Ser Cys Lys Lys Pro Glu His Glu Leu Phe Leu
 515 520 525

Val Tyr Gly Lys Gly Arg Pro Gly Ile Ile Arg Gly Met Asp Met Gly
 530 535 540

Ala Lys Val Pro Asp Glu His Met Ile Pro Ile Glu Asn Leu Met Asn
 545 550 555 560

Pro Arg Ala Leu Asp Phe His Ala Glu Thr Gly Phe Ile Tyr Phe Ala
 565 570 575

Asp Thr Thr Ser Tyr Leu Ile Gly Arg Gln Lys Ile Asp Gly Thr Glu
 580 585 590

Arg Glu Thr Ile Leu Lys Asp Gly Ile His Asn Val Glu Gly Val Ala
 595 600 605

Val Asp Trp Met Gly Asp Asn Leu Tyr Trp Thr Asp Asp Gly Pro Lys
 610 615 620

Lys Thr Ile Ser Val Ala Arg Leu Glu Lys Ala Ala Gln Thr Arg Lys
 625 630 635 640

Thr Leu Ile Glu Gly Lys Met Thr His Pro Arg Ala Ile Met Val Asp
 645 650 655

Pro Leu Asn Gly Trp Met Tyr Trp Thr Asp Trp Glu Glu Asp Pro Lys
 660 665 670

Asp Ser Arg Arg Gly Arg Leu Glu Arg Ala Trp Met Asp Gly Ser His
 675 680 685

Arg Asp Ile Phe Val Thr Ser Lys Thr Val Leu Trp Pro Asn Gly Leu
 690 695 700

Ser Leu Asp Ile Pro Ala Gly Arg Leu Tyr Trp Val Asp Ala Phe Tyr
 705 710 715 720

Asp Arg Ile Glu Thr Ile Leu Leu Asn Gly Thr Asp Arg Lys Ile Val
 725 730 735

Tyr Glu Gly Pro Glu Leu Asn His Ala Phe Gly Leu Cys His His Gly
 740 745 750

Asn Tyr Leu Phe Trp Thr Glu Tyr Arg Ser Gly Ser Val Tyr Arg Leu
 755 760 765

Glu Arg Gly Val Gly Gly Ala Pro Pro Thr Val Thr Leu Leu Arg Ser
 770 775 780

Glu Arg Pro Pro Ile Phe Glu Ile Arg Met Tyr Asp Ala Gln Gln Gln
 785 790 795 800

Gln Val Gly Thr Asn Lys Cys Arg Val Asn Asn Gly Gly Cys Ser Ser
 805 810 815

Leu Cys Leu Ala Thr Pro Gly Ser Arg Gln Cys Ala Cys Ala Glu Asp
 820 825 830

Gln Val Leu Asp Ala Asp Gly Val Thr Cys Leu Ala Asn Pro Ser Tyr
 835 840 845

Ala Pro Pro
 850

<210> 3
 <211> 896
 <212> PRT
 <213> H. sapiens

<400> 3

Met Leu Thr Pro Pro Leu Leu Leu Leu Leu Pro Leu Leu Ser Ala Leu
 1 5 10 15

Ala Ala Ala Ala Ile Asp Ala Pro Lys Thr Cys Ser Pro Lys Gln Phe
 20 25 30

Ala Cys Arg Asp Gln Ile Thr Cys Ile Ser Lys Gly Trp Arg Cys Asp
 35 40 45

Gly Glu Arg Asp Cys Pro Asp Gly Ser Asp Glu Ala Pro Glu Ile Cys
 50 55 60

Pro Gln Ser Lys Ala Gln Arg Cys Gln Pro Asn Glu His Asn Cys Leu
 65 70 75 80

Gly Thr Glu Leu Cys Val Pro Met Ser Arg Leu Cys Asn Gly Val Gln
 85 90 95

Asp Cys Met Asp Gly Ser Asp Glu Gly Pro His Cys Arg Glu Leu Gln
 100 105 110

Gly Asn Cys Ser Arg Leu Gly Cys Gln His His Cys Val Pro Thr Leu
 115 120 125

Asp Gly Pro Thr Cys Tyr Cys Asn Ser Ser Phe Gln Leu Gln Ala Asp
 130 135 140

Gly Lys Thr Cys Lys Asp Phe Asp Glu Cys Ser Val Tyr Gly Thr Cys
 145 150 155 160

Ser Gln Leu Cys Thr Asn Thr Asp Gly Ser Phe Ile Cys Gly Cys Val
 165 170 175

Glu Gly Tyr Leu Leu Gln Pro Asp Asn Arg Ser Cys Lys Ala Lys Asn
 180 185 190

Glu Pro Val Asp Arg Pro Pro Val Leu Leu Ile Ala Asn Ser Gln Asn
 195 200 205

Ile Leu Ala Thr Tyr Leu Ser Gly Ala Gln Val Ser Thr Ile Thr Pro
 210 215 220

Thr Ser Thr Arg Gln Thr Thr Ala Met Asp Phe Ser Tyr Ala Asn Glu
 225 230 235 240

Thr Val Cys Trp Val His Val Gly Asp Ser Ala Ala Gln Thr Gln Leu
 245 250 255

Lys Cys Ala Arg Met Pro Gly Leu Lys Gly Phe Val Asp Glu His Thr
 260 265 270

Ile Asn Ile Ser Leu Ser Leu His His Val Glu Gln Met Ala Ile Asp
 275 280 285

Trp Leu Thr Gly Asn Phe Tyr Phe Val Asp Asp Ile Asp Asp Arg Ile
 290 295 300

Phe Val Cys Asn Arg Asn Gly Asp Thr Cys Val Thr Leu Leu Asp Leu
 305 310 315 320

Glu Leu Tyr Asn Pro Lys Gly Ile Ala Leu Asp Pro Ala Met Gly Lys
 325 330 335

Val Phe Phe Thr Asp Tyr Gly Gln Ile Pro Lys Val Glu Arg Cys Asp
 340 345 350

Met Asp Gly Gln Asn Arg Thr Lys Leu Val Asp Ser Lys Ile Val Phe
 355 360 365

Pro His Gly Ile Thr Leu Asp Leu Val Ser Arg Leu Val Tyr Trp Ala
 370 375 380

Asp Ala Tyr Leu Asp Tyr Ile Glu Val Val Asp Tyr Glu Gly Lys Gly
 385 390 395 400

Arg Gln Thr Ile Ile Gln Gly Ile Leu Ile Glu His Leu Tyr Gly Leu
 405 410 415

Thr Val Phe Glu Asn Tyr Leu Tyr Ala Thr Asn Ser Asp Asn Ala Asn
 420 425 430

Ala Gln Gln Lys Thr Ser Val Ile Arg Val Asn Arg Phe Asn Ser Thr
 435 440 445

Glu Tyr Gln Val Val Thr Arg Val Asp Lys Gly Gly Ala Leu His Ile
 450 455 460

Tyr His Gln Arg Arg Gln Pro Arg Val Arg Ser His Ala Cys Glu Asn
 465 470 475 480

Asp Gln Tyr Gly Lys Pro Gly Gly Cys Ser Asp Ile Cys Leu Leu Ala
 485 490 495

Asn Ser His Lys Ala Arg Thr Cys Arg Cys Arg Ser Gly Phe Ser Leu
 500 505 510

Gly Ser Asp Gly Lys Ser Cys Lys Lys Pro Glu His Glu Leu Phe Leu
 515 520 525

Val Tyr Gly Lys Gly Arg Pro Gly Ile Ile Arg Gly Met Asp Met Gly
 530 535 540

Ala Lys Val Pro Asp Glu His Met Ile Pro Ile Glu Asn Leu Met Asn
 545 550 555 560

Pro Arg Ala Leu Asp Phe His Ala Glu Thr Gly Phe Ile Tyr Phe Ala
 565 570 575

Asp Thr Thr Ser Tyr Leu Ile Gly Arg Gln Lys Ile Asp Gly Thr Glu
580 585 590

Arg Glu Thr Ile Leu Lys Asp Gly Ile His Asn Val Glu Gly Val Ala
595 600 605

Val Asp Trp Met Gly Asp Asn Leu Tyr Trp Thr Asp Asp Gly Pro Lys
610 615 620

Lys Thr Ile Ser Val Ala Arg Leu Glu Lys Ala Ala Gln Thr Arg Lys
625 630 635 640

Thr Leu Ile Glu Gly Lys Met Thr His Pro Arg Ala Ile Met Val Asp
645 650 655

Pro Leu Asn Gly Trp Met Tyr Trp Thr Asp Trp Glu Glu Asp Pro Lys
660 665 670

Asp Ser Arg Arg Gly Arg Leu Glu Arg Ala Trp Met Asp Gly Ser His
675 680 685

Arg Asp Ile Phe Val Thr Ser Lys Thr Val Leu Trp Pro Asn Gly Leu
690 695 700

Ser Leu Asp Ile Pro Ala Gly Arg Leu Tyr Trp Val Asp Ala Phe Tyr
705 710 715 720

Asp Arg Ile Glu Thr Ile Leu Leu Asn Gly Thr Asp Arg Lys Ile Val
725 730 735

Trp Glu Gly Pro Glu Leu Asn His Ala Phe Gly Leu Cys His His Gly
740 745 750

Asn Tyr Leu Phe Trp Thr Glu Tyr Arg Ser Gly Ser Val Tyr Arg Leu
755 760 765

Glu Arg Gly Val Gly Gly Ala Pro Pro Thr Val Thr Leu Leu Arg Ser
770 775 780

Glu Arg Pro Pro Ile Phe Glu Ile Arg Met Tyr Asp Ala Gln Gln Gln
785 790 795 800

Gln Val Gly Thr Asn Lys Cys Arg Val Asn Asn Gly Gly Cys Ser Ser
805 810 815

Leu Cys Leu Ala Thr Pro Gly Ser Arg Gln Cys Ala Cys Ala Glu Asp
820 825 830

Gln Val Leu Asp Ala Asp Gly Val Thr Cys Leu Ala Asn Pro Ser Tyr
835 840 845

Val Pro Pro Gly Gly Arg Leu Val Pro Arg Gly Ser Tyr Pro Tyr Asp
850 855 860

Val Pro Asp Tyr Ala Ile Glu Gly His Val Gly Leu Asn Asp Ile Phe
865 870 875 880

Glu Ala Gln Lys Ile Glu Trp His Glu Gly His His His His His His
885 890 895

<210> 4
<211> 844
<212> PRT
<213> M.

<400> 4

Met Leu Thr Pro Pro Leu Leu Leu Leu Val Pro Leu Leu Ser Ala Leu
1 5 10 15

Val Ser Gly Ala Thr Met Asp Ala Pro Lys Thr Cys Ser Pro Lys Gln
20 25 30

Phe Ala Cys Arg Asp Gln Ile Thr Cys Ile Ser Lys Gly Trp Arg Cys
35 40 45

Asp Gly Glu Arg Asp Cys Pro Asp Gly Ser Asp Glu Ala Pro Glu Ile
50 55 60

Cys Pro Gln Ser Lys Ala Gln Arg Cys Pro Pro Asn Glu His Ser Cys
65 70 75 80

Leu Gly Thr Glu Leu Cys Val Pro Met Ser Arg Leu Cys Asn Gly Ile
85 90 95

Gln Asp Cys Met Asp Gly Ser Asp Glu Gly Ala His Cys Arg Glu Leu
100 105 110

Arg Ala Asn Cys Ser Arg Met Gly Cys Gln His His Cys Val Pro Thr
115 120 125

Pro Ser Gly Pro Thr Cys Tyr Cys Asn Ser Ser Phe Gln Leu Glu Ala
130 135 140

Asp Gly Lys Thr Cys Lys Asp Phe Asp Glu Cys Ser Val Tyr Gly Thr
 145 150 155 160

Cys Ser Gln Leu Cys Thr Asn Thr Asp Gly Ser Phe Thr Cys Gly Cys
 165 170 175

Val Glu Gly Tyr Leu Leu Gln Pro Asp Asn Arg Ser Cys Lys Ala Lys
 180 185 190

Asn Glu Pro Val Asp Arg Pro Pro Val Leu Leu Ile Ala Asn Ser Gln
 195 200 205

Asn Ile Leu Ala Thr Tyr Leu Ser Gly Ala Gln Val Ser Thr Ile Thr
 210 215 220

Pro Thr Ser Thr Arg Gln Thr Thr Ala Met Asp Phe Ser Tyr Ala Asn
 225 230 235 240

Glu Thr Val Cys Trp Val His Val Gly Asp Ser Ala Ala Gln Thr Gln
 245 250 255

Leu Lys Cys Ala Arg Met Pro Gly Leu Lys Gly Phe Val Asp Glu His
 260 265 270

Thr Ile Asn Ile Ser Leu Ser Leu His His Val Glu Gln Met Ala Ile
 275 280 285

Asp Trp Leu Thr Gly Asn Phe Tyr Phe Val Asp Asp Ile Asp Asp Arg
 290 295 300

Phe Val Cys Asn Arg Asn Gly Asp Thr Cys Val Thr Leu Leu Asp
 305 310 315 320

Leu Glu Leu Tyr Asn Pro Lys Gly Ile Ala Leu Asp Pro Ala Met Gly
 325 330 335

Lys Val Phe Phe Thr Asp Tyr Gly Gln Ile Pro Lys Val Glu Arg Cys
 340 345 350

Asp Met Asp Gly Gln Asn Arg Thr Lys Leu Val Asp Ser Lys Ile Val
 355 360 365

Phe Pro His Gly Ile Thr Leu Asp Leu Val Ser Arg Leu Val Tyr Trp
 370 375 380

Ala Asp Ala Tyr Leu Asp Tyr Ile Glu Val Val Asp Tyr Glu Gly Lys
385 390 395 400

Gly Arg Gln Thr Ile Ile Gln Gly Ile Leu Ile Glu His Leu Tyr Gly
405 410 415

Leu Thr Val Phe Glu Asn Tyr Leu Tyr Ala Thr Asn Ser Asp Asn Ala
420 425 430

Asn Thr Gln Gln Lys Thr Ser Val Ile Arg Val Asn Arg Phe Asn Ser
435 440 445

Thr Glu Tyr Gln Val Val Thr Arg Val Asp Lys Gly Gly Ala Leu His
450 455 460

Ile Tyr His Gln Arg Arg Gln Pro Arg Val Arg Ser His Ala Cys Glu
465 470 475 480

Asn Asp Gln Tyr Gly Lys Pro Gly Gly Cys Ser Asp Ile Cys Leu Leu
485 490 495

Ala Asn Ser His Lys Ala Arg Thr Cys Arg Cys Arg Ser Gly Phe Ser
500 505 510

Leu Gly Ser Asp Gly Lys Ser Cys Lys Lys Pro Glu His Glu Leu Phe
515 520 525

Leu Val Tyr Gly Lys Gly Arg Pro Gly Ile Ile Arg Gly Met Asp Met
530 535 540

Gly Ala Lys Val Pro Asp Glu His Met Ile Pro Ile Glu Asn Leu Met
545 550 555 560

Asn Pro Arg Ala Leu Asp Phe His Ala Glu Thr Gly Phe Ile Tyr Phe
565 570 575

Ala Asp Thr Thr Ser Tyr Leu Ile Gly Arg Gln Lys Ile Asp Gly Thr
580 585 590

Glu Arg Glu Thr Ile Leu Lys Asp Gly Ile His Asn Val Glu Gly Val
595 600 605

Ala Val Asp Trp Met Gly Asp Asn Leu Tyr Trp Thr Asp Asp Gly Pro
610 615 620

Lys Lys Thr Ile Ser Val Ala Arg Leu Glu Lys Ala Ala Gln Thr Arg
625 630 635 640

Lys Thr Leu Ile Glu Gly Lys Met Thr His Pro Arg Ala Ile Val Val
645 650 655

Asp Pro Leu Asn Gly Trp Met Tyr Trp Thr Asp Trp Glu Glu Asp Pro
660 665 670

Lys Asp Ser Arg Arg Gly Arg Leu Glu Arg Ala Trp Met Asp Gly Ser
675 680 685

His Arg Asp Ile Phe Val Thr Ser Lys Thr Val Leu Trp Pro Asn Gly
690 695 700

Leu Ser Leu Asp Ile Pro Ala Gly Arg Leu Tyr Trp Val Asp Ala Phe
705 710 715 720

Tyr Asp Arg Ile Glu Thr Ile Leu Leu Asn Gly Thr Asp Arg Lys Ile
725 730 735

Val Tyr Glu Gly Pro Glu Leu Asn His Ala Phe Gly Leu Cys His His
740 745 750

Gly Asn Tyr Leu Phe Trp Thr Glu Tyr Arg Ser Gly Ser Val Tyr Arg
755 760 765

Leu Glu Arg Gly Val Ala Gly Ala Pro Pro Thr Val Thr Leu Leu Arg
770 775 780

Ser Glu Arg Pro Pro Ile Phe Glu Ile Arg Met Tyr Asp Ala His Glu
785 790 795 800

Gln Gln Val Gly Thr Asn Lys Cys Arg Val Asn Asn Gly Gly Cys Ser
805 810 815

Ser Leu Cys Leu Ala Thr Pro Gly Ser Arg Gln Cys Ala Cys Ala Glu
820 825 830

Asp Gln Val Leu Asp Thr Asp Gly Val Thr Cys Leu
835 840

<210> 5
<211> 4544
<212> PRT
<213> H. sapiens

<400> 5

Met Leu Thr Pro Pro Leu Leu Leu Leu Leu Pro Leu Leu Ser Ala Leu
 1 5 10 15

Val Ala Ala Ala Ile Asp Ala Pro Lys Thr Cys Ser Pro Lys Gln Phe
 20 25 30

Ala Cys Arg Asp Gln Ile Thr Cys Ile Ser Lys Gly Trp Arg Cys Asp
 35 40 45

Gly Glu Arg Asp Cys Pro Asp Gly Ser Asp Glu Ala Pro Glu Ile Cys
 50 55 60

Pro Gln Ser Lys Ala Gln Arg Cys Gln Pro Asn Glu His Asn Cys Leu
 65 70 75 80

Gly Thr Glu Leu Cys Val Pro Met Ser Arg Leu Cys Asn Gly Val Gln
 85 90 95

Asp Cys Met Asp Gly Ser Asp Glu Gly Pro His Cys Arg Glu Leu Gln
 100 105 110

Gly Asn Cys Ser Arg Leu Gly Cys Gln His His Cys Val Pro Thr Leu
 115 120 125

Asp Gly Pro Thr Cys Tyr Cys Asn Ser Ser Phe Gln Leu Gln Ala Asp
 130 135 140

Gly Lys Thr Cys Lys Asp Phe Asp Glu Cys Ser Val Tyr Gly Thr Cys
 145 150 155 160

Ser Gln Leu Cys Thr Asn Thr Asp Gly Ser Phe Ile Cys Gly Cys Val
 165 170 175

Glu Gly Tyr Leu Leu Gln Pro Asp Asn Arg Ser Cys Lys Ala Lys Asn
 180 185 190

Glu Pro Val Asp Arg Pro Pro Val Leu Leu Ile Ala Asn Ser Gln Asn
 195 200 205

Ile Leu Ala Thr Tyr Leu Ser Gly Ala Gln Val Ser Thr Ile Thr Pro
 210 215 220

Thr Ser Thr Arg Gln Thr Thr Ala Met Asp Phe Ser Tyr Ala Asn Glu
 225 230 235 240

Thr Val Cys Trp Val His Val Gly Asp Ser Ala Ala Gln Thr Gln Leu
 245 250 255

Lys Cys Ala Arg Met Pro Gly Leu Lys Gly Phe Val Asp Glu His Thr
 260 265 270

Ile Asn Ile Ser Leu Ser Leu His His Val Glu Gln Met Ala Ile Asp
 275 280 285

Trp Leu Thr Gly Asn Phe Tyr Phe Val Asp Asp Ile Asp Asp Arg Ile
 290 295 300

Phe Val Cys Asn Arg Asn Gly Asp Thr Cys Val Thr Leu Leu Asp Leu
 305 310 315 320

Glu Leu Tyr Asn Pro Lys Gly Ile Ala Leu Asp Pro Ala Met Gly Lys
 325 330 335

Val Phe Phe Thr Asp Tyr Gly Gln Ile Pro Lys Val Glu Arg Cys Asp
 340 345 350

Met Asp Gly Gln Asn Arg Thr Lys Leu Val Asp Ser Lys Ile Val Phe
 355 360 365

Pro His Gly Ile Thr Leu Asp Leu Val Ser Arg Leu Val Tyr Trp Ala
 370 375 380

Asp Ala Tyr Leu Asp Tyr Ile Glu Val Val Asp Tyr Glu Gly Lys Gly
 385 390 395 400

Gln Thr Ile Ile Gln Gly Ile Leu Ile Glu His Leu Tyr Gly Leu
 405 410 415

Thr Val Phe Glu Asn Tyr Leu Tyr Ala Thr Asn Ser Asp Asn Ala Asn
 420 425 430

Ala Gln Gln Lys Thr Ser Val Ile Arg Val Asn Arg Phe Asn Ser Thr
 435 440 445

Glu Tyr Gln Val Val Thr Arg Val Asp Lys Gly Gly Ala Leu His Ile
 450 455 460

Tyr His Gln Arg Arg Gln Pro Arg Val Arg Ser His Ala Cys Glu Asn
 465 470 475 480

Asp Gln Tyr Gly Lys Pro Gly Gly Cys Ser Asp Ile Cys Leu Leu Ala
 485 490 495

Asn Ser His Lys Ala Arg Thr Cys Arg Cys Arg Ser Gly Phe Ser Leu
 500 505 510

Gly Ser Asp Gly Lys Ser Cys Lys Lys Pro Glu His Glu Leu Phe Leu
 515 520 525

Val Tyr Gly Lys Gly Arg Pro Gly Ile Ile Arg Gly Met Asp Met Gly
 530 535 540

Ala Lys Val Pro Asp Glu His Met Ile Pro Ile Glu Asn Leu Met Asn
 545 550 555 560

Pro Arg Ala Leu Asp Phe His Ala Glu Thr Gly Phe Ile Tyr Phe Ala
 565 570 575

Asp Thr Thr Ser Tyr Leu Ile Gly Arg Gln Lys Ile Asp Gly Thr Glu
 580 585 590

Arg Glu Thr Ile Leu Lys Asp Gly Ile His Asn Val Glu Gly Val Ala
 595 600 605

Val Asp Trp Met Gly Asp Asn Leu Tyr Trp Thr Asp Asp Gly Pro Lys
 610 615 620

Lys Thr Ile Ser Val Ala Arg Leu Glu Lys Ala Ala Gln Thr Arg Lys
 625 630 635 640

Thr Leu Ile Glu Gly Lys Met Thr His Pro Arg Ala Ile Val Val Asp
 645 650 655

Pro Leu Asn Gly Trp Met Tyr Trp Thr Asp Trp Glu Glu Asp Pro Lys
 660 665 670

Asp Ser Arg Arg Gly Arg Leu Glu Arg Ala Trp Met Asp Gly Ser His
 675 680 685

Arg Asp Ile Phe Val Thr Ser Lys Thr Val Leu Trp Pro Asn Gly Leu
 690 695 700

Ser Leu Asp Ile Pro Ala Gly Arg Leu Tyr Trp Val Asp Ala Phe Tyr
 705 710 715 720

Asp Arg Ile Glu Thr Ile Leu Leu Asn Gly Thr Asp Arg Lys Ile Val
725 730 735

Tyr Glu Gly Pro Glu Leu Asn His Ala Phe Gly Leu Cys His His Gly
740 745 750

Asn Tyr Leu Phe Trp Thr Glu Tyr Arg Ser Gly Ser Val Tyr Arg Leu
755 760 765

Glu Arg Gly Val Gly Gly Ala Pro Pro Thr Val Thr Leu Leu Arg Ser
770 775 780

Glu Arg Pro Pro Ile Phe Glu Ile Arg Met Tyr Asp Ala Gln Gln Gln
785 790 795 800

Gln Val Gly Thr Asn Lys Cys Arg Val Asn Asn Gly Gly Cys Ser Ser
805 810 815

Leu Cys Leu Ala Thr Pro Gly Ser Arg Gln Cys Ala Cys Ala Glu Asp
820 825 830

Gln Val Leu Asp Ala Asp Gly Val Thr Cys Leu Ala Asn Pro Ser Tyr
835 840 845

Val Pro Pro Pro Gln Cys Gln Pro Gly Glu Phe Ala Cys Ala Asn Ser
850 855 860

Arg Cys Ile Gln Glu Arg Trp Lys Cys Asp Gly Asp Asn Asp Cys Leu
865 870 875 880

Asp Asn Ser Asp Glu Ala Pro Ala Leu Cys His Gln His Thr Cys Pro
885 890 895

Ser Asp Arg Phe Lys Cys Glu Asn Asn Arg Cys Ile Pro Asn Arg Trp
900 905 910

Leu Cys Asp Gly Asp Asn Asp Cys Gly Asn Ser Glu Asp Glu Ser Asn
915 920 925

Ala Thr Cys Ser Ala Arg Thr Cys Pro Pro Asn Gln Phe Ser Cys Ala
930 935 940

Ser Gly Arg Cys Ile Pro Ile Ser Trp Thr Cys Asp Leu Asp Asp Asp
945 950 955 960

Cys Gly Asp Arg Ser Asp Glu Ser Ala Ser Cys Ala Tyr Pro Thr Cys
 965 970 975

Phe Pro Leu Thr Gln Phe Thr Cys Asn Asn Gly Arg Cys Ile Asn Ile
 980 985 990

Asn Trp Arg Cys Asp Asn Asp Asn Asp Cys Gly Asp Asn Ser Asp Glu
 995 1000 1005

Ala Gly Cys Ser His Ser Cys Ser Ser Thr Gln Phe Lys Cys Asn
 1010 1015 1020

Ser Gly Arg Cys Ile Pro Glu His Trp Thr Cys Asp Gly Asp Asn
 1025 1030 1035

Asp Cys Gly Asp Tyr Ser Asp Glu Thr His Ala Asn Cys Thr Asn
 1040 1045 1050

Gln Ala Thr Arg Pro Pro Gly Gly Cys His Thr Asp Glu Phe Gln
 1055 1060 1065

Cys Arg Leu Asp Gly Leu Cys Ile Pro Leu Arg Trp Arg Cys Asp
 1070 1075 1080

Gly Asp Thr Asp Cys Met Asp Ser Ser Asp Glu Lys Ser Cys Glu
 1085 1090 1095

Gly Val Thr His Val Cys Asp Pro Ser Val Lys Phe Gly Cys Lys
 1100 1105 1110

Asp Ser Ala Arg Cys Ile Ser Lys Ala Trp Val Cys Asp Gly Asp
 1115 1120 1125

Asn Asp Cys Glu Asp Asn Ser Asp Glu Glu Asn Cys Glu Ser Leu
 1130 1135 1140

Ala Cys Arg Pro Pro Ser His Pro Cys Ala Asn Asn Thr Ser Val
 1145 1150 1155

Cys Leu Pro Pro Asp Lys Leu Cys Asp Gly Asn Asp Asp Cys Gly
 1160 1165 1170

Asp Gly Ser Asp Glu Gly Glu Leu Cys Asp Gln Cys Ser Leu Asn
 1175 1180 1185

Asn Gly 1190	Gly Cys Ser His	Asn Cys Ser Val Ala Pro 1195 1200	Gly Glu Gly
Ile Val 1205	Cys Ser Cys Pro	Leu Gly Met Glu Leu Gly 1210 1215	Pro Asp Asn
His Thr 1220	Cys Gln Ile Gln	Ser Tyr Cys Ala Lys His 1225 1230	Leu Lys Cys
Ser Gln 1235	Lys Cys Asp Gln	Asn Lys Phe Ser Val Lys 1240 1245	Cys Ser Cys
Tyr Glu 1250	Gly Trp Val Leu	Glu Pro Asp Gly Glu Ser 1255 1260	Cys Arg Ser
Leu Asp 1265	Pro Phe Lys Pro	Phe Ile Ile Phe Ser Asn 1270 1275	Arg His Glu
Ile Arg 1280	Arg Ile Asp Leu	His Lys Gly Asp Tyr Ser 1285 1290	Val Leu Val
Pro Gly 1295	Leu Arg Asn Thr	Ile Ala Leu Asp Phe His 1300 1305	Leu Ser Gln
Ser Ala 1310	Leu Tyr Trp Thr	Asp Val Val Glu Asp Lys 1315 1320	Ile Tyr Arg
Gly Lys 1325	Leu Leu Asp Asn	Gly Ala Leu Thr Ser Phe 1330 1335	Glu Val Val
Ile Gln 1340	Tyr Gly Leu Ala	Thr Pro Glu Gly Leu Ala 1345 1350	Val Asp Trp
Ile Ala 1355	Gly Asn Ile Tyr	Trp Val Glu Ser Asn Leu 1360 1365	Asp Gln Ile
Glu Val 1370	Ala Lys Leu Asp	Gly Thr Leu Arg Thr Thr 1375 1380	Leu Leu Ala
Gly Asp 1385	Ile Glu His Pro	Arg Ala Ile Ala Leu Asp 1390 1395	Pro Arg Asp
Gly Ile 1400	Leu Phe Trp Thr	Asp Trp Asp Ala Ser Leu 1405 1410	Pro Arg Ile

Glu Ala Ala Ser Met Ser Gly Ala Gly Arg Arg Thr Val His Arg
 1415 1420 1425
 Glu Thr Gly Ser Gly Gly Trp Pro Asn Gly Leu Thr Val Asp Tyr
 1430 1435 1440
 Leu Glu Lys Arg Ile Leu Trp Ile Asp Ala Arg Ser Asp Ala Ile
 1445 1450 1455
 Tyr Ser Ala Arg Tyr Asp Gly Ser Gly His Met Glu Val Leu Arg
 1460 1465 1470
 Gly His Glu Phe Leu Ser His Pro Phe Ala Val Thr Leu Tyr Gly
 1475 1480 1485
 Gly Glu Val Tyr Trp Thr Asp Trp Arg Thr Asn Thr Leu Ala Lys
 1490 1495 1500
 Ala Asn Lys Trp Thr Gly His Asn Val Thr Val Val Gln Arg Thr
 1505 1510 1515
 Asn Thr Gln Pro Phe Asp Leu Gln Val Tyr His Pro Ser Arg Gln
 1520 1525 1530
 Pro Met Ala Pro Asn Pro Cys Glu Ala Asn Gly Gly Gln Gly Pro
 1535 1540 1545
 Cys Ser His Leu Cys Leu Ile Asn Tyr Asn Arg Thr Val Ser Cys
 1550 1555 1560
 Ala Cys Pro His Leu Met Lys Leu His Lys Asp Asn Thr Thr Cys
 1565 1570 1575
 Tyr Glu Phe Lys Lys Phe Leu Leu Tyr Ala Arg Gln Met Glu Ile
 1580 1585 1590
 Arg Gly Val Asp Leu Asp Ala Pro Tyr Tyr Asn Tyr Ile Ile Ser
 1595 1600 1605
 Phe Thr Val Pro Asp Ile Asp Asn Val Thr Val Leu Asp Tyr Asp
 1610 1615 1620
 Ala Arg Glu Gln Arg Val Tyr Trp Ser Asp Val Arg Thr Gln Ala
 1625 1630 1635

Ile Lys Arg Ala Phe Ile Asn Gly Thr Gly Val Glu Thr Val Val	1640	1645	1650
Ser Ala Asp Leu Pro Asn Ala His Gly Leu Ala Val Asp Trp Val	1655	1660	1665
Ser Arg Asn Leu Phe Trp Thr Ser Tyr Asp Thr Asn Lys Lys Gln	1670	1675	1680
Ile Asn Val Ala Arg Leu Asp Gly Ser Phe Lys Asn Ala Val Val	1685	1690	1695
Gln Gly Leu Glu Gln Pro His Gly Leu Val Val His Pro Leu Arg	1700	1705	1710
Gly Lys Leu Tyr Trp Thr Asp Gly Asp Asn Ile Ser Met Ala Asn	1715	1720	1725
Met Asp Gly Ser Asn Arg Thr Leu Leu Phe Ser Gly Gln Lys Gly	1730	1735	1740
Pro Val Gly Leu Ala Ile Asp Phe Pro Glu Ser Lys Leu Tyr Trp	1745	1750	1755
Ile Ser Ser Gly Asn His Thr Ile Asn Arg Cys Asn Leu Asp Gly	1760	1765	1770
Ser Gly Leu Glu Val Ile Asp Ala Met Arg Ser Gln Leu Gly Lys	1775	1780	1785
Ala Thr Ala Leu Ala Ile Met Gly Asp Lys Leu Trp Trp Ala Asp	1790	1795	1800
Gln Val Ser Glu Lys Met Gly Thr Cys Ser Lys Ala Asp Gly Ser	1805	1810	1815
Gly Ser Val Val Leu Arg Asn Ser Thr Thr Leu Val Met His Met	1820	1825	1830
Lys Val Tyr Asp Glu Ser Ile Gln Leu Asp His Lys Gly Thr Asn	1835	1840	1845
Pro Cys Ser Val Asn Asn Gly Asp Cys Ser Gln Leu Cys Leu Pro	1850	1855	1860

Thr Ser Glu Thr Thr Arg Ser Cys Met Cys Thr Ala Gly Tyr Ser
1865 1870 1875

Leu Arg Ser Gly Gln Gln Ala Cys Glu Gly Val Gly Ser Phe Leu
1880 1885 1890

Leu Tyr Ser Val His Glu Gly Ile Arg Gly Ile Pro Leu Asp Pro
1895 1900 1905

Asn Asp Lys Ser Asp Ala Leu Val Pro Val Ser Gly Thr Ser Leu
1910 1915 1920

Ala Val Gly Ile Asp Phe His Ala Glu Asn Asp Thr Ile Tyr Trp
1925 1930 1935

Val Asp Met Gly Leu Ser Thr Ile Ser Arg Ala Lys Arg Asp Gln
1940 1945 1950

Thr Trp Arg Glu Asp Val Val Thr Asn Gly Ile Gly Arg Val Glu
1955 1960 1965

Gly Ile Ala Val Asp Trp Ile Ala Gly Asn Ile Tyr Trp Thr Asp
1970 1975 1980

Gln Gly Phe Asp Val Ile Glu Val Ala Arg Leu Asn Gly Ser Phe
1985 1990 1995

Arg Tyr Val Val Ile Ser Gln Gly Leu Asp Lys Pro Arg Ala Ile
2000 2005 2010

Thr Val His Pro Glu Lys Gly Tyr Leu Phe Trp Thr Glu Trp Gly
2015 2020 2025

Gln Tyr Pro Arg Ile Glu Arg Ser Arg Leu Asp Gly Thr Glu Arg
2030 2035 2040

Val Val Leu Val Asn Val Ser Ile Ser Trp Pro Asn Gly Ile Ser
2045 2050 2055

Val Asp Tyr Gln Asp Gly Lys Leu Tyr Trp Cys Asp Ala Arg Thr
2060 2065 2070

Asp Lys Ile Glu Arg Ile Asp Leu Glu Thr Gly Glu Asn Arg Glu
2075 2080 2085

Val Val Leu Ser Ser Asn Asn Met Asp Met Phe Ser Val Ser Val
 2090 2095 2100

Phe Glu Asp Phe Ile Tyr Trp Ser Asp Arg Thr His Ala Asn Gly
 2105 2110 2115

Ser Ile Lys Arg Gly Ser Lys Asp Asn Ala Thr Asp Ser Val Pro
 2120 2125 2130

Leu Arg Thr Gly Ile Gly Val Gln Leu Lys Asp Ile Lys Val Phe
 2135 2140 2145

Asn Arg Asp Arg Gln Lys Gly Thr Asn Val Cys Ala Val Ala Asn
 2150 2155 2160

Gly Gly Cys Gln Gln Leu Cys Leu Tyr Arg Gly Arg Gly Gln Arg
 2165 2170 2175

Ala Cys Ala Cys Ala His Gly Met Leu Ala Glu Asp Gly Ala Ser
 2180 2185 2190

Cys Arg Glu Tyr Ala Gly Tyr Leu Leu Tyr Ser Glu Arg Thr Ile
 2195 2200 2205

Leu Lys Ser Ile His Leu Ser Asp Glu Arg Asn Leu Asn Ala Pro
 2210 2215 2220

Val Gln Pro Phe Glu Asp Pro Glu His Met Lys Asn Val Ile Ala
 2225 2230 2235

Leu Ala Phe Asp Tyr Arg Ala Gly Thr Ser Pro Gly Thr Pro Asn
 2240 2245 2250

Arg Ile Phe Phe Ser Asp Ile His Phe Gly Asn Ile Gln Gln Ile
 2255 2260 2265

Asn Asp Asp Gly Ser Arg Arg Ile Thr Ile Val Glu Asn Val Gly
 2270 2275 2280

Ser Val Glu Gly Leu Ala Tyr His Arg Gly Trp Asp Thr Leu Tyr
 2285 2290 2295

Trp Thr Ser Tyr Thr Thr Ser Thr Ile Thr Arg His Thr Val Asp
 2300 2305 2310

Gln Thr Arg Pro Gly Ala Phe	Glu Arg Glu Thr Val	Ile Thr Met
2315	2320	2325
Ser Gly Asp Asp His Pro Arg	Ala Phe Val Leu Asp	Glu Cys Gln
2330	2335	2340
Asn Leu Met Phe Trp Thr Asn	Trp Asn Glu Gln His	Pro Ser Ile
2345	2350	2355
Met Arg Ala Ala Leu Ser Gly	Ala Asn Val Leu Thr	Leu Ile Glu
2360	2365	2370
Lys Asp Ile Arg Thr Pro Asn	Gly Leu Ala Ile Asp	His Arg Ala
2375	2380	2385
Glu Lys Leu Tyr Phe Ser Asp	Ala Thr Leu Asp Lys	Ile Glu Arg
2390	2395	2400
Cys Glu Tyr Asp Gly Ser His	Arg Tyr Val Ile Leu	Lys Ser Glu
2405	2410	2415
Pro Val His Pro Phe Gly Leu	Ala Val Tyr Gly Glu	His Ile Phe
2420	2425	2430
Trp Thr Asp Trp Val Arg Arg	Ala Val Gln Arg Ala	Asn Lys His
2435	2440	2445
Val Gly Ser Asn Met Lys Leu	Leu Arg Val Asp Ile	Pro Gln Gln
2450	2455	2460
Pro Met Gly Ile Ile Ala Val	Ala Asn Asp Thr Asn	Ser Cys Glu
2465	2470	2475
Leu Ser Pro Cys Arg Ile Asn	Asn Gly Gly Cys Gln	Asp Leu Cys
2480	2485	2490
Leu Leu Thr His Gln Gly His	Val Asn Cys Ser Cys	Arg Gly Gly
2495	2500	2505
Arg Ile Leu Gln Asp Asp Leu	Thr Cys Arg Ala Val	Asn Ser Ser
2510	2515	2520
Cys Arg Ala Gln Asp Glu Phe	Glu Cys Ala Asn Gly	Glu Cys Ile
2525	2530	2535

Asn Phe	Ser Leu Thr Cys	Asp	Gly Val Pro His	Cys	Lys Asp Lys
2540		2545		2550	
Ser Asp	Glu Lys Pro Ser	Tyr	Cys Asn Ser Arg	Arg	Cys Lys Lys
2555		2560		2565	
Thr Phe	Arg Gln Cys Ser	Asn	Gly Arg Cys Val	Ser	Asn Met Leu
2570		2575		2580	
Trp Cys	Asn Gly Ala Asp	Asp	Cys Gly Asp Gly	Ser	Asp Glu Ile
2585		2590		2595	
Pro Cys	Asn Lys Thr Ala	Cys	Gly Val Gly Glu	Phe	Arg Cys Arg
2600		2605		2610	
Asp Gly	Thr Cys Ile Gly	Asn	Ser Ser Arg Cys	Asn	Gln Phe Val
2615		2620		2625	
Asp Cys	Glu Asp Ala Ser	Asp	Glu Met Asn Cys	Ser	Ala Thr Asp
2630		2635		2640	
Cys Ser	Ser Tyr Phe Arg	Leu	Gly Val Lys Gly	Val	Leu Phe Gln
2645		2650		2655	
Pro Cys	Glu Arg Thr Ser	Leu	Cys Tyr Ala Pro	Ser	Trp Val Cys
2660		2665		2670	
Asp Gly	Ala Asn Asp Cys	Gly	Asp Tyr Ser Asp	Glu	Arg Asp Cys
2675		2680		2685	
Pro Gly	Val Lys Arg Pro	Arg	Cys Pro Leu Asn	Tyr	Phe Ala Cys
2690		2695		2700	
Pro Ser	Gly Arg Cys Ile	Pro	Met Ser Trp Thr	Cys	Asp Lys Glu
2705		2710		2715	
Asp Asp	Cys Glu His Gly	Glu	Asp Glu Thr His	Cys	Asn Lys Phe
2720		2725		2730	
Cys Ser	Glu Ala Gln Phe	Glu	Cys Gln Asn His	Arg	Cys Ile Ser
2735		2740		2745	
Lys Gln	Trp Leu Cys Asp	Gly	Ser Asp Asp Cys	Gly	Asp Gly Ser
2750		2755		2760	

Asp Glu Ala Ala His Cys Glu Gly Lys Thr Cys Gly Pro Ser Ser
 2765 2770 2775

 Phe Ser Cys Pro Gly Thr His Val Cys Val Pro Glu Arg Trp Leu
 2780 2785 2790

 Cys Asp Gly Asp Lys Asp Cys Ala Asp Gly Ala Asp Glu Ser Ile
 2795 2800 2805

 Ala Ala Gly Cys Leu Tyr Asn Ser Thr Cys Asp Asp Arg Glu Phe
 2810 2815 2820

 Met Cys Gln Asn Arg Gln Cys Ile Pro Lys His Phe Val Cys Asp
 2825 2830 2835

 His Asp Arg Asp Cys Ala Asp Gly Ser Asp Glu Ser Pro Glu Cys
 2840 2845 2850

 Glu Tyr Pro Thr Cys Gly Pro Ser Glu Phe Arg Cys Ala Asn Gly
 2855 2860 2865

 Arg Cys Leu Ser Ser Arg Gln Trp Glu Cys Asp Gly Glu Asn Asp
 2870 2875 2880

 Cys His Asp Gln Ser Asp Glu Ala Pro Lys Asn Pro His Cys Thr
 2885 2890 2895

 Ser Pro Glu His Lys Cys Asn Ala Ser Ser Gln Phe Leu Cys Ser
 2900 2905 2910

 Ser Gly Arg Cys Val Ala Glu Ala Leu Leu Cys Asn Gly Gln Asp
 2915 2920 2925

 Asp Cys Gly Asp Ser Ser Asp Glu Arg Gly Cys His Ile Asn Glu
 2930 2935 2940

 Cys Leu Ser Arg Lys Leu Ser Gly Cys Ser Gln Asp Cys Glu Asp
 2945 2950 2955

 Leu Lys Ile Gly Phe Lys Cys Arg Cys Arg Pro Gly Phe Arg Leu
 2960 2965 2970

 Lys Asp Asp Gly Arg Thr Cys Ala Asp Val Asp Glu Cys Ser Thr
 2975 2980 2985

Thr Phe Pro Cys Ser Gln Arg Cys Ile Asn Thr His Gly Ser Tyr
 2990 2995 3000
 Lys Cys Leu Cys Val Glu Gly Tyr Ala Pro Arg Gly Gly Asp Pro
 3005 3010 3015
 His Ser Cys Lys Ala Val Thr Asp Glu Glu Pro Phe Leu Ile Phe
 3020 3025 3030
 Ala Asn Arg Tyr Tyr Leu Arg Lys Leu Asn Leu Asp Gly Ser Asn
 3035 3040 3045
 Tyr Thr Leu Leu Lys Gln Gly Leu Asn Asn Ala Val Ala Leu Asp
 3050 3055 3060
 Phe Asp Tyr Arg Glu Gln Met Ile Tyr Trp Thr Asp Val Thr Thr
 3065 3070 3075
 Gln Gly Ser Met Ile Arg Arg Met His Leu Asn Gly Ser Asn Val
 3080 3085 3090
 Gln Val Leu His Arg Thr Gly Leu Ser Asn Pro Asp Gly Leu Ala
 3095 3100 3105
 Val Asp Trp Val Gly Gly Asn Leu Tyr Trp Cys Asp Lys Gly Arg
 3110 3115 3120
 Asp Thr Ile Glu Val Ser Lys Leu Asn Gly Ala Tyr Arg Thr Val
 3125 3130 3135
 Leu Val Ser Ser Gly Leu Arg Glu Pro Arg Ala Leu Val Val Asp
 3140 3145 3150
 Val Gln Asn Gly Tyr Leu Tyr Trp Thr Asp Trp Gly Asp His Ser
 3155 3160 3165
 Leu Ile Gly Arg Ile Gly Met Asp Gly Ser Ser Arg Ser Val Ile
 3170 3175 3180
 Val Asp Thr Lys Ile Thr Trp Pro Asn Gly Leu Thr Leu Asp Tyr
 3185 3190 3195
 Val Thr Glu Arg Ile Tyr Trp Ala Asp Ala Arg Glu Asp Tyr Ile
 3200 3205 3210

Glu	Phe	Ala	Ser	Leu	Asp	Gly	Ser	Asn	Arg	His	Val	Val	Leu	Ser
3215						3220					3225			
Gln	Asp	Ile	Pro	His	Ile	Phe	Ala	Leu	Thr	Leu	Phe	Glu	Asp	Tyr
3230						3235					3240			
Val	Tyr	Trp	Thr	Asp	Trp	Glu	Thr	Lys	Ser	Ile	Asn	Arg	Ala	His
3245						3250					3255			
Lys	Thr	Thr	Gly	Thr	Asn	Lys	Thr	Leu	Leu	Ile	Ser	Thr	Leu	His
3260						3265					3270			
Arg	Pro	Met	Asp	Leu	His	Val	Phe	His	Ala	Leu	Arg	Gln	Pro	Asp
3275						3280					3285			
Val	Pro	Asn	His	Pro	Cys	Lys	Val	Asn	Asn	Gly	Gly	Cys	Ser	Asn
3290						3295					3300			
Leu	Cys	Leu	Leu	Ser	Pro	Gly	Gly	Gly	His	Lys	Cys	Ala	Cys	Pro
3305						3310					3315			
Thr	Asn	Phe	Tyr	Leu	Gly	Ser	Asp	Gly	Arg	Thr	Cys	Val	Ser	Asn
3320						3325					3330			
Cys	Thr	Ala	Ser	Gln	Phe	Val	Cys	Lys	Asn	Asp	Lys	Cys	Ile	Pro
3335						3340					3345			
Phe	Trp	Trp	Lys	Cys	Asp	Thr	Glu	Asp	Asp	Cys	Gly	Asp	His	Ser
3350						3355					3360			
Asp	Glu	Pro	Pro	Asp	Cys	Pro	Glu	Phe	Lys	Cys	Arg	Pro	Gly	Gln
3365						3370					3375			
Phe	Gln	Cys	Ser	Thr	Gly	Ile	Cys	Thr	Asn	Pro	Ala	Phe	Ile	Cys
3380						3385					3390			
Asp	Gly	Asp	Asn	Asp	Cys	Gln	Asp	Asn	Ser	Asp	Glu	Ala	Asn	Cys
3395						3400					3405			
Asp	Ile	His	Val	Cys	Leu	Pro	Ser	Gln	Phe	Lys	Cys	Thr	Asn	Thr
3410						3415					3420			
Asn	Arg	Cys	Ile	Pro	Gly	Ile	Phe	Arg	Cys	Asn	Gly	Gln	Asp	Asn
3425						3430					3435			

Cys Gly Asp Gly Glu Asp Glu Arg Asp Cys Pro Glu Val Thr Cys
 3440 3445 3450
 Ala Pro Asn Gln Phe Gln Cys Ser Ile Thr Lys Arg Cys Ile Pro
 3455 3460 3465
 Arg Val Trp Val Cys Asp Arg Asp Asn Asp Cys Val Asp Gly Ser
 3470 3475 3480
 Asp Glu Pro Ala Asn Cys Thr Gln Met Thr Cys Gly Val Asp Glu
 3485 3490 3495
 Phe Arg Cys Lys Asp Ser Gly Arg Cys Ile Pro Ala Arg Trp Lys
 3500 3505 3510
 Cys Asp Gly Glu Asp Asp Cys Gly Asp Gly Ser Asp Glu Pro Lys
 3515 3520 3525
 Glu Glu Cys Asp Glu Arg Thr Cys Glu Pro Tyr Gln Phe Arg Cys
 3530 3535 3540
 Lys Asn Asn Arg Cys Val Pro Gly Arg Trp Gln Cys Asp Tyr Asp
 3545 3550 3555
 Asn Asp Cys Gly Asp Asn Ser Asp Glu Glu Ser Cys Thr Pro Arg
 3560 3565 3570
 Pro Cys Ser Glu Ser Glu Phe Ser Cys Ala Asn Gly Arg Cys Ile
 3575 3580 3585
 Ala Gly Arg Trp Lys Cys Asp Gly Asp His Asp Cys Ala Asp Gly
 3590 3595 3600
 Ser Asp Glu Lys Asp Cys Thr Pro Arg Cys Asp Met Asp Gln Phe
 3605 3610 3615
 Gln Cys Lys Ser Gly His Cys Ile Pro Leu Arg Trp Arg Cys Asp
 3620 3625 3630
 Ala Asp Ala Asp Cys Met Asp Gly Ser Asp Glu Glu Ala Cys Gly
 3635 3640 3645
 Thr Gly Val Arg Thr Cys Pro Leu Asp Glu Phe Gln Cys Asn Asn
 3650 3655 3660

Thr Leu Cys Lys Pro Leu Ala Trp Lys Cys Asp Gly Glu Asp Asp
3665 3670 3675

Cys Gly Asp Asn Ser Asp Glu Asn Pro Glu Glu Cys Ala Arg Phe
3680 3685 3690

Val Cys Pro Pro Asn Arg Pro Phe Arg Cys Lys Asn Asp Arg Val
3695 3700 3705

Cys Leu Trp Ile Gly Arg Gln Cys Asp Gly Thr Asp Asn Cys Gly
3710 3715 3720

Asp Gly Thr Asp Glu Glu Asp Cys Glu Pro Pro Thr Ala His Thr
3725 3730 3735

Thr His Cys Lys Asp Lys Lys Glu Phe Leu Cys Arg Asn Gln Arg
3740 3745 3750

Cys Leu Ser Ser Ser Leu Arg Cys Asn Met Phe Asp Asp Cys Gly
3755 3760 3765

Asp Gly Ser Asp Glu Glu Asp Cys Ser Ile Asp Pro Lys Leu Thr
3770 3775 3780

Ser Cys Ala Thr Asn Ala Ser Ile Cys Gly Asp Glu Ala Arg Cys
3785 3790 3795

Val Arg Thr Glu Lys Ala Ala Tyr Cys Ala Cys Arg Ser Gly Phe
3800 3805 3810

His Thr Val Pro Gly Gln Pro Gly Cys Gln Asp Ile Asn Glu Cys
3815 3820 3825

Leu Arg Phe Gly Thr Cys Ser Gln Leu Cys Asn Asn Thr Lys Gly
3830 3835 3840

Gly His Leu Cys Ser Cys Ala Arg Asn Phe Met Lys Thr His Asn
3845 3850 3855

Thr Cys Lys Ala Glu Gly Ser Glu Tyr Gln Val Leu Tyr Ile Ala
3860 3865 3870

Asp Asp Asn Glu Ile Arg Ser Leu Phe Pro Gly His Pro His Ser
3875 3880 3885

Ala Tyr Glu Gln Ala Phe Gln Gly Asp Glu Ser Val Arg Ile Asp
3890 3895 3900

Ala Met Asp Val His Val Lys Ala Gly Arg Val Tyr Trp Thr Asn
3905 3910 3915

Trp His Thr Gly Thr Ile Ser Tyr Arg Ser Leu Pro Pro Ala Ala
3920 3925 3930

Pro Pro Thr Thr Ser Asn Arg His Arg Arg Gln Ile Asp Arg Gly
3935 3940 3945

Val Thr His Leu Asn Ile Ser Gly Leu Lys Met Pro Arg Gly Ile
3950 3955 3960

Ala Ile Asp Trp Val Ala Gly Asn Val Tyr Trp Thr Asp Ser Gly
3965 3970 3975

Arg Asp Val Ile Glu Val Ala Gln Met Lys Gly Glu Asn Arg Lys
3980 3985 3990

Thr Leu Ile Ser Gly Met Ile Asp Glu Pro His Ala Ile Val Val
3995 4000 4005

Asp Pro Leu Arg Gly Thr Met Tyr Trp Ser Asp Trp Gly Asn His
4010 4015 4020

Pro Lys Ile Glu Thr Ala Ala Met Asp Gly Thr Leu Arg Glu Thr
4025 4030 4035

Leu Val Gln Asp Asn Ile Gln Trp Pro Thr Gly Leu Ala Val Asp
4040 4045 4050

Tyr His Asn Glu Arg Leu Tyr Trp Ala Asp Ala Lys Leu Ser Val
4055 4060 4065

Ile Gly Ser Ile Arg Leu Asn Gly Thr Asp Pro Ile Val Ala Ala
4070 4075 4080

Asp Ser Lys Arg Gly Leu Ser His Pro Phe Ser Ile Asp Val Phe
4085 4090 4095

Glu Asp Tyr Ile Tyr Gly Val Thr Tyr Ile Asn Asn Arg Val Phe
4100 4105 4110

Lys Ile His Lys Phe Gly His Ser Pro Leu Val Asn Leu Thr Gly
 4115 4120 4125
 Gly Leu Ser His Ala Ser Asp Val Val Leu Tyr His Gln His Lys
 4130 4135 4140
 Gln Pro Glu Val Thr Asn Pro Cys Asp Arg Lys Lys Cys Glu Trp
 4145 4150 4155
 Leu Cys Leu Leu Ser Pro Ser Gly Pro Val Cys Thr Cys Pro Asn
 4160 4165 4170
 Gly Lys Arg Leu Asp Asn Gly Thr Cys Val Pro Val Pro Ser Pro
 4175 4180 4185
 Thr Pro Pro Pro Asp Ala Pro Arg Pro Gly Thr Cys Asn Leu Gln
 4190 4195 4200
 Cys Phe Asn Gly Gly Ser Cys Phe Leu Asn Ala Arg Arg Gln Pro
 4205 4210 4215
 Lys Cys Arg Cys Gln Pro Arg Tyr Thr Gly Asp Lys Cys Glu Leu
 4220 4225 4230
 Asp Gln Cys Trp Glu His Cys Arg Asn Gly Gly Thr Cys Ala Ala
 4235 4240 4245
 Ser Pro Ser Gly Met Pro Thr Cys Arg Cys Pro Thr Gly Phe Thr
 4250 4255 4260
 Gly Pro Lys Cys Thr Gln Gln Val Cys Ala Gly Tyr Cys Ala Asn
 4265 4270 4275
 Asn Ser Thr Cys Thr Val Asn Gln Gly Asn Gln Pro Gln Cys Arg
 4280 4285 4290
 Cys Leu Pro Gly Phe Leu Gly Asp Arg Cys Gln Tyr Arg Gln Cys
 4295 4300 4305
 Ser Gly Tyr Cys Glu Asn Phe Gly Thr Cys Gln Met Ala Ala Asp
 4310 4315 4320
 Gly Ser Arg Gln Cys Arg Cys Thr Ala Tyr Phe Glu Gly Ser Arg
 4325 4330 4335

Cys Glu Val Asn Lys Cys Ser Arg Cys Leu Glu Gly Ala Cys Val
 4340 4345 4350

Val Asn Lys Gln Ser Gly Asp Val Thr Cys Asn Cys Thr Asp Gly
 4355 4360 4365

Arg Val Ala Pro Ser Cys Leu Thr Cys Val Gly His Cys Ser Asn
 4370 4375 4380

Gly Gly Ser Cys Thr Met Asn Ser Lys Met Met Pro Glu Cys Gln
 4385 4390 4395

Cys Pro Pro His Met Thr Gly Pro Arg Cys Glu Glu His Val Phe
 4400 4405 4410

Ser Gln Gln Gln Pro Gly His Ile Ala Ser Ile Leu Ile Pro Leu
 4415 4420 4425

Leu Leu Leu Leu Leu Val Leu Val Ala Gly Val Val Phe Trp
 4430 4435 4440

Tyr Lys Arg Arg Val Gln Gly Ala Lys Gly Phe Gln His Gln Arg
 4445 4450 4455

Met Thr Asn Gly Ala Met Asn Val Glu Ile Gly Asn Pro Thr Tyr
 4460 4465 4470

Lys Met Tyr Glu Gly Gly Glu Pro Asp Asp Val Gly Gly Leu Leu
 4475 4480 4485

Asp Ala Asp Phe Ala Leu Asp Pro Asp Lys Pro Thr Asn Phe Thr
 4490 4495 4500

Asn Pro Val Tyr Ala Thr Leu Tyr Met Gly Gly His Gly Ser Arg
 4505 4510 4515

His Ser Leu Ala Ser Thr Asp Glu Lys Arg Glu Leu Leu Gly Arg
 4520 4525 4530

Gly Pro Glu Asp Glu Ile Gly Asp Pro Leu Ala
 4535 4540

<210> 6
 <211> 2565
 <212> PRT
 <213> H. sapiens

<400> 6

Met Leu Thr Pro Pro Leu Leu Leu Leu Leu Pro Leu Leu Ser Ala Leu
 1 5 10 15

Val Ala Ala Ala Ile Asp Ala Pro Lys Thr Cys Ser Pro Lys Gln Phe
 20 25 30

Ala Cys Arg Asp Gln Ile Thr Cys Ile Ser Lys Gly Trp Arg Cys Asp
 35 40 45

Gly Glu Arg Asp Cys Pro Asp Gly Ser Asp Glu Ala Pro Glu Ile Cys
 50 55 60

Pro Gln Ser Lys Ala Gln Arg Cys Gln Pro Asn Glu His Asn Cys Leu
 65 70 75 80

Leu Thr Glu Leu Cys Val Pro Met Ser Arg Leu Cys Asn Gly Val Gln
 85 90 95

Asp Cys Met Asp Gly Ser Asp Glu Gly Pro His Cys Arg Glu Leu Gln
 100 105 110

Gly Asn Cys Ser Arg Leu Gly Cys Gln His His Cys Val Pro Thr Leu
 115 120 125

Asp Gly Pro Thr Cys Tyr Cys Asn Ser Ser Phe Gln Leu Gln Ala Asp
 130 135 140

Gly Lys Thr Cys Lys Asp Phe Asp Glu Cys Ser Val Tyr Gly Thr Cys
 145 150 155 160

Ser Gln Leu Cys Thr Asn Thr Asp Gly Ser Phe Ile Cys Gly Cys Val
 165 170 175

Glu Gly Tyr Leu Leu Gln Pro Asp Asn Arg Ser Cys Lys Ala Lys Asn
 180 185 190

Glu Pro Val Asp Arg Pro Pro Val Leu Leu Ile Ala Asn Ser Gln Asn
 195 200 205

Ile Leu Ala Thr Tyr Leu Ser Gly Ala Gln Val Ser Thr Ile Thr Pro
 210 215 220

Thr Ser Thr Arg Gln Thr Thr Ala Met Asp Phe Ser Tyr Ala Asn Glu
 225 230 235 240

Thr Val Cys Trp Val His Val Gly Asp Ser Ala Ala Gln Thr Gln Leu
 245 250 255

Lys Cys Ala Arg Met Pro Gly Leu Lys Gly Phe Val Asp Glu His Thr
 260 265 270

Ile Asn Ile Ser Leu Ser Leu His His Val Glu Gln Met Ala Ile Asp
 275 280 285

Trp Leu Thr Gly Asn Phe Tyr Phe Val Asp Asp Ile Asp Asp Arg Ile
 290 295 300

Phe Val Cys Asn Arg Asn Gly Asp Thr Cys Val Thr Leu Leu Asp Leu
 305 310 315 320

Glu Leu Tyr Asn Pro Lys Gly Ile Ala Leu Asp Pro Ala Met Gly Lys
 325 330 335

Val Phe Phe Thr Asp Tyr Gly Gln Ile Pro Lys Val Glu Arg Cys Asp
 340 345 350

Met Asp Gly Gln Asn Arg Thr Lys Leu Val Asp Ser Lys Ile Val Phe
 355 360 365

Pro His Gly Ile Thr Leu Asp Leu Val Ser Arg Leu Val Tyr Trp Ala
 370 375 380

Asp Ala Tyr Leu Asp Tyr Ile Glu Val Val Asp Tyr Glu Gly Lys Gly
 385 390 395 400

Gln Thr Ile Ile Gln Gly Ile Leu Ile Glu His Leu Tyr Gly Leu
 405 410 415

Thr Val Phe Glu Asn Tyr Leu Tyr Ala Thr Asn Ser Asp Asn Ala Asn
 420 425 430

Ala Gln Gln Lys Thr Ser Val Ile Arg Val Asn Arg Phe Asn Ser Thr
 435 440 445

Glu Tyr Gln Val Val Thr Arg Val Asp Lys Gly Gly Ala Leu His Ile
 450 455 460

Tyr His Gln Arg Arg Gln Pro Arg Val Arg Ser His Ala Cys Glu Asn
 465 470 475 480

Asp Gln Tyr Gly Lys Pro Gly Gly Cys Ser Asp Ile Cys Leu Leu Ala
485 490 495

Asn Ser His Lys Ala Arg Thr Cys Arg Cys Arg Ser Gly Phe Ser Leu
500 505 510

Gly Ser Asp Gly Lys Ser Cys Lys Lys Pro Glu His Glu Leu Phe Leu
515 520 525

Val Tyr Gly Lys Gly Arg Pro Gly Ile Ile Arg Gly Met Asp Met Gly
530 535 540

Ala Lys Val Pro Asp Glu His Met Ile Pro Ile Glu Asn Leu Met Asn
545 550 555 560

Pro Arg Ala Leu Asp Phe His Ala Glu Thr Gly Phe Ile Tyr Phe Ala
565 570 575

Asp Thr Thr Ser Tyr Leu Ile Gly Arg Gln Lys Ile Asp Gly Thr Glu
580 585 590

Arg Glu Thr Ile Leu Lys Asp Gly Ile His Asn Val Glu Gly Val Ala
595 600 605

Val Asp Trp Met Gly Asp Asn Leu Tyr Trp Thr Asp Asp Gly Pro Lys
610 615 620

Lys Thr Ile Ser Val Ala Arg Leu Glu Lys Ala Ala Gln Thr Arg Lys
625 630 635 640

Thr Leu Ile Glu Gly Lys Met Thr His Pro Arg Ala Ile Val Val Asp
645 650 655

Pro Leu Asn Gly Trp Met Tyr Trp Thr Asp Trp Glu Glu Asp Pro Lys
660 665 670

Asp Ser Arg Arg Gly Arg Leu Glu Arg Ala Trp Met Asp Gly Ser His
675 680 685

Arg Asp Ile Phe Val Thr Ser Lys Thr Val Leu Trp Pro Asn Gly Leu
690 695 700

Ser Leu Asp Ile Pro Ala Gly Arg Leu Tyr Trp Val Asp Ala Phe Tyr
705 710 715 720

Asp Arg Ile Glu Thr Ile Leu Leu Asn Gly Thr Asp Arg Lys Ile Val
725 730 735

Tyr Glu Gly Pro Glu Leu Asn His Ala Phe Gly Leu Cys His His Gly
740 745 750

Asn Tyr Leu Phe Trp Thr Glu Tyr Arg Ser Gly Ser Val Tyr Arg Leu
755 760 765

Glu Arg Gly Val Gly Gly Ala Pro Pro Thr Val Thr Leu Leu Arg Ser
770 775 780

Glu Arg Pro Pro Ile Phe Glu Ile Arg Met Tyr Asp Ala Gln Gln Gln
785 790 795 800

Gln Val Gly Thr Asn Lys Cys Arg Val Asn Asn Gly Gly Cys Ser Ser
805 810 815

Leu Cys Leu Ala Thr Pro Gly Ser Arg Gln Cys Ala Cys Ala Glu Asp
820 825 830

Gln Val Leu Asp Ala Asp Gly Val Thr Cys Leu Ala Asn Pro Ser Tyr
835 840 845

Val Pro Pro Pro Gln Cys Gln Pro Gly Glu Phe Ala Cys Ala Asn Ser
850 855 860

Arg Cys Ile Gln Glu Arg Trp Lys Cys Asp Gly Asp Asn Asp Cys Leu
865 870 875 880

Asp Asn Ser Asp Glu Ala Pro Ala Leu Cys His Gln His Thr Cys Pro
885 890 895

Ser Asp Arg Phe Lys Cys Glu Asn Asn Arg Cys Ile Pro Asn Arg Trp
900 905 910

Leu Cys Asp Gly Asp Asn Asp Cys Gly Asn Ser Glu Asp Glu Ser Asn
915 920 925

Ala Thr Cys Ser Ala Arg Thr Cys Pro Pro Asn Gln Phe Ser Cys Ala
930 935 940

Ser Gly Arg Cys Ile Pro Ile Ser Trp Thr Cys Asp Leu Asp Asp Asp
945 950 955 960

Cys Gly Asp Arg Ser Asp Glu Ser Ala Ser Cys Ala Tyr Pro Thr Cys
 965 970 975

Phe Pro Leu Thr Gln Phe Thr Cys Asn Asn Gly Arg Cys Ile Asn Ile
 980 985 990

Asn Trp Arg Cys Asp Asn Asp Asn Asp Cys Gly Asp Asn Ser Asp Glu
 995 1000 1005

Ala Gly Cys Ser His Ser Cys Ser Ser Thr Gln Phe Lys Cys Asn
 1010 1015 1020

Ser Gly Arg Cys Ile Pro Glu His Trp Thr Cys Asp Gly Asp Asn
 1025 1030 1035

Asp Cys Gly Asp Tyr Ser Asp Glu Thr His Ala Asn Cys Thr Asn
 1040 1045 1050

Gln Ala Thr Arg Pro Pro Gly Gly Cys His Thr Asp Glu Phe Gln
 1055 1060 1065

Cys Arg Leu Asp Gly Leu Cys Ile Pro Leu Arg Trp Arg Cys Asp
 1070 1075 1080

Gly Asp Thr Asp Cys Met Asp Ser Ser Asp Glu Lys Ser Cys Glu
 1085 1090 1095

Gly Val Thr His Val Cys Asp Pro Ser Val Lys Phe Gly Cys Lys
 1100 1105 1110

Pro Ser Ala Arg Cys Ile Ser Lys Ala Trp Val Cys Asp Gly Asp
 1115 1120 1125

Asn Asp Cys Glu Asp Asn Ser Asp Glu Glu Asn Cys Glu Ser Leu
 1130 1135 1140

Ala Cys Arg Pro Pro Ser His Pro Cys Ala Asn Asn Thr Ser Val
 1145 1150 1155

Cys Leu Pro Pro Asp Lys Leu Cys Asp Gly Asn Asp Asp Cys Gly
 1160 1165 1170

Asp Gly Ser Asp Glu Gly Glu Leu Cys Asp Gln Cys Ser Leu Asn
 1175 1180 1185

Asn Gly Gly Cys Ser His Asn Cys Ser Val Ala Pro Gly Glu Gly
 1190 1195 1200

Ile Val Cys Ser Cys Pro Leu Gly Met Glu Leu Gly Pro Asp Asn
 1205 1210 1215

His Thr Cys Gln Ile Gln Ser Tyr Cys Ala Lys His Leu Lys Cys
 1220 1225 1230

Ser Gln Lys Cys Asp Gln Asn Lys Phe Ser Val Lys Cys Ser Cys
 1235 1240 1245

Tyr Glu Gly Trp Val Leu Glu Pro Asp Gly Glu Ser Cys Arg Ser
 1250 1255 1260

Leu Asp Pro Phe Lys Pro Phe Ile Ile Phe Ser Asn Arg His Glu
 1265 1270 1275

Ile Arg Arg Ile Asp Leu His Lys Gly Asp Tyr Ser Val Leu Val
 1280 1285 1290

Pro Gly Leu Arg Asn Thr Ile Ala Leu Asp Phe His Leu Ser Gln
 1295 1300 1305

Ser Ala Leu Tyr Trp Thr Asp Val Val Glu Asp Lys Ile Tyr Arg
 1310 1315 1320

Gly Lys Leu Leu Asp Asn Gly Ala Leu Thr Ser Phe Glu Val Val
 1325 1330 1335

Ile Gln Tyr Gly Leu Ala Thr Pro Glu Gly Leu Ala Val Asp Trp
 1340 1345 1350

Ile Ala Gly Asn Ile Tyr Trp Val Glu Ser Asn Leu Asp Gln Ile
 1355 1360 1365

Glu Val Ala Lys Leu Asp Gly Thr Leu Arg Thr Thr Leu Leu Ala
 1370 1375 1380

Gly Asp Ile Glu His Pro Arg Ala Ile Ala Leu Asp Pro Arg Asp
 1385 1390 1395

Gly Ile Leu Phe Trp Thr Asp Trp Asp Ala Ser Leu Pro Arg Ile
 1400 1405 1410

Glu Ala Ala Ser Met Ser Gly Ala Gly Arg Arg Thr Val His Arg
1415 1420 1425

Glu Thr Gly Ser Gly Gly Trp Pro Asn Gly Leu Thr Val Asp Tyr
1430 1435 1440

Leu Glu Lys Arg Ile Leu Trp Ile Asp Ala Arg Ser Asp Ala Ile
1445 1450 1455

Tyr Ser Ala Arg Tyr Asp Gly Ser Gly His Met Glu Val Leu Arg
1460 1465 1470

Gly His Glu Phe Leu Ser His Pro Phe Ala Val Thr Leu Tyr Gly
1475 1480 1485

Gly Glu Val Tyr Trp Thr Asp Trp Arg Thr Asn Thr Leu Ala Lys
1490 1495 1500

Ala Asn Lys Trp Thr Gly His Asn Val Thr Val Val Gln Arg Thr
1505 1510 1515

Asn Thr Gln Pro Phe Asp Leu Gln Val Tyr His Pro Ser Arg Gln
1520 1525 1530

Pro Met Ala Pro Asn Pro Cys Glu Ala Asn Gly Gly Gln Gly Pro
1535 1540 1545

Cys Ser His Leu Cys Leu Ile Asn Tyr Asn Arg Thr Val Ser Cys
1550 1555 1560

Ala Cys Pro His Leu Met Lys Leu His Lys Asp Asn Thr Thr Cys
1565 1570 1575

Tyr Glu Phe Lys Lys Phe Leu Leu Tyr Ala Arg Gln Met Glu Ile
1580 1585 1590

Arg Gly Val Asp Leu Asp Ala Pro Tyr Tyr Asn Tyr Ile Ile Ser
1595 1600 1605

Phe Thr Val Pro Asp Ile Asp Asn Val Thr Val Leu Asp Tyr Asp
1610 1615 1620

Ala Arg Glu Gln Arg Val Tyr Trp Ser Asp Val Arg Thr Gln Ala
1625 1630 1635

Ile Lys Arg Ala Phe Ile Asn Gly Thr Gly Val Glu Thr Val Val
 1640 1645 1650

Ser Ala Asp Leu Pro Asn Ala His Gly Leu Ala Val Asp Trp Val
 1655 1660 1665

Ser Arg Asn Leu Phe Trp Thr Ser Tyr Asp Thr Asn Lys Lys Gln
 1670 1675 1680

Ile Asn Val Ala Arg Leu Asp Gly Ser Phe Lys Asn Ala Val Val
 1685 1690 1695

Gln Gly Leu Glu Gln Pro His Gly Leu Val Val His Pro Leu Arg
 1700 1705 1710

Gly Lys Leu Tyr Trp Thr Asp Gly Asp Asn Ile Ser Met Ala Asn
 1715 1720 1725

Met Asp Gly Ser Asn Arg Thr Leu Leu Phe Ser Gly Gln Lys Gly
 1730 1735 1740

Pro Val Gly Leu Ala Ile Asp Phe Pro Glu Ser Lys Leu Tyr Trp
 1745 1750 1755

Ile Ser Ser Gly Asn His Thr Ile Asn Arg Cys Asn Leu Asp Gly
 1760 1765 1770

Ser Gly Leu Glu Val Ile Asp Ala Met Arg Ser Gln Leu Gly Lys
 1775 1780 1785

Ala Thr Ala Leu Ala Ile Met Gly Asp Lys Leu Trp Trp Ala Asp
 1790 1795 1800

Gln Val Ser Glu Lys Met Gly Thr Cys Ser Lys Ala Asp Gly Ser
 1805 1810 1815

Gly Ser Val Val Leu Arg Asn Ser Thr Thr Leu Val Met His Met
 1820 1825 1830

Lys Val Tyr Asp Glu Ser Ile Gln Leu Asp His Lys Gly Thr Asn
 1835 1840 1845

Pro Cys Ser Val Asn Asn Gly Asp Cys Ser Gln Leu Cys Leu Pro
 1850 1855 1860

Thr	Ser	Glu	Thr	Thr	Arg	Ser	Cys	Met	Cys	Thr	Ala	Gly	Tyr	Ser
1865						1870					1875			
Leu	Arg	Ser	Gly	Gln	Gln	Ala	Cys	Glu	Gly	Val	Gly	Ser	Phe	Leu
1880						1885					1890			
Leu	Tyr	Ser	Val	His	Glu	Gly	Ile	Arg	Gly	Ile	Pro	Leu	Asp	Pro
1895						1900					1905			
Asn	Asp	Lys	Ser	Asp	Ala	Leu	Val	Pro	Val	Ser	Gly	Thr	Ser	Leu
1910						1915					1920			
Ala	Val	Gly	Ile	Asp	Phe	His	Ala	Glu	Asn	Asp	Thr	Ile	Tyr	Trp
1925						1930					1935			
Val	Asp	Met	Gly	Leu	Ser	Thr	Ile	Ser	Arg	Ala	Lys	Arg	Asp	Gln
1940						1945					1950			
Thr	Trp	Arg	Glu	Asp	Val	Val	Thr	Asn	Gly	Ile	Gly	Arg	Val	Glu
1955						1960					1965			
Gly	Ile	Ala	Val	Asp	Trp	Ile	Ala	Gly	Asn	Ile	Tyr	Trp	Thr	Asp
1970						1975					1980			
Gln	Gly	Phe	Asp	Val	Ile	Glu	Val	Ala	Arg	Leu	Asn	Gly	Ser	Phe
1985						1990					1995			
Arg	Tyr	Val	Val	Ile	Ser	Gln	Gly	Leu	Asp	Lys	Pro	Arg	Ala	Ile
2000						2005					2010			
Thr	Val	His	Pro	Glu	Lys	Gly	Tyr	Leu	Phe	Trp	Thr	Glu	Trp	Gly
2015						2020					2025			
Gln	Tyr	Pro	Arg	Ile	Glu	Arg	Ser	Arg	Leu	Asp	Gly	Thr	Glu	Arg
2030						2035					2040			
Val	Val	Leu	Val	Asn	Val	Ser	Ile	Ser	Trp	Pro	Asn	Gly	Ile	Ser
2045						2050					2055			
Val	Asp	Tyr	Gln	Asp	Gly	Lys	Leu	Tyr	Trp	Cys	Asp	Ala	Arg	Thr
2060						2065					2070			
Asp	Lys	Ile	Glu	Arg	Ile	Asp	Leu	Glu	Thr	Gly	Glu	Asn	Arg	Glu
2075						2080					2085			

Val	Val	Leu	Ser	Ser	Asn	Asn	Met	Asp	Met	Phe	Ser	Val	Ser	Val
2090						2095					2100			
Phe	Glu	Asp	Phe	Ile	Tyr	Trp	Ser	Asp	Arg	Thr	His	Ala	Asn	Gly
2105						2110					2115			
Ser	Ile	Lys	Arg	Gly	Ser	Lys	Asp	Asn	Ala	Thr	Asp	Ser	Val	Pro
2120						2125					2130			
Leu	Arg	Thr	Gly	Ile	Gly	Val	Gln	Leu	Lys	Asp	Ile	Lys	Val	Phe
2135						2140					2145			
Asn	Arg	Asp	Arg	Gln	Lys	Gly	Thr	Asn	Val	Cys	Ala	Val	Ala	Asn
2150						2155					2160			
Gly	Gly	Cys	Gln	Gln	Leu	Cys	Leu	Tyr	Arg	Gly	Arg	Gly	Gln	Arg
2165						2170					2175			
Ala	Cys	Ala	Cys	Ala	His	Gly	Met	Leu	Ala	Glu	Asp	Gly	Ala	Ser
2180						2185					2190			
Cys	Arg	Glu	Tyr	Ala	Gly	Tyr	Leu	Leu	Tyr	Ser	Glu	Arg	Thr	Ile
2195						2200					2205			
Leu	Lys	Ser	Ile	His	Leu	Ser	Asp	Glu	Arg	Asn	Leu	Asn	Ala	Pro
2210						2215					2220			
Val	Gln	Pro	Phe	Glu	Asp	Pro	Glu	His	Met	Lys	Asn	Val	Ile	Ala
2225						2230					2235			
Leu	Ala	Phe	Asp	Tyr	Arg	Ala	Gly	Thr	Ser	Pro	Gly	Thr	Pro	Asn
2240						2245					2250			
Arg	Ile	Phe	Phe	Ser	Asp	Ile	His	Phe	Gly	Asn	Ile	Gln	Gln	Ile
2255						2260					2265			
Asn	Asp	Asp	Gly	Ser	Arg	Arg	Ile	Thr	Ile	Val	Glu	Asn	Val	Gly
2270						2275					2280			
Ser	Val	Glu	Gly	Leu	Ala	Tyr	His	Arg	Gly	Trp	Asp	Thr	Leu	Tyr
2285						2290					2295			
Trp	Thr	Ser	Tyr	Thr	Thr	Ser	Thr	Ile	Thr	Arg	His	Thr	Val	Asp
2300						2305					2310			

Gln Thr Arg Pro Gly Ala Phe Glu Arg Glu Thr Val Ile Thr Met
 2315 2320 2325
 Ser Gly Asp Asp His Pro Arg Ala Phe Val Leu Asp Glu Cys Gln
 2330 2335 2340
 Asn Leu Met Phe Trp Thr Asn Trp Asn Glu Gln His Pro Ser Ile
 2345 2350 2355
 Met Arg Ala Ala Leu Ser Gly Ala Asn Val Leu Thr Leu Ile Glu
 2360 2365 2370
 Lys Asp Ile Arg Thr Pro Asn Gly Leu Ala Ile Asp His Arg Ala
 2375 2380 2385
 Glu Lys Leu Tyr Phe Ser Asp Ala Thr Leu Asp Lys Ile Glu Arg
 2390 2395 2400
 Cys Glu Tyr Asp Gly Ser His Arg Tyr Val Ile Leu Lys Ser Glu
 2405 2410 2415
 Pro Val His Pro Phe Gly Leu Ala Val Tyr Gly Glu His Ile Phe
 2420 2425 2430
 Trp Thr Asp Trp Val Arg Arg Ala Val Gln Arg Ala Asn Lys His
 2435 2440 2445
 Val Gly Ser Asn Met Lys Leu Leu Arg Val Asp Ile Pro Gln Gln
 2450 2455 2460
 Pro Met Gly Ile Ile Ala Val Ala Asn Asp Thr Asn Ser Cys Glu
 2465 2470 2475
 Leu Ser Pro Cys Arg Ile Asn Asn Gly Gly Cys Gln Asp Leu Cys
 2480 2485 2490
 Leu Leu Thr His Gln Gly His Val Asn Cys Ser Cys Arg Gly Gly
 2495 2500 2505
 Arg Ile Leu Gln Asp Asp Leu Thr Cys Arg Ala Val Gly Gly Arg
 2510 2515 2520
 Leu Val Pro Arg Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala
 2525 2530 2535

Ile Glu Gly His Val Gly Leu Asn Asp Ile Phe Glu Ala Gln Lys
 2540 2545 2550

Ile Glu Trp His Glu Gly His His His His His His
 2555 2560 2565

<210> 7
 <211> 2520
 <212> PRT
 <213> H. sapiens

<400> 7

Met Leu Thr Pro Pro Leu Leu Leu Leu Leu Pro Leu Leu Ser Ala Leu
 1 5 10 15

Val Ala Ala Ala Ile Asp Ala Pro Lys Thr Cys Ser Pro Lys Gln Phe
 20 25 30

a Cys Arg Asp Gln Ile Thr Cys Ile Ser Lys Gly Trp Arg Cys Asp
 35 40 45

Gly Glu Arg Asp Cys Pro Asp Gly Ser Asp Glu Ala Pro Glu Ile Cys
 50 55 60

Pro Gln Ser Lys Ala Gln Arg Cys Gln Pro Asn Glu His Asn Cys Leu
 65 70 75 80

Gly Thr Glu Leu Cys Val Pro Met Ser Arg Leu Cys Asn Gly Val Gln
 85 90 95

Asp Cys Met Asp Gly Ser Asp Glu Gly Pro His Cys Arg Glu Leu Gln
 100 105 110

Gly Asn Cys Ser Arg Leu Gly Cys Gln His His Cys Val Pro Thr Leu
 115 120 125

Asp Gly Pro Thr Cys Tyr Cys Asn Ser Ser Phe Gln Leu Gln Ala Asp
 130 135 140

Gly Lys Thr Cys Lys Asp Phe Asp Glu Cys Ser Val Tyr Gly Thr Cys
 145 150 155 160

Ser Gln Leu Cys Thr Asn Thr Asp Gly Ser Phe Ile Cys Gly Cys Val
 165 170 175

Glu Gly Tyr Leu Leu Gln Pro Asp Asn Arg Ser Cys Lys Ala Lys Asn
 180 185 190

Glu Pro Val Asp Arg Pro Pro Val Leu Leu Ile Ala Asn Ser Gln Asn
 195 200 205

Ile Leu Ala Thr Tyr Leu Ser Gly Ala Gln Val Ser Thr Ile Thr Pro
 210 215 220

Thr Ser Thr Arg Gln Thr Thr Ala Met Asp Phe Ser Tyr Ala Asn Glu
 225 230 235 240

Thr Val Cys Trp Val His Val Gly Asp Ser Ala Ala Gln Thr Gln Leu
 245 250 255

Lys Cys Ala Arg Met Pro Gly Leu Lys Gly Phe Val Asp Glu His Thr
 260 265 270

Ile Asn Ile Ser Leu Ser Leu His His Val Glu Gln Met Ala Ile Asp
 275 280 285

Trp Leu Thr Gly Asn Phe Tyr Phe Val Asp Asp Ile Asp Asp Arg Ile
 290 295 300

Phe Val Cys Asn Arg Asn Gly Asp Thr Cys Val Thr Leu Leu Asp Leu
 305 310 315 320

Glu Leu Tyr Asn Pro Lys Gly Ile Ala Leu Asp Pro Ala Met Gly Lys
 325 330 335

Val Phe Phe Thr Asp Tyr Gly Gln Ile Pro Lys Val Glu Arg Cys Asp
 340 345 350

Met Asp Gly Gln Asn Arg Thr Lys Leu Val Asp Ser Lys Ile Val Phe
 355 360 365

Pro His Gly Ile Thr Leu Asp Leu Val Ser Arg Leu Val Tyr Trp Ala
 370 375 380

Asp Ala Tyr Leu Asp Tyr Ile Glu Val Val Asp Tyr Glu Gly Lys Gly
 385 390 395 400

Arg Gln Thr Ile Ile Gln Gly Ile Leu Ile Glu His Leu Tyr Gly Leu
 405 410 415

Thr Val Phe Glu Asn Tyr Leu Tyr Ala Thr Asn Ser Asp Asn Ala Asn
 420 425 430

Ala Gln Gln Lys Thr Ser Val Ile Arg Val Asn Arg Phe Asn Ser Thr
435 440 445

Glu Tyr Gln Val Val Thr Arg Val Asp Lys Gly Gly Ala Leu His Ile
450 455 460

Tyr His Gln Arg Arg Gln Pro Arg Val Arg Ser His Ala Cys Glu Asn
465 470 475 480

Asp Gln Tyr Gly Lys Pro Gly Gly Cys Ser Asp Ile Cys Leu Leu Ala
485 490 495

Asn Ser His Lys Ala Arg Thr Cys Arg Cys Arg Ser Gly Phe Ser Leu
500 505 510

Gly Ser Asp Gly Lys Ser Cys Lys Lys Pro Glu His Glu Leu Phe Leu
515 520 525

Val Tyr Gly Lys Gly Arg Pro Gly Ile Ile Arg Gly Met Asp Met Gly
530 535 540

Ala Lys Val Pro Asp Glu His Met Ile Pro Ile Glu Asn Leu Met Asn
545 550 555 560

Pro Arg Ala Leu Asp Phe His Ala Glu Thr Gly Phe Ile Tyr Phe Ala
565 570 575

Asp Thr Thr Ser Tyr Leu Ile Gly Arg Gln Lys Ile Asp Gly Thr Glu
580 585 590

Glu Thr Ile Leu Lys Asp Gly Ile His Asn Val Glu Gly Val Ala
595 600 605

Val Asp Trp Met Gly Asp Asn Leu Tyr Trp Thr Asp Asp Gly Pro Lys
610 615 620

Lys Thr Ile Ser Val Ala Arg Leu Glu Lys Ala Ala Gln Thr Arg Lys
625 630 635 640

Thr Leu Ile Glu Gly Lys Met Thr His Pro Arg Ala Ile Val Val Asp
645 650 655

Pro Leu Asn Gly Trp Met Tyr Trp Thr Asp Trp Glu Glu Asp Pro Lys
660 665 670

Asp Ser Arg Arg Gly Arg Leu Glu Arg Ala Trp Met Asp Gly Ser His
 675 680 685

Arg Asp Ile Phe Val Thr Ser Lys Thr Val Leu Trp Pro Asn Gly Leu
 690 695 700

Ser Leu Asp Ile Pro Ala Gly Arg Leu Tyr Trp Val Asp Ala Phe Tyr
 705 710 715 720

Asp Arg Ile Glu Thr Ile Leu Leu Asn Gly Thr Asp Arg Lys Ile Val
 725 730 735

Tyr Glu Gly Pro Glu Leu Asn His Ala Phe Gly Leu Cys His His Gly
 740 745 750

Asn Tyr Leu Phe Trp Thr Glu Tyr Arg Ser Gly Ser Val Tyr Arg Leu
 755 760 765

Glu Arg Gly Val Gly Gly Ala Pro Pro Thr Val Thr Leu Leu Arg Ser
 770 775 780

Glu Arg Pro Pro Ile Phe Glu Ile Arg Met Tyr Asp Ala Gln Gln Gln
 785 790 795 800

Gln Val Gly Thr Asn Lys Cys Arg Val Asn Asn Gly Gly Cys Ser Ser
 805 810 815

Leu Cys Leu Ala Thr Pro Gly Ser Arg Gln Cys Ala Cys Ala Glu Asp
 820 825 830

Gln Val Leu Asp Ala Asp Gly Val Thr Cys Leu Ala Asn Pro Ser Tyr
 835 840 845

Val Pro Pro Pro Gln Cys Gln Pro Gly Glu Phe Ala Cys Ala Asn Ser
 850 855 860

Arg Cys Ile Gln Glu Arg Trp Lys Cys Asp Gly Asp Asn Asp Cys Leu
 865 870 875 880

Asp Asn Ser Asp Glu Ala Pro Ala Leu Cys His Gln His Thr Cys Pro
 885 890 895

Ser Asp Arg Phe Lys Cys Glu Asn Asn Arg Cys Ile Pro Asn Arg Trp
 900 905 910

Leu Cys Asp Gly Asp Asn Asp Cys Gly Asn Ser Glu Asp Glu Ser Asn
 915 920 925

Ala Thr Cys Ser Ala Arg Thr Cys Pro Pro Asn Gln Phe Ser Cys Ala
 930 935 940

Ser Gly Arg Cys Ile Pro Ile Ser Trp Thr Cys Asp Leu Asp Asp Asp
 945 950 955 960

Cys Gly Asp Arg Ser Asp Glu Ser Ala Ser Cys Ala Tyr Pro Thr Cys
 965 970 975

Phe Pro Leu Thr Gln Phe Thr Cys Asn Asn Gly Arg Cys Ile Asn Ile
 980 985 990

Asn Trp Arg Cys Asp Asn Asp Asn Asp Cys Gly Asp Asn Ser Asp Glu
 995 1000 1005

Ala Gly Cys Ser His Ser Cys Ser Ser Thr Gln Phe Lys Cys Asn
 1010 1015 1020

Ser Gly Arg Cys Ile Pro Glu His Trp Thr Cys Asp Gly Asp Asn
 1025 1030 1035

Asp Cys Gly Asp Tyr Ser Asp Glu Thr His Ala Asn Cys Thr Asn
 1040 1045 1050

Gln Ala Thr Arg Pro Pro Gly Gly Cys His Thr Asp Glu Phe Gln
 1055 1060 1065

As Arg Leu Asp Gly Leu Cys Ile Pro Leu Arg Trp Arg Cys Asp
 1070 1075 1080

Gly Asp Thr Asp Cys Met Asp Ser Ser Asp Glu Lys Ser Cys Glu
 1085 1090 1095

Gly Val Thr His Val Cys Asp Pro Ser Val Lys Phe Gly Cys Lys
 1100 1105 1110

Asp Ser Ala Arg Cys Ile Ser Lys Ala Trp Val Cys Asp Gly Asp
 1115 1120 1125

Asn Asp Cys Glu Asp Asn Ser Asp Glu Glu Asn Cys Glu Ser Leu
 1130 1135 1140

Ala Cys Arg Pro Pro Ser His Pro Cys Ala Asn Asn Thr Ser Val
 1145 1150 1155
 Cys Leu Pro Pro Asp Lys Leu Cys Asp Gly Asn Asp Asp Cys Gly
 1160 1165 1170
 Asp Gly Ser Asp Glu Gly Glu Leu Cys Asp Gln Cys Ser Leu Asn
 1175 1180 1185
 Asn Gly Gly Cys Ser His Asn Cys Ser Val Ala Pro Gly Glu Gly
 1190 1195 1200
 Ile Val Cys Ser Cys Pro Leu Gly Met Glu Leu Gly Pro Asp Asn
 1205 1210 1215
 His Thr Cys Gln Ile Gln Ser Tyr Cys Ala Lys His Leu Lys Cys
 1220 1225 1230
 Ser Gln Lys Cys Asp Gln Asn Lys Phe Ser Val Lys Cys Ser Cys
 1235 1240 1245
 Tyr Glu Gly Trp Val Leu Glu Pro Asp Gly Glu Ser Cys Arg Ser
 1250 1255 1260
 Leu Asp Pro Phe Lys Pro Phe Ile Ile Phe Ser Asn Arg His Glu
 1265 1270 1275
 Ile Arg Arg Ile Asp Leu His Lys Gly Asp Tyr Ser Val Leu Val
 1280 1285 1290
 Pro Gly Leu Arg Asn Thr Ile Ala Leu Asp Phe His Leu Ser Gln
 1295 1300 1305
 Ser Ala Leu Tyr Trp Thr Asp Val Val Glu Asp Lys Ile Tyr Arg
 1310 1315 1320
 Gly Lys Leu Leu Asp Asn Gly Ala Leu Thr Ser Phe Glu Val Val
 1325 1330 1335
 Ile Gln Tyr Gly Leu Ala Thr Pro Glu Gly Leu Ala Val Asp Trp
 1340 1345 1350
 Ile Ala Gly Asn Ile Tyr Trp Val Glu Ser Asn Leu Asp Gln Ile
 1355 1360 1365

Glu Val Ala Lys Leu Asp Gly Thr Leu Arg Thr Thr Leu Leu Ala
 1370 1375 1380
 Gly Asp Ile Glu His Pro Arg Ala Ile Ala Leu Asp Pro Arg Asp
 1385 1390 1395
 Gly Ile Leu Phe Trp Thr Asp Trp Asp Ala Ser Leu Pro Arg Ile
 1400 1405 1410
 Glu Ala Ala Ser Met Ser Gly Ala Gly Arg Arg Thr Val His Arg
 1415 1420 1425
 Glu Thr Gly Ser Gly Gly Trp Pro Asn Gly Leu Thr Val Asp Tyr
 1430 1435 1440
 Leu Glu Lys Arg Ile Leu Trp Ile Asp Ala Arg Ser Asp Ala Ile
 1445 1450 1455
 Tyr Ser Ala Arg Tyr Asp Gly Ser Gly His Met Glu Val Leu Arg
 1460 1465 1470
 Gly His Glu Phe Leu Ser His Pro Phe Ala Val Thr Leu Tyr Gly
 1475 1480 1485
 Gly Glu Val Tyr Trp Thr Asp Trp Arg Thr Asn Thr Leu Ala Lys
 1490 1495 1500
 Ala Asn Lys Trp Thr Gly His Asn Val Thr Val Val Gln Arg Thr
 1505 1510 1515
 Asn Thr Gln Pro Phe Asp Leu Gln Val Tyr His Pro Ser Arg Gln
 1520 1525 1530
 Pro Met Ala Pro Asn Pro Cys Glu Ala Asn Gly Gly Gln Gly Pro
 1535 1540 1545
 Cys Ser His Leu Cys Leu Ile Asn Tyr Asn Arg Thr Val Ser Cys
 1550 1555 1560
 Ala Cys Pro His Leu Met Lys Leu His Lys Asp Asn Thr Thr Cys
 1565 1570 1575
 Tyr Glu Phe Lys Lys Phe Leu Leu Tyr Ala Arg Gln Met Glu Ile
 1580 1585 1590

Arg Gly Val Asp Leu Asp Ala Pro Tyr Tyr Asn Tyr Ile Ile Ser
 1595 1600 1605
 Phe Thr Val Pro Asp Ile Asp Asn Val Thr Val Leu Asp Tyr Asp
 1610 1615 1620
 Ala Arg Glu Gln Arg Val Tyr Trp Ser Asp Val Arg Thr Gln Ala
 1625 1630 1635
 Ile Lys Arg Ala Phe Ile Asn Gly Thr Gly Val Glu Thr Val Val
 1640 1645 1650
 Ser Ala Asp Leu Pro Asn Ala His Gly Leu Ala Val Asp Trp Val
 1655 1660 1665
 Ser Arg Asn Leu Phe Trp Thr Ser Tyr Asp Thr Asn Lys Lys Gln
 1670 1675 1680
 Ile Asn Val Ala Arg Leu Asp Gly Ser Phe Lys Asn Ala Val Val
 1685 1690 1695
 Gln Gly Leu Glu Gln Pro His Gly Leu Val Val His Pro Leu Arg
 1700 1705 1710
 Gly Lys Leu Tyr Trp Thr Asp Gly Asp Asn Ile Ser Met Ala Asn
 1715 1720 1725
 Met Asp Gly Ser Asn Arg Thr Leu Leu Phe Ser Gly Gln Lys Gly
 1730 1735 1740
 Pro Val Gly Leu Ala Ile Asp Phe Pro Glu Ser Lys Leu Tyr Trp
 1745 1750 1755
 Ile Ser Ser Gly Asn His Thr Ile Asn Arg Cys Asn Leu Asp Gly
 1760 1765 1770
 Ser Gly Leu Glu Val Ile Asp Ala Met Arg Ser Gln Leu Gly Lys
 1775 1780 1785
 Ala Thr Ala Leu Ala Ile Met Gly Asp Lys Leu Trp Trp Ala Asp
 1790 1795 1800
 Gln Val Ser Glu Lys Met Gly Thr Cys Ser Lys Ala Asp Gly Ser
 1805 1810 1815

Gly Ser Val Val Leu Arg Asn Ser Thr Thr Leu Val Met His Met
 1820 1825 1830

Lys Val Tyr Asp Glu Ser Ile Gln Leu Asp His Lys Gly Thr Asn
 1835 1840 1845

Pro Cys Ser Val Asn Asn Gly Asp Cys Ser Gln Leu Cys Leu Pro
 1850 1855 1860

Thr Ser Glu Thr Thr Arg Ser Cys Met Cys Thr Ala Gly Tyr Ser
 1865 1870 1875

Leu Arg Ser Gly Gln Gln Ala Cys Glu Gly Val Gly Ser Phe Leu
 1880 1885 1890

Leu Tyr Ser Val His Glu Gly Ile Arg Gly Ile Pro Leu Asp Pro
 1895 1900 1905

Asn Asp Lys Ser Asp Ala Leu Val Pro Val Ser Gly Thr Ser Leu
 1910 1915 1920

Ala Val Gly Ile Asp Phe His Ala Glu Asn Asp Thr Ile Tyr Trp
 1925 1930 1935

Val Asp Met Gly Leu Ser Thr Ile Ser Arg Ala Lys Arg Asp Gln
 1940 1945 1950

Thr Trp Arg Glu Asp Val Val Thr Asn Gly Ile Gly Arg Val Glu
 1955 1960 1965

Gly Ile Ala Val Asp Trp Ile Ala Gly Asn Ile Tyr Trp Thr Asp
 1970 1975 1980

Gln Gly Phe Asp Val Ile Glu Val Ala Arg Leu Asn Gly Ser Phe
 1985 1990 1995

Arg Tyr Val Val Ile Ser Gln Gly Leu Asp Lys Pro Arg Ala Ile
 2000 2005 2010

Thr Val His Pro Glu Lys Gly Tyr Leu Phe Trp Thr Glu Trp Gly
 2015 2020 2025

Gln Tyr Pro Arg Ile Glu Arg Ser Arg Leu Asp Gly Thr Glu Arg
 2030 2035 2040

Val Val Leu Val Asn Val Ser Ile Ser Trp Pro Asn Gly Ile Ser
2045 2050 2055

Val Asp Tyr Gln Asp Gly Lys Leu Tyr Trp Cys Asp Ala Arg Thr
2060 2065 2070

Asp Lys Ile Glu Arg Ile Asp Leu Glu Thr Gly Glu Asn Arg Glu
2075 2080 2085

Val Val Leu Ser Ser Asn Asn Met Asp Met Phe Ser Val Ser Val
2090 2095 2100

Phe Glu Asp Phe Ile Tyr Trp Ser Asp Arg Thr His Ala Asn Gly
2105 2110 2115

Ser Ile Lys Arg Gly Ser Lys Asp Asn Ala Thr Asp Ser Val Pro
2120 2125 2130

Leu Arg Thr Gly Ile Gly Val Gln Leu Lys Asp Ile Lys Val Phe
2135 2140 2145

Asn Arg Asp Arg Gln Lys Gly Thr Asn Val Cys Ala Val Ala Asn
2150 2155 2160

Gly Gly Cys Gln Gln Leu Cys Leu Tyr Arg Gly Arg Gly Gln Arg
2165 2170 2175

Ala Cys Ala Cys Ala His Gly Met Leu Ala Glu Asp Gly Ala Ser
2180 2185 2190

Cys Arg Glu Tyr Ala Gly Tyr Leu Leu Tyr Ser Glu Arg Thr Ile
2195 2200 2205

Leu Lys Ser Ile His Leu Ser Asp Glu Arg Asn Leu Asn Ala Pro
2210 2215 2220

Val Gln Pro Phe Glu Asp Pro Glu His Met Lys Asn Val Ile Ala
2225 2230 2235

Leu Ala Phe Asp Tyr Arg Ala Gly Thr Ser Pro Gly Thr Pro Asn
2240 2245 2250

Arg Ile Phe Phe Ser Asp Ile His Phe Gly Asn Ile Gln Gln Ile
2255 2260 2265

Asn Asp 2270	Asp Gly Ser Arg Arg 2275	Ile Thr Ile Val Glu 2280	Asn Val Gly
Ser Val 2285	Glu Gly Leu Ala Tyr 2290	His Arg Gly Trp Asp 2295	Thr Leu Tyr
Trp Thr 2300	Ser Tyr Thr Thr Ser 2305	Thr Ile Thr Arg His 2310	Thr Val Asp
Gln Thr 2315	Arg Pro Gly Ala Phe 2320	Glu Arg Glu Thr Val 2325	Ile Thr Met
Ser Gly 2330	Asp Asp His Pro Arg 2335	Ala Phe Val Leu Asp 2340	Glu Cys Gln
Asn Leu 2345	Met Phe Trp Thr Asn 2350	Trp Asn Glu Gln His 2355	Pro Ser Ile
Met Arg 2360	Ala Ala Leu Ser Gly 2365	Ala Asn Val Leu Thr 2370	Leu Ile Glu
Lys Asp 2375	Ile Arg Thr Pro Asn 2380	Gly Leu Ala Ile Asp 2385	His Arg Ala
Glu Lys 2390	Leu Tyr Phe Ser Asp 2395	Ala Thr Leu Asp Lys 2400	Ile Glu Arg
Cys Glu 2405	Tyr Asp Gly Ser His 2410	Arg Tyr Val Ile Leu 2415	Lys Ser Glu
Pro Val 2420	His Pro Phe Gly Leu 2425	Ala Val Tyr Gly Glu 2430	His Ile Phe
Trp Thr 2435	Asp Trp Val Arg Arg 2440	Ala Val Gln Arg Ala 2445	Asn Lys His
Val Gly 2450	Ser Asn Met Lys Leu 2455	Leu Arg Val Asp Ile 2460	Pro Gln Gln
Pro Met 2465	Gly Ile Ile Ala Val 2470	Ala Asn Asp Thr Asn 2475	Ser Cys Glu
Leu Ser 2480	Pro Cys Arg Ile Asn 2485	Asn Gly Gly Cys Gln 2490	Asp Leu Cys

Leu Leu Thr His Gln Gly His Val Asn Cys Ser Cys Arg Gly Gly
 2495 2500 2505

Arg Ile Leu Gln Asp Asp Leu Thr Cys Arg Ala Val
 2510 2515 2520

<210> 8
 <211> 4464
 <212> PRT
 <213> H. sapiens

<400> 8

Met Leu Thr Pro Pro Leu Leu Leu Leu Leu Pro Leu Leu Ser Ala Leu
 1 5 10 15

Val Ala Ala Ala Ile Asp Ala Pro Lys Thr Cys Ser Pro Lys Gln Phe
 20 25 30

Ala Cys Arg Asp Gln Ile Thr Cys Ile Ser Lys Gly Trp Arg Cys Asp
 35 40 45

Gly Glu Arg Asp Cys Pro Asp Gly Ser Asp Glu Ala Pro Glu Ile Cys
 50 55 60

Pro Gln Ser Lys Ala Gln Arg Cys Gln Pro Asn Glu His Asn Cys Leu
 65 70 75 80

Gly Thr Glu Leu Cys Val Pro Met Ser Arg Leu Cys Asn Gly Val Gln
 85 90 95

Asp Cys Met Asp Gly Ser Asp Glu Gly Pro His Cys Arg Glu Leu Gln
 100 105 110

Gly Asn Cys Ser Arg Leu Gly Cys Gln His His Cys Val Pro Thr Leu
 115 120 125

Asp Gly Pro Thr Cys Tyr Cys Asn Ser Ser Phe Gln Leu Gln Ala Asp
 130 135 140

Gly Lys Thr Cys Lys Asp Phe Asp Glu Cys Ser Val Tyr Gly Thr Cys
 145 150 155 160

Ser Gln Leu Cys Thr Asn Thr Asp Gly Ser Phe Ile Cys Gly Cys Val
 165 170 175

Glu Gly Tyr Leu Leu Gln Pro Asp Asn Arg Ser Cys Lys Ala Lys Asn
 180 185 190

Glu Pro Val Asp Arg Pro Pro Val Leu Leu Ile Ala Asn Ser Gln Asn
 195 200 205

Ile Leu Ala Thr Tyr Leu Ser Gly Ala Gln Val Ser Thr Ile Thr Pro
 210 215 220

Thr Ser Thr Arg Gln Thr Thr Ala Met Asp Phe Ser Tyr Ala Asn Glu
 225 230 235 240

Thr Val Cys Trp Val His Val Gly Asp Ser Ala Ala Gln Thr Gln Leu
 245 250 255

Lys Cys Ala Arg Met Pro Gly Leu Lys Gly Phe Val Asp Glu His Thr
 260 265 270

Ile Asn Ile Ser Leu Ser Leu His His Val Glu Gln Met Ala Ile Asp
 275 280 285

Trp Leu Thr Gly Asn Phe Tyr Phe Val Asp Asp Ile Asp Asp Arg Ile
 290 295 300

Phe Val Cys Asn Arg Asn Gly Asp Thr Cys Val Thr Leu Leu Asp Leu
 305 310 315 320

Glu Leu Tyr Asn Pro Lys Gly Ile Ala Leu Asp Pro Ala Met Gly Lys
 325 330 335

Val Phe Phe Thr Asp Tyr Gly Gln Ile Pro Lys Val Glu Arg Cys Asp
 340 345 350

Met Asp Gly Gln Asn Arg Thr Lys Leu Val Asp Ser Lys Ile Val Phe
 355 360 365

Pro His Gly Ile Thr Leu Asp Leu Val Ser Arg Leu Val Tyr Trp Ala
 370 375 380

Asp Ala Tyr Leu Asp Tyr Ile Glu Val Val Asp Tyr Glu Gly Lys Gly
 385 390 395 400

Arg Gln Thr Ile Ile Gln Gly Ile Leu Ile Glu His Leu Tyr Gly Leu
 405 410 415

Thr Val Phe Glu Asn Tyr Leu Tyr Ala Thr Asn Ser Asp Asn Ala Asn
 420 425 430

Ala Gln Gln Lys Thr Ser Val Ile Arg Val Asn Arg Phe Asn Ser Thr
 435 440 445

Glu Tyr Gln Val Val Thr Arg Val Asp Lys Gly Gly Ala Leu His Ile
 450 455 460

Tyr His Gln Arg Arg Gln Pro Arg Val Arg Ser His Ala Cys Glu Asn
 465 470 475 480

Asp Gln Tyr Gly Lys Pro Gly Gly Cys Ser Asp Ile Cys Leu Leu Ala
 485 490 495

Asn Ser His Lys Ala Arg Thr Cys Arg Cys Arg Ser Gly Phe Ser Leu
 500 505 510

Gly Ser Asp Gly Lys Ser Cys Lys Lys Pro Glu His Glu Leu Phe Leu
 515 520 525

Val Tyr Gly Lys Gly Arg Pro Gly Ile Ile Arg Gly Met Asp Met Gly
 530 535 540

Ala Lys Val Pro Asp Glu His Met Ile Pro Ile Glu Asn Leu Met Asn
 545 550 555 560

Pro Arg Ala Leu Asp Phe His Ala Glu Thr Gly Phe Ile Tyr Phe Ala
 565 570 575

Asp Thr Thr Ser Tyr Leu Ile Gly Arg Gln Lys Ile Asp Gly Thr Glu
 580 585 590

Arg Glu Thr Ile Leu Lys Asp Gly Ile His Asn Val Glu Gly Val Ala
 595 600 605

Val Asp Trp Met Gly Asp Asn Leu Tyr Trp Thr Asp Asp Gly Pro Lys
 610 615 620

Lys Thr Ile Ser Val Ala Arg Leu Glu Lys Ala Ala Gln Thr Arg Lys
 625 630 635 640

Thr Leu Ile Glu Gly Lys Met Thr His Pro Arg Ala Ile Val Val Asp
 645 650 655

Pro Leu Asn Gly Trp Met Tyr Trp Thr Asp Trp Glu Glu Asp Pro Lys
 660 665 670

Asp Ser Arg Arg Gly Arg Leu Glu Arg Ala Trp Met Asp Gly Ser His
 675 680 685

Arg Asp Ile Phe Val Thr Ser Lys Thr Val Leu Trp Pro Asn Gly Leu
 690 695 700

Ser Leu Asp Ile Pro Ala Gly Arg Leu Tyr Trp Val Asp Ala Phe Tyr
 705 710 715 720

Asp Arg Ile Glu Thr Ile Leu Leu Asn Gly Thr Asp Arg Lys Ile Val
 725 730 735

Tyr Glu Gly Pro Glu Leu Asn His Ala Phe Gly Leu Cys His His Gly
 740 745 750

Asn Tyr Leu Phe Trp Thr Glu Tyr Arg Ser Gly Ser Val Tyr Arg Leu
 755 760 765

Glu Arg Gly Val Gly Gly Ala Pro Pro Thr Val Thr Leu Leu Arg Ser
 770 775 780

Glu Arg Pro Pro Ile Phe Glu Ile Arg Met Tyr Asp Ala Gln Gln Gln
 785 790 795 800

Gln Val Gly Thr Asn Lys Cys Arg Val Asn Asn Gly Gly Cys Ser Ser
 805 810 815

Leu Cys Leu Ala Thr Pro Gly Ser Arg Gln Cys Ala Cys Ala Glu Asp
 820 825 830

Asn Val Leu Asp Ala Asp Gly Val Thr Cys Leu Ala Asn Pro Ser Tyr
 835 840 845

Val Pro Pro Pro Gln Cys Gln Pro Gly Glu Phe Ala Cys Ala Asn Ser
 850 855 860

Arg Cys Ile Gln Glu Arg Trp Lys Cys Asp Gly Asp Asn Asp Cys Leu
 865 870 875 880

Asp Asn Ser Asp Glu Ala Pro Ala Leu Cys His Gln His Thr Cys Pro
 885 890 895

Ser Asp Arg Phe Lys Cys Glu Asn Asn Arg Cys Ile Pro Asn Arg Trp
 900 905 910

Leu Cys Asp Gly Asp Asn Asp Cys Gly Asn Ser Glu Asp Glu Ser Asn
 915 920 925

Ala Thr Cys Ser Ala Arg Thr Cys Pro Pro Asn Gln Phe Ser Cys Ala
 930 935 940

Ser Gly Arg Cys Ile Pro Ile Ser Trp Thr Cys Asp Leu Asp Asp Asp
 945 950 955 960

Cys Gly Asp Arg Ser Asp Glu Ser Ala Ser Cys Ala Tyr Pro Thr Cys
 965 970 975

Phe Pro Leu Thr Gln Phe Thr Cys Asn Asn Gly Arg Cys Ile Asn Ile
 980 985 990

Asn Trp Arg Cys Asp Asn Asp Asn Asp Cys Gly Asp Asn Ser Asp Glu
 995 1000 1005

Ala Gly Cys Ser His Ser Cys Ser Ser Thr Gln Phe Lys Cys Asn
 1010 1015 1020

Ser Gly Arg Cys Ile Pro Glu His Trp Thr Cys Asp Gly Asp Asn
 1025 1030 1035

Asp Cys Gly Asp Tyr Ser Asp Glu Thr His Ala Asn Cys Thr Asn
 1040 1045 1050

Gln Ala Thr Arg Pro Pro Gly Gly Cys His Thr Asp Glu Phe Gln
 1055 1060 1065

Asp Arg Leu Asp Gly Leu Cys Ile Pro Leu Arg Trp Arg Cys Asp
 1070 1075 1080

Gly Asp Thr Asp Cys Met Asp Ser Ser Asp Glu Lys Ser Cys Glu
 1085 1090 1095

Gly Val Thr His Val Cys Asp Pro Ser Val Lys Phe Gly Cys Lys
 1100 1105 1110

Asp Ser Ala Arg Cys Ile Ser Lys Ala Trp Val Cys Asp Gly Asp
 1115 1120 1125

Asn Asp Cys Glu Asp Asn Ser Asp Glu Glu Asn Cys Glu Ser Leu
 1130 1135 1140

Ala Cys Arg Pro Pro Ser His Pro Cys Ala Asn Asn Thr Ser Val
 1145 1150 1155

Cys Leu Pro Pro Asp Lys Leu Cys Asp Gly Asn Asp Asp Cys Gly
 1160 1165 1170

Asp Gly Ser Asp Glu Gly Glu Leu Cys Asp Gln Cys Ser Leu Asn
 1175 1180 1185

Asn Gly Gly Cys Ser His Asn Cys Ser Val Ala Pro Gly Glu Gly
 1190 1195 1200

Ile Val Cys Ser Cys Pro Leu Gly Met Glu Leu Gly Pro Asp Asn
 1205 1210 1215

His Thr Cys Gln Ile Gln Ser Tyr Cys Ala Lys His Leu Lys Cys
 1220 1225 1230

Ser Gln Lys Cys Asp Gln Asn Lys Phe Ser Val Lys Cys Ser Cys
 1235 1240 1245

Tyr Glu Gly Trp Val Leu Glu Pro Asp Gly Glu Ser Cys Arg Ser
 1250 1255 1260

Leu Asp Pro Phe Lys Pro Phe Ile Ile Phe Ser Asn Arg His Glu
 1265 1270 1275

Ile Arg Arg Ile Asp Leu His Lys Gly Asp Tyr Ser Val Leu Val
 1280 1285 1290

Pro Gly Leu Arg Asn Thr Ile Ala Leu Asp Phe His Leu Ser Gln
 1295 1300 1305

Ser Ala Leu Tyr Trp Thr Asp Val Val Glu Asp Lys Ile Tyr Arg
 1310 1315 1320

Gly Lys Leu Leu Asp Asn Gly Ala Leu Thr Ser Phe Glu Val Val
 1325 1330 1335

Ile Gln Tyr Gly Leu Ala Thr Pro Glu Gly Leu Ala Val Asp Trp
 1340 1345 1350

Ile Ala Gly Asn Ile Tyr Trp Val Glu Ser Asn Leu Asp Gln Ile
 1355 1360 1365

Glu Val Ala Lys Leu Asp Gly Thr Leu Arg Thr Thr Leu Leu Ala
 1370 1375 1380

Gly Asp Ile Glu His Pro Arg Ala Ile Ala Leu Asp Pro Arg Asp
 1385 1390 1395

Gly Ile Leu Phe Trp Thr Asp Trp Asp Ala Ser Leu Pro Arg Ile
 1400 1405 1410

Glu Ala Ala Ser Met Ser Gly Ala Gly Arg Arg Thr Val His Arg
 1415 1420 1425

Glu Thr Gly Ser Gly Gly Trp Pro Asn Gly Leu Thr Val Asp Tyr
 1430 1435 1440

Leu Glu Lys Arg Ile Leu Trp Ile Asp Ala Arg Ser Asp Ala Ile
 1445 1450 1455

Tyr Ser Ala Arg Tyr Asp Gly Ser Gly His Met Glu Val Leu Arg
 1460 1465 1470

Gly His Glu Phe Leu Ser His Pro Phe Ala Val Thr Leu Tyr Gly
 1475 1480 1485

Gly Glu Val Tyr Trp Thr Asp Trp Arg Thr Asn Thr Leu Ala Lys
 1490 1495 1500

Ala Asn Lys Trp Thr Gly His Asn Val Thr Val Val Gln Arg Thr
 1505 1510 1515

Asn Thr Gln Pro Phe Asp Leu Gln Val Tyr His Pro Ser Arg Gln
 1520 1525 1530

Pro Met Ala Pro Asn Pro Cys Glu Ala Asn Gly Gly Gln Gly Pro
 1535 1540 1545

Cys Ser His Leu Cys Leu Ile Asn Tyr Asn Arg Thr Val Ser Cys
 1550 1555 1560

Ala Cys Pro His Leu Met Lys Leu His Lys Asp Asn Thr Thr Cys
 1565 1570 1575

Tyr Glu Phe Lys Lys Phe Leu Leu Tyr Ala Arg Gln Met Glu Ile
 1580 1585 1590

Arg Gly Val Asp Leu Asp Ala Pro Tyr Tyr Asn Tyr Ile Ile Ser
1595 1600 1605

Phe Thr Val Pro Asp Ile Asp Asn Val Thr Val Leu Asp Tyr Asp
1610 1615 1620

Ala Arg Glu Gln Arg Val Tyr Trp Ser Asp Val Arg Thr Gln Ala
1625 1630 1635

Ile Lys Arg Ala Phe Ile Asn Gly Thr Gly Val Glu Thr Val Val
1640 1645 1650

Ser Ala Asp Leu Pro Asn Ala His Gly Leu Ala Val Asp Trp Val
1655 1660 1665

Ser Arg Asn Leu Phe Trp Thr Ser Tyr Asp Thr Asn Lys Lys Gln
1670 1675 1680

Ile Asn Val Ala Arg Leu Asp Gly Ser Phe Lys Asn Ala Val Val
1685 1690 1695

Gln Gly Leu Glu Gln Pro His Gly Leu Val Val His Pro Leu Arg
1700 1705 1710

Gly Lys Leu Tyr Trp Thr Asp Gly Asp Asn Ile Ser Met Ala Asn
1715 1720 1725

Met Asp Gly Ser Asn Arg Thr Leu Leu Phe Ser Gly Gln Lys Gly
1730 1735 1740

Pro Val Gly Leu Ala Ile Asp Phe Pro Glu Ser Lys Leu Tyr Trp
1745 1750 1755

Ile Ser Ser Gly Asn His Thr Ile Asn Arg Cys Asn Leu Asp Gly
1760 1765 1770

Ser Gly Leu Glu Val Ile Asp Ala Met Arg Ser Gln Leu Gly Lys
1775 1780 1785

Ala Thr Ala Leu Ala Ile Met Gly Asp Lys Leu Trp Trp Ala Asp
1790 1795 1800

Gln Val Ser Glu Lys Met Gly Thr Cys Ser Lys Ala Asp Gly Ser
1805 1810 1815

Gly Ser Val Val Leu Arg Asn Ser Thr Thr Leu Val Met His Met
 1820 1825 1830

Lys Val Tyr Asp Glu Ser Ile Gln Leu Asp His Lys Gly Thr Asn
 1835 1840 1845

Pro Cys Ser Val Asn Asn Gly Asp Cys Ser Gln Leu Cys Leu Pro
 1850 1855 1860

Thr Ser Glu Thr Thr Arg Ser Cys Met Cys Thr Ala Gly Tyr Ser
 1865 1870 1875

Leu Arg Ser Gly Gln Gln Ala Cys Glu Gly Val Gly Ser Phe Leu
 1880 1885 1890

Leu Tyr Ser Val His Glu Gly Ile Arg Gly Ile Pro Leu Asp Pro
 1895 1900 1905

Asn Asp Lys Ser Asp Ala Leu Val Pro Val Ser Gly Thr Ser Leu
 1910 1915 1920

Ala Val Gly Ile Asp Phe His Ala Glu Asn Asp Thr Ile Tyr Trp
 1925 1930 1935

Val Asp Met Gly Leu Ser Thr Ile Ser Arg Ala Lys Arg Asp Gln
 1940 1945 1950

Thr Trp Arg Glu Asp Val Val Thr Asn Gly Ile Gly Arg Val Glu
 1955 1960 1965

Tyr Ile Ala Val Asp Trp Ile Ala Gly Asn Ile Tyr Trp Thr Asp
 1970 1975 1980

Gln Gly Phe Asp Val Ile Glu Val Ala Arg Leu Asn Gly Ser Phe
 1985 1990 1995

Arg Tyr Val Val Ile Ser Gln Gly Leu Asp Lys Pro Arg Ala Ile
 2000 2005 2010

Thr Val His Pro Glu Lys Gly Tyr Leu Phe Trp Thr Glu Trp Gly
 2015 2020 2025

Gln Tyr Pro Arg Ile Glu Arg Ser Arg Leu Asp Gly Thr Glu Arg
 2030 2035 2040

Val Val Leu Val Asn Val Ser Ile Ser Trp Pro Asn Gly Ile Ser
 2045 2050 2055

Val Asp Tyr Gln Asp Gly Lys Leu Tyr Trp Cys Asp Ala Arg Thr
 2060 2065 2070

Asp Lys Ile Glu Arg Ile Asp Leu Glu Thr Gly Glu Asn Arg Glu
 2075 2080 2085

Val Val Leu Ser Ser Asn Asn Met Asp Met Phe Ser Val Ser Val
 2090 2095 2100

Phe Glu Asp Phe Ile Tyr Trp Ser Asp Arg Thr His Ala Asn Gly
 2105 2110 2115

Ser Ile Lys Arg Gly Ser Lys Asp Asn Ala Thr Asp Ser Val Pro
 2120 2125 2130

Leu Arg Thr Gly Ile Gly Val Gln Leu Lys Asp Ile Lys Val Phe
 2135 2140 2145

Asn Arg Asp Arg Gln Lys Gly Thr Asn Val Cys Ala Val Ala Asn
 2150 2155 2160

Gly Gly Cys Gln Gln Leu Cys Leu Tyr Arg Gly Arg Gly Gln Arg
 2165 2170 2175

Ala Cys Ala Cys Ala His Gly Met Leu Ala Glu Asp Gly Ala Ser
 2180 2185 2190

As Arg Glu Tyr Ala Gly Tyr Leu Leu Tyr Ser Glu Arg Thr Ile
 2195 2200 2205

Leu Lys Ser Ile His Leu Ser Asp Glu Arg Asn Leu Asn Ala Pro
 2210 2215 2220

Val Gln Pro Phe Glu Asp Pro Glu His Met Lys Asn Val Ile Ala
 2225 2230 2235

Leu Ala Phe Asp Tyr Arg Ala Gly Thr Ser Pro Gly Thr Pro Asn
 2240 2245 2250

Arg Ile Phe Phe Ser Asp Ile His Phe Gly Asn Ile Gln Gln Ile
 2255 2260 2265

Asn Asp Asp Gly Ser Arg Arg Ile Thr Ile Val Glu Asn Val Gly
 2270 2275 2280

Ser Val Glu Gly Leu Ala Tyr His Arg Gly Trp Asp Thr Leu Tyr
 2285 2290 2295

Trp Thr Ser Tyr Thr Thr Ser Thr Ile Thr Arg His Thr Val Asp
 2300 2305 2310

Gln Thr Arg Pro Gly Ala Phe Glu Arg Glu Thr Val Ile Thr Met
 2315 2320 2325

Ser Gly Asp Asp His Pro Arg Ala Phe Val Leu Asp Glu Cys Gln
 2330 2335 2340

Asn Leu Met Phe Trp Thr Asn Trp Asn Glu Gln His Pro Ser Ile
 2345 2350 2355

Met Arg Ala Ala Leu Ser Gly Ala Asn Val Leu Thr Leu Ile Glu
 2360 2365 2370

Lys Asp Ile Arg Thr Pro Asn Gly Leu Ala Ile Asp His Arg Ala
 2375 2380 2385

Glu Lys Leu Tyr Phe Ser Asp Ala Thr Leu Asp Lys Ile Glu Arg
 2390 2395 2400

Cys Glu Tyr Asp Gly Ser His Arg Tyr Val Ile Leu Lys Ser Glu
 2405 2410 2415

Pro Val His Pro Phe Gly Leu Ala Val Tyr Gly Glu His Ile Phe
 2420 2425 2430

Trp Thr Asp Trp Val Arg Arg Ala Val Gln Arg Ala Asn Lys His
 2435 2440 2445

Val Gly Ser Asn Met Lys Leu Leu Arg Val Asp Ile Pro Gln Gln
 2450 2455 2460

Pro Met Gly Ile Ile Ala Val Ala Asn Asp Thr Asn Ser Cys Glu
 2465 2470 2475

Leu Ser Pro Cys Arg Ile Asn Asn Gly Gly Cys Gln Asp Leu Cys
 2480 2485 2490

Leu Leu Thr His Gln Gly His Val Asn Cys Ser Cys Arg Gly Gly
 2495 2500 2505

Arg Ile Leu Gln Asp Asp Leu Thr Cys Arg Ala Val Asn Ser Ser
 2510 2515 2520

Cys Arg Ala Gln Asp Glu Phe Glu Cys Ala Asn Gly Glu Cys Ile
 2525 2530 2535

Asn Phe Ser Leu Thr Cys Asp Gly Val Pro His Cys Lys Asp Lys
 2540 2545 2550

Ser Asp Glu Lys Pro Ser Tyr Cys Asn Ser Arg Arg Cys Lys Lys
 2555 2560 2565

Thr Phe Arg Gln Cys Ser Asn Gly Arg Cys Val Ser Asn Met Leu
 2570 2575 2580

Trp Cys Asn Gly Ala Asp Asp Cys Gly Asp Gly Ser Asp Glu Ile
 2585 2590 2595

Pro Cys Asn Lys Thr Ala Cys Gly Val Gly Glu Phe Arg Cys Arg
 2600 2605 2610

Asp Gly Thr Cys Ile Gly Asn Ser Ser Arg Cys Asn Gln Phe Val
 2615 2620 2625

Asp Cys Glu Asp Ala Ser Asp Glu Met Asn Cys Ser Ala Thr Asp
 2630 2635 2640

Cys Ser Ser Tyr Phe Arg Leu Gly Val Lys Gly Val Leu Phe Gln
 2645 2650 2655

Pro Cys Glu Arg Thr Ser Leu Cys Tyr Ala Pro Ser Trp Val Cys
 2660 2665 2670

Asp Gly Ala Asn Asp Cys Gly Asp Tyr Ser Asp Glu Arg Asp Cys
 2675 2680 2685

Pro Gly Val Lys Arg Pro Arg Cys Pro Leu Asn Tyr Phe Ala Cys
 2690 2695 2700

Pro Ser Gly Arg Cys Ile Pro Met Ser Trp Thr Cys Asp Lys Glu
 2705 2710 2715

Asp Asp Cys Glu His Gly Glu Asp Glu Thr His Cys Asn Lys Phe
 2720 2725 2730

 Cys Ser Glu Ala Gln Phe Glu Cys Gln Asn His Arg Cys Ile Ser
 2735 2740 2745

 Lys Gln Trp Leu Cys Asp Gly Ser Asp Asp Cys Gly Asp Gly Ser
 2750 2755 2760

 Asp Glu Ala Ala His Cys Glu Gly Lys Thr Cys Gly Pro Ser Ser
 2765 2770 2775

 Phe Ser Cys Pro Gly Thr His Val Cys Val Pro Glu Arg Trp Leu
 2780 2785 2790

 Cys Asp Gly Asp Lys Asp Cys Ala Asp Gly Ala Asp Glu Ser Ile
 2795 2800 2805

 Ala Ala Gly Cys Leu Tyr Asn Ser Thr Cys Asp Asp Arg Glu Phe
 2810 2815 2820

 Met Cys Gln Asn Arg Gln Cys Ile Pro Lys His Phe Val Cys Asp
 2825 2830 2835

 His Asp Arg Asp Cys Ala Asp Gly Ser Asp Glu Ser Pro Glu Cys
 2840 2845 2850

 Glu Tyr Pro Thr Cys Gly Pro Ser Glu Phe Arg Cys Ala Asn Gly
 2855 2860 2865

 Arg Cys Leu Ser Ser Arg Gln Trp Glu Cys Asp Gly Glu Asn Asp
 2870 2875 2880

 Cys His Asp Gln Ser Asp Glu Ala Pro Lys Asn Pro His Cys Thr
 2885 2890 2895

 Ser Pro Glu His Lys Cys Asn Ala Ser Ser Gln Phe Leu Cys Ser
 2900 2905 2910

 Ser Gly Arg Cys Val Ala Glu Ala Leu Leu Cys Asn Gly Gln Asp
 2915 2920 2925

 Asp Cys Gly Asp Ser Ser Asp Glu Arg Gly Cys His Ile Asn Glu
 2930 2935 2940

Cys Leu Ser Arg Lys Leu Ser Gly Cys Ser Gln Asp Cys Glu Asp
 2945 2950 2955
 Leu Lys Ile Gly Phe Lys Cys Arg Cys Arg Pro Gly Phe Arg Leu
 2960 2965 2970
 Lys Asp Asp Gly Arg Thr Cys Ala Asp Val Asp Glu Cys Ser Thr
 2975 2980 2985
 Thr Phe Pro Cys Ser Gln Arg Cys Ile Asn Thr His Gly Ser Tyr
 2990 2995 3000
 Lys Cys Leu Cys Val Glu Gly Tyr Ala Pro Arg Gly Gly Asp Pro
 3005 3010 3015
 His Ser Cys Lys Ala Val Thr Asp Glu Glu Pro Phe Leu Ile Phe
 3020 3025 3030
 Ala Asn Arg Tyr Tyr Leu Arg Lys Leu Asn Leu Asp Gly Ser Asn
 3035 3040 3045
 Tyr Thr Leu Leu Lys Gln Gly Leu Asn Asn Ala Val Ala Leu Asp
 3050 3055 3060
 Phe Asp Tyr Arg Glu Gln Met Ile Tyr Trp Thr Asp Val Thr Thr
 3065 3070 3075
 Gln Gly Ser Met Ile Arg Arg Met His Leu Asn Gly Ser Asn Val
 3080 3085 3090
 Gln Val Leu His Arg Thr Gly Leu Ser Asn Pro Asp Gly Leu Ala
 3095 3100 3105
 Val Asp Trp Val Gly Gly Asn Leu Tyr Trp Cys Asp Lys Gly Arg
 3110 3115 3120
 Asp Thr Ile Glu Val Ser Lys Leu Asn Gly Ala Tyr Arg Thr Val
 3125 3130 3135
 Leu Val Ser Ser Gly Leu Arg Glu Pro Arg Ala Leu Val Val Asp
 3140 3145 3150
 Val Gln Asn Gly Tyr Leu Tyr Trp Thr Asp Trp Gly Asp His Ser
 3155 3160 3165

Leu Ile Gly Arg Ile Gly Met Asp Gly Ser Ser Arg Ser Val Ile
 3170 3175 3180

Val Asp Thr Lys Ile Thr Trp Pro Asn Gly Leu Thr Leu Asp Tyr
 3185 3190 3195

Val Thr Glu Arg Ile Tyr Trp Ala Asp Ala Arg Glu Asp Tyr Ile
 3200 3205 3210

Glu Phe Ala Ser Leu Asp Gly Ser Asn Arg His Val Val Leu Ser
 3215 3220 3225

Gln Asp Ile Pro His Ile Phe Ala Leu Thr Leu Phe Glu Asp Tyr
 3230 3235 3240

Val Tyr Trp Thr Asp Trp Glu Thr Lys Ser Ile Asn Arg Ala His
 3245 3250 3255

Lys Thr Thr Gly Thr Asn Lys Thr Leu Leu Ile Ser Thr Leu His
 3260 3265 3270

Arg Pro Met Asp Leu His Val Phe His Ala Leu Arg Gln Pro Asp
 3275 3280 3285

Val Pro Asn His Pro Cys Lys Val Asn Asn Gly Gly Cys Ser Asn
 3290 3295 3300

Leu Cys Leu Leu Ser Pro Gly Gly Gly His Lys Cys Ala Cys Pro
 3305 3310 3315

r Asn Phe Tyr Leu Gly Ser Asp Gly Arg Thr Cys Val Ser Asn
 3320 3325 3330

Cys Thr Ala Ser Gln Phe Val Cys Lys Asn Asp Lys Cys Ile Pro
 3335 3340 3345

Phe Trp Trp Lys Cys Asp Thr Glu Asp Asp Cys Gly Asp His Ser
 3350 3355 3360

Asp Glu Pro Pro Asp Cys Pro Glu Phe Lys Cys Arg Pro Gly Gln
 3365 3370 3375

Phe Gln Cys Ser Thr Gly Ile Cys Thr Asn Pro Ala Phe Ile Cys
 3380 3385 3390

Asp Gly Asp Asn Asp Cys Gln Asp Asn Ser Asp Glu Ala Asn Cys
3395 3400 3405

Asp Ile His Val Cys Leu Pro Ser Gln Phe Lys Cys Thr Asn Thr
3410 3415 3420

Asn Arg Cys Ile Pro Gly Ile Phe Arg Cys Asn Gly Gln Asp Asn
3425 3430 3435

Cys Gly Asp Gly Glu Asp Glu Arg Asp Cys Pro Glu Val Thr Cys
3440 3445 3450

Ala Pro Asn Gln Phe Gln Cys Ser Ile Thr Lys Arg Cys Ile Pro
3455 3460 3465

Arg Val Trp Val Cys Asp Arg Asp Asn Asp Cys Val Asp Gly Ser
3470 3475 3480

Asp Glu Pro Ala Asn Cys Thr Gln Met Thr Cys Gly Val Asp Glu
3485 3490 3495

Phe Arg Cys Lys Asp Ser Gly Arg Cys Ile Pro Ala Arg Trp Lys
3500 3505 3510

Cys Asp Gly Glu Asp Asp Cys Gly Asp Gly Ser Asp Glu Pro Lys
3515 3520 3525

Glu Glu Cys Asp Glu Arg Thr Cys Glu Pro Tyr Gln Phe Arg Cys
3530 3535 3540

Asn Asn Arg Cys Val Pro Gly Arg Trp Gln Cys Asp Tyr Asp
3545 3550 3555

Asn Asp Cys Gly Asp Asn Ser Asp Glu Glu Ser Cys Thr Pro Arg
3560 3565 3570

Pro Cys Ser Glu Ser Glu Phe Ser Cys Ala Asn Gly Arg Cys Ile
3575 3580 3585

Ala Gly Arg Trp Lys Cys Asp Gly Asp His Asp Cys Ala Asp Gly
3590 3595 3600

Ser Asp Glu Lys Asp Cys Thr Pro Arg Cys Asp Met Asp Gln Phe
3605 3610 3615

Gln Cys Lys Ser Gly His Cys Ile Pro Leu Arg Trp Arg Cys Asp
 3620 3625 3630
 Ala Asp Ala Asp Cys Met Asp Gly Ser Asp Glu Glu Ala Cys Gly
 3635 3640 3645
 Thr Gly Val Arg Thr Cys Pro Leu Asp Glu Phe Gln Cys Asn Asn
 3650 3655 3660
 Thr Leu Cys Lys Pro Leu Ala Trp Lys Cys Asp Gly Glu Asp Asp
 3665 3670 3675
 Cys Gly Asp Asn Ser Asp Glu Asn Pro Glu Glu Cys Ala Arg Phe
 3680 3685 3690
 Val Cys Pro Pro Asn Arg Pro Phe Arg Cys Lys Asn Asp Arg Val
 3695 3700 3705
 Cys Leu Trp Ile Gly Arg Gln Cys Asp Gly Thr Asp Asn Cys Gly
 3710 3715 3720
 Asp Gly Thr Asp Glu Glu Asp Cys Glu Pro Pro Thr Ala His Thr
 3725 3730 3735
 Thr His Cys Lys Asp Lys Lys Glu Phe Leu Cys Arg Asn Gln Arg
 3740 3745 3750
 Cys Leu Ser Ser Ser Leu Arg Cys Asn Met Phe Asp Asp Cys Gly
 3755 3760 3765
 Asp Gly Ser Asp Glu Glu Asp Cys Ser Ile Asp Pro Lys Leu Thr
 3770 3775 3780
 Ser Cys Ala Thr Asn Ala Ser Ile Cys Gly Asp Glu Ala Arg Cys
 3785 3790 3795
 Val Arg Thr Glu Lys Ala Ala Tyr Cys Ala Cys Arg Ser Gly Phe
 3800 3805 3810
 His Thr Val Pro Gly Gln Pro Gly Cys Gln Asp Ile Asn Glu Cys
 3815 3820 3825
 Leu Arg Phe Gly Thr Cys Ser Gln Leu Cys Asn Asn Thr Lys Gly
 3830 3835 3840

Gly His 3845	Leu Cys Ser Cys 3850	Ala Arg Asn Phe Met Lys 3855	Thr His Asn
Thr Cys 3860	Lys Ala Glu Gly Ser 3865	Glu Tyr Gln Val Leu 3870	Tyr Ile Ala
Asp Asp 3875	Asn Glu Ile Arg Ser 3880	Leu Phe Pro Gly His 3885	Pro His Ser
Ala Tyr 3890	Glu Gln Ala Phe Gln 3895	Gly Asp Glu Ser Val 3900	Arg Ile Asp
Ala Met 3905	Asp Val His Val Lys 3910	Ala Gly Arg Val Tyr 3915	Trp Thr Asn
Trp His 3920	Thr Gly Thr Ile Ser 3925	Tyr Arg Ser Leu Pro 3930	Pro Ala Ala
Pro Pro 3935	Thr Thr Ser Asn Arg 3940	His Arg Arg Gln Ile 3945	Asp Arg Gly
Val Thr 3950	His Leu Asn Ile Ser 3955	Gly Leu Lys Met Pro 3960	Arg Gly Ile
Ala Ile 3965	Asp Trp Val Ala Gly 3970	Asn Val Tyr Trp Thr 3975	Asp Ser Gly
Arg Asp 3980	Val Ile Glu Val Ala 3985	Gln Met Lys Gly Glu 3990	Asn Arg Lys
Thr Leu 3995	Ile Ser Gly Met Ile 4000	Asp Glu Pro His Ala 4005	Ile Val Val
Asp Pro 4010	Leu Arg Gly Thr Met 4015	Tyr Trp Ser Asp Trp 4020	Gly Asn His
Pro Lys 4025	Ile Glu Thr Ala Ala 4030	Met Asp Gly Thr Leu 4035	Arg Glu Thr
Leu Val 4040	Gln Asp Asn Ile Gln 4045	Trp Pro Thr Gly Leu 4050	Ala Val Asp
Tyr His 4055	Asn Glu Arg Leu Tyr 4060	Trp Ala Asp Ala Lys 4065	Leu Ser Val

Ile Gly Ser Ile Arg Leu Asn Gly Thr Asp Pro Ile Val Ala Ala
4070 4075 4080

Asp Ser Lys Arg Gly Leu Ser His Pro Phe Ser Ile Asp Val Phe
4085 4090 4095

Glu Asp Tyr Ile Tyr Gly Val Thr Tyr Ile Asn Asn Arg Val Phe
4100 4105 4110

Lys Ile His Lys Phe Gly His Ser Pro Leu Val Asn Leu Thr Gly
4115 4120 4125

Gly Leu Ser His Ala Ser Asp Val Val Leu Tyr His Gln His Lys
4130 4135 4140

Gln Pro Glu Val Thr Asn Pro Cys Asp Arg Lys Lys Cys Glu Trp
4145 4150 4155

Leu Cys Leu Leu Ser Pro Ser Gly Pro Val Cys Thr Cys Pro Asn
4160 4165 4170

Gly Lys Arg Leu Asp Asn Gly Thr Cys Val Pro Val Pro Ser Pro
4175 4180 4185

Thr Pro Pro Pro Asp Ala Pro Arg Pro Gly Thr Cys Asn Leu Gln
4190 4195 4200

Cys Phe Asn Gly Gly Ser Cys Phe Leu Asn Ala Arg Arg Gln Pro
4205 4210 4215

s Cys Arg Cys Gln Pro Arg Tyr Thr Gly Asp Lys Cys Glu Leu
4220 4225 4230

Asp Gln Cys Trp Glu His Cys Arg Asn Gly Gly Thr Cys Ala Ala
4235 4240 4245

Ser Pro Ser Gly Met Pro Thr Cys Arg Cys Pro Thr Gly Phe Thr
4250 4255 4260

Gly Pro Lys Cys Thr Gln Gln Val Cys Ala Gly Tyr Cys Ala Asn
4265 4270 4275

Asn Ser Thr Cys Thr Val Asn Gln Gly Asn Gln Pro Gln Cys Arg
4280 4285 4290

Cys Leu Pro Gly Phe Leu Gly Asp Arg Cys Gln Tyr Arg Gln Cys
4295 4300 4305

Ser Gly Tyr Cys Glu Asn Phe Gly Thr Cys Gln Met Ala Ala Asp
4310 4315 4320

Gly Ser Arg Gln Cys Arg Cys Thr Ala Tyr Phe Glu Gly Ser Arg
4325 4330 4335

Cys Glu Val Asn Lys Cys Ser Arg Cys Leu Glu Gly Ala Cys Val
4340 4345 4350

Val Asn Lys Gln Ser Gly Asp Val Thr Cys Asn Cys Thr Asp Gly
4355 4360 4365

Arg Val Ala Pro Ser Cys Leu Thr Cys Val Gly His Cys Ser Asn
4370 4375 4380

Gly Gly Ser Cys Thr Met Asn Ser Lys Met Met Pro Glu Cys Gln
4385 4390 4395

Cys Pro Pro His Met Thr Gly Pro Arg Cys Glu Glu His Val Phe
4400 4405 4410

Ser Gln Gln Gln Pro Gly Gly Gly Arg Leu Val Pro Arg Gly Ser
4415 4420 4425

Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ile Glu Gly His Val Gly
4430 4435 4440

u Asn Asp Ile Phe Glu Ala Gln Lys Ile Glu Trp His Glu Gly
4445 4450 4455

His His His His His His
4460

<210> 9
<211> 4419
<212> PRT
<213> H. sapiens

<400> 9

Met Leu Thr Pro Pro Leu Leu Leu Leu Pro Leu Leu Ser Ala Leu
1 5 10 15

Val Ala Ala Ala Ile Asp Ala Pro Lys Thr Cys Ser Pro Lys Gln Phe
20 25 30

Ala Cys Arg Asp Gln Ile Thr Cys Ile Ser Lys Gly Trp Arg Cys Asp
 35 40 45

Gly Glu Arg Asp Cys Pro Asp Gly Ser Asp Glu Ala Pro Glu Ile Cys
 50 55 60

Pro Gln Ser Lys Ala Gln Arg Cys Gln Pro Asn Glu His Asn Cys Leu
 65 70 75 80

Gly Thr Glu Leu Cys Val Pro Met Ser Arg Leu Cys Asn Gly Val Gln
 85 90 95

Asp Cys Met Asp Gly Ser Asp Glu Gly Pro His Cys Arg Glu Leu Gln
 100 105 110

Gly Asn Cys Ser Arg Leu Gly Cys Gln His His Cys Val Pro Thr Leu
 115 120 125

Asp Gly Pro Thr Cys Tyr Cys Asn Ser Ser Phe Gln Leu Gln Ala Asp
 130 135 140

Gly Lys Thr Cys Lys Asp Phe Asp Glu Cys Ser Val Tyr Gly Thr Cys
 145 150 155 160

Ser Gln Leu Cys Thr Asn Thr Asp Gly Ser Phe Ile Cys Gly Cys Val
 165 170 175

Glu Gly Tyr Leu Leu Gln Pro Asp Asn Arg Ser Cys Lys Ala Lys Asn
 180 185 190

Glu Pro Val Asp Arg Pro Pro Val Leu Leu Ile Ala Asn Ser Gln Asn
 195 200 205

Ile Leu Ala Thr Tyr Leu Ser Gly Ala Gln Val Ser Thr Ile Thr Pro
 210 215 220

Thr Ser Thr Arg Gln Thr Thr Ala Met Asp Phe Ser Tyr Ala Asn Glu
 225 230 235 240

Thr Val Cys Trp Val His Val Gly Asp Ser Ala Ala Gln Thr Gln Leu
 245 250 255

Lys Cys Ala Arg Met Pro Gly Leu Lys Gly Phe Val Asp Glu His Thr
 260 265 270

Ile Asn Ile Ser Leu Ser Leu His His Val Glu Gln Met Ala Ile Asp
275 280 285

Trp Leu Thr Gly Asn Phe Tyr Phe Val Asp Asp Ile Asp Asp Arg Ile
290 295 300

Phe Val Cys Asn Arg Asn Gly Asp Thr Cys Val Thr Leu Leu Asp Leu
305 310 315 320

Glu Leu Tyr Asn Pro Lys Gly Ile Ala Leu Asp Pro Ala Met Gly Lys
325 330 335

Val Phe Phe Thr Asp Tyr Gly Gln Ile Pro Lys Val Glu Arg Cys Asp
340 345 350

Met Asp Gly Gln Asn Arg Thr Lys Leu Val Asp Ser Lys Ile Val Phe
355 360 365

Pro His Gly Ile Thr Leu Asp Leu Val Ser Arg Leu Val Tyr Trp Ala
370 375 380

Asp Ala Tyr Leu Asp Tyr Ile Glu Val Val Asp Tyr Glu Gly Lys Gly
385 390 395 400

Arg Gln Thr Ile Ile Gln Gly Ile Leu Ile Glu His Leu Tyr Gly Leu
405 410 415

Thr Val Phe Glu Asn Tyr Leu Tyr Ala Thr Asn Ser Asp Asn Ala Asn
420 425 430

Ile Gln Gln Lys Thr Ser Val Ile Arg Val Asn Arg Phe Asn Ser Thr
435 440 445

Glu Tyr Gln Val Val Thr Arg Val Asp Lys Gly Gly Ala Leu His Ile
450 455 460

Tyr His Gln Arg Arg Gln Pro Arg Val Arg Ser His Ala Cys Glu Asn
465 470 475 480

Asp Gln Tyr Gly Lys Pro Gly Gly Cys Ser Asp Ile Cys Leu Leu Ala
485 490 495

Asn Ser His Lys Ala Arg Thr Cys Arg Cys Arg Ser Gly Phe Ser Leu
500 505 510

Gly Ser Asp Gly Lys Ser Cys Lys Lys Pro Glu His Glu Leu Phe Leu
515 520 525

Val Tyr Gly Lys Gly Arg Pro Gly Ile Ile Arg Gly Met Asp Met Gly
530 535 540

Ala Lys Val Pro Asp Glu His Met Ile Pro Ile Glu Asn Leu Met Asn
545 550 555 560

Pro Arg Ala Leu Asp Phe His Ala Glu Thr Gly Phe Ile Tyr Phe Ala
565 570 575

Asp Thr Thr Ser Tyr Leu Ile Gly Arg Gln Lys Ile Asp Gly Thr Glu
580 585 590

Arg Glu Thr Ile Leu Lys Asp Gly Ile His Asn Val Glu Gly Val Ala
595 600 605

Val Asp Trp Met Gly Asp Asn Leu Tyr Trp Thr Asp Asp Gly Pro Lys
610 615 620

Lys Thr Ile Ser Val Ala Arg Leu Glu Lys Ala Ala Gln Thr Arg Lys
625 630 635 640

Thr Leu Ile Glu Gly Lys Met Thr His Pro Arg Ala Ile Val Val Asp
645 650 655

Pro Leu Asn Gly Trp Met Tyr Trp Thr Asp Trp Glu Glu Asp Pro Lys
660 665 670

Asp Ser Arg Arg Gly Arg Leu Glu Arg Ala Trp Met Asp Gly Ser His
675 680 685

Arg Asp Ile Phe Val Thr Ser Lys Thr Val Leu Trp Pro Asn Gly Leu
690 695 700

Ser Leu Asp Ile Pro Ala Gly Arg Leu Tyr Trp Val Asp Ala Phe Tyr
705 710 715 720

Asp Arg Ile Glu Thr Ile Leu Leu Asn Gly Thr Asp Arg Lys Ile Val
725 730 735

Tyr Glu Gly Pro Glu Leu Asn His Ala Phe Gly Leu Cys His His Gly
740 745 750

Asn Tyr Leu Phe Trp Thr Glu Tyr Arg Ser Gly Ser Val Tyr Arg Leu
755 760 765

Glu Arg Gly Val Gly Gly Ala Pro Pro Thr Val Thr Leu Leu Arg Ser
770 775 780

Glu Arg Pro Pro Ile Phe Glu Ile Arg Met Tyr Asp Ala Gln Gln Gln
785 790 795 800

Gln Val Gly Thr Asn Lys Cys Arg Val Asn Asn Gly Gly Cys Ser Ser
805 810 815

Leu Cys Leu Ala Thr Pro Gly Ser Arg Gln Cys Ala Cys Ala Glu Asp
820 825 830

Gln Val Leu Asp Ala Asp Gly Val Thr Cys Leu Ala Asn Pro Ser Tyr
835 840 845

Val Pro Pro Pro Gln Cys Gln Pro Gly Glu Phe Ala Cys Ala Asn Ser
850 855 860

Arg Cys Ile Gln Glu Arg Trp Lys Cys Asp Gly Asp Asn Asp Cys Leu
865 870 875 880

Asp Asn Ser Asp Glu Ala Pro Ala Leu Cys His Gln His Thr Cys Pro
885 890 895

Ser Asp Arg Phe Lys Cys Glu Asn Asn Arg Cys Ile Pro Asn Arg Trp
900 905 910

Leu Cys Asp Gly Asp Asn Asp Cys Gly Asn Ser Glu Asp Glu Ser Asn
915 920 925

Ala Thr Cys Ser Ala Arg Thr Cys Pro Pro Asn Gln Phe Ser Cys Ala
930 935 940

Ser Gly Arg Cys Ile Pro Ile Ser Trp Thr Cys Asp Leu Asp Asp Asp
945 950 955 960

Cys Gly Asp Arg Ser Asp Glu Ser Ala Ser Cys Ala Tyr Pro Thr Cys
965 970 975

Phe Pro Leu Thr Gln Phe Thr Cys Asn Asn Gly Arg Cys Ile Asn Ile
980 985 990

Asn Trp Arg Cys Asp Asn Asp Asn Asp Cys Gly Asp Asn Ser Asp Glu
 995 1000 1005

Ala Gly Cys Ser His Ser Cys Ser Ser Thr Gln Phe Lys Cys Asn
 1010 1015 1020

Ser Gly Arg Cys Ile Pro Glu His Trp Thr Cys Asp Gly Asp Asn
 1025 1030 1035

Asp Cys Gly Asp Tyr Ser Asp Glu Thr His Ala Asn Cys Thr Asn
 1040 1045 1050

Gln Ala Thr Arg Pro Pro Gly Gly Cys His Thr Asp Glu Phe Gln
 1055 1060 1065

Cys Arg Leu Asp Gly Leu Cys Ile Pro Leu Arg Trp Arg Cys Asp
 1070 1075 1080

Gly Asp Thr Asp Cys Met Asp Ser Ser Asp Glu Lys Ser Cys Glu
 1085 1090 1095

Gly Val Thr His Val Cys Asp Pro Ser Val Lys Phe Gly Cys Lys
 1100 1105 1110

Asp Ser Ala Arg Cys Ile Ser Lys Ala Trp Val Cys Asp Gly Asp
 1115 1120 1125

Asn Asp Cys Glu Asp Asn Ser Asp Glu Glu Asn Cys Glu Ser Leu
 1130 1135 1140

Asn Cys Arg Pro Pro Ser His Pro Cys Ala Asn Asn Thr Ser Val
 1145 1150 1155

Cys Leu Pro Pro Asp Lys Leu Cys Asp Gly Asn Asp Asp Cys Gly
 1160 1165 1170

Asp Gly Ser Asp Glu Gly Glu Leu Cys Asp Gln Cys Ser Leu Asn
 1175 1180 1185

Asn Gly Gly Cys Ser His Asn Cys Ser Val Ala Pro Gly Glu Gly
 1190 1195 1200

Ile Val Cys Ser Cys Pro Leu Gly Met Glu Leu Gly Pro Asp Asn
 1205 1210 1215

His Thr Cys Gln Ile Gln Ser Tyr Cys Ala Lys His Leu Lys Cys
 1220 1225 1230

 Ser Gln Lys Cys Asp Gln Asn Lys Phe Ser Val Lys Cys Ser Cys
 1235 1240 1245

 Tyr Glu Gly Trp Val Leu Glu Pro Asp Gly Glu Ser Cys Arg Ser
 1250 1255 1260

 Leu Asp Pro Phe Lys Pro Phe Ile Ile Phe Ser Asn Arg His Glu
 1265 1270 1275

 Ile Arg Arg Ile Asp Leu His Lys Gly Asp Tyr Ser Val Leu Val
 1280 1285 1290

 Pro Gly Leu Arg Asn Thr Ile Ala Leu Asp Phe His Leu Ser Gln
 1295 1300 1305

 Ser Ala Leu Tyr Trp Thr Asp Val Val Glu Asp Lys Ile Tyr Arg
 1310 1315 1320

 Gly Lys Leu Leu Asp Asn Gly Ala Leu Thr Ser Phe Glu Val Val
 1325 1330 1335

 Ile Gln Tyr Gly Leu Ala Thr Pro Glu Gly Leu Ala Val Asp Trp
 1340 1345 1350

 Ile Ala Gly Asn Ile Tyr Trp Val Glu Ser Asn Leu Asp Gln Ile
 1355 1360 1365

 Leu Val Ala Lys Leu Asp Gly Thr Leu Arg Thr Thr Leu Leu Ala
 1370 1375 1380

 Gly Asp Ile Glu His Pro Arg Ala Ile Ala Leu Asp Pro Arg Asp
 1385 1390 1395

 Gly Ile Leu Phe Trp Thr Asp Trp Asp Ala Ser Leu Pro Arg Ile
 1400 1405 1410

 Glu Ala Ala Ser Met Ser Gly Ala Gly Arg Arg Thr Val His Arg
 1415 1420 1425

 Glu Thr Gly Ser Gly Gly Trp Pro Asn Gly Leu Thr Val Asp Tyr
 1430 1435 1440

Leu Glu Lys Arg Ile Leu Trp Ile Asp Ala Arg Ser Asp Ala Ile
 1445 1450 1455
 Tyr Ser Ala Arg Tyr Asp Gly Ser Gly His Met Glu Val Leu Arg
 1460 1465 1470
 Gly His Glu Phe Leu Ser His Pro Phe Ala Val Thr Leu Tyr Gly
 1475 1480 1485
 Gly Glu Val Tyr Trp Thr Asp Trp Arg Thr Asn Thr Leu Ala Lys
 1490 1495 1500
 Ala Asn Lys Trp Thr Gly His Asn Val Thr Val Val Gln Arg Thr
 1505 1510 1515
 Asn Thr Gln Pro Phe Asp Leu Gln Val Tyr His Pro Ser Arg Gln
 1520 1525 1530
 Pro Met Ala Pro Asn Pro Cys Glu Ala Asn Gly Gly Gln Gly Pro
 1535 1540 1545
 Cys Ser His Leu Cys Leu Ile Asn Tyr Asn Arg Thr Val Ser Cys
 1550 1555 1560
 Ala Cys Pro His Leu Met Lys Leu His Lys Asp Asn Thr Thr Cys
 1565 1570 1575
 Tyr Glu Phe Lys Lys Phe Leu Leu Tyr Ala Arg Gln Met Glu Ile
 1580 1585 1590
 Arg Gly Val Asp Leu Asp Ala Pro Tyr Tyr Asn Tyr Ile Ile Ser
 1595 1600 1605
 Phe Thr Val Pro Asp Ile Asp Asn Val Thr Val Leu Asp Tyr Asp
 1610 1615 1620
 Ala Arg Glu Gln Arg Val Tyr Trp Ser Asp Val Arg Thr Gln Ala
 1625 1630 1635
 Ile Lys Arg Ala Phe Ile Asn Gly Thr Gly Val Glu Thr Val Val
 1640 1645 1650
 Ser Ala Asp Leu Pro Asn Ala His Gly Leu Ala Val Asp Trp Val
 1655 1660 1665

Ser Arg Asn Leu Phe Trp Thr Ser Tyr Asp Thr Asn Lys Lys Gln
 1670 1675 1680

Ile Asn Val Ala Arg Leu Asp Gly Ser Phe Lys Asn Ala Val Val
 1685 1690 1695

Gln Gly Leu Glu Gln Pro His Gly Leu Val Val His Pro Leu Arg
 1700 1705 1710

Gly Lys Leu Tyr Trp Thr Asp Gly Asp Asn Ile Ser Met Ala Asn
 1715 1720 1725

Met Asp Gly Ser Asn Arg Thr Leu Leu Phe Ser Gly Gln Lys Gly
 1730 1735 1740

Pro Val Gly Leu Ala Ile Asp Phe Pro Glu Ser Lys Leu Tyr Trp
 1745 1750 1755

Ile Ser Ser Gly Asn His Thr Ile Asn Arg Cys Asn Leu Asp Gly
 1760 1765 1770

Ser Gly Leu Glu Val Ile Asp Ala Met Arg Ser Gln Leu Gly Lys
 1775 1780 1785

Ala Thr Ala Leu Ala Ile Met Gly Asp Lys Leu Trp Trp Ala Asp
 1790 1795 1800

Gln Val Ser Glu Lys Met Gly Thr Cys Ser Lys Ala Asp Gly Ser
 1805 1810 1815

Gly Ser Val Val Leu Arg Asn Ser Thr Thr Leu Val Met His Met
 1820 1825 1830

Lys Val Tyr Asp Glu Ser Ile Gln Leu Asp His Lys Gly Thr Asn
 1835 1840 1845

Pro Cys Ser Val Asn Asn Gly Asp Cys Ser Gln Leu Cys Leu Pro
 1850 1855 1860

Thr Ser Glu Thr Thr Arg Ser Cys Met Cys Thr Ala Gly Tyr Ser
 1865 1870 1875

Leu Arg Ser Gly Gln Gln Ala Cys Glu Gly Val Gly Ser Phe Leu
 1880 1885 1890

Leu Tyr Ser Val His Glu Gly Ile Arg Gly Ile Pro Leu Asp Pro
 1895 1900 1905
 Asn Asp Lys Ser Asp Ala Leu Val Pro Val Ser Gly Thr Ser Leu
 1910 1915 1920
 Ala Val Gly Ile Asp Phe His Ala Glu Asn Asp Thr Ile Tyr Trp
 1925 1930 1935
 Val Asp Met Gly Leu Ser Thr Ile Ser Arg Ala Lys Arg Asp Gln
 1940 1945 1950
 Thr Trp Arg Glu Asp Val Val Thr Asn Gly Ile Gly Arg Val Glu
 1955 1960 1965
 Gly Ile Ala Val Asp Trp Ile Ala Gly Asn Ile Tyr Trp Thr Asp
 1970 1975 1980
 Gln Gly Phe Asp Val Ile Glu Val Ala Arg Leu Asn Gly Ser Phe
 1985 1990 1995
 Arg Tyr Val Val Ile Ser Gln Gly Leu Asp Lys Pro Arg Ala Ile
 2000 2005 2010
 Thr Val His Pro Glu Lys Gly Tyr Leu Phe Trp Thr Glu Trp Gly
 2015 2020 2025
 Gln Tyr Pro Arg Ile Glu Arg Ser Arg Leu Asp Gly Thr Glu Arg
 2030 2035 2040
 Val Val Leu Val Asn Val Ser Ile Ser Trp Pro Asn Gly Ile Ser
 2045 2050 2055
 Val Asp Tyr Gln Asp Gly Lys Leu Tyr Trp Cys Asp Ala Arg Thr
 2060 2065 2070
 Asp Lys Ile Glu Arg Ile Asp Leu Glu Thr Gly Glu Asn Arg Glu
 2075 2080 2085
 Val Val Leu Ser Ser Asn Asn Met Asp Met Phe Ser Val Ser Val
 2090 2095 2100
 Phe Glu Asp Phe Ile Tyr Trp Ser Asp Arg Thr His Ala Asn Gly
 2105 2110 2115

Ser Ile Lys Arg Gly Ser Lys Asp Asn Ala Thr Asp Ser Val Pro
 2120 2125 2130
 Leu Arg Thr Gly Ile Gly Val Gln Leu Lys Asp Ile Lys Val Phe
 2135 2140 2145
 Asn Arg Asp Arg Gln Lys Gly Thr Asn Val Cys Ala Val Ala Asn
 2150 2155 2160
 Gly Gly Cys Gln Gln Leu Cys Leu Tyr Arg Gly Arg Gly Gln Arg
 2165 2170 2175
 Ala Cys Ala Cys Ala His Gly Met Leu Ala Glu Asp Gly Ala Ser
 2180 2185 2190
 Cys Arg Glu Tyr Ala Gly Tyr Leu Leu Tyr Ser Glu Arg Thr Ile
 2195 2200 2205
 Leu Lys Ser Ile His Leu Ser Asp Glu Arg Asn Leu Asn Ala Pro
 2210 2215 2220
 Val Gln Pro Phe Glu Asp Pro Glu His Met Lys Asn Val Ile Ala
 2225 2230 2235
 Leu Ala Phe Asp Tyr Arg Ala Gly Thr Ser Pro Gly Thr Pro Asn
 2240 2245 2250
 Arg Ile Phe Phe Ser Asp Ile His Phe Gly Asn Ile Gln Gln Ile
 2255 2260 2265
 Asn Asp Asp Gly Ser Arg Arg Ile Thr Ile Val Glu Asn Val Gly
 2270 2275 2280
 Ser Val Glu Gly Leu Ala Tyr His Arg Gly Trp Asp Thr Leu Tyr
 2285 2290 2295
 Trp Thr Ser Tyr Thr Thr Ser Thr Ile Thr Arg His Thr Val Asp
 2300 2305 2310
 Gln Thr Arg Pro Gly Ala Phe Glu Arg Glu Thr Val Ile Thr Met
 2315 2320 2325
 Ser Gly Asp Asp His Pro Arg Ala Phe Val Leu Asp Glu Cys Gln
 2330 2335 2340

Asn Leu Met Phe Trp Thr Asn Trp Asn Glu Gln His Pro Ser Ile
 2345 2350 2355

Met Arg Ala Ala Leu Ser Gly Ala Asn Val Leu Thr Leu Ile Glu
 2360 2365 2370

Lys Asp Ile Arg Thr Pro Asn Gly Leu Ala Ile Asp His Arg Ala
 2375 2380 2385

Glu Lys Leu Tyr Phe Ser Asp Ala Thr Leu Asp Lys Ile Glu Arg
 2390 2395 2400

Cys Glu Tyr Asp Gly Ser His Arg Tyr Val Ile Leu Lys Ser Glu
 2405 2410 2415

Pro Val His Pro Phe Gly Leu Ala Val Tyr Gly Glu His Ile Phe
 2420 2425 2430

Trp Thr Asp Trp Val Arg Arg Ala Val Gln Arg Ala Asn Lys His
 2435 2440 2445

Val Gly Ser Asn Met Lys Leu Leu Arg Val Asp Ile Pro Gln Gln
 2450 2455 2460

Pro Met Gly Ile Ile Ala Val Ala Asn Asp Thr Asn Ser Cys Glu
 2465 2470 2475

Leu Ser Pro Cys Arg Ile Asn Asn Gly Gly Cys Gln Asp Leu Cys
 2480 2485 2490

u Leu Thr His Gln Gly His Val Asn Cys Ser Cys Arg Gly Gly
 2495 2500 2505

Arg Ile Leu Gln Asp Asp Leu Thr Cys Arg Ala Val Asn Ser Ser
 2510 2515 2520

Cys Arg Ala Gln Asp Glu Phe Glu Cys Ala Asn Gly Glu Cys Ile
 2525 2530 2535

Asn Phe Ser Leu Thr Cys Asp Gly Val Pro His Cys Lys Asp Lys
 2540 2545 2550

Ser Asp Glu Lys Pro Ser Tyr Cys Asn Ser Arg Arg Cys Lys Lys
 2555 2560 2565

Thr Phe Arg Gln Cys Ser Asn Gly Arg Cys Val Ser Asn Met Leu
 2570 2575 2580

Trp Cys Asn Gly Ala Asp Asp Cys Gly Asp Gly Ser Asp Glu Ile
 2585 2590 2595

Pro Cys Asn Lys Thr Ala Cys Gly Val Gly Glu Phe Arg Cys Arg
 2600 2605 2610

Asp Gly Thr Cys Ile Gly Asn Ser Ser Arg Cys Asn Gln Phe Val
 2615 2620 2625

Asp Cys Glu Asp Ala Ser Asp Glu Met Asn Cys Ser Ala Thr Asp
 2630 2635 2640

Cys Ser Ser Tyr Phe Arg Leu Gly Val Lys Gly Val Leu Phe Gln
 2645 2650 2655

Pro Cys Glu Arg Thr Ser Leu Cys Tyr Ala Pro Ser Trp Val Cys
 2660 2665 2670

Asp Gly Ala Asn Asp Cys Gly Asp Tyr Ser Asp Glu Arg Asp Cys
 2675 2680 2685

Pro Gly Val Lys Arg Pro Arg Cys Pro Leu Asn Tyr Phe Ala Cys
 2690 2695 2700

Pro Ser Gly Arg Cys Ile Pro Met Ser Trp Thr Cys Asp Lys Glu
 2705 2710 2715

Asp Asp Cys Glu His Gly Glu Asp Glu Thr His Cys Asn Lys Phe
 2720 2725 2730

Cys Ser Glu Ala Gln Phe Glu Cys Gln Asn His Arg Cys Ile Ser
 2735 2740 2745

Lys Gln Trp Leu Cys Asp Gly Ser Asp Asp Cys Gly Asp Gly Ser
 2750 2755 2760

Asp Glu Ala Ala His Cys Glu Gly Lys Thr Cys Gly Pro Ser Ser
 2765 2770 2775

Phe Ser Cys Pro Gly Thr His Val Cys Val Pro Glu Arg Trp Leu
 2780 2785 2790

Cys Asp Gly Asp Lys Asp Cys Ala Asp Gly Ala Asp Glu Ser Ile
 2795 2800 2805

Ala Ala Gly Cys Leu Tyr Asn Ser Thr Cys Asp Asp Arg Glu Phe
 2810 2815 2820

Met Cys Gln Asn Arg Gln Cys Ile Pro Lys His Phe Val Cys Asp
 2825 2830 2835

His Asp Arg Asp Cys Ala Asp Gly Ser Asp Glu Ser Pro Glu Cys
 2840 2845 2850

Glu Tyr Pro Thr Cys Gly Pro Ser Glu Phe Arg Cys Ala Asn Gly
 2855 2860 2865

Arg Cys Leu Ser Ser Arg Gln Trp Glu Cys Asp Gly Glu Asn Asp
 2870 2875 2880

Cys His Asp Gln Ser Asp Glu Ala Pro Lys Asn Pro His Cys Thr
 2885 2890 2895

Ser Pro Glu His Lys Cys Asn Ala Ser Ser Gln Phe Leu Cys Ser
 2900 2905 2910

Ser Gly Arg Cys Val Ala Glu Ala Leu Leu Cys Asn Gly Gln Asp
 2915 2920 2925

Asp Cys Gly Asp Ser Ser Asp Glu Arg Gly Cys His Ile Asn Glu
 2930 2935 2940

Cys Leu Ser Arg Lys Leu Ser Gly Cys Ser Gln Asp Cys Glu Asp
 2945 2950 2955

Leu Lys Ile Gly Phe Lys Cys Arg Cys Arg Pro Gly Phe Arg Leu
 2960 2965 2970

Lys Asp Asp Gly Arg Thr Cys Ala Asp Val Asp Glu Cys Ser Thr
 2975 2980 2985

Thr Phe Pro Cys Ser Gln Arg Cys Ile Asn Thr His Gly Ser Tyr
 2990 2995 3000

Lys Cys Leu Cys Val Glu Gly Tyr Ala Pro Arg Gly Gly Asp Pro
 3005 3010 3015

His Ser Cys Lys Ala Val Thr Asp Glu Glu Pro Phe Leu Ile Phe
 3020 3025 3030

Ala Asn Arg Tyr Tyr Leu Arg Lys Leu Asn Leu Asp Gly Ser Asn
 3035 3040 3045

Tyr Thr Leu Leu Lys Gln Gly Leu Asn Asn Ala Val Ala Leu Asp
 3050 3055 3060

Phe Asp Tyr Arg Glu Gln Met Ile Tyr Trp Thr Asp Val Thr Thr
 3065 3070 3075

Gln Gly Ser Met Ile Arg Arg Met His Leu Asn Gly Ser Asn Val
 3080 3085 3090

Gln Val Leu His Arg Thr Gly Leu Ser Asn Pro Asp Gly Leu Ala
 3095 3100 3105

Val Asp Trp Val Gly Gly Asn Leu Tyr Trp Cys Asp Lys Gly Arg
 3110 3115 3120

Asp Thr Ile Glu Val Ser Lys Leu Asn Gly Ala Tyr Arg Thr Val
 3125 3130 3135

Leu Val Ser Ser Gly Leu Arg Glu Pro Arg Ala Leu Val Val Asp
 3140 3145 3150

Val Gln Asn Gly Tyr Leu Tyr Trp Thr Asp Trp Gly Asp His Ser
 3155 3160 3165

Leu Ile Gly Arg Ile Gly Met Asp Gly Ser Ser Arg Ser Val Ile
 3170 3175 3180

Val Asp Thr Lys Ile Thr Trp Pro Asn Gly Leu Thr Leu Asp Tyr
 3185 3190 3195

Val Thr Glu Arg Ile Tyr Trp Ala Asp Ala Arg Glu Asp Tyr Ile
 3200 3205 3210

Glu Phe Ala Ser Leu Asp Gly Ser Asn Arg His Val Val Leu Ser
 3215 3220 3225

Gln Asp Ile Pro His Ile Phe Ala Leu Thr Leu Phe Glu Asp Tyr
 3230 3235 3240

Val Tyr Trp Thr Asp Trp Glu Thr Lys Ser Ile Asn Arg Ala His
 3245 3250 3255

 Lys Thr Thr Gly Thr Asn Lys Thr Leu Leu Ile Ser Thr Leu His
 3260 3265 3270

 Arg Pro Met Asp Leu His Val Phe His Ala Leu Arg Gln Pro Asp
 3275 3280 3285

 Val Pro Asn His Pro Cys Lys Val Asn Asn Gly Gly Cys Ser Asn
 3290 3295 3300

 Leu Cys Leu Leu Ser Pro Gly Gly Gly His Lys Cys Ala Cys Pro
 3305 3310 3315

 Thr Asn Phe Tyr Leu Gly Ser Asp Gly Arg Thr Cys Val Ser Asn
 3320 3325 3330

 Cys Thr Ala Ser Gln Phe Val Cys Lys Asn Asp Lys Cys Ile Pro
 3335 3340 3345

 Phe Trp Trp Lys Cys Asp Thr Glu Asp Asp Cys Gly Asp His Ser
 3350 3355 3360

 Asp Glu Pro Pro Asp Cys Pro Glu Phe Lys Cys Arg Pro Gly Gln
 3365 3370 3375

 Phe Gln Cys Ser Thr Gly Ile Cys Thr Asn Pro Ala Phe Ile Cys
 3380 3385 3390

 Asp Gly Asp Asn Asp Cys Gln Asp Asn Ser Asp Glu Ala Asn Cys
 3395 3400 3405

 Asp Ile His Val Cys Leu Pro Ser Gln Phe Lys Cys Thr Asn Thr
 3410 3415 3420

 Asn Arg Cys Ile Pro Gly Ile Phe Arg Cys Asn Gly Gln Asp Asn
 3425 3430 3435

 Cys Gly Asp Gly Glu Asp Glu Arg Asp Cys Pro Glu Val Thr Cys
 3440 3445 3450

 Ala Pro Asn Gln Phe Gln Cys Ser Ile Thr Lys Arg Cys Ile Pro
 3455 3460 3465

Arg Val Trp Val Cys Asp Arg Asp Asn Asp Cys Val Asp Gly Ser
 3470 3475 3480

Asp Glu Pro Ala Asn Cys Thr Gln Met Thr Cys Gly Val Asp Glu
 3485 3490 3495

Phe Arg Cys Lys Asp Ser Gly Arg Cys Ile Pro Ala Arg Trp Lys
 3500 3505 3510

Cys Asp Gly Glu Asp Asp Cys Gly Asp Gly Ser Asp Glu Pro Lys
 3515 3520 3525

Glu Glu Cys Asp Glu Arg Thr Cys Glu Pro Tyr Gln Phe Arg Cys
 3530 3535 3540

Lys Asn Asn Arg Cys Val Pro Gly Arg Trp Gln Cys Asp Tyr Asp
 3545 3550 3555

Asn Asp Cys Gly Asp Asn Ser Asp Glu Glu Ser Cys Thr Pro Arg
 3560 3565 3570

Pro Cys Ser Glu Ser Glu Phe Ser Cys Ala Asn Gly Arg Cys Ile
 3575 3580 3585

Ala Gly Arg Trp Lys Cys Asp Gly Asp His Asp Cys Ala Asp Gly
 3590 3595 3600

Ser Asp Glu Lys Asp Cys Thr Pro Arg Cys Asp Met Asp Gln Phe
 3605 3610 3615

Asn Cys Lys Ser Gly His Cys Ile Pro Leu Arg Trp Arg Cys Asp
 3620 3625 3630

Ala Asp Ala Asp Cys Met Asp Gly Ser Asp Glu Glu Ala Cys Gly
 3635 3640 3645

Thr Gly Val Arg Thr Cys Pro Leu Asp Glu Phe Gln Cys Asn Asn
 3650 3655 3660

Thr Leu Cys Lys Pro Leu Ala Trp Lys Cys Asp Gly Glu Asp Asp
 3665 3670 3675

Cys Gly Asp Asn Ser Asp Glu Asn Pro Glu Glu Cys Ala Arg Phe
 3680 3685 3690

Val Cys Pro Pro Asn Arg Pro Phe Arg Cys Lys Asn Asp Arg Val
 3695 3700 3705

Cys Leu Trp Ile Gly Arg Gln Cys Asp Gly Thr Asp Asn Cys Gly
 3710 3715 3720

Asp Gly Thr Asp Glu Glu Asp Cys Glu Pro Pro Thr Ala His Thr
 3725 3730 3735

Thr His Cys Lys Asp Lys Lys Glu Phe Leu Cys Arg Asn Gln Arg
 3740 3745 3750

Cys Leu Ser Ser Ser Leu Arg Cys Asn Met Phe Asp Asp Cys Gly
 3755 3760 3765

Asp Gly Ser Asp Glu Glu Asp Cys Ser Ile Asp Pro Lys Leu Thr
 3770 3775 3780

Ser Cys Ala Thr Asn Ala Ser Ile Cys Gly Asp Glu Ala Arg Cys
 3785 3790 3795

Val Arg Thr Glu Lys Ala Ala Tyr Cys Ala Cys Arg Ser Gly Phe
 3800 3805 3810

His Thr Val Pro Gly Gln Pro Gly Cys Gln Asp Ile Asn Glu Cys
 3815 3820 3825

Leu Arg Phe Gly Thr Cys Ser Gln Leu Cys Asn Asn Thr Lys Gly
 3830 3835 3840

y His Leu Cys Ser Cys Ala Arg Asn Phe Met Lys Thr His Asn
 3845 3850 3855

Thr Cys Lys Ala Glu Gly Ser Glu Tyr Gln Val Leu Tyr Ile Ala
 3860 3865 3870

Asp Asp Asn Glu Ile Arg Ser Leu Phe Pro Gly His Pro His Ser
 3875 3880 3885

Ala Tyr Glu Gln Ala Phe Gln Gly Asp Glu Ser Val Arg Ile Asp
 3890 3895 3900

Ala Met Asp Val His Val Lys Ala Gly Arg Val Tyr Trp Thr Asn
 3905 3910 3915

Trp His Thr Gly Thr Ile Ser Tyr Arg Ser Leu Pro Pro Ala Ala
 3920 3925 3930
 Pro Pro Thr Thr Ser Asn Arg His Arg Arg Gln Ile Asp Arg Gly
 3935 3940 3945
 Val Thr His Leu Asn Ile Ser Gly Leu Lys Met Pro Arg Gly Ile
 3950 3955 3960
 Ala Ile Asp Trp Val Ala Gly Asn Val Tyr Trp Thr Asp Ser Gly
 3965 3970 3975
 Arg Asp Val Ile Glu Val Ala Gln Met Lys Gly Glu Asn Arg Lys
 3980 3985 3990
 Thr Leu Ile Ser Gly Met Ile Asp Glu Pro His Ala Ile Val Val
 3995 4000 4005
 Asp Pro Leu Arg Gly Thr Met Tyr Trp Ser Asp Trp Gly Asn His
 4010 4015 4020
 Pro Lys Ile Glu Thr Ala Ala Met Asp Gly Thr Leu Arg Glu Thr
 4025 4030 4035
 Leu Val Gln Asp Asn Ile Gln Trp Pro Thr Gly Leu Ala Val Asp
 4040 4045 4050
 Tyr His Asn Glu Arg Leu Tyr Trp Ala Asp Ala Lys Leu Ser Val
 4055 4060 4065
 Ile Gly Ser Ile Arg Leu Asn Gly Thr Asp Pro Ile Val Ala Ala
 4070 4075 4080
 Asp Ser Lys Arg Gly Leu Ser His Pro Phe Ser Ile Asp Val Phe
 4085 4090 4095
 Glu Asp Tyr Ile Tyr Gly Val Thr Tyr Ile Asn Asn Arg Val Phe
 4100 4105 4110
 Lys Ile His Lys Phe Gly His Ser Pro Leu Val Asn Leu Thr Gly
 4115 4120 4125
 Gly Leu Ser His Ala Ser Asp Val Val Leu Tyr His Gln His Lys
 4130 4135 4140

Gln Pro Glu Val Thr Asn Pro Cys Asp Arg Lys Lys Cys Glu Trp
 4145 4150 4155

Leu Cys Leu Leu Ser Pro Ser Gly Pro Val Cys Thr Cys Pro Asn
 4160 4165 4170

Gly Lys Arg Leu Asp Asn Gly Thr Cys Val Pro Val Pro Ser Pro
 4175 4180 4185

Thr Pro Pro Pro Asp Ala Pro Arg Pro Gly Thr Cys Asn Leu Gln
 4190 4195 4200

Cys Phe Asn Gly Gly Ser Cys Phe Leu Asn Ala Arg Arg Gln Pro
 4205 4210 4215

Lys Cys Arg Cys Gln Pro Arg Tyr Thr Gly Asp Lys Cys Glu Leu
 4220 4225 4230

Asp Gln Cys Trp Glu His Cys Arg Asn Gly Gly Thr Cys Ala Ala
 4235 4240 4245

Ser Pro Ser Gly Met Pro Thr Cys Arg Cys Pro Thr Gly Phe Thr
 4250 4255 4260

Gly Pro Lys Cys Thr Gln Gln Val Cys Ala Gly Tyr Cys Ala Asn
 4265 4270 4275

Asn Ser Thr Cys Thr Val Asn Gln Gly Asn Gln Pro Gln Cys Arg
 4280 4285 4290

Cys Leu Pro Gly Phe Leu Gly Asp Arg Cys Gln Tyr Arg Gln Cys
 4295 4300 4305

Ser Gly Tyr Cys Glu Asn Phe Gly Thr Cys Gln Met Ala Ala Asp
 4310 4315 4320

Gly Ser Arg Gln Cys Arg Cys Thr Ala Tyr Phe Glu Gly Ser Arg
 4325 4330 4335

Cys Glu Val Asn Lys Cys Ser Arg Cys Leu Glu Gly Ala Cys Val
 4340 4345 4350

Val Asn Lys Gln Ser Gly Asp Val Thr Cys Asn Cys Thr Asp Gly
 4355 4360 4365

Arg Val Ala Pro Ser Cys Leu Thr Cys Val Gly His Cys Ser Asn
 4370 4375 4380

Gly Gly Ser Cys Thr Met Asn Ser Lys Met Met Pro Glu Cys Gln
 4385 4390 4395

Cys Pro Pro His Met Thr Gly Pro Arg Cys Glu Glu His Val Phe
 4400 4405 4410

Ser Gln Gln Gln Pro Gly
 4415

<210> 10

<211> 4464

<212> PRT

<213> H. sapiens

<400> 10

Met Leu Thr Pro Pro Leu Leu Leu Leu Leu Pro Leu Leu Ser Ala Leu
 1 5 10 15

Val Ala Ala Ala Ile Asp Ala Pro Lys Thr Cys Ser Pro Lys Gln Phe
 20 25 30

Ala Cys Arg Asp Gln Ile Thr Cys Ile Ser Lys Gly Trp Arg Cys Asp
 35 40 45

Gly Glu Arg Asp Cys Pro Asp Gly Ser Asp Glu Ala Pro Glu Ile Cys
 50 55 60

Pro Gln Ser Lys Ala Gln Arg Cys Gln Pro Asn Glu His Asn Cys Leu
 65 70 75 80

Gly Thr Glu Leu Cys Val Pro Met Ser Arg Leu Cys Asn Gly Val Gln
 85 90 95

Asp Cys Met Asp Gly Ser Asp Glu Gly Pro His Cys Arg Glu Leu Gln
 100 105 110

Gly Asn Cys Ser Arg Leu Gly Cys Gln His His Cys Val Pro Thr Leu
 115 120 125

Asp Gly Pro Thr Cys Tyr Cys Asn Ser Ser Phe Gln Leu Gln Ala Asp
 130 135 140

Gly Lys Thr Cys Lys Asp Phe Asp Glu Cys Ser Val Tyr Gly Thr Cys
 145 150 155 160

Ser Gln Leu Cys Thr Asn Thr Asp Gly Ser Phe Ile Cys Gly Cys Val
 165 170 175

Glu Gly Tyr Leu Leu Gln Pro Asp Asn Arg Ser Cys Lys Ala Lys Asn
 180 185 190

Glu Pro Val Asp Arg Pro Pro Val Leu Leu Ile Ala Asn Ser Gln Asn
 195 200 205

Ile Leu Ala Thr Tyr Leu Ser Gly Ala Gln Val Ser Thr Ile Thr Pro
 210 215 220

Thr Ser Thr Arg Gln Thr Thr Ala Met Asp Phe Ser Tyr Ala Asn Glu
 225 230 235 240

Val Cys Trp Val His Val Gly Asp Ser Ala Ala Gln Thr Gln Leu
 245 250 255

Lys Cys Ala Arg Met Pro Gly Leu Lys Gly Phe Val Asp Glu His Thr
 260 265 270

Ile Asn Ile Ser Leu Ser Leu His His Val Glu Gln Met Ala Ile Asp
 275 280 285

Trp Leu Thr Gly Asn Phe Tyr Phe Val Asp Asp Ile Asp Asp Arg Ile
 290 295 300

Phe Val Cys Asn Arg Asn Gly Asp Thr Cys Val Thr Leu Leu Asp Leu
 305 310 315 320

Glu Leu Tyr Asn Pro Lys Gly Ile Ala Leu Asp Pro Ala Met Gly Lys
 325 330 335

Val Phe Phe Thr Asp Tyr Gly Gln Ile Pro Lys Val Glu Arg Cys Asp
 340 345 350

Met Asp Gly Gln Asn Arg Thr Lys Leu Val Asp Ser Lys Ile Val Phe
 355 360 365

Pro His Gly Ile Thr Leu Asp Leu Val Ser Arg Leu Val Tyr Trp Ala
 370 375 380

Asp Ala Tyr Leu Asp Tyr Ile Glu Val Val Asp Tyr Glu Gly Lys Gly
 385 390 395 400

Arg Gln Thr Ile Ile Gln Gly Ile Leu Ile Glu His Leu Tyr Gly Leu
 405 410 415

Thr Val Phe Glu Asn Tyr Leu Tyr Ala Thr Asn Ser Asp Asn Ala Asn
 420 425 430

Ala Gln Gln Lys Thr Ser Val Ile Arg Val Asn Arg Phe Asn Ser Thr
 435 440 445

Glu Tyr Gln Val Val Thr Arg Val Asp Lys Gly Gly Ala Leu His Ile
 450 455 460

Tyr His Gln Arg Arg Gln Pro Arg Val Arg Ser His Ala Cys Glu Asn
 465 470 475 480

Asp Gln Tyr Gly Lys Pro Gly Gly Cys Ser Asp Ile Cys Leu Leu Ala
 485 490 495

Asn Ser His Lys Ala Arg Thr Cys Arg Cys Arg Ser Gly Phe Ser Leu
 500 505 510

Gly Ser Asp Gly Lys Ser Cys Lys Lys Pro Glu His Glu Leu Phe Leu
 515 520 525

Val Tyr Gly Lys Gly Arg Pro Gly Ile Ile Arg Gly Met Asp Met Gly
 530 535 540

Ala Lys Val Pro Asp Glu His Met Ile Pro Ile Glu Asn Leu Met Asn
 545 550 555 560

o Arg Ala Leu Asp Phe His Ala Glu Thr Gly Phe Ile Tyr Phe Ala
 565 570 575

Asp Thr Thr Ser Tyr Leu Ile Gly Arg Gln Lys Ile Asp Gly Thr Glu
 580 585 590

Arg Glu Thr Ile Leu Lys Asp Gly Ile His Asn Val Glu Gly Val Ala
 595 600 605

Val Asp Trp Met Gly Asp Asn Leu Tyr Trp Thr Asp Asp Gly Pro Lys
 610 615 620

Lys Thr Ile Ser Val Ala Arg Leu Glu Lys Ala Ala Gln Thr Arg Lys
 625 630 635 640

Thr Leu Ile Glu Gly Lys Met Thr His Pro Arg Ala Ile Val Val Asp
645 650 655

Pro Leu Asn Gly Trp Met Tyr Trp Thr Asp Trp Glu Glu Asp Pro Lys
660 665 670

Asp Ser Arg Arg Gly Arg Leu Glu Arg Ala Trp Met Asp Gly Ser His
675 680 685

Arg Asp Ile Phe Val Thr Ser Lys Thr Val Leu Trp Pro Asn Gly Leu
690 695 700

Ser Leu Asp Ile Pro Ala Gly Arg Leu Tyr Trp Val Asp Ala Phe Tyr
705 710 715 720

Asp Arg Ile Glu Thr Ile Leu Leu Asn Gly Thr Asp Arg Lys Ile Val
725 730 735

Tyr Glu Gly Pro Glu Leu Asn His Ala Phe Gly Leu Cys His His Gly
740 745 750

Asn Tyr Leu Phe Trp Thr Glu Tyr Arg Ser Gly Ser Val Tyr Arg Leu
755 760 765

Glu Arg Gly Val Gly Gly Ala Pro Pro Thr Val Thr Leu Leu Arg Ser
770 775 780

Glu Arg Pro Pro Ile Phe Glu Ile Arg Met Tyr Asp Ala Gln Gln Gln
785 790 795 800

Gln Val Gly Thr Asn Lys Cys Arg Val Asn Asn Gly Gly Cys Ser Ser
805 810 815

Leu Cys Leu Ala Thr Pro Gly Ser Arg Gln Cys Ala Cys Ala Glu Asp
820 825 830

Gln Val Leu Asp Ala Asp Gly Val Thr Cys Leu Ala Asn Pro Ser Tyr
835 840 845

Val Pro Pro Pro Gln Cys Gln Pro Gly Glu Phe Ala Cys Ala Asn Ser
850 855 860

Arg Cys Ile Gln Glu Arg Trp Lys Cys Asp Gly Asp Asn Asp Cys Leu
865 870 875 880

Asp Asn Ser Asp Glu Ala Pro Ala Leu Cys His Gln His Thr Cys Pro
885 890 895

Ser Asp Arg Phe Lys Cys Glu Asn Asn Arg Cys Ile Pro Asn Arg Trp
900 905 910

Leu Cys Asp Gly Asp Asn Asp Cys Gly Asn Ser Glu Asp Glu Ser Asn
915 920 925

Ala Thr Cys Ser Ala Arg Thr Cys Pro Pro Asn Gln Phe Ser Cys Ala
930 935 940

Ser Gly Arg Cys Ile Pro Ile Ser Trp Thr Cys Asp Leu Asp Asp Asp
945 950 955 960

Cys Gly Asp Arg Ser Asp Glu Ser Ala Ser Cys Ala Tyr Pro Thr Cys
965 970 975

Phe Pro Leu Thr Gln Phe Thr Cys Asn Asn Gly Arg Cys Ile Asn Ile
980 985 990

Asn Trp Arg Cys Asp Asn Asp Asn Asp Cys Gly Asp Asn Ser Asp Glu
995 1000 1005

Ala Gly Cys Ser His Ser Cys Ser Ser Thr Gln Phe Lys Cys Asn
1010 1015 1020

Ser Gly Arg Cys Ile Pro Glu His Trp Thr Cys Asp Gly Asp Asn
1025 1030 1035

Asp Cys Gly Asp Tyr Ser Asp Glu Thr His Ala Asn Cys Thr Asn
1040 1045 1050

Gln Ala Thr Arg Pro Pro Gly Gly Cys His Thr Asp Glu Phe Gln
1055 1060 1065

Cys Arg Leu Asp Gly Leu Cys Ile Pro Leu Arg Trp Arg Cys Asp
1070 1075 1080

Gly Asp Thr Asp Cys Met Asp Ser Ser Asp Glu Lys Ser Cys Glu
1085 1090 1095

Gly Val Thr His Val Cys Asp Pro Ser Val Lys Phe Gly Cys Lys
1100 1105 1110

Asp Ser Ala Arg Cys Ile Ser Lys Ala Trp Val Cys Asp Gly Asp
 1115 1120 1125

Asn Asp Cys Glu Asp Asn Ser Asp Glu Glu Asn Cys Glu Ser Leu
 1130 1135 1140

Ala Cys Arg Pro Pro Ser His Pro Cys Ala Asn Asn Thr Ser Val
 1145 1150 1155

Cys Leu Pro Pro Asp Lys Leu Cys Asp Gly Asn Asp Asp Cys Gly
 1160 1165 1170

Asp Gly Ser Asp Glu Gly Glu Leu Cys Asp Gln Cys Ser Leu Asn
 1175 1180 1185

Asn Gly Gly Cys Ser His Asn Cys Ser Val Ala Pro Gly Glu Gly
 1190 1195 1200

Ile Val Cys Ser Cys Pro Leu Gly Met Glu Leu Gly Pro Asp Asn
 1205 1210 1215

His Thr Cys Gln Ile Gln Ser Tyr Cys Ala Lys His Leu Lys Cys
 1220 1225 1230

Ser Gln Lys Cys Asp Gln Asn Lys Phe Ser Val Lys Cys Ser Cys
 1235 1240 1245

Tyr Glu Gly Trp Val Leu Glu Pro Asp Gly Glu Ser Cys Arg Ser
 1250 1255 1260

Leu Asp Pro Phe Lys Pro Phe Ile Ile Phe Ser Asn Arg His Glu
 1265 1270 1275

Ile Arg Arg Ile Asp Leu His Lys Gly Asp Tyr Ser Val Leu Val
 1280 1285 1290

Pro Gly Leu Arg Asn Thr Ile Ala Leu Asp Phe His Leu Ser Gln
 1295 1300 1305

Ser Ala Leu Tyr Trp Thr Asp Val Val Glu Asp Lys Ile Tyr Arg
 1310 1315 1320

Gly Lys Leu Leu Asp Asn Gly Ala Leu Thr Ser Phe Glu Val Val
 1325 1330 1335

Ile Gln Tyr Gly Leu Ala Thr Pro Glu Gly Leu Ala Val Asp Trp
1340 1345 1350

Ile Ala Gly Asn Ile Tyr Trp Val Glu Ser Asn Leu Asp Gln Ile
1355 1360 1365

Glu Val Ala Lys Leu Asp Gly Thr Leu Arg Thr Thr Leu Leu Ala
1370 1375 1380

Gly Asp Ile Glu His Pro Arg Ala Ile Ala Leu Asp Pro Arg Asp
1385 1390 1395

Gly Ile Leu Phe Trp Thr Asp Trp Asp Ala Ser Leu Pro Arg Ile
1400 1405 1410

Glu Ala Ala Ser Met Ser Gly Ala Gly Arg Arg Thr Val His Arg
1415 1420 1425

Glu Thr Gly Ser Gly Gly Trp Pro Asn Gly Leu Thr Val Asp Tyr
1430 1435 1440

Leu Glu Lys Arg Ile Leu Trp Ile Asp Ala Arg Ser Asp Ala Ile
1445 1450 1455

Tyr Ser Ala Arg Tyr Asp Gly Ser Gly His Met Glu Val Leu Arg
1460 1465 1470

Gly His Glu Phe Leu Ser His Pro Phe Ala Val Thr Leu Tyr Gly
1475 1480 1485

Gly Glu Val Tyr Trp Thr Asp Trp Arg Thr Asn Thr Leu Ala Lys
1490 1495 1500

Ala Asn Lys Trp Thr Gly His Asn Val Thr Val Val Gln Arg Thr
1505 1510 1515

Asn Thr Gln Pro Phe Asp Leu Gln Val Tyr His Pro Ser Arg Gln
1520 1525 1530

Pro Met Ala Pro Asn Pro Cys Glu Ala Asn Gly Gly Gln Gly Pro
1535 1540 1545

Cys Ser His Leu Cys Leu Ile Asn Tyr Asn Arg Thr Val Ser Cys
1550 1555 1560

Ala Cys	Pro His	Leu Met	Lys	Leu His	Lys Asp	Asn	Thr Thr	Cys
1565			1570			1575		
Tyr Glu	Phe Lys	Lys Phe	Leu	Leu Tyr	Ala Arg	Gln	Met Glu	Ile
1580			1585			1590		
Arg Gly	Val Asp	Leu Asp	Ala	Pro Tyr	Tyr Asn	Tyr	Ile Ile	Ser
1595			1600			1605		
Phe Thr	Val Pro	Asp Ile	Asp	Asn Val	Thr Val	Leu	Asp Tyr	Asp
1610			1615			1620		
Ala Arg	Glu Gln	Arg Val	Tyr	Trp Ser	Asp Val	Arg	Thr Gln	Ala
1625			1630			1635		
Ile Lys	Arg Ala	Phe Ile	Asn	Gly Thr	Gly Val	Glu	Thr Val	Val
1640			1645			1650		
Ser Ala	Asp Leu	Pro Asn	Ala	His Gly	Leu Ala	Val	Asp Trp	Val
1655			1660			1665		
Ser Arg	Asn Leu	Phe Trp	Thr	Ser Tyr	Asp Thr	Asn	Lys Lys	Gln
1670			1675			1680		
Ile Asn	Val Ala	Arg Leu	Asp	Gly Ser	Phe Lys	Asn	Ala Val	Val
1685			1690			1695		
Gln Gly	Leu Glu	Gln Pro	His	Gly Leu	Val Val	His	Pro Leu	Arg
1700			1705			1710		
Gly Lys	Leu Tyr	Trp Thr	Asp	Gly Asp	Asn Ile	Ser	Met Ala	Asn
1715			1720			1725		
Met Asp	Gly Ser	Asn Arg	Thr	Leu Leu	Phe Ser	Gly	Gln Lys	Gly
1730			1735			1740		
Pro Val	Gly Leu	Ala Ile	Asp	Phe Pro	Glu Ser	Lys	Leu Tyr	Trp
1745			1750			1755		
Ile Ser	Ser Gly	Asn His	Thr	Ile Asn	Arg Cys	Asn	Leu Asp	Gly
1760			1765			1770		
Ser Gly	Leu Glu	Val Ile	Asp	Ala Met	Arg Ser	Gln	Leu Gly	Lys
1775			1780			1785		

Ala Thr Ala Leu Ala Ile Met Gly Asp Lys Leu Trp Trp Ala Asp
1790 1795 1800

Gln Val Ser Glu Lys Met Gly Thr Cys Ser Lys Ala Asp Gly Ser
1805 1810 1815

Gly Ser Val Val Leu Arg Asn Ser Thr Thr Leu Val Met His Met
1820 1825 1830

Lys Val Tyr Asp Glu Ser Ile Gln Leu Asp His Lys Gly Thr Asn
1835 1840 1845

Pro Cys Ser Val Asn Asn Gly Asp Cys Ser Gln Leu Cys Leu Pro
1850 1855 1860

Thr Ser Glu Thr Thr Arg Ser Cys Met Cys Thr Ala Gly Tyr Ser
1865 1870 1875

Leu Arg Ser Gly Gln Gln Ala Cys Glu Gly Val Gly Ser Phe Leu
1880 1885 1890

Leu Tyr Ser Val His Glu Gly Ile Arg Gly Ile Pro Leu Asp Pro
1895 1900 1905

Asn Asp Lys Ser Asp Ala Leu Val Pro Val Ser Gly Thr Ser Leu
1910 1915 1920

Ala Val Gly Ile Asp Phe His Ala Glu Asn Asp Thr Ile Tyr Trp
1925 1930 1935

Val Asp Met Gly Leu Ser Thr Ile Ser Arg Ala Lys Arg Asp Gln
1940 1945 1950

Thr Trp Arg Glu Asp Val Val Thr Asn Gly Ile Gly Arg Val Glu
1955 1960 1965

Gly Ile Ala Val Asp Trp Ile Ala Gly Asn Ile Tyr Trp Thr Asp
1970 1975 1980

Gln Gly Phe Asp Val Ile Glu Val Ala Arg Leu Asn Gly Ser Phe
1985 1990 1995

Arg Tyr Val Val Ile Ser Gln Gly Leu Asp Lys Pro Arg Ala Ile
2000 2005 2010

Thr Val His Pro Glu Lys Gly Tyr Leu Phe Trp Thr Glu Trp Gly
 2015 2020 2025

 Gln Tyr Pro Arg Ile Glu Arg Ser Arg Leu Asp Gly Thr Glu Arg
 2030 2035 2040

 Val Val Leu Val Asn Val Ser Ile Ser Trp Pro Asn Gly Ile Ser
 2045 2050 2055

 Val Asp Tyr Gln Asp Gly Lys Leu Tyr Trp Cys Asp Ala Arg Thr
 2060 2065 2070

 Asp Lys Ile Glu Arg Ile Asp Leu Glu Thr Gly Glu Asn Arg Glu
 2075 2080 2085

 Val Val Leu Ser Ser Asn Asn Met Asp Met Phe Ser Val Ser Val
 2090 2095 2100

 Phe Glu Asp Phe Ile Tyr Trp Ser Asp Arg Thr His Ala Asn Gly
 2105 2110 2115

 Ser Ile Lys Arg Gly Ser Lys Asp Asn Ala Thr Asp Ser Val Pro
 2120 2125 2130

 Leu Arg Thr Gly Ile Gly Val Gln Leu Lys Asp Ile Lys Val Phe
 2135 2140 2145

 Asn Arg Asp Arg Gln Lys Gly Thr Asn Val Cys Ala Val Ala Asn
 2150 2155 2160

 Gly Gly Cys Gln Gln Leu Cys Leu Tyr Arg Gly Arg Gly Gln Arg
 2165 2170 2175

 Ala Cys Ala Cys Ala His Gly Met Leu Ala Glu Asp Gly Ala Ser
 2180 2185 2190

 Cys Arg Glu Tyr Ala Gly Tyr Leu Leu Tyr Ser Glu Arg Thr Ile
 2195 2200 2205

 Leu Lys Ser Ile His Leu Ser Asp Glu Arg Asn Leu Asn Ala Pro
 2210 2215 2220

 Val Gln Pro Phe Glu Asp Pro Glu His Met Lys Asn Val Ile Ala
 2225 2230 2235

Leu Ala Phe Asp Tyr Arg Ala Gly Thr Ser Pro Gly Thr Pro Asn
 2240 2245 2250

 Arg Ile Phe Phe Ser Asp Ile His Phe Gly Asn Ile Gln Gln Ile
 2255 2260 2265

 Asn Asp Asp Gly Ser Arg Arg Ile Thr Ile Val Glu Asn Val Gly
 2270 2275 2280

 Ser Val Glu Gly Leu Ala Tyr His Arg Gly Trp Asp Thr Leu Tyr
 2285 2290 2295

 Trp Thr Ser Tyr Thr Thr Ser Thr Ile Thr Arg His Thr Val Asp
 2300 2305 2310

 Gln Thr Arg Pro Gly Ala Phe Glu Arg Glu Thr Val Ile Thr Met
 2315 2320 2325

 Ser Gly Asp Asp His Pro Arg Ala Phe Val Leu Asp Glu Cys Gln
 2330 2335 2340

 Asn Leu Met Phe Trp Thr Asn Trp Asn Glu Gln His Pro Ser Ile
 2345 2350 2355

 Met Arg Ala Ala Leu Ser Gly Ala Asn Val Leu Thr Leu Ile Glu
 2360 2365 2370

 Lys Asp Ile Arg Thr Pro Asn Gly Leu Ala Ile Asp His Arg Ala
 2375 2380 2385

 Glu Lys Leu Tyr Phe Ser Asp Ala Thr Leu Asp Lys Ile Glu Arg
 2390 2395 2400

 Cys Glu Tyr Asp Gly Ser His Arg Tyr Val Ile Leu Lys Ser Glu
 2405 2410 2415

 Pro Val His Pro Phe Gly Leu Ala Val Tyr Gly Glu His Ile Phe
 2420 2425 2430

 Trp Thr Asp Trp Val Arg Arg Ala Val Gln Arg Ala Asn Lys His
 2435 2440 2445

 Val Gly Ser Asn Met Lys Leu Leu Arg Val Asp Ile Pro Gln Gln
 2450 2455 2460

Pro Met Gly Ile Ile Ala Val Ala Asn Asp Thr Asn Ser Cys Glu
 2465 2470 2475

Leu Ser Pro Cys Arg Ile Asn Asn Gly Gly Cys Gln Asp Leu Cys
 2480 2485 2490

Leu Leu Thr His Gln Gly His Val Asn Cys Ser Cys Arg Gly Gly
 2495 2500 2505

Arg Ile Leu Gln Asp Asp Leu Thr Cys Arg Ala Val Asn Ser Ser
 2510 2515 2520

Cys Arg Ala Gln Asp Glu Phe Glu Cys Ala Asn Gly Glu Cys Ile
 2525 2530 2535

Asn Phe Ser Leu Thr Cys Asp Gly Val Pro His Cys Lys Asp Lys
 2540 2545 2550

Ser Asp Glu Lys Pro Ser Tyr Cys Asn Ser Arg Arg Cys Lys Lys
 2555 2560 2565

Thr Phe Arg Gln Cys Ser Asn Gly Arg Cys Val Ser Asn Met Leu
 2570 2575 2580

Trp Cys Asn Gly Ala Asp Asp Cys Gly Asp Gly Ser Asp Glu Ile
 2585 2590 2595

Pro Cys Asn Lys Thr Ala Cys Gly Val Gly Glu Phe Arg Cys Arg
 2600 2605 2610

Asp Gly Thr Cys Ile Gly Asn Ser Ser Arg Cys Asn Gln Phe Val
 2615 2620 2625

Asp Cys Glu Asp Ala Ser Asp Glu Met Asn Cys Ser Ala Thr Asp
 2630 2635 2640

Cys Ser Ser Tyr Phe Arg Leu Gly Val Lys Gly Val Leu Phe Gln
 2645 2650 2655

Pro Cys Glu Arg Thr Ser Leu Cys Tyr Ala Pro Ser Trp Val Cys
 2660 2665 2670

Asp Gly Ala Asn Asp Cys Gly Asp Tyr Ser Asp Glu Arg Asp Cys
 2675 2680 2685

Pro Gly Val Lys Arg Pro Arg Cys Pro Leu Asn Tyr Phe Ala Cys
2690 2695 2700

Pro Ser Gly Arg Cys Ile Pro Met Ser Trp Thr Cys Asp Lys Glu
2705 2710 2715

Asp Asp Cys Glu His Gly Glu Asp Glu Thr His Cys Asn Lys Phe
2720 2725 2730

Cys Ser Glu Ala Gln Phe Glu Cys Gln Asn His Arg Cys Ile Ser
2735 2740 2745

Lys Gln Trp Leu Cys Asp Gly Ser Asp Asp Cys Gly Asp Gly Ser
2750 2755 2760

Asp Glu Ala Ala His Cys Glu Gly Lys Thr Cys Gly Pro Ser Ser
2765 2770 2775

Phe Ser Cys Pro Gly Thr His Val Cys Val Pro Glu Arg Trp Leu
2780 2785 2790

Cys Asp Gly Asp Lys Asp Cys Ala Asp Gly Ala Asp Glu Ser Ile
2795 2800 2805

Ala Ala Gly Cys Leu Tyr Asn Ser Thr Cys Asp Asp Arg Glu Phe
2810 2815 2820

Met Cys Gln Asn Arg Gln Cys Ile Pro Lys His Phe Val Cys Asp
2825 2830 2835

His Asp Arg Asp Cys Ala Asp Gly Ser Asp Glu Ser Pro Glu Cys
2840 2845 2850

Glu Tyr Pro Thr Cys Gly Pro Ser Glu Phe Arg Cys Ala Asn Gly
2855 2860 2865

Arg Cys Leu Ser Ser Arg Gln Trp Glu Cys Asp Gly Glu Asn Asp
2870 2875 2880

Cys His Asp Gln Ser Asp Glu Ala Pro Lys Asn Pro His Cys Thr
2885 2890 2895

Ser Pro Glu His Lys Cys Asn Ala Ser Ser Gln Phe Leu Cys Ser
2900 2905 2910

Ser Gly Arg Cys Val Ala Glu Ala Leu Leu Cys Asn Gly Gln Asp
 2915 2920 2925

Asp Cys Gly Asp Ser Ser Asp Glu Arg Gly Cys His Ile Asn Glu
 2930 2935 2940

Cys Leu Ser Arg Lys Leu Ser Gly Cys Ser Gln Asp Cys Glu Asp
 2945 2950 2955

Leu Lys Ile Gly Phe Lys Cys Arg Cys Arg Pro Gly Phe Arg Leu
 2960 2965 2970

Lys Asp Asp Gly Arg Thr Cys Ala Asp Val Asp Glu Cys Ser Thr
 2975 2980 2985

Thr Phe Pro Cys Ser Gln Arg Cys Ile Asn Thr His Gly Ser Tyr
 2990 2995 3000

Lys Cys Leu Cys Val Glu Gly Tyr Ala Pro Arg Gly Gly Asp Pro
 3005 3010 3015

His Ser Cys Lys Ala Val Thr Asp Glu Glu Pro Phe Leu Ile Phe
 3020 3025 3030

Ala Asn Arg Tyr Tyr Leu Arg Lys Leu Asn Leu Asp Gly Ser Asn
 3035 3040 3045

Tyr Thr Leu Leu Lys Gln Gly Leu Asn Asn Ala Val Ala Leu Asp
 3050 3055 3060

Phe Asp Tyr Arg Glu Gln Met Ile Tyr Trp Thr Asp Val Thr Thr
 3065 3070 3075

Gln Gly Ser Met Ile Arg Arg Met His Leu Asn Gly Ser Asn Val
 3080 3085 3090

Gln Val Leu His Arg Thr Gly Leu Ser Asn Pro Asp Gly Leu Ala
 3095 3100 3105

Val Asp Trp Val Gly Gly Asn Leu Tyr Trp Cys Asp Lys Gly Arg
 3110 3115 3120

Asp Thr Ile Glu Val Ser Lys Leu Asn Gly Ala Tyr Arg Thr Val
 3125 3130 3135

Leu Val Ser Ser Gly Leu Arg Glu Pro Arg Ala Leu Val Val Asp
 3140 3145 3150

Val Gln Asn Gly Tyr Leu Tyr Trp Thr Asp Trp Gly Asp His Ser
 3155 3160 3165

Leu Ile Gly Arg Ile Gly Met Asp Gly Ser Ser Arg Ser Val Ile
 3170 3175 3180

Val Asp Thr Lys Ile Thr Trp Pro Asn Gly Leu Thr Leu Asp Tyr
 3185 3190 3195

Val Thr Glu Arg Ile Tyr Trp Ala Asp Ala Arg Glu Asp Tyr Ile
 3200 3205 3210

Glu Phe Ala Ser Leu Asp Gly Ser Asn Arg His Val Val Leu Ser
 3215 3220 3225

Gln Asp Ile Pro His Ile Phe Ala Leu Thr Leu Phe Glu Asp Tyr
 3230 3235 3240

Val Tyr Trp Thr Asp Trp Glu Thr Lys Ser Ile Asn Arg Ala His
 3245 3250 3255

Lys Thr Thr Gly Thr Asn Lys Thr Leu Leu Ile Ser Thr Leu His
 3260 3265 3270

Arg Pro Met Asp Leu His Val Phe His Ala Leu Arg Gln Pro Asp
 3275 3280 3285

Val Pro Asn His Pro Cys Lys Val Asn Asn Gly Gly Cys Ser Asn
 3290 3295 3300

Leu Cys Leu Leu Ser Pro Gly Gly Gly His Lys Cys Ala Cys Pro
 3305 3310 3315

Thr Asn Phe Tyr Leu Gly Ser Asp Gly Arg Thr Cys Val Ser Asn
 3320 3325 3330

Cys Thr Ala Ser Gln Phe Val Cys Lys Asn Asp Lys Cys Ile Pro
 3335 3340 3345

Phe Trp Trp Lys Cys Asp Thr Glu Asp Asp Cys Gly Asp His Ser
 3350 3355 3360

Asp Glu Pro Pro Asp Cys Pro Glu Phe Lys Cys Arg Pro Gly Gln
 3365 3370 3375

Phe Gln Cys Ser Thr Gly Ile Cys Thr Asn Pro Ala Phe Ile Cys
 3380 3385 3390

Asp Gly Asp Asn Asp Cys Gln Asp Asn Ser Asp Glu Ala Asn Cys
 3395 3400 3405

Asp Ile His Val Cys Leu Pro Ser Gln Phe Lys Cys Thr Asn Thr
 3410 3415 3420

Asn Arg Cys Ile Pro Gly Ile Phe Arg Cys Asn Gly Gln Asp Asn
 3425 3430 3435

Cys Gly Asp Gly Glu Asp Glu Arg Asp Cys Pro Glu Val Thr Cys
 3440 3445 3450

Ala Pro Asn Gln Phe Gln Cys Ser Ile Thr Lys Arg Cys Ile Pro
 3455 3460 3465

Arg Val Trp Val Cys Asp Arg Asp Asn Asp Cys Val Asp Gly Ser
 3470 3475 3480

Asp Glu Pro Ala Asn Cys Thr Gln Met Thr Cys Gly Val Asp Glu
 3485 3490 3495

Phe Arg Cys Lys Asp Ser Gly Arg Cys Ile Pro Ala Arg Trp Lys
 3500 3505 3510

Asp Gly Glu Asp Asp Cys Gly Asp Gly Ser Asp Glu Pro Lys
 3515 3520 3525

Glu Glu Cys Asp Glu Arg Thr Cys Glu Pro Tyr Gln Phe Arg Cys
 3530 3535 3540

Lys Asn Asn Arg Cys Val Pro Gly Arg Trp Gln Cys Asp Tyr Asp
 3545 3550 3555

Asn Asp Cys Gly Asp Asn Ser Asp Glu Glu Ser Cys Thr Pro Arg
 3560 3565 3570

Pro Cys Ser Glu Ser Glu Phe Ser Cys Ala Asn Gly Arg Cys Ile
 3575 3580 3585

Ala Gly Arg Trp Lys Cys Asp Gly Asp His Asp Cys Ala Asp Gly
 3590 3595 3600

Ser Asp Glu Lys Asp Cys Thr Pro Arg Cys Asp Met Asp Gln Phe
 3605 3610 3615

Gln Cys Lys Ser Gly His Cys Ile Pro Leu Arg Trp Arg Cys Asp
 3620 3625 3630

Ala Asp Ala Asp Cys Met Asp Gly Ser Asp Glu Glu Ala Cys Gly
 3635 3640 3645

Thr Gly Val Arg Thr Cys Pro Leu Asp Glu Phe Gln Cys Asn Asn
 3650 3655 3660

Thr Leu Cys Lys Pro Leu Ala Trp Lys Cys Asp Gly Glu Asp Asp
 3665 3670 3675

Cys Gly Asp Asn Ser Asp Glu Asn Pro Glu Glu Cys Ala Arg Phe
 3680 3685 3690

Val Cys Pro Pro Asn Arg Pro Phe Arg Cys Lys Asn Asp Arg Val
 3695 3700 3705

Cys Leu Trp Ile Gly Arg Gln Cys Asp Gly Thr Asp Asn Cys Gly
 3710 3715 3720

Asp Gly Thr Asp Glu Glu Asp Cys Glu Pro Pro Thr Ala His Thr
 3725 3730 3735

Thr His Cys Lys Asp Lys Lys Glu Phe Leu Cys Arg Asn Gln Arg
 3740 3745 3750

Cys Leu Ser Ser Ser Leu Arg Cys Asn Met Phe Asp Asp Cys Gly
 3755 3760 3765

Asp Gly Ser Asp Glu Glu Asp Cys Ser Ile Asp Pro Lys Leu Thr
 3770 3775 3780

Ser Cys Ala Thr Asn Ala Ser Ile Cys Gly Asp Glu Ala Arg Cys
 3785 3790 3795

Val Arg Thr Glu Lys Ala Ala Tyr Cys Ala Cys Arg Ser Gly Phe
 3800 3805 3810

His Thr Val Pro Gly Gln Pro Gly Cys Gln Asp Ile Asn Glu Cys
 3815 3820 3825

Leu Arg Phe Gly Thr Cys Ser Gln Leu Cys Asn Asn Thr Lys Gly
 3830 3835 3840

Gly His Leu Cys Ser Cys Ala Arg Asn Phe Met Lys Thr His Asn
 3845 3850 3855

Thr Cys Lys Ala Glu Gly Ser Glu Tyr Gln Val Leu Tyr Ile Ala
 3860 3865 3870

Asp Asp Asn Glu Ile Arg Ser Leu Phe Pro Gly His Pro His Ser
 3875 3880 3885

Ala Tyr Glu Gln Ala Phe Gln Gly Asp Glu Ser Val Arg Ile Asp
 3890 3895 3900

Ala Met Asp Val His Val Lys Ala Gly Arg Val Tyr Trp Thr Asn
 3905 3910 3915

Trp His Thr Gly Thr Ile Ser Tyr Arg Ser Leu Pro Pro Ala Ala
 3920 3925 3930

Pro Pro Thr Thr Ser Asn Arg His Arg Arg Gln Ile Asp Arg Gly
 3935 3940 3945

Val Thr His Leu Asn Ile Ser Gly Leu Lys Met Pro Arg Gly Ile
 3950 3955 3960

Ala Ile Asp Trp Val Ala Gly Asn Val Tyr Trp Thr Asp Ser Gly
 3965 3970 3975

Arg Asp Val Ile Glu Val Ala Gln Met Lys Gly Glu Asn Arg Lys
 3980 3985 3990

Thr Leu Ile Ser Gly Met Ile Asp Glu Pro His Ala Ile Val Val
 3995 4000 4005

Asp Pro Leu Arg Gly Thr Met Tyr Trp Ser Asp Trp Gly Asn His
 4010 4015 4020

Pro Lys Ile Glu Thr Ala Ala Met Asp Gly Thr Leu Arg Glu Thr
 4025 4030 4035

Leu Val Gln Asp Asn Ile Gln Trp Pro Thr Gly Leu Ala Val Asp
 4040 4045 4050

Tyr His Asn Glu Arg Leu Tyr Trp Ala Asp Ala Lys Leu Ser Val
 4055 4060 4065

Ile Gly Ser Ile Arg Leu Asn Gly Thr Asp Pro Ile Val Ala Ala
 4070 4075 4080

Asp Ser Lys Arg Gly Leu Ser His Pro Phe Ser Ile Asp Val Phe
 4085 4090 4095

Glu Asp Tyr Ile Tyr Gly Val Thr Tyr Ile Asn Asn Arg Val Phe
 4100 4105 4110

Lys Ile His Lys Phe Gly His Ser Pro Leu Val Asn Leu Thr Gly
 4115 4120 4125

Gly Leu Ser His Ala Ser Asp Val Val Leu Tyr His Gln His Lys
 4130 4135 4140

Gln Pro Glu Val Thr Asn Pro Cys Asp Arg Lys Lys Cys Glu Trp
 4145 4150 4155

Leu Cys Leu Leu Ser Pro Ser Gly Pro Val Cys Thr Cys Pro Asn
 4160 4165 4170

Gly Lys Arg Leu Asp Asn Gly Thr Cys Val Pro Val Pro Ser Pro
 4175 4180 4185

Thr Pro Pro Pro Asp Ala Pro Arg Pro Gly Thr Cys Asn Leu Gln
 4190 4195 4200

Cys Phe Asn Gly Gly Ser Cys Phe Leu Asn Ala Arg Arg Gln Pro
 4205 4210 4215

Lys Cys Arg Cys Gln Pro Arg Tyr Thr Gly Asp Lys Cys Glu Leu
 4220 4225 4230

Asp Gln Cys Trp Glu His Cys Arg Asn Gly Gly Thr Cys Ala Ala
 4235 4240 4245

Ser Pro Ser Gly Met Pro Thr Cys Arg Cys Pro Thr Gly Phe Thr
 4250 4255 4260

Gly Pro Lys Cys Thr Gln Gln Val Cys Ala Gly Tyr Cys Ala Asn
4265 4270 4275

Asn Ser Thr Cys Thr Val Asn Gln Gly Asn Gln Pro Gln Cys Arg
4280 4285 4290

Cys Leu Pro Gly Phe Leu Gly Asp Arg Cys Gln Tyr Arg Gln Cys
4295 4300 4305

Ser Gly Tyr Cys Glu Asn Phe Gly Thr Cys Gln Met Ala Ala Asp
4310 4315 4320

Gly Ser Arg Gln Cys Arg Cys Thr Ala Tyr Phe Glu Gly Ser Arg
4325 4330 4335

Cys Glu Val Asn Lys Cys Ser Arg Cys Leu Glu Gly Ala Cys Val
4340 4345 4350

Val Asn Lys Gln Ser Gly Asp Val Thr Cys Asn Cys Thr Asp Gly
4355 4360 4365

Arg Val Ala Pro Ser Cys Leu Thr Cys Val Gly His Cys Ser Asn
4370 4375 4380

Gly Gly Ser Cys Thr Met Asn Ser Lys Met Met Pro Glu Cys Gln
4385 4390 4395

Cys Pro Pro His Met Thr Gly Pro Arg Cys Glu Glu His Val Phe
4400 4405 4410

Ser Gln Gln Gln Pro Gly Gly Gly Arg Leu Val Pro Arg Gly Ser
4415 4420 4425

Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ile Glu Gly His Val Gly
4430 4435 4440

Leu Asn Asp Ile Phe Glu Ala Gln Lys Ile Glu Trp His Glu Gly
4445 4450 4455

His His His His His His
4460

<210> 11
<211> 4419
<212> PRT
<213> H. sapiens

<400> 11

Met Leu Thr Pro Pro Leu Leu Leu Leu Leu Pro Leu Leu Ser Ala Leu
 1 5 10 15

Val Ala Ala Ala Ile Asp Ala Pro Lys Thr Cys Ser Pro Lys Gln Phe
 20 25 30

Ala Cys Arg Asp Gln Ile Thr Cys Ile Ser Lys Gly Trp Arg Cys Asp
 35 40 45

Gly Glu Arg Asp Cys Pro Asp Gly Ser Asp Glu Ala Pro Glu Ile Cys
 50 55 60

Pro Gln Ser Lys Ala Gln Arg Cys Gln Pro Asn Glu His Asn Cys Leu
 65 70 75 80

Gly Thr Glu Leu Cys Val Pro Met Ser Arg Leu Cys Asn Gly Val Gln
 85 90 95

Asp Cys Met Asp Gly Ser Asp Glu Gly Pro His Cys Arg Glu Leu Gln
 100 105 110

Gly Asn Cys Ser Arg Leu Gly Cys Gln His His Cys Val Pro Thr Leu
 115 120 125

Asp Gly Pro Thr Cys Tyr Cys Asn Ser Ser Phe Gln Leu Gln Ala Asp
 130 135 140

Gly Lys Thr Cys Lys Asp Phe Asp Glu Cys Ser Val Tyr Gly Thr Cys
 145 150 155 160

Ser Gln Leu Cys Thr Asn Thr Asp Gly Ser Phe Ile Cys Gly Cys Val
 165 170 175

Glu Gly Tyr Leu Leu Gln Pro Asp Asn Arg Ser Cys Lys Ala Lys Asn
 180 185 190

Glu Pro Val Asp Arg Pro Pro Val Leu Leu Ile Ala Asn Ser Gln Asn
 195 200 205

Ile Leu Ala Thr Tyr Leu Ser Gly Ala Gln Val Ser Thr Ile Thr Pro
 210 215 220

Thr Ser Thr Arg Gln Thr Thr Ala Met Asp Phe Ser Tyr Ala Asn Glu
 225 230 235 240

Thr Val Cys Trp Val His Val Gly Asp Ser Ala Ala Gln Thr Gln Leu
245 250 255

Lys Cys Ala Arg Met Pro Gly Leu Lys Gly Phe Val Asp Glu His Thr
260 265 270

Ile Asn Ile Ser Leu Ser Leu His His Val Glu Gln Met Ala Ile Asp
275 280 285

Trp Leu Thr Gly Asn Phe Tyr Phe Val Asp Asp Ile Asp Asp Arg Ile
290 295 300

Phe Val Cys Asn Arg Asn Gly Asp Thr Cys Val Thr Leu Leu Asp Leu
305 310 315 320

Glu Leu Tyr Asn Pro Lys Gly Ile Ala Leu Asp Pro Ala Met Gly Lys
325 330 335

Val Phe Phe Thr Asp Tyr Gly Gln Ile Pro Lys Val Glu Arg Cys Asp
340 345 350

Met Asp Gly Gln Asn Arg Thr Lys Leu Val Asp Ser Lys Ile Val Phe
355 360 365

Pro His Gly Ile Thr Leu Asp Leu Val Ser Arg Leu Val Tyr Trp Ala
370 375 380

Asp Ala Tyr Leu Asp Tyr Ile Glu Val Val Asp Tyr Glu Gly Lys Gly
385 390 395 400

Gln Thr Ile Ile Gln Gly Ile Leu Ile Glu His Leu Tyr Gly Leu
405 410 415

Thr Val Phe Glu Asn Tyr Leu Tyr Ala Thr Asn Ser Asp Asn Ala Asn
420 425 430

Ala Gln Gln Lys Thr Ser Val Ile Arg Val Asn Arg Phe Asn Ser Thr
435 440 445

Glu Tyr Gln Val Val Thr Arg Val Asp Lys Gly Gly Ala Leu His Ile
450 455 460

Tyr His Gln Arg Arg Gln Pro Arg Val Arg Ser His Ala Cys Glu Asn
465 470 475 480

Asp Gln Tyr Gly Lys Pro Gly Gly Cys Ser Asp Ile Cys Leu Leu Ala
 485 490 495

Asn Ser His Lys Ala Arg Thr Cys Arg Cys Arg Ser Gly Phe Ser Leu
 500 505 510

Gly Ser Asp Gly Lys Ser Cys Lys Lys Pro Glu His Glu Leu Phe Leu
 515 520 525

Val Tyr Gly Lys Gly Arg Pro Gly Ile Ile Arg Gly Met Asp Met Gly
 530 535 540

Ala Lys Val Pro Asp Glu His Met Ile Pro Ile Glu Asn Leu Met Asn
 545 550 555 560

Pro Arg Ala Leu Asp Phe His Ala Glu Thr Gly Phe Ile Tyr Phe Ala
 565 570 575

Asp Thr Thr Ser Tyr Leu Ile Gly Arg Gln Lys Ile Asp Gly Thr Glu
 580 585 590

Arg Glu Thr Ile Leu Lys Asp Gly Ile His Asn Val Glu Gly Val Ala
 595 600 605

Val Asp Trp Met Gly Asp Asn Leu Tyr Trp Thr Asp Asp Gly Pro Lys
 610 615 620

Lys Thr Ile Ser Val Ala Arg Leu Glu Lys Ala Ala Gln Thr Arg Lys
 625 630 635 640

Thr Leu Ile Glu Gly Lys Met Thr His Pro Arg Ala Ile Val Val Asp
 645 650 655

Pro Leu Asn Gly Trp Met Tyr Trp Thr Asp Trp Glu Glu Asp Pro Lys
 660 665 670

Asp Ser Arg Arg Gly Arg Leu Glu Arg Ala Trp Met Asp Gly Ser His
 675 680 685

Arg Asp Ile Phe Val Thr Ser Lys Thr Val Leu Trp Pro Asn Gly Leu
 690 695 700

Ser Leu Asp Ile Pro Ala Gly Arg Leu Tyr Trp Val Asp Ala Phe Tyr
 705 710 715 720

Asp Arg Ile Glu Thr Ile Leu Leu Asn Gly Thr Asp Arg Lys Ile Val
 725 730 735

Tyr Glu Gly Pro Glu Leu Asn His Ala Phe Gly Leu Cys His His Gly
 740 745 750

Asn Tyr Leu Phe Trp Thr Glu Tyr Arg Ser Gly Ser Val Tyr Arg Leu
 755 760 765

Glu Arg Gly Val Gly Gly Ala Pro Pro Thr Val Thr Leu Leu Arg Ser
 770 775 780

Glu Arg Pro Pro Ile Phe Glu Ile Arg Met Tyr Asp Ala Gln Gln Gln
 785 790 795 800

Gln Val Gly Thr Asn Lys Cys Arg Val Asn Asn Gly Gly Cys Ser Ser
 805 810 815

Leu Cys Leu Ala Thr Pro Gly Ser Arg Gln Cys Ala Cys Ala Glu Asp
 820 825 830

Gln Val Leu Asp Ala Asp Gly Val Thr Cys Leu Ala Asn Pro Ser Tyr
 835 840 845

Val Pro Pro Pro Gln Cys Gln Pro Gly Glu Phe Ala Cys Ala Asn Ser
 850 855 860

Arg Cys Ile Gln Glu Arg Trp Lys Cys Asp Gly Asp Asn Asp Cys Leu
 865 870 875 880

Asp Asn Ser Asp Glu Ala Pro Ala Leu Cys His Gln His Thr Cys Pro
 885 890 895

Ser Asp Arg Phe Lys Cys Glu Asn Asn Arg Cys Ile Pro Asn Arg Trp
 900 905 910

Leu Cys Asp Gly Asp Asn Asp Cys Gly Asn Ser Glu Asp Glu Ser Asn
 915 920 925

Ala Thr Cys Ser Ala Arg Thr Cys Pro Pro Asn Gln Phe Ser Cys Ala
 930 935 940

Ser Gly Arg Cys Ile Pro Ile Ser Trp Thr Cys Asp Leu Asp Asp Asp
 945 950 955 960

Cys Gly Asp Arg Ser Asp Glu Ser Ala Ser Cys Ala Tyr Pro Thr Cys
 965 970 975

Phe Pro Leu Thr Gln Phe Thr Cys Asn Asn Gly Arg Cys Ile Asn Ile
 980 985 990

Asn Trp Arg Cys Asp Asn Asp Asn Asp Cys Gly Asp Asn Ser Asp Glu
 995 1000 1005

Ala Gly Cys Ser His Ser Cys Ser Ser Thr Gln Phe Lys Cys Asn
 1010 1015 1020

Ser Gly Arg Cys Ile Pro Glu His Trp Thr Cys Asp Gly Asp Asn
 1025 1030 1035

Asp Cys Gly Asp Tyr Ser Asp Glu Thr His Ala Asn Cys Thr Asn
 1040 1045 1050

Gln Ala Thr Arg Pro Pro Gly Gly Cys His Thr Asp Glu Phe Gln
 1055 1060 1065

Cys Arg Leu Asp Gly Leu Cys Ile Pro Leu Arg Trp Arg Cys Asp
 1070 1075 1080

Gly Asp Thr Asp Cys Met Asp Ser Ser Asp Glu Lys Ser Cys Glu
 1085 1090 1095

Gly Val Thr His Val Cys Asp Pro Ser Val Lys Phe Gly Cys Lys
 1100 1105 1110

Asp Ser Ala Arg Cys Ile Ser Lys Ala Trp Val Cys Asp Gly Asp
 1115 1120 1125

Asn Asp Cys Glu Asp Asn Ser Asp Glu Glu Asn Cys Glu Ser Leu
 1130 1135 1140

Ala Cys Arg Pro Pro Ser His Pro Cys Ala Asn Asn Thr Ser Val
 1145 1150 1155

Cys Leu Pro Pro Asp Lys Leu Cys Asp Gly Asn Asp Asp Cys Gly
 1160 1165 1170

Asp Gly Ser Asp Glu Gly Glu Leu Cys Asp Gln Cys Ser Leu Asn
 1175 1180 1185

Asn Gly	Gly Cys Ser His	Asn Cys Ser Val Ala Pro	Gly Glu Gly
1190		1195	1200
Ile Val	Cys Ser Cys Pro Leu	Gly Met Glu Leu Gly	Pro Asp Asn
1205		1210	1215
His Thr	Cys Gln Ile Gln Ser	Tyr Cys Ala Lys His	Leu Lys Cys
1220		1225	1230
Ser Gln	Lys Cys Asp Gln Asn	Lys Phe Ser Val Lys	Cys Ser Cys
1235		1240	1245
Tyr Glu	Gly Trp Val Leu Glu	Pro Asp Gly Glu Ser	Cys Arg Ser
1250		1255	1260
Leu Asp	Pro Phe Lys Pro Phe	Ile Ile Phe Ser Asn	Arg His Glu
1265		1270	1275
Ile Arg	Arg Ile Asp Leu His	Lys Gly Asp Tyr Ser	Val Leu Val
1280		1285	1290
Pro Gly	Leu Arg Asn Thr Ile	Ala Leu Asp Phe His	Leu Ser Gln
1295		1300	1305
Ser Ala	Leu Tyr Trp Thr Asp	Val Val Glu Asp Lys	Ile Tyr Arg
1310		1315	1320
Gly Lys	Leu Leu Asp Asn Gly	Ala Leu Thr Ser Phe	Glu Val Val
1325		1330	1335
e Gln	Tyr Gly Leu Ala Thr	Pro Glu Gly Leu Ala	Val Asp Trp
1340		1345	1350
Ile Ala	Gly Asn Ile Tyr Trp	Val Glu Ser Asn Leu	Asp Gln Ile
1355		1360	1365
Glu Val	Ala Lys Leu Asp Gly	Thr Leu Arg Thr Thr	Leu Leu Ala
1370		1375	1380
Gly Asp	Ile Glu His Pro Arg	Ala Ile Ala Leu Asp	Pro Arg Asp
1385		1390	1395
Gly Ile	Leu Phe Trp Thr Asp	Trp Asp Ala Ser Leu	Pro Arg Ile
1400		1405	1410

Glu Ala Ala Ser Met Ser Gly Ala Gly Arg Arg Thr Val His Arg
 1415 1420 1425

Glu Thr Gly Ser Gly Gly Trp Pro Asn Gly Leu Thr Val Asp Tyr
 1430 1435 1440

Leu Glu Lys Arg Ile Leu Trp Ile Asp Ala Arg Ser Asp Ala Ile
 1445 1450 1455

Tyr Ser Ala Arg Tyr Asp Gly Ser Gly His Met Glu Val Leu Arg
 1460 1465 1470

Gly His Glu Phe Leu Ser His Pro Phe Ala Val Thr Leu Tyr Gly
 1475 1480 1485

Gly Glu Val Tyr Trp Thr Asp Trp Arg Thr Asn Thr Leu Ala Lys
 1490 1495 1500

Ala Asn Lys Trp Thr Gly His Asn Val Thr Val Val Gln Arg Thr
 1505 1510 1515

Asn Thr Gln Pro Phe Asp Leu Gln Val Tyr His Pro Ser Arg Gln
 1520 1525 1530

Pro Met Ala Pro Asn Pro Cys Glu Ala Asn Gly Gly Gln Gly Pro
 1535 1540 1545

Cys Ser His Leu Cys Leu Ile Asn Tyr Asn Arg Thr Val Ser Cys
 1550 1555 1560

Ala Cys Pro His Leu Met Lys Leu His Lys Asp Asn Thr Thr Cys
 1565 1570 1575

Tyr Glu Phe Lys Lys Phe Leu Leu Tyr Ala Arg Gln Met Glu Ile
 1580 1585 1590

Arg Gly Val Asp Leu Asp Ala Pro Tyr Tyr Asn Tyr Ile Ile Ser
 1595 1600 1605

Phe Thr Val Pro Asp Ile Asp Asn Val Thr Val Leu Asp Tyr Asp
 1610 1615 1620

Ala Arg Glu Gln Arg Val Tyr Trp Ser Asp Val Arg Thr Gln Ala
 1625 1630 1635

Ile Lys	Arg Ala Phe Ile	Asn Gly Thr Gly Val	Glu Thr Val Val
1640		1645	1650
Ser Ala	Asp Leu Pro Asn Ala	His Gly Leu Ala Val	Asp Trp Val
1655		1660	1665
Ser Arg	Asn Leu Phe Trp Thr	Ser Tyr Asp Thr Asn	Lys Lys Gln
1670		1675	1680
Ile Asn	Val Ala Arg Leu Asp	Gly Ser Phe Lys Asn	Ala Val Val
1685		1690	1695
Gln Gly	Leu Glu Gln Pro His	Gly Leu Val Val His	Pro Leu Arg
1700		1705	1710
Gly Lys	Leu Tyr Trp Thr Asp	Gly Asp Asn Ile Ser	Met Ala Asn
1715		1720	1725
Met Asp	Gly Ser Asn Arg Thr	Leu Leu Phe Ser Gly	Gln Lys Gly
1730		1735	1740
Pro Val	Gly Leu Ala Ile Asp	Phe Pro Glu Ser Lys	Leu Tyr Trp
1745		1750	1755
Ile Ser	Ser Gly Asn His Thr	Ile Asn Arg Cys Asn	Leu Asp Gly
1760		1765	1770
Ser Gly	Leu Glu Val Ile Asp	Ala Met Arg Ser Gln	Leu Gly Lys
1775		1780	1785
Ala Thr	Ala Leu Ala Ile Met	Gly Asp Lys Leu Trp	Trp Ala Asp
1790		1795	1800
Gln Val	Ser Glu Lys Met Gly	Thr Cys Ser Lys Ala	Asp Gly Ser
1805		1810	1815
Gly Ser	Val Val Leu Arg Asn	Ser Thr Thr Leu Val	Met His Met
1820		1825	1830
Lys Val	Tyr Asp Glu Ser Ile	Gln Leu Asp His Lys	Gly Thr Asn
1835		1840	1845
Pro Cys	Ser Val Asn Asn Gly	Asp Cys Ser Gln Leu	Cys Leu Pro
1850		1855	1860

Thr Ser Glu Thr Thr Arg Ser Cys Met Cys Thr Ala Gly Tyr Ser
 1865 1870 1875

Leu Arg Ser Gly Gln Gln Ala Cys Glu Gly Val Gly Ser Phe Leu
 1880 1885 1890

Leu Tyr Ser Val His Glu Gly Ile Arg Gly Ile Pro Leu Asp Pro
 1895 1900 1905

Asn Asp Lys Ser Asp Ala Leu Val Pro Val Ser Gly Thr Ser Leu
 1910 1915 1920

Ala Val Gly Ile Asp Phe His Ala Glu Asn Asp Thr Ile Tyr Trp
 1925 1930 1935

Val Asp Met Gly Leu Ser Thr Ile Ser Arg Ala Lys Arg Asp Gln
 1940 1945 1950

Thr Trp Arg Glu Asp Val Val Thr Asn Gly Ile Gly Arg Val Glu
 1955 1960 1965

Gly Ile Ala Val Asp Trp Ile Ala Gly Asn Ile Tyr Trp Thr Asp
 1970 1975 1980

Gln Gly Phe Asp Val Ile Glu Val Ala Arg Leu Asn Gly Ser Phe
 1985 1990 1995

Arg Tyr Val Val Ile Ser Gln Gly Leu Asp Lys Pro Arg Ala Ile
 2000 2005 2010

Thr Val His Pro Glu Lys Gly Tyr Leu Phe Trp Thr Glu Trp Gly
 2015 2020 2025

Gln Tyr Pro Arg Ile Glu Arg Ser Arg Leu Asp Gly Thr Glu Arg
 2030 2035 2040

Val Val Leu Val Asn Val Ser Ile Ser Trp Pro Asn Gly Ile Ser
 2045 2050 2055

Val Asp Tyr Gln Asp Gly Lys Leu Tyr Trp Cys Asp Ala Arg Thr
 2060 2065 2070

Asp Lys Ile Glu Arg Ile Asp Leu Glu Thr Gly Glu Asn Arg Glu
 2075 2080 2085

Val	Val	Leu	Ser	Ser	Asn	Asn	Met	Asp	Met	Phe	Ser	Val	Ser	Val
2090						2095					2100			
Phe	Glu	Asp	Phe	Ile	Tyr	Trp	Ser	Asp	Arg	Thr	His	Ala	Asn	Gly
2105						2110					2115			
Ser	Ile	Lys	Arg	Gly	Ser	Lys	Asp	Asn	Ala	Thr	Asp	Ser	Val	Pro
2120						2125					2130			
Leu	Arg	Thr	Gly	Ile	Gly	Val	Gln	Leu	Lys	Asp	Ile	Lys	Val	Phe
2135						2140					2145			
Asn	Arg	Asp	Arg	Gln	Lys	Gly	Thr	Asn	Val	Cys	Ala	Val	Ala	Asn
2150						2155					2160			
Gly	Gly	Cys	Gln	Gln	Leu	Cys	Leu	Tyr	Arg	Gly	Arg	Gly	Gln	Arg
2165						2170					2175			
Ala	Cys	Ala	Cys	Ala	His	Gly	Met	Leu	Ala	Glu	Asp	Gly	Ala	Ser
2180						2185					2190			
Cys	Arg	Glu	Tyr	Ala	Gly	Tyr	Leu	Leu	Tyr	Ser	Glu	Arg	Thr	Ile
2195						2200					2205			
Leu	Lys	Ser	Ile	His	Leu	Ser	Asp	Glu	Arg	Asn	Leu	Asn	Ala	Pro
2210						2215					2220			
Val	Gln	Pro	Phe	Glu	Asp	Pro	Glu	His	Met	Lys	Asn	Val	Ile	Ala
2225						2230					2235			
Leu	Ala	Phe	Asp	Tyr	Arg	Ala	Gly	Thr	Ser	Pro	Gly	Thr	Pro	Asn
2240						2245					2250			
Arg	Ile	Phe	Phe	Ser	Asp	Ile	His	Phe	Gly	Asn	Ile	Gln	Gln	Ile
2255						2260					2265			
Asn	Asp	Asp	Gly	Ser	Arg	Arg	Ile	Thr	Ile	Val	Glu	Asn	Val	Gly
2270						2275					2280			
Ser	Val	Glu	Gly	Leu	Ala	Tyr	His	Arg	Gly	Trp	Asp	Thr	Leu	Tyr
2285						2290					2295			
Trp	Thr	Ser	Tyr	Thr	Thr	Ser	Thr	Ile	Thr	Arg	His	Thr	Val	Asp
2300						2305					2310			

Gln Thr Arg Pro Gly Ala Phe Glu Arg Glu Thr Val Ile Thr Met
 2315 2320 2325

Ser Gly Asp Asp His Pro Arg Ala Phe Val Leu Asp Glu Cys Gln
 2330 2335 2340

Asn Leu Met Phe Trp Thr Asn Trp Asn Glu Gln His Pro Ser Ile
 2345 2350 2355

Met Arg Ala Ala Leu Ser Gly Ala Asn Val Leu Thr Leu Ile Glu
 2360 2365 2370

Lys Asp Ile Arg Thr Pro Asn Gly Leu Ala Ile Asp His Arg Ala
 2375 2380 2385

Glu Lys Leu Tyr Phe Ser Asp Ala Thr Leu Asp Lys Ile Glu Arg
 2390 2395 2400

Cys Glu Tyr Asp Gly Ser His Arg Tyr Val Ile Leu Lys Ser Glu
 2405 2410 2415

Pro Val His Pro Phe Gly Leu Ala Val Tyr Gly Glu His Ile Phe
 2420 2425 2430

Trp Thr Asp Trp Val Arg Arg Ala Val Gln Arg Ala Asn Lys His
 2435 2440 2445

Val Gly Ser Asn Met Lys Leu Leu Arg Val Asp Ile Pro Gln Gln
 2450 2455 2460

Pro Met Gly Ile Ile Ala Val Ala Asn Asp Thr Asn Ser Cys Glu
 2465 2470 2475

Leu Ser Pro Cys Arg Ile Asn Asn Gly Gly Cys Gln Asp Leu Cys
 2480 2485 2490

Leu Leu Thr His Gln Gly His Val Asn Cys Ser Cys Arg Gly Gly
 2495 2500 2505

Arg Ile Leu Gln Asp Asp Leu Thr Cys Arg Ala Val Asn Ser Ser
 2510 2515 2520

Cys Arg Ala Gln Asp Glu Phe Glu Cys Ala Asn Gly Glu Cys Ile
 2525 2530 2535

Asn Phe Ser Leu Thr Cys Asp Gly Val Pro His Cys Lys Asp Lys
2540 2545 2550

Ser Asp Glu Lys Pro Ser Tyr Cys Asn Ser Arg Arg Cys Lys Lys
2555 2560 2565

Thr Phe Arg Gln Cys Ser Asn Gly Arg Cys Val Ser Asn Met Leu
2570 2575 2580

Trp Cys Asn Gly Ala Asp Asp Cys Gly Asp Gly Ser Asp Glu Ile
2585 2590 2595

Pro Cys Asn Lys Thr Ala Cys Gly Val Gly Glu Phe Arg Cys Arg
2600 2605 2610

Asp Gly Thr Cys Ile Gly Asn Ser Ser Arg Cys Asn Gln Phe Val
2615 2620 2625

Asp Cys Glu Asp Ala Ser Asp Glu Met Asn Cys Ser Ala Thr Asp
2630 2635 2640

Cys Ser Ser Tyr Phe Arg Leu Gly Val Lys Gly Val Leu Phe Gln
2645 2650 2655

Pro Cys Glu Arg Thr Ser Leu Cys Tyr Ala Pro Ser Trp Val Cys
2660 2665 2670

Asp Gly Ala Asn Asp Cys Gly Asp Tyr Ser Asp Glu Arg Asp Cys
2675 2680 2685

Pro Gly Val Lys Arg Pro Arg Cys Pro Leu Asn Tyr Phe Ala Cys
2690 2695 2700

Pro Ser Gly Arg Cys Ile Pro Met Ser Trp Thr Cys Asp Lys Glu
2705 2710 2715

Asp Asp Cys Glu His Gly Glu Asp Glu Thr His Cys Asn Lys Phe
2720 2725 2730

Cys Ser Glu Ala Gln Phe Glu Cys Gln Asn His Arg Cys Ile Ser
2735 2740 2745

Lys Gln Trp Leu Cys Asp Gly Ser Asp Asp Cys Gly Asp Gly Ser
2750 2755 2760

Asp Glu Ala Ala His Cys Glu Gly Lys Thr Cys Gly Pro Ser Ser
 2765 2770 2775

Phe Ser Cys Pro Gly Thr His Val Cys Val Pro Glu Arg Trp Leu
 2780 2785 2790

Cys Asp Gly Asp Lys Asp Cys Ala Asp Gly Ala Asp Glu Ser Ile
 2795 2800 2805

Ala Ala Gly Cys Leu Tyr Asn Ser Thr Cys Asp Asp Arg Glu Phe
 2810 2815 2820

Met Cys Gln Asn Arg Gln Cys Ile Pro Lys His Phe Val Cys Asp
 2825 2830 2835

His Asp Arg Asp Cys Ala Asp Gly Ser Asp Glu Ser Pro Glu Cys
 2840 2845 2850

Glu Tyr Pro Thr Cys Gly Pro Ser Glu Phe Arg Cys Ala Asn Gly
 2855 2860 2865

Arg Cys Leu Ser Ser Arg Gln Trp Glu Cys Asp Gly Glu Asn Asp
 2870 2875 2880

Cys His Asp Gln Ser Asp Glu Ala Pro Lys Asn Pro His Cys Thr
 2885 2890 2895

Ser Pro Glu His Lys Cys Asn Ala Ser Ser Gln Phe Leu Cys Ser
 2900 2905 2910

Ser Gly Arg Cys Val Ala Glu Ala Leu Leu Cys Asn Gly Gln Asp
 2915 2920 2925

Asp Cys Gly Asp Ser Ser Asp Glu Arg Gly Cys His Ile Asn Glu
 2930 2935 2940

Cys Leu Ser Arg Lys Leu Ser Gly Cys Ser Gln Asp Cys Glu Asp
 2945 2950 2955

Leu Lys Ile Gly Phe Lys Cys Arg Cys Arg Pro Gly Phe Arg Leu
 2960 2965 2970

Lys Asp Asp Gly Arg Thr Cys Ala Asp Val Asp Glu Cys Ser Thr
 2975 2980 2985

Thr Phe Pro Cys Ser Gln Arg Cys Ile Asn Thr His Gly Ser Tyr
 2990 2995 3000

Lys Cys Leu Cys Val Glu Gly Tyr Ala Pro Arg Gly Gly Asp Pro
 3005 3010 3015

His Ser Cys Lys Ala Val Thr Asp Glu Glu Pro Phe Leu Ile Phe
 3020 3025 3030

Ala Asn Arg Tyr Tyr Leu Arg Lys Leu Asn Leu Asp Gly Ser Asn
 3035 3040 3045

Tyr Thr Leu Leu Lys Gln Gly Leu Asn Asn Ala Val Ala Leu Asp
 3050 3055 3060

Phe Asp Tyr Arg Glu Gln Met Ile Tyr Trp Thr Asp Val Thr Thr
 3065 3070 3075

Gln Gly Ser Met Ile Arg Arg Met His Leu Asn Gly Ser Asn Val
 3080 3085 3090

Gln Val Leu His Arg Thr Gly Leu Ser Asn Pro Asp Gly Leu Ala
 3095 3100 3105

Val Asp Trp Val Gly Gly Asn Leu Tyr Trp Cys Asp Lys Gly Arg
 3110 3115 3120

Asp Thr Ile Glu Val Ser Lys Leu Asn Gly Ala Tyr Arg Thr Val
 3125 3130 3135

Leu Val Ser Ser Gly Leu Arg Glu Pro Arg Ala Leu Val Val Asp
 3140 3145 3150

Val Gln Asn Gly Tyr Leu Tyr Trp Thr Asp Trp Gly Asp His Ser
 3155 3160 3165

Leu Ile Gly Arg Ile Gly Met Asp Gly Ser Ser Arg Ser Val Ile
 3170 3175 3180

Val Asp Thr Lys Ile Thr Trp Pro Asn Gly Leu Thr Leu Asp Tyr
 3185 3190 3195

Val Thr Glu Arg Ile Tyr Trp Ala Asp Ala Arg Glu Asp Tyr Ile
 3200 3205 3210

Glu Phe Ala Ser Leu Asp Gly Ser Asn Arg His Val Val Leu Ser
 3215 3220 3225

Gln Asp Ile Pro His Ile Phe Ala Leu Thr Leu Phe Glu Asp Tyr
 3230 3235 3240

Val Tyr Trp Thr Asp Trp Glu Thr Lys Ser Ile Asn Arg Ala His
 3245 3250 3255

Lys Thr Thr Gly Thr Asn Lys Thr Leu Leu Ile Ser Thr Leu His
 3260 3265 3270

Arg Pro Met Asp Leu His Val Phe His Ala Leu Arg Gln Pro Asp
 3275 3280 3285

Val Pro Asn His Pro Cys Lys Val Asn Asn Gly Gly Cys Ser Asn
 3290 3295 3300

Leu Cys Leu Leu Ser Pro Gly Gly Gly His Lys Cys Ala Cys Pro
 3305 3310 3315

Thr Asn Phe Tyr Leu Gly Ser Asp Gly Arg Thr Cys Val Ser Asn
 3320 3325 3330

Cys Thr Ala Ser Gln Phe Val Cys Lys Asn Asp Lys Cys Ile Pro
 3335 3340 3345

Phe Trp Trp Lys Cys Asp Thr Glu Asp Asp Cys Gly Asp His Ser
 3350 3355 3360

Asp Glu Pro Pro Asp Cys Pro Glu Phe Lys Cys Arg Pro Gly Gln
 3365 3370 3375

Phe Gln Cys Ser Thr Gly Ile Cys Thr Asn Pro Ala Phe Ile Cys
 3380 3385 3390

Asp Gly Asp Asn Asp Cys Gln Asp Asn Ser Asp Glu Ala Asn Cys
 3395 3400 3405

Asp Ile His Val Cys Leu Pro Ser Gln Phe Lys Cys Thr Asn Thr
 3410 3415 3420

Asn Arg Cys Ile Pro Gly Ile Phe Arg Cys Asn Gly Gln Asp Asn
 3425 3430 3435

Cys Gly Asp Gly Glu Asp Glu Arg Asp Cys Pro Glu Val Thr Cys
 3440 3445 3450

Ala Pro Asn Gln Phe Gln Cys Ser Ile Thr Lys Arg Cys Ile Pro
 3455 3460 3465

Arg Val Trp Val Cys Asp Arg Asp Asn Asp Cys Val Asp Gly Ser
 3470 3475 3480

Asp Glu Pro Ala Asn Cys Thr Gln Met Thr Cys Gly Val Asp Glu
 3485 3490 3495

Phe Arg Cys Lys Asp Ser Gly Arg Cys Ile Pro Ala Arg Trp Lys
 3500 3505 3510

Cys Asp Gly Glu Asp Asp Cys Gly Asp Gly Ser Asp Glu Pro Lys
 3515 3520 3525

Glu Glu Cys Asp Glu Arg Thr Cys Glu Pro Tyr Gln Phe Arg Cys
 3530 3535 3540

Lys Asn Asn Arg Cys Val Pro Gly Arg Trp Gln Cys Asp Tyr Asp
 3545 3550 3555

Asn Asp Cys Gly Asp Asn Ser Asp Glu Glu Ser Cys Thr Pro Arg
 3560 3565 3570

Pro Cys Ser Glu Ser Glu Phe Ser Cys Ala Asn Gly Arg Cys Ile
 3575 3580 3585

Ala Gly Arg Trp Lys Cys Asp Gly Asp His Asp Cys Ala Asp Gly
 3590 3595 3600

Ser Asp Glu Lys Asp Cys Thr Pro Arg Cys Asp Met Asp Gln Phe
 3605 3610 3615

Gln Cys Lys Ser Gly His Cys Ile Pro Leu Arg Trp Arg Cys Asp
 3620 3625 3630

Ala Asp Ala Asp Cys Met Asp Gly Ser Asp Glu Glu Ala Cys Gly
 3635 3640 3645

Thr Gly Val Arg Thr Cys Pro Leu Asp Glu Phe Gln Cys Asn Asn
 3650 3655 3660

Thr Leu Cys Lys Pro Leu Ala Trp Lys Cys Asp Gly Glu Asp Asp
 3665 3670 3675

Cys Gly Asp Asn Ser Asp Glu Asn Pro Glu Glu Cys Ala Arg Phe
 3680 3685 3690

Val Cys Pro Pro Asn Arg Pro Phe Arg Cys Lys Asn Asp Arg Val
 3695 3700 3705

Cys Leu Trp Ile Gly Arg Gln Cys Asp Gly Thr Asp Asn Cys Gly
 3710 3715 3720

Asp Gly Thr Asp Glu Glu Asp Cys Glu Pro Pro Thr Ala His Thr
 3725 3730 3735

Thr His Cys Lys Asp Lys Lys Glu Phe Leu Cys Arg Asn Gln Arg
 3740 3745 3750

Cys Leu Ser Ser Ser Leu Arg Cys Asn Met Phe Asp Asp Cys Gly
 3755 3760 3765

Asp Gly Ser Asp Glu Glu Asp Cys Ser Ile Asp Pro Lys Leu Thr
 3770 3775 3780

Ser Cys Ala Thr Asn Ala Ser Ile Cys Gly Asp Glu Ala Arg Cys
 3785 3790 3795

Val Arg Thr Glu Lys Ala Ala Tyr Cys Ala Cys Arg Ser Gly Phe
 3800 3805 3810

As Thr Val Pro Gly Gln Pro Gly Cys Gln Asp Ile Asn Glu Cys
 3815 3820 3825

Leu Arg Phe Gly Thr Cys Ser Gln Leu Cys Asn Asn Thr Lys Gly
 3830 3835 3840

Gly His Leu Cys Ser Cys Ala Arg Asn Phe Met Lys Thr His Asn
 3845 3850 3855

Thr Cys Lys Ala Glu Gly Ser Glu Tyr Gln Val Leu Tyr Ile Ala
 3860 3865 3870

Asp Asp Asn Glu Ile Arg Ser Leu Phe Pro Gly His Pro His Ser
 3875 3880 3885

Lys Ile His Lys Phe Gly His Ser Pro Leu Val Asn Leu Thr Gly
4115 4120 4125

Gly Leu Ser His Ala Ser Asp Val Val Leu Tyr His Gln His Lys
4130 4135 4140

Gln Pro Glu Val Thr Asn Pro Cys Asp Arg Lys Lys Cys Glu Trp
4145 4150 4155

Leu Cys Leu Leu Ser Pro Ser Gly Pro Val Cys Thr Cys Pro Asn
4160 4165 4170

Gly Lys Arg Leu Asp Asn Gly Thr Cys Val Pro Val Pro Ser Pro
4175 4180 4185

Thr Pro Pro Pro Asp Ala Pro Arg Pro Gly Thr Cys Asn Leu Gln
4190 4195 4200

Cys Phe Asn Gly Gly Ser Cys Phe Leu Asn Ala Arg Arg Gln Pro
4205 4210 4215

Lys Cys Arg Cys Gln Pro Arg Tyr Thr Gly Asp Lys Cys Glu Leu
4220 4225 4230

Asp Gln Cys Trp Glu His Cys Arg Asn Gly Gly Thr Cys Ala Ala
4235 4240 4245

Ser Pro Ser Gly Met Pro Thr Cys Arg Cys Pro Thr Gly Phe Thr
4250 4255 4260

Gly Pro Lys Cys Thr Gln Gln Val Cys Ala Gly Tyr Cys Ala Asn
4265 4270 4275

Asn Ser Thr Cys Thr Val Asn Gln Gly Asn Gln Pro Gln Cys Arg
4280 4285 4290

Cys Leu Pro Gly Phe Leu Gly Asp Arg Cys Gln Tyr Arg Gln Cys
4295 4300 4305

Ser Gly Tyr Cys Glu Asn Phe Gly Thr Cys Gln Met Ala Ala Asp
4310 4315 4320

Gly Ser Arg Gln Cys Arg Cys Thr Ala Tyr Phe Glu Gly Ser Arg
4325 4330 4335

Cys Glu Val Asn Lys Cys Ser Arg Cys Leu Glu Gly Ala Cys Val
 4340 4345 4350

Val Asn Lys Gln Ser Gly Asp Val Thr Cys Asn Cys Thr Asp Gly
 4355 4360 4365

Arg Val Ala Pro Ser Cys Leu Thr Cys Val Gly His Cys Ser Asn
 4370 4375 4380

Gly Gly Ser Cys Thr Met Asn Ser Lys Met Met Pro Glu Cys Gln
 4385 4390 4395

Cys Pro Pro His Met Thr Gly Pro Arg Cys Glu Glu His Val Phe
 4400 4405 4410

Ser Gln Gln Gln Pro Gly
 4415

<210> 12
 <211> 986
 <212> PRT
 <213> H. sapiens

<400> 12

Met Leu Thr Pro Pro Leu Leu Leu Leu Pro Leu Leu Ser Ala Leu
 1 5 10 15

Val Ala Ala Ala Ile Asp Ala Pro Lys Thr Cys Ser Pro Lys Gln Phe
 20 25 30

Ala Cys Arg Asp Gln Ile Thr Cys Ile Ser Lys Gly Trp Arg Cys Asp
 35 40 45

Gly Glu Arg Asp Cys Pro Asp Gly Ser Asp Glu Ala Pro Glu Ile Cys
 50 55 60

Pro Gln Ser Lys Ala Gln Arg Cys Gln Pro Asn Glu His Asn Cys Leu
 65 70 75 80

Gly Thr Glu Leu Cys Val Pro Met Ser Arg Leu Cys Asn Gly Val Gln
 85 90 95

Asp Cys Met Asp Gly Ser Asp Glu Gly Pro His Cys Arg Glu Leu Gln
 100 105 110

Gly Asn Cys Ser Arg Leu Gly Cys Gln His His Cys Val Pro Thr Leu
 115 120 125

Asp Gly Pro Thr Cys Tyr Cys Asn Ser Ser Phe Gln Leu Gln Ala Asp
 130 135 140

Gly Lys Thr Cys Lys Asp Phe Asp Glu Cys Ser Val Tyr Gly Thr Cys
 145 150 155 160

Ser Gln Leu Cys Thr Asn Thr Asp Gly Ser Phe Ile Cys Gly Cys Val
 165 170 175

Glu Gly Tyr Leu Leu Gln Pro Asp Asn Arg Ser Cys Lys Ala Lys Asn
 180 185 190

Glu Pro Val Asp Arg Pro Pro Val Leu Leu Ile Ala Asn Ser Gln Asn
 195 200 205

Ile Leu Ala Thr Tyr Leu Ser Gly Ala Gln Val Ser Thr Ile Thr Pro
 210 215 220

Thr Ser Thr Arg Gln Thr Thr Ala Met Asp Phe Ser Tyr Ala Asn Glu
 225 230 235 240

Thr Val Cys Trp Val His Val Gly Asp Ser Ala Ala Gln Thr Gln Leu
 245 250 255

Lys Cys Ala Arg Met Pro Gly Leu Lys Gly Phe Val Asp Glu His Thr
 260 265 270

Ile Asn Ile Ser Leu Ser Leu His His Val Glu Gln Met Ala Ile Asp
 275 280 285

Trp Leu Thr Gly Asn Phe Tyr Phe Val Asp Asp Ile Asp Asp Arg Ile
 290 295 300

Phe Val Cys Asn Arg Asn Gly Asp Thr Cys Val Thr Leu Leu Asp Leu
 305 310 315 320

Glu Leu Tyr Asn Pro Lys Gly Ile Ala Leu Asp Pro Ala Met Gly Lys
 325 330 335

Val Phe Phe Thr Asp Tyr Gly Gln Ile Pro Lys Val Glu Arg Cys Asp
 340 345 350

Met Asp Gly Gln Asn Arg Thr Lys Leu Val Asp Ser Lys Ile Val Phe
 355 360 365

Pro His Gly Ile Thr Leu Asp Leu Val Ser Arg Leu Val Tyr Trp Ala
 370 375 380

Asp Ala Tyr Leu Asp Tyr Ile Glu Val Val Asp Tyr Glu Gly Lys Gly
 385 390 395 400

Arg Gln Thr Ile Ile Gln Gly Ile Leu Ile Glu His Leu Tyr Gly Leu
 405 410 415

Thr Val Phe Glu Asn Tyr Leu Tyr Ala Thr Asn Ser Asp Asn Ala Asn
 420 425 430

Ala Gln Gln Lys Thr Ser Val Ile Arg Val Asn Arg Phe Asn Ser Thr
 435 440 445

Glu Tyr Gln Val Val Thr Arg Val Asp Lys Gly Gly Ala Leu His Ile
 450 455 460

Tyr His Gln Arg Arg Gln Pro Arg Val Arg Ser His Ala Cys Glu Asn
 465 470 475 480

Asp Gln Tyr Gly Lys Pro Gly Gly Cys Ser Asp Ile Cys Leu Leu Ala
 485 490 495

Asn Ser His Lys Ala Arg Thr Cys Arg Cys Arg Ser Gly Phe Ser Leu
 500 505 510

Gly Ser Asp Gly Lys Ser Cys Lys Lys Pro Glu His Glu Leu Phe Leu
 515 520 525

Val Tyr Gly Lys Gly Arg Pro Gly Ile Ile Arg Gly Met Asp Met Gly
 530 535 540

Ala Lys Val Pro Asp Glu His Met Ile Pro Ile Glu Asn Leu Met Asn
 545 550 555 560

Pro Arg Ala Leu Asp Phe His Ala Glu Thr Gly Phe Ile Tyr Phe Ala
 565 570 575

Asp Thr Thr Ser Tyr Leu Ile Gly Arg Gln Lys Ile Asp Gly Thr Glu
 580 585 590

Arg Glu Thr Ile Leu Lys Asp Gly Ile His Asn Val Glu Gly Val Ala
595 600 605

Val Asp Trp Met Gly Asp Asn Leu Tyr Trp Thr Asp Asp Gly Pro Lys
610 615 620

Lys Thr Ile Ser Val Ala Arg Leu Glu Lys Ala Ala Gln Thr Arg Lys
625 630 635 640

Thr Leu Ile Glu Gly Lys Met Thr His Pro Arg Ala Ile Val Val Asp
645 650 655

Pro Leu Asn Gly Trp Met Tyr Trp Thr Asp Trp Glu Glu Asp Pro Lys
660 665 670

Asp Ser Arg Arg Gly Arg Leu Glu Arg Ala Trp Met Asp Gly Ser His
675 680 685

Arg Asp Ile Phe Val Thr Ser Lys Thr Val Leu Trp Pro Asn Gly Leu
690 695 700

Ser Leu Asp Ile Pro Ala Gly Arg Leu Tyr Trp Val Asp Ala Phe Tyr
705 710 715 720

Asp Arg Ile Glu Thr Ile Leu Leu Asn Gly Thr Asp Arg Lys Ile Val
725 730 735

Tyr Glu Gly Pro Glu Leu Asn His Ala Phe Gly Leu Cys His His Gly
740 745 750

Asn Tyr Leu Phe Trp Thr Glu Tyr Arg Ser Gly Ser Val Tyr Arg Leu
755 760 765

Glu Arg Gly Val Gly Gly Ala Pro Pro Thr Val Thr Leu Leu Arg Ser
770 775 780

Glu Arg Pro Pro Ile Phe Glu Ile Arg Met Tyr Asp Ala Gln Gln Gln
785 790 795 800

Gln Val Gly Thr Asn Lys Cys Arg Val Asn Asn Gly Gly Cys Ser Ser
805 810 815

Leu Cys Leu Ala Thr Pro Gly Ser Arg Gln Cys Ala Cys Ala Glu Asp
820 825 830

Gln Val Leu Asp Ala Asp Gly Val Thr Cys Leu Ala Asn Pro Ser Tyr
835 840 845

Val Pro Pro Pro Gln Cys Gln Pro Gly Glu Phe Ala Cys Ala Asn Ser
850 855 860

Arg Cys Ile Gln Glu Arg Trp Lys Cys Asp Gly Asp Asn Asp Cys Leu
865 870 875 880

Asp Asn Ser Asp Glu Ala Pro Ala Leu Cys His Gln His Thr Cys Pro
885 890 895

Ser Asp Arg Phe Lys Cys Glu Asn Asn Arg Cys Ile Pro Asn Arg Trp
900 905 910

Leu Cys Asp Gly Asp Asn Asp Cys Gly Asn Ser Glu Asp Glu Ser Asn
915 920 925

Ala Thr Cys Ser Ala Arg Thr Cys Pro Pro Asn Gln Phe Ser Cys Ala
930 935 940

Ser Gly Arg Cys Ile Pro Ile Ser Trp Thr Cys Asp Leu Asp Asp Asp
945 950 955 960

Cys Gly Asp Arg Ser Asp Glu Ser Ala Ser Cys Ala Tyr Pro Thr Cys
965 970 975

Phe Pro Leu Thr Gln Phe Thr Cys Asn Asn
980 985

<210> 13

<211> 896

<212> PRT

<213> H. sapiens

<400> 13

Met Leu Thr Pro Pro Leu Leu Leu Leu Leu Pro Leu Leu Ser Ala Leu
1 5 10 15

Ala Ala Ala Ala Ile Asp Ala Pro Lys Thr Cys Ser Pro Lys Gln Phe
20 25 30

Ala Cys Arg Asp Gln Ile Thr Cys Ile Ser Lys Gly Trp Arg Cys Asp
35 40 45

Gly Glu Arg Asp Cys Pro Asp Gly Ser Asp Glu Ala Pro Glu Ile Cys
50 55 60

Pro Gln Ser Lys Ala Gln Arg Cys Gln Pro Asn Glu His Asn Cys Leu
65 70 75 80

Gly Thr Glu Leu Cys Val Pro Met Ser Arg Leu Cys Asn Gly Val Gln
85 90 95

Asp Cys Met Asp Gly Ser Asp Glu Gly Pro His Cys Arg Glu Leu Gln
100 105 110

Gly Asn Cys Ser Arg Leu Gly Cys Gln His His Cys Val Pro Thr Leu
115 120 125

Asp Gly Pro Thr Cys Tyr Cys Asn Ser Ser Phe Gln Leu Gln Ala Asp
130 135 140

Y Lys Thr Cys Lys Asp Phe Asp Glu Cys Ser Val Tyr Gly Thr Cys
15 150 155 160

Ser Gln Leu Cys Thr Asn Thr Asp Gly Ser Phe Ile Cys Gly Cys Val
165 170 175

Glu Gly Tyr Leu Leu Gln Pro Asp Asn Arg Ser Cys Lys Ala Lys Asn
180 185 190

Glu Pro Val Asp Arg Pro Pro Val Leu Leu Ile Ala Asn Ser Gln Asn
195 200 205

Ile Leu Ala Thr Tyr Leu Ser Gly Ala Gln Val Ser Thr Ile Thr Pro
210 215 220

Thr Ser Thr Arg Gln Thr Thr Ala Met Asp Phe Ser Tyr Ala Asn Glu
225 230 235 240

Thr Val Cys Trp Val His Val Gly Asp Ser Ala Ala Gln Thr Gln Leu
245 250 255

Lys Cys Ala Arg Met Pro Gly Leu Lys Gly Phe Val Asp Glu His Thr
260 265 270

Ile Asn Ile Ser Leu Ser Leu His His Val Glu Gln Met Ala Ile Asp
275 280 285

Trp Leu Thr Gly Asn Phe Tyr Phe Val Asp Asp Ile Asp Asp Arg Ile
290 295 300

Phe Val Cys Asn Arg Asn Gly Asp Thr Cys Val Thr Leu Leu Asp Leu
 305 310 315 320

Glu Leu Tyr Asn Pro Lys Gly Ile Ala Leu Asp Pro Ala Met Gly Lys
 325 330 335

Val Phe Phe Thr Asp Tyr Gly Gln Ile Pro Lys Val Glu Arg Cys Asp
 340 345 350

Met Asp Gly Gln Asn Arg Thr Lys Leu Val Asp Ser Lys Ile Val Phe
 355 360 365

Pro His Gly Ile Thr Leu Asp Leu Val Ser Arg Leu Val Tyr Trp Ala
 370 375 380

Asp Ala Tyr Leu Asp Tyr Ile Glu Val Val Asp Tyr Glu Gly Lys Gly
 385 390 395 400

Arg Gln Thr Ile Ile Gln Gly Ile Leu Ile Glu His Leu Tyr Gly Leu
 405 410 415

Thr Val Phe Glu Asn Tyr Leu Tyr Ala Thr Asn Ser Asp Asn Ala Asn
 420 425 430

Ala Gln Gln Lys Thr Ser Val Ile Arg Val Asn Arg Phe Asn Ser Thr
 435 440 445

Glu Tyr Gln Val Val Thr Arg Val Asp Lys Gly Gly Ala Leu His Ile
 450 455 460

Thr His Gln Arg Arg Gln Pro Arg Val Arg Ser His Ala Cys Glu Asn
 465 470 475 480

Asp Gln Tyr Gly Lys Pro Gly Gly Cys Ser Asp Ile Cys Leu Leu Ala
 485 490 495

Asn Ser His Lys Ala Arg Thr Cys Arg Cys Arg Ser Gly Phe Ser Leu
 500 505 510

Gly Ser Asp Gly Lys Ser Cys Lys Lys Pro Glu His Glu Leu Phe Leu
 515 520 525

Val Tyr Gly Lys Gly Arg Pro Gly Ile Ile Arg Gly Met Asp Met Gly
 530 535 540

Ala Lys Val Pro Asp Glu His Met Ile Pro Ile Glu Asn Leu Met Asn
 545 550 555 560

Pro Arg Ala Leu Asp Phe His Ala Glu Thr Gly Phe Ile Tyr Phe Ala
 565 570 575

Asp Thr Thr Ser Tyr Leu Ile Gly Arg Gln Lys Ile Asp Gly Thr Glu
 580 585 590

Arg Glu Thr Ile Leu Lys Asp Gly Ile His Asn Val Glu Gly Val Ala
 595 600 605

Val Asp Trp Met Gly Asp Asn Leu Tyr Trp Thr Asp Asp Gly Pro Lys
 610 615 620

Lys Thr Ile Ser Val Ala Arg Leu Glu Lys Ala Ala Gln Thr Arg Lys
 625 630 635 640

Thr Leu Ile Glu Gly Lys Met Thr His Pro Arg Ala Ile Met Val Asp
 645 650 655

Pro Leu Asn Gly Trp Met Tyr Trp Thr Asp Trp Glu Glu Asp Pro Lys
 660 665 670

Asp Ser Arg Arg Gly Arg Leu Glu Arg Ala Trp Met Asp Gly Ser His
 675 680 685

Arg Asp Ile Phe Val Thr Ser Lys Thr Val Leu Trp Pro Asn Gly Leu
 690 695 700

er Leu Asp Ile Pro Ala Gly Arg Leu Tyr Trp Val Asp Ala Phe Tyr
 5 710 715 720

Asp Arg Ile Glu Thr Ile Leu Leu Asn Gly Thr Asp Arg Lys Ile Val
 725 730 735

Tyr Glu Gly Pro Glu Leu Asn His Ala Phe Gly Leu Cys His His Gly
 740 745 750

Asn Tyr Leu Phe Trp Thr Glu Tyr Arg Ser Gly Ser Val Tyr Arg Leu
 755 760 765

Glu Arg Gly Val Gly Gly Ala Pro Pro Thr Val Thr Leu Leu Arg Ser
 770 775 780

Glu Arg Pro Pro Ile Phe Glu Ile Arg Met Tyr Asp Ala Gln Gln Gln
785 790 795 800

Gln Val Gly Thr Asn Lys Cys Arg Val Asn Asn Gly Gly Cys Ser Ser
805 810 815

Leu Cys Leu Ala Thr Pro Gly Ser Arg Gln Cys Ala Cys Ala Glu Asp
820 825 830

Gln Val Leu Asp Ala Asp Gly Val Thr Cys Leu Ala Asn Pro Ser Tyr
835 840 845

Val Pro Pro Gly Gly Arg Leu Val Pro Arg Gly Ser Tyr Pro Tyr Asp
850 855 860

Val Pro Asp Tyr Ala Ile Glu Gly His Val Gly Leu Asn Asp Ile Phe
865 870 875 880

Glu Ala Gln Lys Ile Glu Trp His Glu Gly His His His His His His
885 890 895

<210> 14
<211> 2688
<212> PRT
<213> H. sapiens

<400> 14

Ala Thr Gly Cys Thr Gly Ala Cys Cys Cys Cys Gly Cys Cys Gly Thr
1 5 10 15

Thr Gly Cys Thr Cys Cys Thr Gly Cys Thr Gly Cys Thr Gly Cys Cys
20 25 30

Cys Cys Thr Gly Cys Thr Cys Thr Cys Ala Gly Cys Thr Cys Thr Gly
35 40 45

Gly Thr Cys Gly Cys Gly Gly Cys Gly Gly Cys Thr Ala Thr Cys Gly
50 55 60

Ala Cys Gly Cys Cys Cys Cys Thr Ala Ala Gly Ala Cys Thr Thr Gly
65 70 75 80

Cys Ala Gly Cys Cys Cys Cys Ala Ala Gly Cys Ala Gly Thr Thr Thr
85 90 95

Gly Cys Cys Thr Gly Cys Ala Gly Ala Gly Ala Thr Cys Ala Ala Ala
100 105 110

Thr Ala Ala Cys Cys Thr Gly Thr Ala Thr Cys Thr Cys Ala Ala Ala
 115 120 125

Gly Gly Gly Cys Thr Gly Gly Cys Gly Gly Thr Gly Cys Gly Ala Cys
 130 135 140

Gly Gly Thr Gly Ala Gly Ala Gly Gly Gly Ala Cys Thr Gly Cys Cys
 145 150 155 160

Cys Ala Gly Ala Cys Gly Gly Ala Thr Cys Thr Gly Ala Cys Gly Ala
 165 170 175

Gly Gly Cys Cys Cys Cys Thr Gly Ala Gly Ala Thr Thr Thr Gly Thr
 180 185 190

Cys Cys Ala Cys Ala Gly Ala Gly Thr Ala Ala Gly Gly Cys Cys Cys
 195 200 205

Ala Gly Cys Gly Ala Thr Gly Cys Cys Ala Gly Cys Cys Ala Ala Ala
 210 215 220

Cys Gly Ala Gly Cys Ala Thr Ala Ala Cys Thr Gly Cys Cys Thr Gly
 225 230 235 240

Gly Gly Thr Ala Cys Thr Gly Ala Gly Cys Thr Gly Thr Gly Thr Gly
 245 250 255

Thr Thr Cys Cys Cys Ala Thr Gly Thr Cys Cys Cys Gly Cys Cys Thr
 260 265 270

Cys Thr Gly Cys Ala Ala Thr Gly Gly Gly Gly Thr Cys Cys Ala Gly
 275 280 285

Gly Ala Cys Thr Gly Cys Ala Thr Gly Gly Ala Cys Gly Gly Cys Thr
 290 295 300

Cys Ala Gly Ala Thr Gly Ala Gly Gly Gly Gly Cys Cys Cys Cys Ala
 305 310 315 320

Cys Thr Gly Cys Cys Gly Ala Gly Ala Gly Cys Thr Cys Cys Ala Ala
 325 330 335

Gly Gly Cys Ala Ala Cys Thr Gly Cys Thr Cys Thr Cys Gly Cys Cys
 340 345 350

Thr Gly Gly Gly Cys Thr Gly Cys Cys Ala Gly Cys Ala Cys Cys Ala
355 360 365

Thr Thr Gly Thr Gly Thr Cys Cys Cys Cys Ala Cys Ala Cys Thr Cys
370 375 380

Gly Ala Thr Gly Gly Gly Cys Cys Cys Ala Cys Cys Thr Gly Cys Thr
385 390 395 400

Ala Cys Thr Gly Cys Ala Ala Cys Ala Gly Cys Ala Gly Cys Thr Thr
405 410 415

Thr Cys Ala Gly Cys Thr Thr Cys Ala Gly Gly Cys Ala Gly Ala Thr
420 425 430

Gly Gly Cys Ala Ala Gly Ala Cys Cys Thr Gly Cys Ala Ala Ala Gly
435 440 445

Ala Thr Thr Thr Thr Gly Ala Thr Gly Ala Gly Thr Gly Cys Thr Cys
450 455 460

Ala Gly Thr Gly Thr Ala Cys Gly Gly Cys Ala Cys Cys Thr Gly Cys
465 470 475 480

Ala Gly Cys Cys Ala Gly Cys Thr Ala Thr Gly Cys Ala Cys Cys Ala
485 490 495

Ala Cys Ala Cys Ala Gly Ala Cys Gly Gly Cys Thr Cys Cys Thr Thr
500 505 510

Cys Ala Thr Ala Thr Gly Thr Gly Gly Cys Thr Gly Thr Gly Thr Thr
515 520 525

Gly Ala Ala Gly Gly Ala Thr Ala Cys Cys Thr Cys Cys Thr Gly Cys
530 535 540

Ala Gly Cys Cys Gly Gly Ala Thr Ala Ala Cys Cys Gly Cys Thr Cys
545 550 555 560

Cys Thr Gly Cys Ala Ala Gly Gly Cys Cys Ala Ala Gly Ala Ala Cys
565 570 575

Gly Ala Gly Cys Cys Ala Gly Thr Ala Gly Ala Cys Cys Gly Gly Cys
580 585 590

Cys Cys Cys Cys Thr Gly Thr Gly Cys Thr Gly Thr Thr Gly Ala Thr
 595 600 605

Ala Gly Cys Cys Ala Ala Cys Thr Cys Cys Cys Ala Gly Ala Ala Cys
 610 615 620

Ala Thr Cys Thr Thr Gly Gly Cys Cys Ala Cys Gly Thr Ala Cys Cys
 625 630 635 640

Thr Gly Ala Gly Thr Gly Gly Gly Gly Cys Cys Cys Ala Gly Gly Thr
 645 650 655

Gly Thr Cys Thr Ala Cys Cys Ala Thr Cys Ala Cys Ala Cys Cys Thr
 660 665 670

Ala Cys Gly Ala Gly Cys Ala Cys Gly Cys Gly Gly Cys Ala Gly Ala
 675 680 685

Cys Cys Ala Cys Ala Gly Cys Cys Ala Thr Gly Gly Ala Cys Thr Thr
 690 695 700

Cys Ala Gly Cys Thr Ala Thr Gly Cys Cys Ala Ala Cys Gly Ala Gly
 705 710 715 720

Ala Cys Cys Gly Thr Ala Thr Gly Cys Thr Gly Gly Gly Thr Gly Cys
 725 730 735

Ala Thr Gly Thr Thr Gly Gly Gly Gly Ala Cys Ala Gly Thr Gly Cys
 740 745 750

Thr Gly Cys Thr Cys Ala Gly Ala Cys Gly Cys Ala Gly Cys Thr Cys
 755 760 765

Ala Ala Gly Thr Gly Thr Gly Cys Cys Cys Gly Cys Ala Thr Gly Cys
 770 775 780

Cys Thr Gly Gly Cys Cys Thr Ala Ala Ala Gly Gly Gly Cys Thr Thr
 785 790 795 800

Cys Gly Thr Gly Gly Ala Thr Gly Ala Gly Cys Ala Cys Ala Cys Cys
 805 810 815

Ala Thr Cys Ala Ala Cys Ala Thr Cys Thr Cys Cys Cys Thr Cys Ala
 820 825 830

Gly Thr Cys Thr Gly Cys Ala Cys Cys Ala Cys Gly Thr Gly Gly Ala
835 840 845

Ala Cys Ala Gly Ala Thr Gly Gly Cys Cys Ala Thr Cys Gly Ala Cys
850 855 860

Thr Gly Gly Cys Thr Gly Ala Cys Ala Gly Gly Cys Ala Ala Cys Thr
865 870 875 880

Thr Cys Thr Ala Cys Thr Thr Thr Gly Thr Gly Gly Ala Thr Gly Ala
885 890 895

Cys Ala Thr Cys Gly Ala Thr Gly Ala Thr Ala Gly Gly Ala Thr Cys
900 905 910

Thr Thr Thr Gly Thr Cys Thr Gly Cys Ala Ala Cys Ala Gly Ala Ala
915 920 925

Ala Thr Gly Gly Gly Gly Ala Cys Ala Cys Ala Thr Gly Thr Gly Thr
930 935 940

Cys Ala Cys Ala Thr Thr Gly Cys Thr Ala Gly Ala Cys Cys Thr Gly
945 950 955 960

Gly Ala Ala Cys Thr Cys Thr Ala Cys Ala Ala Cys Cys Cys Cys Ala
965 970 975

Ala Gly Gly Gly Cys Ala Thr Thr Gly Cys Cys Cys Thr Gly Gly Ala
980 985 990

Cys Cys Cys Thr Gly Cys Cys Ala Thr Gly Gly Gly Gly Ala Ala Gly
995 1000 1005

Gly Thr Gly Thr Thr Thr Thr Thr Cys Ala Cys Thr Gly Ala Cys
1010 1015 1020

Thr Ala Thr Gly Gly Gly Cys Ala Gly Ala Thr Cys Cys Cys Ala
1025 1030 1035

Ala Ala Gly Gly Thr Gly Gly Ala Ala Cys Gly Cys Thr Gly Thr
1040 1045 1050

Gly Ala Cys Ala Thr Gly Gly Ala Thr Gly Gly Gly Cys Ala Gly
1055 1060 1065

Ala Ala Cys Cys Gly Cys Ala Cys Cys Ala Ala Gly Cys Thr Cys
1070 1075 1080

Gly Thr Cys Gly Ala Cys Ala Gly Cys Ala Ala Gly Ala Thr Thr
1085 1090 1095

Gly Thr Gly Thr Thr Thr Cys Cys Thr Cys Ala Thr Gly Gly Cys
1100 1105 1110

Ala Thr Cys Ala Cys Gly Cys Thr Gly Gly Ala Cys Cys Thr Gly
1115 1120 1125

Gly Thr Cys Ala Gly Cys Cys Gly Cys Cys Thr Thr Gly Thr Cys
1130 1135 1140

Thr Ala Cys Thr Gly Gly Gly Cys Ala Gly Ala Thr Gly Cys Cys
1145 1150 1155

Thr Ala Thr Cys Thr Gly Gly Ala Cys Thr Ala Thr Ala Thr Thr
1160 1165 1170

Gly Ala Ala Gly Thr Gly Gly Thr Gly Gly Ala Cys Thr Ala Thr
1175 1180 1185

Gly Ala Gly Gly Gly Cys Ala Ala Gly Gly Gly Cys Cys Gly Cys
1190 1195 1200

Cys Ala Gly Ala Cys Cys Ala Thr Cys Ala Thr Cys Cys Ala Gly
1205 1210 1215

Gly Gly Cys Ala Thr Cys Cys Thr Gly Ala Thr Thr Gly Ala Gly
1220 1225 1230

Cys Ala Cys Cys Thr Gly Thr Ala Cys Gly Gly Cys Cys Thr Gly
1235 1240 1245

Ala Cys Thr Gly Thr Gly Thr Thr Thr Gly Ala Gly Ala Ala Thr
1250 1255 1260

Thr Ala Thr Cys Thr Cys Thr Ala Thr Gly Cys Cys Ala Cys Cys
1265 1270 1275

Ala Ala Cys Thr Cys Gly Gly Ala Cys Ala Ala Thr Gly Cys Cys
1280 1285 1290

Ala Ala Thr Gly Cys Cys Cys Ala Gly Cys Ala Gly Ala Ala Gly
1295 1300 1305

Ala Cys Gly Ala Gly Thr Gly Thr Gly Ala Thr Cys Cys Gly Thr
1310 1315 1320

Gly Thr Gly Ala Ala Cys Cys Gly Cys Thr Thr Thr Ala Ala Cys
1325 1330 1335

Ala Gly Cys Ala Cys Cys Gly Ala Gly Thr Ala Cys Cys Ala Gly
1340 1345 1350

Gly Thr Thr Gly Thr Cys Ala Cys Cys Cys Gly Gly Gly Thr Gly
1355 1360 1365

Gly Ala Cys Ala Ala Gly Gly Gly Thr Gly Gly Thr Gly Cys Cys
1370 1375 1380

Cys Thr Cys Cys Ala Cys Ala Thr Cys Thr Ala Cys Cys Ala Cys
1385 1390 1395

Cys Ala Gly Ala Gly Gly Cys Gly Thr Cys Ala Gly Cys Cys Cys
1400 1405 1410

Cys Gly Ala Gly Thr Gly Ala Gly Gly Ala Gly Cys Cys Ala Thr
1415 1420 1425

Gly Cys Cys Thr Gly Thr Gly Ala Ala Ala Ala Cys Gly Ala Cys
1430 1435 1440

Cys Ala Gly Thr Ala Thr Gly Gly Gly Ala Ala Gly Cys Cys Gly
1445 1450 1455

Gly Gly Thr Gly Gly Cys Thr Gly Cys Thr Cys Thr Gly Ala Cys
1460 1465 1470

Ala Thr Cys Thr Gly Cys Cys Thr Gly Cys Thr Gly Gly Cys Cys
1475 1480 1485

Ala Ala Cys Ala Gly Cys Cys Ala Cys Ala Ala Gly Gly Cys Gly
1490 1495 1500

Cys Gly Gly Ala Cys Cys Thr Gly Cys Cys Gly Cys Thr Gly Cys
1505 1510 1515

Cys Gly Thr Thr Cys Cys Gly Gly Cys Thr Thr Cys Ala Gly Cys
1520 1525 1530

Cys Thr Gly Gly Gly Cys Ala Gly Thr Gly Ala Cys Gly Gly Gly
1535 1540 1545

Ala Ala Gly Thr Cys Ala Thr Gly Cys Ala Ala Gly Ala Ala Gly
1550 1555 1560

Cys Cys Gly Gly Ala Gly Cys Ala Thr Gly Ala Gly Cys Thr Gly
1565 1570 1575

Thr Thr Cys Cys Thr Cys Gly Thr Gly Thr Ala Thr Gly Gly Cys
1580 1585 1590

Ala Ala Gly Gly Gly Cys Cys Gly Gly Cys Cys Ala Gly Gly Cys
1595 1600 1605

Ala Thr Cys Ala Thr Cys Cys Gly Gly Gly Gly Cys Ala Thr Gly
1610 1615 1620

Gly Ala Thr Ala Thr Gly Gly Gly Gly Gly Cys Cys Ala Ala Gly
1625 1630 1635

Gly Thr Cys Cys Cys Gly Gly Ala Thr Gly Ala Gly Cys Ala Cys
1640 1645 1650

Ala Thr Gly Ala Thr Cys Cys Cys Cys Ala Thr Thr Gly Ala Ala
1655 1660 1665

Ala Ala Cys Cys Thr Cys Ala Thr Gly Ala Ala Cys Cys Cys Cys
1670 1675 1680

Cys Gly Ala Gly Cys Cys Cys Thr Gly Gly Ala Cys Thr Thr Cys
1685 1690 1695

Cys Ala Cys Gly Cys Thr Gly Ala Gly Ala Cys Cys Gly Gly Cys
1700 1705 1710

Thr Thr Cys Ala Thr Cys Thr Ala Cys Thr Thr Thr Gly Cys Cys
1715 1720 1725

Gly Ala Cys Ala Cys Cys Ala Cys Cys Ala Gly Cys Thr Ala Cys
1730 1735 1740

Cys Thr Cys Ala Thr Thr Gly Gly Cys Cys Gly Cys Cys Ala Gly
1745 1750 1755

Ala Ala Gly Ala Thr Thr Gly Ala Thr Gly Gly Cys Ala Cys Thr
1760 1765 1770

Gly Ala Gly Cys Gly Gly Gly Ala Gly Ala Cys Cys Ala Thr Cys
1775 1780 1785

Cys Thr Gly Ala Ala Gly Gly Ala Cys Gly Gly Cys Ala Thr Cys
1790 1795 1800

Cys Ala Cys Ala Ala Thr Gly Thr Gly Gly Ala Gly Gly Gly Thr
1805 1810 1815

Gly Thr Gly Gly Cys Cys Gly Thr Gly Gly Ala Cys Thr Gly Gly
1820 1825 1830

Ala Thr Gly Gly Gly Ala Gly Ala Cys Ala Ala Thr Cys Thr Gly
1835 1840 1845

Thr Ala Cys Thr Gly Gly Ala Cys Gly Gly Ala Cys Gly Ala Thr
1850 1855 1860

Gly Gly Gly Cys Cys Cys Ala Ala Ala Ala Gly Ala Cys Ala
1865 1870 1875

Ala Thr Cys Ala Gly Cys Gly Thr Gly Gly Cys Cys Ala Gly Gly
1880 1885 1890

Cys Thr Gly Gly Ala Gly Ala Ala Ala Gly Cys Thr Gly Cys Thr
1895 1900 1905

Cys Ala Gly Ala Cys Cys Cys Gly Cys Ala Ala Gly Ala Cys Thr
1910 1915 1920

Thr Thr Ala Ala Thr Cys Gly Ala Gly Gly Gly Cys Ala Ala Ala
1925 1930 1935

Ala Thr Gly Ala Cys Ala Cys Ala Cys Cys Cys Cys Ala Gly Gly
1940 1945 1950

Gly Cys Thr Ala Thr Thr Gly Thr Gly Gly Thr Gly Gly Ala Thr
1955 1960 1965

Cys Cys Ala Cys Thr Cys Ala Ala Thr Gly Gly Gly Thr Gly Gly
 1970 1975 1980
 Ala Thr Gly Thr Ala Cys Thr Gly Gly Ala Cys Ala Gly Ala Cys
 1985 1990 1995
 Thr Gly Gly Gly Ala Gly Gly Ala Gly Gly Ala Cys Cys Cys Cys
 2000 2005 2010
 Ala Ala Gly Gly Ala Cys Ala Gly Thr Cys Gly Gly Cys Gly Thr
 2015 2020 2025
 Gly Gly Gly Cys Gly Gly Cys Thr Gly Gly Ala Gly Ala Gly Gly
 2030 2035 2040
 Gly Cys Gly Thr Gly Gly Ala Thr Gly Gly Ala Thr Gly Gly Cys
 2045 2050 2055
 Thr Cys Ala Cys Ala Cys Cys Gly Ala Gly Ala Cys Ala Thr Cys
 2060 2065 2070
 Thr Thr Thr Gly Thr Cys Ala Cys Cys Thr Cys Cys Ala Ala Gly
 2075 2080 2085
 Ala Cys Ala Gly Thr Gly Cys Thr Thr Thr Gly Gly Cys Cys Cys
 2090 2095 2100
 Ala Ala Thr Gly Gly Gly Cys Thr Ala Ala Gly Cys Cys Thr Gly
 2105 2110 2115
 Gly Ala Cys Ala Thr Cys Cys Cys Gly Gly Cys Thr Gly Gly Gly
 2120 2125 2130
 Cys Gly Cys Cys Thr Cys Thr Ala Cys Thr Gly Gly Gly Thr Gly
 2135 2140 2145
 Gly Ala Thr Gly Cys Cys Thr Thr Cys Thr Ala Cys Gly Ala Cys
 2150 2155 2160
 Cys Gly Cys Ala Thr Cys Gly Ala Gly Ala Cys Gly Ala Thr Ala
 2165 2170 2175
 Cys Thr Gly Cys Thr Cys Ala Ala Thr Gly Gly Cys Ala Cys Ala
 2180 2185 2190

Gly Ala Cys Cys Gly Gly Ala Ala Gly Ala Thr Thr Gly Thr Gly
 2195 2200 2205

Thr Ala Thr Gly Ala Ala Gly Gly Thr Cys Cys Thr Gly Ala Gly
 2210 2215 2220

Cys Thr Gly Ala Ala Cys Cys Ala Cys Gly Cys Cys Thr Thr Thr
 2225 2230 2235

Gly Gly Cys Cys Thr Gly Thr Gly Thr Cys Ala Cys Cys Ala Thr
 2240 2245 2250

Gly Gly Cys Ala Ala Cys Thr Ala Cys Cys Thr Cys Thr Thr Cys
 2255 2260 2265

Thr Gly Gly Ala Cys Thr Gly Ala Gly Thr Ala Thr Cys Gly Gly
 2270 2275 2280

Ala Gly Thr Gly Gly Cys Ala Gly Thr Gly Thr Cys Thr Ala Cys
 2285 2290 2295

Cys Gly Cys Thr Thr Gly Gly Ala Ala Cys Gly Gly Gly Gly Thr
 2300 2305 2310

Gly Thr Ala Gly Gly Ala Gly Gly Cys Gly Cys Ala Cys Cys Cys
 2315 2320 2325

Cys Cys Cys Ala Cys Thr Gly Thr Gly Ala Cys Cys Cys Thr Thr
 2330 2335 2340

Cys Thr Gly Cys Gly Cys Ala Gly Thr Gly Ala Gly Cys Gly Gly
 2345 2350 2355

Cys Cys Cys Cys Cys Cys Ala Thr Cys Thr Thr Thr Gly Ala Gly
 2360 2365 2370

Ala Thr Cys Cys Gly Ala Ala Thr Gly Thr Ala Thr Gly Ala Thr
 2375 2380 2385

Gly Cys Cys Cys Ala Gly Cys Ala Gly Cys Ala Gly Cys Ala Ala
 2390 2395 2400

Gly Thr Thr Gly Gly Cys Ala Cys Cys Ala Ala Cys Ala Ala Ala
 2405 2410 2415

Thr Gly Cys Cys Gly Gly Gly Thr Gly Ala Ala Cys Ala Ala Thr
2420 2425 2430

Gly Gly Cys Gly Gly Cys Thr Gly Cys Ala Gly Cys Ala Gly Cys
2435 2440 2445

Cys Thr Gly Thr Gly Cys Thr Thr Gly Gly Cys Cys Ala Cys Cys
2450 2455 2460

Cys Cys Thr Gly Gly Gly Ala Gly Cys Cys Gly Cys Cys Ala Gly
2465 2470 2475

Thr Gly Cys Gly Cys Cys Thr Gly Thr Gly Cys Thr Gly Ala Gly
2480 2485 2490

Gly Ala Cys Cys Ala Gly Gly Thr Gly Thr Thr Gly Gly Ala Cys
2495 2500 2505

Gly Cys Ala Gly Ala Cys Gly Gly Cys Gly Thr Cys Ala Cys Thr
2510 2515 2520

Thr Gly Cys Thr Thr Gly Gly Cys Gly Ala Ala Cys Cys Cys Ala
2525 2530 2535

Thr Cys Cys Thr Ala Cys Gly Thr Gly Cys Cys Thr Cys Cys Ala
2540 2545 2550

Cys Cys Cys Cys Ala Gly Thr Gly Cys Cys Ala Gly Cys Cys Ala
2555 2560 2565

Gly Gly Cys Gly Ala Gly Thr Thr Thr Gly Cys Cys Thr Gly Thr
2570 2575 2580

Gly Cys Cys Ala Ala Cys Ala Gly Cys Cys Gly Cys Thr Gly Cys
2585 2590 2595

Ala Thr Cys Cys Ala Gly Gly Ala Gly Cys Gly Cys Thr Gly Gly
2600 2605 2610

Ala Ala Gly Thr Gly Thr Gly Ala Cys Gly Gly Ala Gly Ala Cys
2615 2620 2625

Ala Ala Cys Gly Ala Thr Thr Gly Cys Cys Thr Gly Gly Ala Cys
2630 2635 2640

Ala Ala Cys Ala Gly Thr Gly Ala Thr Gly Ala Gly Gly Cys Cys
 2645 2650 2655

Cys Cys Ala Gly Cys Cys Cys Thr Cys Thr Gly Cys Cys Ala Thr
 2660 2665 2670

Cys Ala Gly Cys Ala Cys Ala Cys Cys Thr Gly Cys Cys Cys Cys
 2675 2680 2685

<210> 15
 <211> 7551
 <212> DNA
 <213> H. sapiens

<400> 15
 atgctgaccc cgccgttget cctgctgctg cccttgcctt cagctctggt cgccggcggct 60
 atcgacgccc ctaagacttg cagccccaag cagtttgctt gcagagatca aataacctgt 120
 atctcaaagg gctggcgggtg cgacggtgag agggactgcc cagacggatc tgacgaggcc 180
 ctgagattt gtccacagag taaggcccag cgatgccagc caaacgagca taactgcctg 240
 ggtactgagc tgtgtgttcc catgtcccgc ctctgcaatg ggggtccagga ctgcatggac 300
 ggctcagatg aggggcccga ctgccgagag ctccaaggca actgctctcg cctgggctgc 360
 cagcaccatt gtgtccccac actcgatggg cccacctgct actgcaacag cagctttcag 420
 cttcaggcag atggcaagac ctgcaaagat tttgatgagt gctcagtgtg cggcacctgc 480
 agccagctat gcaccaacac agacggctcc ttcatatgtg gctgtgttga aggatacctc 540
 ctgcagccgg ataaccgtc ctgcaaggcc aagaacgagc cagtagaccg gccccctgtg 600
 ctgttgatag ccaactccca gaacatcttg gccacgtacc tgagtggggc ccagggtgtct 660
 accatcacac ctacgagcac gcggcagacc acagccatgg acttcagcta tgccaacgag 720
 ccgtatgct ggggtgcatgt tggggacagt gctgctcaga cgcagctcaa gtgtgcccgc 780
 atgcctggcc taaagggtt cgtggatgag cacaccatca acatctccct cagtctgcac 840
 cacgtggaac agatggccat cgactggctg acaggcaact tctactttgt ggatgacatc 900
 gatgatagga tctttgtctg caacagaaat ggggacacat gtgtcacatt gctagacctg 960
 gaactctaca accccaaggg cattgccctg gaccctgcca tggggaagggt gtttttcaact 1020
 gactatgggc agatcccaaa ggtggaacgc tgtgacatgg atgggcagaa ccgcaccaag 1080
 ctcgctgaca gcaagattgt gtttcctcat ggcacacgc tggacctggg cagccgcctt 1140
 gtctactggg cagatgccta tctggactat attgaagtgg tggactatga gggcaagggc 1200
 cgccagacca tcatccaggg catcctgatt gagcacctgt acggcctgac tgtgtttgag 1260
 aattatctct atgccaccaa ctcggaacaat gccaatgcc agcagaagac gagtgtgatc 1320

cgtgtgaacc gctttaacag caccgagtac caggttgtca cccgggtgga caagggtggt 1380
gccctccaca tctaccacca gaggcgtcag ccccgagtga ggagccatgc ctgtgaaaac 1440
gaccagtatg ggaagccggg tggtgtctct gacatctgcc tgctggccaa cagccacaag 1500
gcgcggacct gccgctgccg ttccggcttc agcctgggca gtgacgggaa gtcattgcaag 1560
aagccggagc atgagctggt cctcgtgtat ggcaagggcc ggccaggcat catccggggc 1620
atggatatgg gggccaaggt cccgatgag ccatgatcc ccattgaaaa cctcatgaac 1680
ccccgagccc tggacttcca cgctgagacc ggcttcatct actttgccga caccaccagc 1740
tacctcattg gccgccagaa gattgatggc actgagcggg agaccatcct gaaggacggc 1800
atccacaatg tggagggtgt ggccgtggac tggatgggag acaatctgta ctggacggac 1860
gatgggcccc aaaagacaat cagcgtggcc aggctggaga aagctgctca gacccgcaag 1920
actttaatcg agggcaaaat gacacacccc agggctattg tggatgatcc actcaatggg 1980
ggatgtact ggacagactg ggaggaggac cccaaggaca gtcggcgtgg gcggtggag 2040
agggcgtgga tggatggctc acaccgagac atctttgtca cctccaagac agtgctttgg 2100
cccaatgggc taagcctgga catcccggtt gggcgctctt actgggtgga tgcttctac 2160
gaccgcatcg agacgatact gctcaatggc acagaccgga agattgtgta tgaaggctcct 2220
gagctgaacc acgccttttg cctgtgtcac catggcaact acctcttctg gactgagtat 2280
cggagtggca gtgtctaccg cttggaacgg ggtgtaggag gcgcaccccc cactgtgacc 2340
cttctgcgca gtgagcggcc ccccatcttt gagatccgaa tgtatgatgc ccagcagcag 2400
caagttggca ccaacaaatg ccgggtgaac aatggcggct gcagcagcct gtgcttggcc 2460
acctctggga gccgccagtg cgcctgtgct gaggaccagg tggtggacgc agacggcgtc 2520
cttgcttgg cgaacccatc ctacgtgcct ccacccagc gccagccagg cgagtttgcc 2580
tgtgccaaca gccgctgcat ccaggagcgc tggaagtgtg acggagacaa cgattgcctg 2640
gacaacagtg atgaggcccc agccctctgc catcagcaca cctgcccctc ggaccgatc 2700
aagtgcgaga acaaccgggt catccccaac cgctggctct gcgacgggga caatgactgt 2760
gggaacagtg aagatgagtc caatgccact tgttcagccc gcacctgccc cccaaccag 2820
ttctcctgtg ccagtggccg ctgcatcccc atctcctgga cgtgtgatct ggatgacgac 2880
tgtggggacc gctctgatga gtctgcttcg tgtgcctatc ccacctgctt cccctgact 2940
cagtttacct gcaacaatgg cagatgtatc aacatcaact ggagatgcca caatgacaat 3000
gactgtgggg acaacagtga cgaagccggc tgcagccact cctgttctag caccagttc 3060
aagtgcaaca gcgggcgttg catccccgag cactggacct gcgatgggga caatgactgc 3120

ggagactaca gtgatgagac acacgccaac tgcaccaacc aggccacgag gccccctggt 3180
ggctgccaca ctgatgagtt ccagtgcgg ctggatggac tatgcatccc cctgcggtgg 3240
cgctgcgatg gggacactga ctgcatggac tccagcgatg agaagagctg tgagggagtg 3300
accacgtct gcgatcccag tgtcaagttt ggctgcaagg actcagctcg gtgcatcagc 3360
aaagcgtggg tgtgtgatgg cgacaatgac tgtgaggata actcggacga ggagaactgc 3420
gagtccctgg cctgcaggcc accctcgcac ccttgtgcca acaacacctc agtctgcctg 3480
ccccctgaca agctgtgtga tggcaacgac gactgtggcg acggctcaga tgagggcgag 3540
ctctgcgacc agtgctctct gaataacggg ggctgcagcc acaactgctc agtggcacct 3600
ggcgaaggca ttgtgtgttc ctgccctctg ggcatggagc tggggcccga caaccacacc 3660
tgccagatcc agagctactg tgccaagcat ctcaaagca gccaaaagtg cgaccagaac 3720
aagttcagcg tgaagtgtc ctgctacgag ggctgggtcc tggaaactga cggcgagagc 3780
tgccgcagcc tggaccctt caagccgttc atcattttct ccaaccgcca tgaaatccgg 3840
cgcatcgatc ttcacaaagg agactacagc gtctgtgtgc cgggctgcg caacaccatc 3900
gccctggact tccacctcag ccagagcgcc ctctactgga ccgacgtggt ggaggacaag 3960
atctaccgcg ggaagctgct ggacaacgga gccctgacta gtttcgaggt ggtgattcag 4020
tatggcctgg ccacaccgga gggcctggct gtagactgga ttgcaggcaa catctactgg 4080
gtggagagta acctggatca gatcgaggtg gccaaagtgg atgggaccct ccggaccacc 4140
ctgctggccg gtgacattga gcaccaagg gcaatcgcac tggatccccg ggatgggatc 4200
ctgttttgga cagactggga tgccagcctg ccccgcatg aggcagcctc catgagtggg 4260
gctgggccc gcaccgtgca ccgggagacc ggctctgggg gctggcccaa cgggctcacc 4320
gtggactacc tggagaagcg catcctttgg attgacgcca ggtcagatgc catttactca 4380
gcccgttacg acggctctgg ccacatggag gtgcttcggg gacacgagtt cctgtcgac 4440
ccgtttgcag tgacgtgta cgggggggag gtctactgga ctgactggcg aacaaacaca 4500
ctggctaagg ccaacaagtg gaccggccac aatgtcaccg tggtagagag gaccaacacc 4560
cagccctttg acctgcaggt gtaccacccc tcccgccagc ccatggctcc caatccctgt 4620
gaggccaatg ggggcccagg cccctgctcc cacctgtgtc tcatcaacta caaccggacc 4680
gtgtcctgcg cctgccccca cctcatgaag ctccacaagg acaacaccac ctgctatgag 4740
tttaagaagt tcctgtgta cgcacgtcag atggagatcc gaggtgtgga cctggatgct 4800
ccctactaca actacatcat ctcttcacg gtgcccgaca tcgacaacgt cacagtgcta 4860
gactacgatg cccgcgagca gcgtgtgtac tggctgacg tgcggaacaca ggccatcaag 4920
cgggccttca tcaacggcac aggcgtggag acagtcgtct ctgcagactt gccaaatgcc 4980

cacgggctgg ctgtggactg ggtctcccga aacctgttct ggacaagcta tgacaccaat 5040
aagaagcaga tcaatgtggc ccggctggat ggctccttca agaacgcagt ggtgcagggc 5100
ctggagcagc cccatggcct tgtcgtccac cctctgcgtg ggaagctcta ctggaccgat 5160
ggtgacaaca tcagcatggc caacatggat ggcagcaatc gcaccctgct cttcagtggc 5220
cagaagggcc ccgtgggcct ggctattgac ttccctgaaa gcaaactcta ctggatcagc 5280
tccgggaacc ataccatcaa ccgctgcaac ctggatggga gtgggctgga ggtcatcgat 5340
gccatgcgga gccagctggg caaggccacc gccctggcca tcatggggga caagctgtgg 5400
tgggctgatc aggtgtcgga aaagatgggc acatgcagca aggctgacgg ctcgggctcc 5460
gtggtccttc ggaacagcac caccctggtg atgcacatga aggtctatga cgagagcatc 5520
cagctggacc ataagggcac caaccctgc agtgtcaaca acggtgactg ctcccagctc 5580
tgctgcccc cgtcagagac gaccgctcc tgcattgtgca cagccggcta tagcctccgg 5640
gtggccagc aggcctgcga gggcgtaggt tcctttctcc tgtactctgt gcatgagggg 5700
atcaggggaa ttccccctgga tcccaatgac aagtcagatg ccctggctcc agtgtccggg 5760
acctcgctgg ctgtcggcat cgacttccac gctgaaaatg acaccatcta ctgggtggac 5820
atgggcctga gcacgatcag ccgggccaag cgggaccaga cgtggcgtga agacgtgggtg 5880
accaatggca ttggccgtgt ggagggcatt gcagtggact ggatcgagg caacatctac 5940
tggacagacc agggctttga tgtcatcgag gtcgcccggc tcaatggctc cttccgctac 6000
gtggtgatct cccagggctc agacaagccc cgggcatca ccgtccacc ggagaaaggg 6060
tacttgttct ggactgagt gggtcagtat ccgcgtattg agcggctctg gctagatggc 6120
acggagcgtg tgggtgctgg caacgtcagc atcagctggc ccaacggcat ctcagtggac 6180
ccaggatg ggaagctgta ctggtgcat gcacggacag acaagattga acggatcgac 6240
ctggagacag gtgagaaccg cgaggtgggt ctgtccagca acaacatgga catgttttca 6300
gtgtctgtgt ttgaggattt catctactgg agtgacagga ctcatgcaa cggctctatc 6360
aagcgcgga gcaaagacaa tgccacagac tccgtgcccc tgcaaccgg catcggcgtc 6420
cagcttaaag acatcaaagt cttcaaccgg gaccggcaga aaggcaccaa cgtgtgcgcg 6480
gtggccaatg gcgggtgcca gcagctgtgc ctgtaccggg gccgtgggca gcgggcctgc 6540
gcctgtgccc acgggatgct ggctgaagac ggagcatcgt gccgcgagta tgccggctac 6600
ctgctctact cagagcgcac cattctcaag agtatccacc tgtcgatga gcgcaacctc 6660
aatgcgcccg tgcagccctt cgaggaccct gagcacatga agaacgtcat cgcctggcc 6720
tttgactacc gggcaggcac ctctccgggc accccaatc gcatcttctt cagcgacatc 6780

cactttggga acatccaaca gatcaacgac gatggctcca ggaggatcac cattgtggaa 6840
 aacgtgggct cegtgaagg cctggcctat caccgtggct gggacactct ctattggaca 6900
 agctacacga catccaccat cacgcgccac acagtggacc agaccgccc aggggccttc 6960
 gagcgtgaga cegtcatcac tatgtctgga gatgaccacc cacgggcctt cgttttggac 7020
 gagtgccaga acctcatgtt ctggaccaac tggaatgagc agcatcccag catcatgcgg 7080
 gcggcgctct cgggagccaa tgtcctgacc cttatcgaga aggacatccg tcccccaat 7140
 ggctggcca tcgaccaccg tgccgagaag ctctacttct ctgacgccac cctggacaag 7200
 atcgagcggg gcgagtatga cggctccac cgctatgtga tcctaaagtc agagcctgtc 7260
 cacccttcg ggctggccgt gtatggggag cacattttct ggactgactg ggtgcggcgg 7320
 gcagtgcagc gggccaacaa gcacgtgggc agcaacatga agctgctgcg cgtggacatc 7380
 cccagcagc ccatgggcat catcgccgtg gccaacgaca ccaacagctg tgaactctct 7440
 ccatgccgaa tcaacaacgg tggctgccag gacctgtgtc tgctcactca ccagggccat 7500
 gtcaactgct catgccgagg gggccgaatc ctccaggatg acctcacctg c 7551

<210> 16
 <211> 9900
 <212> DNA
 <213> H. sapiens

<400> 16
 atgctgaccc cgccgttget cctgctgctg cccctgctct cagctctggt cgcggcggct 60
 atcgacgccc ctaagacttg cagccccaag cagtttgctt gcagagatca aataacctgt 120
 atctcaaagg gctggcgggt cgacggtgag agggactgcc cagacggatc tgacgaggcc 180
 cctgagattt gtccacagag taaggcccag cgatgccagc caaacgagca taactgcctg 240
 gtactgagc tgtgtgttcc catgtcccgc ctctgcaatg ggggtccagga ctgcatggac 300
 ggctcagatg aggggcccga ctgccgagag ctccaaggca actgctctcg cctgggctgc 360
 cagcaccatt gtgtccccac actcgatggg cccacctgct actgcaacag cagctttcag 420
 cttcaggcag atggcaagac ctgcaaagat tttgatgagt gctcagtgtg cggcacctgc 480
 agccagctat gcaccaacac agacggctcc ttcatatgtg gctgtgttga aggatacctc 540
 ctgcagccgg ataaccgctc ctgcaaggcc aagaacgagc cagtagaccg gcccctgtg 600
 ctgttgatag ccaactccca gaacatcttg gccacgtacc tgagtggggc ccagggtgtc 660
 accatcacac ctacgagcac gcggcagacc acagccatgg acttcagcta tgccaacgag 720
 accgtatgct ggggtgcatgt tggggacagt gctgctcaga cgcagctcaa gtgtgcccgc 780
 atgcctggcc taaagggtt cgtggatgag cacaccatca acatctccct cagtctgcac 840

cacgtggaac agatggccat cgactggctg acaggcaact tctactttgt ggatgacatc 900
gatgatagga tctttgtctg caacagaaat ggggacacat gtgtcacatt gctagacctg 960
gaactctaca accccaaggg cattgccctg gaccctgcca tggggaaggt gtttttcaact 1020
gactatgggc agatcccaaa ggtggaacgc tgtgacatgg atgggcagaa ccgcaccaag 1080
ctcgtcgaca gcaagattgt gtttcctcat ggcatcacgc tggacctggc cagccgcctt 1140
gtctactggg cagatgccta tctggactat attgaagtgg tggactatga gggcaagggc 1200
cgccagacca tcatccaggg catcctgatt gagcacctgt acggcctgac tgtgtttgag 1260
aattatctct atgccacca ctcggacaat gccaatgccc agcagaagac gagtgtgatc 1320
cgtgtgaacc gctttaacag caccgagtac caggttgtca cccgggtgga caaggggtgg 1380
gccctccaca tctaccacca gaggcgtcag ccccgagtga ggagccatgc ctgtgaaaac 1440
gaccagtatg ggaagccggg tggctgctct gacatctgcc tgctggccaa cagccacaag 1500
gcgcggacct gccgctgccg ttccggcttc agcctgggca gtgacgggaa gtcattgcaag 1560
cagccggagc atgagctgtt cctcgtgtat ggcaagggcc ggccaggcat catccggggc 1620
atggatatgg gggccaaggt cccggatgag cacatgatcc ccattgaaaa cctcatgaac 1680
ccccgagccc tggacttcca cgctgagacc ggcttcatct actttgccga caccaccagc 1740
tacctcattg gccgccagaa gattgatggc actgagcggg agaccatcct gaaggacggc 1800
atccacaatg tggaggggtg ggccgtggac tggatgggag acaatctgta ctggacggac 1860
gatggggcca aaaagacaat cagcgtggcc aggctggaga aagctgctca gaccgcaag 1920
actttaatcg agggcaaaat gacacacccc agggctattg tggatggatcc actcaatggg 1980
tggatgtact ggacagactg ggaggaggac cccaaggaca gtcggcgtgg gcggctggag 2040
agggcgtgga tggatggctc acaccgagac atctttgtca cctccaagac agtgctttgg 2100
ccaatgggc taagcctgga catccggct gggcgctct actgggtgga tgccttctac 2160
gaccgcatcg agacgatact gctcaatggc acagaccgga agattgtgta tgaaggctct 2220
gagctgaacc acgcctttgg cctgtgtcac catggcaact acctcttctg gactgagtat 2280
cggagtggca gtgtctaccg cttggaacgg ggtgtaggag gcgcaccccc cactgtgacc 2340
cttctgcgca gtgagcggcc ccccatcttt gagatccgaa tgtatgatgc ccagcagcag 2400
caagttggca ccaacaaatg ccgggtgaac aatggcggct gcagcagcct gtgcttggcc 2460
acctctggga gccgccagtg cgctgtgct gaggaccagg tgttgagcgc agacggcgct 2520
acttgcttgg cgaaccatc ctacgtgcct ccacccagc gccagccagg cgagtttgcc 2580
tgtgccaaca gccgctgcat ccaggagcgc tgggaagtgt acggagacaa cgattgcctg 2640
gacaacagtg atgaggcccc agcctctgct catcagcaca cctgcccctc ggaccgatcc 2700

aagtgcgaga acaaccggtg catccccaac cgctggctct gcgacgggga caatgactgt 2760
gggaacagtg aagatgagtc caatgccact tgttcagccc gcacctgccc cccaaccag 2820
ttctcctgtg ccagtggccg ctgcatcccc atctcctgga cgtgtgatct ggatgacgac 2880
tgtggggacc gctctgatga gtctgcttcg tgtgcctatc ccacctgctt cccctgact 2940
cagtttacct gcaacaatgg cagatgtatc aacatcaact ggagatgcga caatgacaat 3000
gactgtgggg acaacagtga cgaagccggc tgcagccact cctgttctag caccagttc 3060
aagtgcaca gcgggcgttg catccccgag cactggacct gcgatgggga caatgactgc 3120
ggagactaca gtgatgagac acacgccaac tgcaccaacc agggcacgag gccccctggt 3180
ggctgccaca ctgatgagtt ccagtgccgg ctggatggac tatgcatccc cctgcgggtg 3240
cgctgcgatg gggacactga ctgcatggac tccagcgatg agaagagctg tgagggagtg 3300
accacgtct gcgatcccag tgtcaagttt ggctgcaagg actcagctcg gtgcatcagc 3360
aagcgtggg tgtgtgatgg cgacaatgac tgtgaggata actcggacga ggagaactgc 3420
gagtccttg cctgcaggcc accctcgac ccttggtcca acaacacctc agtctgcctg 3480
ccccctgaca agctgtgtga tggcaacgac gactgtggcg acggctcaga tgagggcgag 3540
ctctgcgacc agtgcctct gaataacggg ggctgcagcc acaactgctc agtggcacct 3600
ggcgaaggca ttgtgtgttc ctgccctctg ggcatggagc tggggccccga caaccacacc 3660
tgccagatcc agagctactg tgccaagcat ctcaaagca gccaaaagtg cgaccagaac 3720
aagttcagcg tgaagtgtc ctgctacgag ggctgggtcc tggaaacctga cggcgagagc 3780
tgccgcagcc tggaccctt caagccgttc atcattttct ccaaccgcca tgaaatccgg 3840
cgcatcgatc ttcacaaagg agactacagc gtccctggtgc ccggcctgcg caacaccatc 3900
ccctggact tccacctcag ccagagcgcc ctctactgga ccgacgtggg ggaggacaag 3960
atctaccgcg ggaagctgct ggacaacgga gccctgacta gtttcgaggt ggtgattcag 4020
tatggcctgg ccacaccgga gggcctggct gtagactgga ttgcaggcaa catctactgg 4080
gtggagagta acctggatca gatcgaggtg gccaaagtgg atgggaccct ccggaccacc 4140
ctgctggccg gtgacattga gcaccaagg gcaatcgac tggatccccg ggatgggatc 4200
ctgttttgga cagactggga tgccagcctg ccccgcatg aggcagcctc catgagtggg 4260
gctggggcgcc gcaccgtgca ccgggagacc ggctctgggg gctggcccaa cgggctcacc 4320
gtggactacc tggagaagcg catcctttgg attgacgcca ggtcagatgc catttactca 4380
gcccgttacg acggctctgg ccacatggag gtgcttcggg gacacgagtt cctgtcgac 4440
ccgtttgcag tgacgctgta cgggggggag gtctactgga ctgactggcg acaaacaca 4500

ctggctaagg ccaacaagtg gaccggccac aatgtcaccg tggtagagag gaccaacacc 4560
cagccctttg acctgcaggt gtaccacccc tcccgccagc ccatggctcc caatccctgt 4620
gaggccaatg gggggccaggg cccctgtctc cacctgtgtc tcatcaacta caaccggacc 4680
gtgtcctgcg cctgccccca cctcatgaag ctccacaagg acaacaccac ctgctatgag 4740
tttaagaagt tcctgctgta cgcacgtcag atggagatcc gaggtgtgga cctggatgct 4800
ccctactaca actacatcat ctcccttcacg gtgcccagaca tcgacaacgt cacagtgtcta 4860
gactacgatg cccgcgagca gcgtgtgtac tgggtctgacg tgcggacaca ggccatcaag 4920
cgggccttca tcaacggcac aggcgtggag acagtcgtct ctgcagactt gccaaatgcc 4980
cacgggctgg ctgtggactg ggtctcccga aacctgttct ggacaagcta tgacaccaat 5040
aagaagcaga tcaatgtggc ccggtggat ggctccttca agaacgcagt ggtgcagggc 5100
ctggagcagc cccatggcct tgtcgtccac cctctgcgtg ggaagctcta ctggaccgat 5160
ggtgacaaca tcagcatggc caacatggat ggagcaatc gcaccctgct cttcagtggc 5220
tgaagggcc ccgtgggcct ggctattgac ttccctgaaa gcaaactcta ctggatcagc 5280
tccgggaacc ataccatcaa ccgctgcaac ctggatggga gtgggctgga ggtcatcgat 5340
gccatgcgga gccagctggg caaggccacc gccctggcca tcatggggga caagctgtgg 5400
tgggctgatc aggtgtcgga aaagatggg acatgcagca aggctgacgg ctcggtctcc 5460
gtggctcttc ggaacagcac caccctggtg atgcacatga aggtctatga cgagagcatc 5520
cagctggacc ataagggcac caaccctgc agtgtcaaca acggtgactg ctcccagctc 5580
tgcttccca cgtcagagac gaccgctcc tgcattgtga cagccggcta tagcctccgg 5640
agtggccagc aggcctgcga gggcgtagg tctttctcc tgtactctgt gcatgaggga 5700
atcaggggaa ttccctgga tccaatgac aagtcagatg ccctgggtccc agtgtccggg 5760
ctcgtgg ctgtcgcat cgacttcac gctgaaaatg acaccatcta ctgggtggac 5820
atgggcctga gcacgatcag ccgggccaag cgggaccaga cgtggcgtga agacgtgggtg 5880
accaatggca ttggccgtgt ggagggcatt gcagtggact ggatcgagg caacatctac 5940
tggaagacc agggctttga tgtcatcgag gtcgcccggc tcaatggctc cttccgctac 6000
gtggtgatct cccagggctc agacaagccc cgggcatca ccgtccaccc ggagaaaggg 6060
tacttgttct ggactgagtg gggtcagtat ccgctattg agcgggtctcg gctagatggc 6120
acggagcgtg tgggtgctgg caacgtcagc atcagctggc ccaacggcat ctcagtggac 6180
taccaggatg ggaagctgta ctggtgcgat gcacggacag acaagattga acggatcgac 6240
ctggagacag gtgagaaccg cgaggtggtt ctgtccagca acaacatgga catgttttca 6300
gtgtctgtgt ttgaggattt catctactgg agtgacagga ctcatgccaa cggctctatc 6360

aagcgcggga gcaaagacaa tgccacagac tccgtgcccc tgccaaccgg catcggcgctc 6420
cagcttaaag acatcaaagt cttcaaccgg gaccggcaga aaggcaccaa cgtgtgcgcg 6480
gtggccaatg gcgggtgcca gcagctgtgc ctgtaccggg gccgtgggca gcgggcctgc 6540
gcctgtgccc acgggatgct ggctgaagac ggagcatcgt gccgcgagta tgccggctac 6600
ctgctctact cagagcgcac cattctcaag agtatccacc tgtcggatga gcgcaacctc 6660
aatgcgcccc tgcagccctt cgaggaccct gagcacatga agaacgtcat cgccctggcc 6720
tttgactacc gggcaggcac ctctccgggc accccaatc gcatcttctt cagcgacatc 6780
cactttggga acatccaaca gatcaacgac gatggctcca ggaggatcac cattgtggaa 6840
aacgtgggct ccgtggaagg cctggcctat caccgtggct gggacactct ctattggaca 6900
agctacacga catccaccat cacgcgccac acagtggacc agaccgccc aggggccttc 6960
gagcgtgaga ccgtcatcac tatgtctgga gatgaccacc cacgggcctt cgttttggac 7020
agtgccaga acctcatgtt ctggaccaac tggaatgagc agcatcccag catcatgcgg 7080
gcggcgctct cgggagccaa tgtcctgacc cttatcgaga aggacatccg taccaccaat 7140
ggcctggcca tcgaccaccg tgccgagaag ctctacttct ctgacgccac cctggacaag 7200
atcgagcggg gcgagtatga cggctccac cgctatgtga tcctaaagtc agagcctgtc 7260
cacccttcg ggctggccgt gtatggggag cacattttct ggactgactg ggtgcggcgg 7320
gcagtgcagc gggccaacaa gcacgtgggc agcaacatga agctgctgcg cgtggacatc 7380
ccccagcagc ccatgggcat catcgccgtg gccaacgaca ccaacagctg tgaactctct 7440
ccatgccgaa tcaacaacgg tggctgccag gacctgtgtc tgctcactca ccagggccat 7500
gtcaactgct catgccgagg gggccgaatc ctccaggatg acctcacctg ccgagcgggtg 7560
cttctctt gccgagcaca agatgagttt gagtgtgcca atggcgagtg catcaacttc 7620
agcctgacct gcgacggcgt cccccactgc aaggacaagt ccgatgagaa gccatcctac 7680
tgcaactccc gccgctgcaa gaagactttc cggcagtgca gcaatgggcg ctgtgtgtcc 7740
aacatgctgt ggtgcaacgg ggccgacgac tgtggggatg gctctgacga gatcccttgc 7800
aacaagacag cctgtggtgt gggcgagtgc cgctgccggg acgggacctg catcgggaac 7860
tccagccgct gcaaccagtt tgtggattgt gaggacgcct cagatgagat gaactgcagt 7920
gccaccgact gcagcagcta cttccgcctg ggctgaagg gcgtgctctt ccagccctgc 7980
gagcggacct cactctgcta cgcaccacgc tgggtgtgtg atggcgccaa tgactgtggg 8040
gactacagtg atgagcgcga ctgcccagggt gtgaaacgcc ccagatgccc tctgaattac 8100
ttcgctgccc ctagtgggcg ctgcatcccc atgagctgga cgtgtgacaa agaggatgac 8160

tgtgaacatg gcgaggacga gaccactgc aacaagttct gctcagaggc ccagtttgag 8220
tgccagaacc atcgctgcat ctccaagcag tggctgtgtg acggcagcga tgactgtggg 8280
gatggctcag acgaggctgc tcaactgtgaa ggcaagacgt gcggccccctc ctccttctcc 8340
tgccctggca cccacgtgtg cgtccccgag cgctggctct gtgacgggtga caaagactgt 8400
gctgatggtg cagacgagag catcgagct ggttgcttgt acaacagcac ttgtgacgac 8460
cgtgagttca tgtgccagaa ccgccagtgc atcccaagc acttcgtgtg tgaccacgac 8520
cgtgactgtg cagatggctc tgatgagtc cccgagtgtg agtaccgac ctgcggcccc 8580
agtgagttcc gctgtgcaa tgggcgctgt ctgagctccc gccagtggga gtgtgatggc 8640
gagaatgact gccacgacca gagtgcgag gctccaaga acccactg caccagccca 8700
gagcacaagt gcaatgcctc gtcacagttc ctgtgcagca gtgggcgctg tgtggctgag 8760
gcaactgctc gcaacggcca ggatgactgt ggcgacagct cggacgagcg tggctgccac 8820
atcaatgagt gtctcagccg caagctcagt ggctgcagcc aggactgtga ggacctcaag 8880
atggcttca agtgccgctg tcgccctggc ttccggctga aggatgacgg ccggacgtgt 8940
gctgatgtgg acgagtgcag caccaccttc ccctgcagcc agcgtgcat caacacccat 9000
ggcagctata agtgtctgtg tgtggagggc tatgcacccc gcggcgccga cccccacagc 9060
tgcaaggctg tgactgacga ggaaccgttt ctgatcttcg ccaaccggta ctacctgcg 9120
aagctcaacc tggacgggtc caactacag ttacttaagc agggcctgaa caacgccgtt 9180
gccttggatt ttgactaccg agagcagatg atctactgga cagatgtgac caccagggc 9240
agcatgatcc gaaggatgca ccttaacggg agcaatgtgc aggtcctaca ccgtacaggc 9300
ctcagcaacc ccgatgggct ggctgtggac tgggtgggtg gcaacctgta ctggtgcgac 9360
aaaggccggg acaccatcga ggtgtccaag ctcaatgggg cctatcggac ggtgctggtc 9420
gctctggcc tccgtgagcc cagggtctg gtggtgatg tgcagaatgg gtacctgtac 9480
tggacagact ggggtgacca ttcaactgat gcccgcatcg gcatggatgg gtccagccgc 9540
agcgtcatcg tggacaccaa gatcacatgg cccaatggcc tgacgctgga ctatgtcact 9600
gagcgcatt actgggccga cggccgag gactacattg aatttgccag cctggatggc 9660
tccaatcgcc acgttgtgct gagccaggac atccgcaca tctttgact gaccctgttt 9720
gaggactacg tctactggac cgactgggaa acaaagtcca ttaaccgagc ccacaagacc 9780
acgggcacca acaaaacgct cctcatcagc acgtgcacc ggcccatgga cctgcatgtc 9840
ttccatgccc tgcgccagcc agacgtgccc aatcaccct gcaagggtcaa caatggtggc 9900

<210> 17

<211> 13260

<212> DNA

<213> H. sapiens

<400> 17

atgctgaccc cgccgttgct cctgctgctg cccctgctct cagctctggt cgcggcggct 60
atcgacgccc ctaagacttg cagccccaag cagtttgctt gcagagatca aataacctgt 120
atctcaaagg gctggcgggt cgacgggtgag agggactgcc cagacggatc tgacgaggcc 180
cctgagattt gtccacagag taaggcccag cgatgccagc caaacgagca taactgcctg 240
ggctactgagc tgtgtgttcc catgtcccgc ctctgcaatg ggggtccagga ctgcatggac 300
ggctcagatg agggggccca ctgccgagag ctccaaggca actgctctcg cctgggctgc 360
cagcaccatt gtgtccccac actcgatggg cccacctgct actgcaacag cagctttcag 420
cttcaggcag atggcaagac ctgcaaagat tttgatgagt gctcagtgtg cggcacctgc 480
agccagctat gcaccaaac acagggctcc ttcataatgt gctgtgttga aggataacct 540
ctgcagccgg ataaccgctc ctgcaaggcc aagaacgagc cagtagaccg gccccctgtg 600
ctgttgatag ccaactccca gaacatcttg gccacgtacc tgagtggggc ccaggtgtct 660
accatcacac ctacgagcac gcggcagacc acagccatgg acttcagcta tgccaacgag 720
accgtatgct ggggtgcatgt tggggacagt gctgctcaga cgcagctcaa gtgtgccccg 780
atgcctggcc taaagggtct cgtggatgag cacaccatca acatctccct cagtctgcac 840
cacgtggaac agatggccat cgactggctg acaggcaact tctactttgt ggatgacatc 900
gatgatagga tctttgtctg caacagaaat ggggacacat gtgtcacatt gctagacctg 960
gaactctaca accccaaggg cattgcctg gacctgcca tggggaagggt gtttttctact 1020
gactatgggc agatcccaaa ggtggaacgc tgtgacatgg atgggcagaa ccgcaccaag 1080
ctcgtcgaca gcaagattgt gtttctcat ggcacacgc tggacctggt cagccgcctt 1140
ctctactggg cagatgccta tctggactat attgaagtgg tggactatga gggcaagggc 1200
cgccagacca tcatccaggg catcctgatt gagcacctgt acggcctgac tgtgtttgag 1260
aattatctct atgccaccaa ctcggaacaat gccaatgccc agcagaagac gagtgtgatc 1320
cgtgtgaacc gctttaacag caccgagtac caggttgtca cccgggtgga caagggtggt 1380
gccctccaca tctaccacca gaggcgtcag ccccgagtga ggagccatgc ctgtgaaaac 1440
gaccagtatg ggaagccggg tggtctgctt gacatctgcc tgctggccaa cagccacaag 1500
gcgcggacct gccgctgccg ttccggcttc agcctgggca gtgacgggaa gtcatgcaag 1560
aagccggagc atgagctgtt cctcgtgtat ggcaagggcc ggccaggcat catccggggc 1620
atggatatgg gggccaaggc cccggatgag cacatgatcc ccattgaaaa cctcatgaac 1680
ccccgagccc tggacttcca cgctgagacc ggcttcatct actttgccga caccaccagc 1740

tacctcattg gccgccagaa gattgatggc actgagcggg agaccatcct gaaggacggc 1800
atccacaatg tggaggggtgt ggccgtggac tggatgggag acaatctgta ctggacggac 1860
gatgggcca aaaagacaat cagcgtggcc aggctggaga aagctgctca gacccgcaag 1920
actttaatcg agggcaaaat gacacacccc agggctattg tggatggatcc actcaatggg 1980
tggatgtact ggacagactg ggaggaggac cccaaggaca gtcggcgtgg gcggctggag 2040
agggcgtgga tggatggctc acaccgagac atctttgtca cctccaagac agtgctttgg 2100
cccaatgggc taagcctgga catcccggtt gggcgctctt actgggtgga tgccttctac 2160
gaccgcatcg agacgatact gctcaatggc acagaccgga agattgtgta tgaaggctct 2220
gagctgaacc acgcctttgg cctgtgtcac catggcaact acctcttctg gactgagtat 2280
cggagtggca gtgtctaccg cttggaacgg ggtgtaggag gcgcaccccc cactgtgacc 2340
cttctgcgca gtgagcggcc ccccatcttt gagatccgaa tgtatgatgc ccagcagcag 2400
agttggca ccaacaaatg ccgggtgaac aatggcggct gcagcagcct gtgcttggcc 2460
acccctggga gccgccagtg cgcctgtgct gaggaccagg tgttgagcgc agacggcgtc 2520
acttgcttgg cgaaccatc ctacgtgcct ccacccagc gccagccagg cgagtttgcc 2580
tgtgccaaca gccgctgcat ccaggagcgc tggaaagtgt acggagacaa cgattgcctg 2640
gacaacagt atgaggcccc agccctctgc catcagcaca cctgcccctc ggaccgatcc 2700
aagtgcgaga acaaccggtg catccccaac cgctggctct gcgacgggga caatgactgt 2760
gggaacagt aagatgagtc caatgccact tgttcagccc gcacctgcc cccaaccag 2820
ttctcctgt ccagtggccg ctgcatcccc atctcctgga cgtgtgatct ggatgacgac 2880
tgtggggacc gctctgatga gtctgcttcg tgtgcctatc ccacctgctt cccctgact 2940
gtttacct gcaacaatgg cagatgtatc aacatcaact ggagatgcga caatgacaat 3000
gactgtgggg acaacagtga cgaagccggc tgcagccact cctgttctag caccagttc 3060
aagtgaaca gggggcgttg catccccgag cactggacct gcgatgggga caatgactgc 3120

ggagactaca gtgatgagac acacgccaac tgcaccaacc aggccacgag gcccctggt 3180
ggctgccaca ctgatgagtt ccagtgccgg ctggatggac tatgcatccc cctgcggtgg 3240
cgctgcgatg gggacactga ctgcatggac tccagcgatg agaagagctg tgagggagtg 3300
acccacgtct gcgatcccag tgtcaagttt ggctgcaagg actcagctcg gtgcatcagc 3360
aaagcgtggg tgtgtgatgg cgacaatgac tgtgaggata actcggacga ggagaactgc 3420
gagtccttgg cctgcaggcc accctcgcac ccttgtgcca acaacacctc agtctgcctg 3480
ccccctgaca agctgtgtga tggcaacgac gactgtggcg acggctcaga tgagggcgag 3540

ctctgcgacc agtgctctct gaataacggt ggctgcagcc acaactgctc agtggcacct 3600
ggcgaaggca ttgtgtgttc ctgccctctg ggcattggagc tggggcccga caaccacacc 3660
tgccagatcc agagctactg tgccaagcat ctcaaagca gccaaaagtg cgaccagaac 3720
aagttcagcg tgaagtgtc ctgctacgag ggctgggtcc tggaaacctga cggcgagagc 3780
tgccgcagcc tggacccctt caagccgttc atcattttct ccaaccgcca tgaaatccgg 3840
cgcatcgatc ttcacaaagg agactacagc gtccctgggtc ccggcctgcg caacaccatc 3900
gccctggact tccacctcag ccagagcgcc ctctactgga ccgacgtggt ggaggacaag 3960
atctaccgcg ggaagctgct ggacaacgga gccctgacta gtttcgaggt ggtgattcag 4020
tatggcctgg ccacaccoga gggcctggct gtagactgga ttgcaggcaa catctactgg 4080
gtggagagta acctggatca gatcgaggtg gccaagctgg atgggaccct ccggaccacc 4140
ctgctggccg gtgacattga gcaccaagg gcaatcgac tggatccccg ggatgggac 4200
gtttttgga cagactggga tgccagcctg ccccgcatg aggcagcctc catgagtggg 4260
gctgggcgcc gcaccgtgca ccgggagacc ggctctgggg gctggcccaa cgggctcacc 4320
gtggactacc tggagaagcg catcctttgg attgacgcca ggtcagatgc catttactca 4380
gcccgttacg acggctctgg ccacatggag gtgcttcggg gacacgagtt cctgtcgcac 4440
ccgtttgcag tgacgctgta cgggggggag gtctactgga ctgactggcg acaaacaca 4500
ctggctaagg ccaacaagtg gaccggccac aatgtcaccg tggtagagag gaccaacacc 4560
cagccctttg acctgcaggt gtaccacccc tcccgccagc ccatggctcc caatccctgt 4620
gaggccaatg ggggcccagg cccctgctcc cacctgtgtc tcatcaacta caaccggacc 4680
gtgtcctgcg cctgccccca cctcatgaag ctccacaagg acaacaccac ctgctatgag 4740
taagaagt tctgtctgta cgcacgtcag atggagatcc gaggtgtgga cctggatgct 4800
ccctactaca actacatcat ctccctcacg gtgcccgaca tcgacaacgt cacagtgtca 4860
gactacgatg cccgcgagca gcgtgtgtac tggctgtacg tgcggacaca ggccatcaag 4920
cgggccttca tcaacggcac aggcgtggag acagtcgtct ctgcagactt gccaaatgcc 4980
cacgggctgg ctgtggactg ggtctcccga aacctgttct ggacaagcta tgacaccaat 5040
aagaagcaga tcaatgtggc ccggctggat ggctccttca agaacgcagt ggtgcagggc 5100
ctggagcagc cccatggcct tgcgtccac cctctgcgtg ggaagctcta ctggaccgat 5160
ggtgacaaca tcagcatggc caacatggat ggcagcaatc gcaccctgct cttcagtggc 5220
cagaagggcc ccgtgggcct ggctattgac ttccctgaaa gcaaactcta ctggatcagc 5280
tccgggaacc ataccatcaa ccgctgcaac ctggatggga gtgggctgga ggtcatcgat 5340

gccatgcgga gccagctggg caagggcacc gccctggcca tcatggggga caagctgtgg 5400
 tgggctgatc aggtgtcgga aaagatgggc acatgcagca aggtgacgg ctggggctcc 5460
 gtggctccttc ggaacagcac caccctgggtg atgcacatga aggtctatga cgagagcatc 5520
 cagctggacc ataagggcac caaccctgc agtgtcaaca acggtgactg ctcccagctc 5580
 tgctgcccga cgtcagagac gaccgctcc tgcattgtgca cagccggcta tagcctccgg 5640
 agtggccagc aggcctgcga gggcgtaggt tcctttctcc tgtactctgt gcatgagggga 5700
 atcaggggaa ttccctgga tcccaatgac aagtcagatg ccctgggtccc agtgtccggg 5760
 acctcgctgg ctgtcggcat cgacttccac gctgaaaatg acaccatcta ctgggtggac 5820
 atgggcctga gcacgatcag ccgggccaag cgggaccaga cgtggcgatga agacgtgggtg 5880
 accaatggca ttggccgtgt ggagggcatt gcagtggact ggatcgcagg caacatctac 5940
 tggacagacc agggctttga tgtcatcgag gtcgcccggc tcaatggctc cttccgctac 6000
 tgggtgatct cccagggctc agacaagccc cgggccatca ccgtccaccc ggagaaaggg 6060
 tacttgttct ggactgagtg gggtcagtat ccgcgtattg agcgggtctcg gctagatggc 6120
 acggagcgtg tgggtgctggt caacgtcagc atcagctggc ccaacggcat ctcatgtggac 6180
 taccaggatg ggaagctgta ctgggtgcgat gcacggacag acaagattga acggatcgac 6240
 ctggagacag gtgagaaccg cgaggtgggt ctgtccagca acaacatgga catgttttca 6300
 gtgtctgtgt ttgaggattt catctactgg agtgacagga ctcatgccaa cggctctatc 6360
 aagcgcggga gcaaagacaa tgccacagac tccgtgcccc tgcgaaccgg catcggcgctc 6420
 cagcttaaag acatcaaagt cttcaaccgg gaccggcaga aaggcaccaa cgtgtgcgcy 6480
 gtggccaatg gcgggtgcca gcagctgtgc ctgtaccggg gccgtgggca gcgggcctgc 6540
 cctgtgccc acgggatgct ggctgaagac ggagcatcgt gccgcgagta tgccggctac 6600
 ctgctctact cagagcgcac cattctcaag agtatccacc tgtcggatga gcgcaacctc 6660
 aatgcgcccc tgcagccctt cgaggacct gagcacatga agaacgtcat cgccctggcc 6720
 tttgactacc gggcaggcac ctctccgggc accccaatc gcatcttctt cagcgacatc 6780
 cactttggga acatccaaca gatcaacgac gatgggtcca ggaggatcac cattgtggaa 6840
 aacgtgggct ccgtggaagg cctggcctat caccgtggct gggacactct ctattggaca 6900
 agctacacga catccaccat cacgcgccac acagtggacc agaccgccc aggggccttc 6960
 gagcgtgaga ccgtcatcac tatgtctgga gatgaccacc cacgggcctt cgttttggac 7020
 gagtgcgaga acctcatgtt ctggaccaac tggaatgagc agcatcccag catcatgcgg 7080
 gcggcgctct cgggagccaa tgcctgacc cttatcgaga aggacatccg taccaccaat 7140

ggcctggcca tcgaccaccg tgccgagaag ctctacttct ctgacgccac cctggacaag 7200
atcgagcggg gcgagtatga cggctccac cgctatgtga tcctaaagtc agagcctgtc 7260
caccoccttcg ggctggccgt gtatggggag cacattttct ggactgactg ggtgcggcgg 7320
gcagtgcagc gggccaacaa gcacgtgggc agcaacatga agctgctgcg cgtggacatc 7380
ccccagcagc ccatgggcat catcgccgtg gccaacgaca ccaacagctg tgaactctct 7440
ccatgccgaa tcaacaacgg tggtgccag gacctgtgtc tgctcactca ccagggccat 7500
gtcaactgct catgccgagg gggccgaatc ctccaggatg acctcacctg ccgagcgggtg 7560
aattcctctt gccgagcaca agatgagttt gagtgtgtcca atggcgagtg catcaacttc 7620
agcctgacct gcgacggcgt cccccactgc aaggacaagt ccgatgagaa gccatcctac 7680
tgcaactccc gccgctgcaa gaagactttc cggcagtga gcaatgggcg ctgtgtgtcc 7740
aacatgctgt ggtgcaacgg ggccgacgac tgtggggatg gctctgacga gatcccttgc 7800
caagacag cctgtggtgt gggcgagttc cgctgccggg acgggacctg catcggaac 7860
tccagccgct gcaaccagtt tgtggattgt gaggacgcct cagatgagat gaactgcagt 7920
gccaccgact gcagcagcta cttccgctg ggcgtgaagg gcgtgctctt ccagccctgc 7980
gagcggacct cactctgcta cgcaccacg cgggtgtgtg atggcgccaa tgactgtggg 8040
gactacagtg atgagcgcga ctgccaggt gtgaaacgcc ccagatgccc tctgaattac 8100
ttcgctgcc ctagtgggcg ctgcatcccc atgagctgga cgtgtgacaa agaggatgac 8160
tgtgaacatg gcgaggacga gaccactgc aacaagttct gctcagaggc ccagtttgag 8220
tgccagaacc atcgctgcat ctccaagcag tggtgtgtg acggcagcga tgactgtggg 8280
gatggctcag acgaggctgc tcaactgtgaa ggcaagacgt gcggcccctc ctcttctcc 8340
ggcctggcca cccacgtgtg cgtccccgag cgctggctct gtgacggtga caaagactgt 8400
gctgatgggt cagacgagag catgcagct ggttgcctgt acaacagcac ttgtgacgac 8460
cgtgagttca tgtgccagaa ccgccagtgc atcccaagc acttcgtgtg tgaccacgac 8520
cgtgactgtg cagatggctc tgatgagtcc cccgagtgtg agtaccgac ctgcggcccc 8580
agtgagttcc gctgtgccaa tgggcgctgt ctgagctccc gccagtggga gtgtgatggc 8640
gagaatgact gccacgacca gagtgcagag gctcccaaga accacactg caccagccca 8700
gagcacaagt gcaatgcctc gtcacagttc ctgtgcagca gtgggcgctg tgtggctgag 8760
gcactgctct gcaacggcca ggatgactgt ggcgacagct cggacgagcg tggtgccac 8820
atcaatgagt gtctcagccg caagctcagt ggctgcagcc aggactgtga ggacctcaag 8880
atcggttca agtgccgctg tcgccctggc ttccggctga aggatgacgg ccggacgtgt 8940
gctgatgtgg acgagtgcag caccacctc cctgcagcc agcgtgcat caacacccat 9000

ggcagctata agtgtctgtg tgtggagggc tatgcacccc gcggcggcga cccccacagc 9060
tgcaaggctg tgactgacga ggaaccgttt ctgatcttcg ccaaccggta ctacctgcgc 9120
aagctcaacc tggacgggtc caactacacg ttacttaagc agggcctgaa caacgccgtt 9180
gccttggatt ttgactaccg agagcagatg atctactgga cagatgtgac caccagggc 9240
agcatgatcc gaaggatgca ccttaacggg agcaatgtgc aggtcctaca ccgtacaggc 9300
ctcagcaacc ccgatgggct ggctgtggac tgggtgggtg gcaacctgta ctggtgcgac 9360
aaaggccggg acaccatcga ggtgtccaag ctcaatgggg cctatcggac ggtgctggtc 9420
agctctggcc tccgtgagcc cagggtctg gtggtggatg tgcagaatgg gtacctgtac 9480
tggacagact ggggtgacca ttactgatc ggccgcacgc gcatggatgg gtccagccgc 9540
agcgtcatcg tggacaccaa gatcacatgg cccaatggcc tgacgctgga ctatgtcact 9600
gagcgcactc actgggcccga cgcccgag gactacattg aatttgccag cctggatggc 9660
taacgcc acgttgtgt gagccaggac atccgcaca tctttgact gaccctgttt 9720
gaggactacg tctactggac cgactgggaa acaaagtcca ttaaccgagc ccacaagacc 9780
acgggcacca aaaaaacgt cctcatcagc acgtgcacc ggcccatgga cctgcatgtc 9840
ttccatgccc tgcgccagcc agacgtgccc aatcacccct gcaagggtcaa caatggtggc 9900
tgcagcaacc tgtgcctgt gtccccggg ggagggcaca aatgtgcctg ccccaaccaac 9960
ttctacctgg gcagcgatgg gcgcacctgt gtgtccaact gcacggctag ccagtttgta 10020
tgcaagaacg acaagtgcac ccccttctgg tggaagtgtg acaccgagga cgactgcggg 10080
gaccactcag acgagcccc ggactgcct gagttcaagt gccggcccg acagttccag 10140
tgctccacag gtatctgcac aaaccctgcc ttcatctgcg atggcgacaa tgactgccag 10200
taacagt acgaggccaa ctgtgacatc cacgtctgct tgcccagtca gttcaaattgc 10260
accaacacca accgtgtat tcccgcatc ttccgctgca atgggcagga caactgcgga 10320
gatggggagg atgagaggga ctgccccgag gtgacctgcg ccccaacca gttccagtgc 10380
tccattacca aacggtgcat ccccggtc tgggtctgcg accgggacaa tgactgtgtg 10440
gatggcagt atgagccgc caactgcacc cagatgacct gtggtgtgga cgagttccgc 10500
tgcaaggatt cgggccgctg catcccagcg cgttggaagt gtgacggaga ggatgactgt 10560
ggggatggct cggatgagcc caaggaagag tgtgatgaac gcacctgtga gccataccag 10620
ttccgctgca agaacaaccg ctgcgtgccc ggccgctggc agtgcgacta cgacaacgat 10680
tgcggtgaca actccgatga agagagctgc accctcggc cctgctccga gagtgagttc 10740
tcctgtgcca acggccgctg catcgcgggg cgctggaaat gcgatggaga ccacgactgc 10800

gcggacggct cggacgagaa agactgcacc ccccgctgtg acatggacca gttccagtgc 10860
aagagcggcc actgcatccc cctgcgctgg cgctgtgacg cagacgccga ctgcatggac 10920
ggcagcgacg aggaggcctg cggcactggc gtgcggacct gccccctgga cgagttccag 10980
tgcaacaaca ccttgtgcaa gccgctggcc tggaaagtgcg atggcgagga tgactgtggg 11040
gacaactcag atgagaaccc cgaggagtgt gcccggttcg tgtgccctcc caaccggccc 11100
ttccgttgca agaatgaccg cgtctgtctg tggatcgggc gccaatgcga tggcacggac 11160
aactgtgggg atgggactga tgaagaggac tgtgagcccc ccacagccca caccacccac 11220
tgcaaagaca agaaggagtt tctgtgccgg aaccagcgct gcctctctc ctccttgcgc 11280
tgcaacatgt tcgatgactg cggggacggc tctgacgagg aggactgcag catcgacccc 11340
aagctgacca gctgcgccac caatgccagc atctgtgggg acgaggcacg ctgcgtgcgc 11400
accgagaaaag cggcctactg tgccctgccg tcgggcttcc acaccgtgcc cggccagccc 11460
atgccaaag acatcaacga gtgcctgcgc ttcggcacct gctcccagct ctgcaacaac 11520
accaagggcg gccacctctg cagctgcgct cggaacttca tgaagacgca caacacctgc 11580
aaggccgaag gctctgagta ccaggtcctg tacatcgctg atgacaatga gatccgcagc 11640
ctgttccccg gccaccccca ttcggcttac gagcaggcat tccagggtga cgagagtgtc 11700
cgcatgtatg ctatggatgt ccatgtcaag gctggccgtg tctattggac caactggcac 11760
acgggcacca tctcctaccg cagcctgccca cctgctgcgc ctctaccac ttccaaccgc 11820
caccggcgac agattgaccg ggggtgtcacc cacctcaaca tttcagggtc gaagatgccc 11880
agaggcatcg ccatcgactg ggtggccgga aacgtgtact ggaccgactc gggccgagat 11940
gtgattgagg tggcgagat gaagggcgag aaccgcaaga cgctcatctc gggcatgatt 12000
cgagcccc acgccattgt ggtggaccca ctgaggggga ccatgtactg gtcagactgg 12060
ggcaaccacc ccaagattga gacggcagcg atggatggga cgcttcggga gacactggtg 12120
caggacaaca ttcagtggcc cacaggcctg gccgtggatt atcacaatga gcggctgtac 12180
tgggcagacg ccaagctttc agtcatcggc agcatccggc tcaatggcac ggacccatt 12240
gtggctgctg acagcaaagc aggcctaagt cacccttca gcacgacgt ctttgaggat 12300
tacatctatg gtgtcaccta catcaataat cgtgtcttca agatccataa gtttggccac 12360
agccccttgg tcaacctgac agggggcctg agccacgcct ctgacgtggc cctttaccat 12420
cagcacaagc agcccgaagt gaccaacca tgtgaccgca agaaatgcga gtggctctgc 12480
ctgctgagcc ccagtgggccc tgtctgcacc tgtcccaatg ggaagcggct ggacaacggc 12540
acatgcgtgc ctgtgccctc tccaacgccc ccccagatg ctcgccggcc tggaaacctgt 12600

aacctgcagt gcttcaacgg tggcagctgt ttcctcaatg cacggaggca gcccaagtgc 12660
cgctgccaac cccgctacac gggtgacaag tgtgaactgg accagtgctg ggagcactgt 12720
cgcaatgggg gcacctgtgc tgccctcccc tctggcatgc ccacgtgccg gtgccccacg 12780
ggcttcacgg gcccctaatg caccagcag gtgtgtgcgg gctactgtgc caacaacagc 12840
acctgcactg tcaaccaggg caaccagccc cagtgccgat gcctaccggg cttcctgggc 12900
gaccgctgcc agtaccggca gtgctctggc tactgtgaga actttggcac atgccagatg 12960
gctgctgatg gctcccgaca atgccgctgc actgcctact ttgagggatc gaggtgtgag 13020
gtgaacaagt gcagccgctg tctcgaaggg gcctgtgtgg tcaacaagca gagtggggat 13080
gtcacctgca actgcacgga tggccgggtg gccccagct gtctgacctg cgtcggccac 13140
tgagcaatg gcggctcctg taccatgaac agcaaatga tgctgagtg ccagtgccca 13200
ccccacatga caggggcccc gtgtgaggag cacgtcttca gccagcagca gccaggacat 13260

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ ~~BLACK BORDERS~~
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ ~~FADED TEXT OR DRAWING~~
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.